{"ac45f663ed3b7143b944a5385b5d82754087a6af": [["Background Wild birds are the natural hosts for influenza A viruses (IAVs) and provide a niche for the maintenance of this virus.", [["influenza A viruses", "DISEASE", 48, 67], ["Wild birds", "ORGANISM", 11, 21], ["influenza A viruses", "ORGANISM", 48, 67], ["IAVs", "CANCER", 69, 73], ["influenza A viruses", "SPECIES", 48, 67], ["influenza A viruses", "SPECIES", 48, 67], ["influenza", "PROBLEM", 48, 57], ["this virus", "PROBLEM", 118, 128]]]], "bdb43c308b9a0f04d6d108e1b4ae71ad03c87d3f": [["INTRODUCTIONThe study of pathogenesis was formerly regarded as a messy, unsatisfactory area for virus research-a sad state of affairs that was lamented by early enthusiasts (Mimms, 1964) .", [["The study", "TEST", 12, 21], ["virus research", "TEST", 96, 110]]], ["That view has changed now and there is an urgent need to know how viruses cause diseases.", [["diseases", "PROBLEM", 80, 88]]], ["The study of mechanisms of pathogenicity was recently placed at the top of the research objectives proposed for priority treatment by an ad hoc group on vaccinology (Bourne, 1996) .", [["The study", "TEST", 0, 9], ["pathogenicity", "PROBLEM", 27, 40], ["priority treatment", "TREATMENT", 112, 130]]], ["This review attempts to concisely present the current state of knowl-edge on the immunopathogenesis of infection in chickens with infectious bronchitis virus (IBV).INTRODUCTIONIn 1931 a 'new respiratory disease of baby chicks' was identified in the USA by Schalk & Hawn and named infectious bronchitis (IB).", [["respiratory", "ANATOMY", 191, 202], ["infection", "DISEASE", 103, 112], ["infectious bronchitis virus", "DISEASE", 130, 157], ["respiratory disease", "DISEASE", 191, 210], ["infectious bronchitis", "DISEASE", 280, 301], ["chickens", "ORGANISM", 116, 124], ["infectious bronchitis virus", "ORGANISM", 130, 157], ["IBV", "ORGANISM", 159, 162], ["chickens", "SPECIES", 116, 124], ["infectious bronchitis virus", "SPECIES", 130, 157], ["chicks", "SPECIES", 219, 225], ["chickens", "SPECIES", 116, 124], ["infectious bronchitis virus", "SPECIES", 130, 157], ["IBV", "SPECIES", 159, 162], ["infection", "PROBLEM", 103, 112], ["infectious bronchitis virus", "PROBLEM", 130, 157], ["new respiratory disease", "PROBLEM", 187, 210], ["baby chicks'", "PROBLEM", 214, 226], ["infection", "OBSERVATION", 103, 112], ["infectious", "OBSERVATION_MODIFIER", 130, 140], ["respiratory disease", "OBSERVATION", 191, 210], ["infectious", "OBSERVATION_MODIFIER", 280, 290], ["bronchitis", "OBSERVATION", 291, 301]]], ["Following infection of chickens with IBV, falls in egg production and quality were reported for the first time by Van Roekel et al. (1951) and Broadfoot & Smith (1954) .", [["egg", "ANATOMY", 51, 54], ["infection", "DISEASE", 10, 19], ["chickens", "ORGANISM", 23, 31], ["IBV", "ORGANISM", 37, 40], ["egg", "ORGANISM_SUBSTANCE", 51, 54], ["chickens", "SPECIES", 23, 31], ["chickens", "SPECIES", 23, 31], ["IBV", "SPECIES", 37, 40], ["infection", "PROBLEM", 10, 19], ["chickens", "PROBLEM", 23, 31], ["IBV", "PROBLEM", 37, 40], ["falls in egg production", "PROBLEM", 42, 65], ["infection", "OBSERVATION", 10, 19]]], ["In 1962, Cumming found that IBV was the cause of nephrosis-nephritis syndrome seen in Australia.", [["nephrosis-nephritis syndrome", "DISEASE", 49, 77], ["IBV", "ORGANISM", 28, 31], ["IBV", "SPECIES", 28, 31], ["IBV", "PROBLEM", 28, 31], ["nephrosis", "PROBLEM", 49, 58], ["nephritis syndrome", "PROBLEM", 59, 77], ["IBV", "OBSERVATION", 28, 31], ["nephrosis", "OBSERVATION", 49, 58], ["nephritis", "OBSERVATION", 59, 68]]], ["In more recent years, IBV has also been isolated from cloacal swabs and gut tissues, but while infection has sometimes been associated with diarrhoea, no pathological changes have been described in the alimentary tract.", [["cloacal swabs", "ANATOMY", 54, 67], ["gut tissues", "ANATOMY", 72, 83], ["alimentary tract", "ANATOMY", 202, 218], ["infection", "DISEASE", 95, 104], ["diarrhoea", "DISEASE", 140, 149], ["IBV", "ORGANISM", 22, 25], ["cloacal swabs", "ORGANISM_SUBSTANCE", 54, 67], ["gut tissues", "TISSUE", 72, 83], ["alimentary tract", "ORGANISM_SUBDIVISION", 202, 218], ["IBV", "SPECIES", 22, 25], ["IBV", "PROBLEM", 22, 25], ["cloacal swabs and gut tissues", "PROBLEM", 54, 83], ["infection", "PROBLEM", 95, 104], ["diarrhoea", "PROBLEM", 140, 149], ["pathological changes", "PROBLEM", 154, 174], ["gut tissues", "ANATOMY", 72, 83], ["infection", "OBSERVATION", 95, 104], ["diarrhoea", "OBSERVATION", 140, 149], ["alimentary tract", "ANATOMY", 202, 218]]], ["Swollen head syndrome (SHS) in chickens has generally been associated with infection with the avian pneumovirus (APV), turkey rhinotracheitis virus (TRTV) (Picault et al, 1987; Lu et al, 1994) .", [["head", "ANATOMY", 8, 12], ["Swollen head syndrome", "DISEASE", 0, 21], ["SHS", "DISEASE", 23, 26], ["infection", "DISEASE", 75, 84], ["avian pneumovirus", "DISEASE", 94, 111], ["APV", "CHEMICAL", 113, 116], ["turkey rhinotracheitis virus", "DISEASE", 119, 147], ["chickens", "ORGANISM", 31, 39], ["avian pneumovirus", "ORGANISM", 94, 111], ["turkey rhinotracheitis virus", "ORGANISM", 119, 147], ["TRTV", "ORGANISM", 149, 153], ["chickens", "SPECIES", 31, 39], ["avian pneumovirus", "SPECIES", 94, 111], ["turkey rhinotracheitis virus", "SPECIES", 119, 147], ["chickens", "SPECIES", 31, 39], ["APV", "SPECIES", 113, 116], ["turkey rhinotracheitis virus", "SPECIES", 119, 147], ["TRTV", "SPECIES", 149, 153], ["Swollen head syndrome", "PROBLEM", 0, 21], ["infection", "PROBLEM", 75, 84], ["the avian pneumovirus", "PROBLEM", 90, 111], ["turkey rhinotracheitis virus", "PROBLEM", 119, 147], ["head", "ANATOMY", 8, 12], ["syndrome", "OBSERVATION", 13, 21], ["infection", "OBSERVATION", 75, 84]]], ["However, in the first description of SHS, Morley & Thomson (1984) isolated a coronavirus, while in other reports, Massachusetts strains of IBV have also been isolated (Shirai et al., 1993; Droual & Woolcock, 1994) .", [["coronavirus", "DISEASE", 77, 88], ["coronavirus", "ORGANISM", 77, 88], ["Massachusetts strains", "ORGANISM", 114, 135], ["IBV", "ORGANISM", 139, 142], ["IBV", "SPECIES", 139, 142], ["a coronavirus", "PROBLEM", 75, 88], ["IBV", "PROBLEM", 139, 142]]], ["Recently, a variant strain of IBV, 793/B was isolated from broiler breeder flocks where the affected birds had bilateral myopathy affecting both superficial and deep pectoral muscles (Gough et ah, 1992) .INTRODUCTIONThus, it is clear that strains of IBV have wide and variable tissue tropisms, and the clinical manifestations of the disease can be diverse.", [["superficial", "ANATOMY", 145, 156], ["pectoral muscles", "ANATOMY", 166, 182], ["tissue", "ANATOMY", 277, 283], ["myopathy", "DISEASE", 121, 129], ["IBV", "ORGANISM", 30, 33], ["793/B", "CANCER", 35, 40], ["birds", "ORGANISM", 101, 106], ["superficial", "TISSUE", 145, 156], ["pectoral muscles", "ORGAN", 166, 182], ["IBV", "ORGANISM", 250, 253], ["tissue", "TISSUE", 277, 283], ["IBV", "SPECIES", 30, 33], ["broiler breeder flocks", "SPECIES", 59, 81], ["IBV", "SPECIES", 250, 253], ["a variant strain of IBV", "PROBLEM", 10, 33], ["broiler breeder flocks", "TREATMENT", 59, 81], ["bilateral myopathy", "PROBLEM", 111, 129], ["IBV", "PROBLEM", 250, 253], ["variable tissue tropisms", "PROBLEM", 268, 292], ["the disease", "PROBLEM", 329, 340], ["breeder flocks", "OBSERVATION", 67, 81], ["bilateral", "ANATOMY_MODIFIER", 111, 120], ["myopathy", "OBSERVATION", 121, 129], ["both", "ANATOMY_MODIFIER", 140, 144], ["superficial", "ANATOMY_MODIFIER", 145, 156], ["deep", "ANATOMY_MODIFIER", 161, 165], ["pectoral muscles", "ANATOMY", 166, 182], ["variable tissue", "OBSERVATION_MODIFIER", 268, 283], ["disease", "OBSERVATION", 333, 340]]], ["Although the name IB does not encompass the varied clinical manifestations observed with IBV infections, for the present this name has still been retained to avoid confusion.RESPIRATORY INFECTIONReplication of IBV in the respiratory tissues causes characteristic, but not pathognomonic signs such as gasping, coughing, tracheal rales and nasal discharge.", [["respiratory tissues", "ANATOMY", 221, 240], ["tracheal", "ANATOMY", 319, 327], ["nasal", "ANATOMY", 338, 343], ["IBV infections", "DISEASE", 89, 103], ["confusion", "DISEASE", 164, 173], ["coughing", "DISEASE", 309, 317], ["IBV", "ORGANISM", 89, 92], ["IBV", "ORGANISM", 210, 213], ["respiratory tissues", "TISSUE", 221, 240], ["nasal", "ORGANISM_SUBDIVISION", 338, 343], ["IBV", "SPECIES", 89, 92], ["IBV", "SPECIES", 210, 213], ["the varied clinical manifestations", "PROBLEM", 40, 74], ["IBV infections", "PROBLEM", 89, 103], ["confusion", "PROBLEM", 164, 173], ["RESPIRATORY INFECTIONReplication", "TREATMENT", 174, 206], ["IBV", "PROBLEM", 210, 213], ["pathognomonic signs", "PROBLEM", 272, 291], ["gasping", "PROBLEM", 300, 307], ["coughing", "PROBLEM", 309, 317], ["tracheal rales", "PROBLEM", 319, 333], ["nasal discharge", "PROBLEM", 338, 353], ["infections", "OBSERVATION", 93, 103], ["INFECTIONReplication", "OBSERVATION", 186, 206], ["IBV", "OBSERVATION", 210, 213], ["respiratory tissues", "ANATOMY", 221, 240], ["gasping", "OBSERVATION", 300, 307], ["tracheal", "ANATOMY", 319, 327], ["rales", "OBSERVATION", 328, 333], ["nasal", "ANATOMY", 338, 343]]], ["Occasionally, puffy, inflamed eyes and swollen sinuses may be seen (Parsons et al, 1992; Capua et al, 1994) .", [["puffy", "ANATOMY", 14, 19], ["eyes", "ANATOMY", 30, 34], ["swollen sinuses", "ANATOMY", 39, 54], ["eyes", "ORGAN", 30, 34], ["swollen sinuses", "MULTI-TISSUE_STRUCTURE", 39, 54], ["inflamed eyes and swollen sinuses", "PROBLEM", 21, 54], ["puffy", "OBSERVATION", 14, 19], ["inflamed", "OBSERVATION", 21, 29], ["eyes", "ANATOMY", 30, 34], ["swollen sinuses", "ANATOMY", 39, 54]]], ["The affected chickens also appear depressed, and feed consumption and weight gain are significantly reduced from 3 days after infection (Otsuki et al, 1990) .", [["depressed", "DISEASE", 34, 43], ["weight gain", "DISEASE", 70, 81], ["infection", "DISEASE", 126, 135], ["chickens", "ORGANISM", 13, 21], ["chickens", "SPECIES", 13, 21], ["chickens", "SPECIES", 13, 21], ["depressed", "PROBLEM", 34, 43], ["weight gain", "PROBLEM", 70, 81], ["infection", "PROBLEM", 126, 135], ["affected", "OBSERVATION_MODIFIER", 4, 12], ["chickens", "OBSERVATION", 13, 21], ["depressed", "OBSERVATION_MODIFIER", 34, 43]]], ["In uncomplicated cases, mortalities are generally low and have been attributed to asphyxiation due to blocking of the lower trachea or bronchi by plugs of mucus.RESPIRATORY INFECTIONThe upper respiratory tract is the main site of IBV replication, following which a viraemia occurs and the virus gets widely disseminated to other tissues (Mc-Martin, 1993) .", [["lower trachea", "ANATOMY", 118, 131], ["bronchi", "ANATOMY", 135, 142], ["mucus", "ANATOMY", 155, 160], ["upper respiratory tract", "ANATOMY", 186, 209], ["tissues", "ANATOMY", 329, 336], ["asphyxiation", "DISEASE", 82, 94], ["viraemia", "DISEASE", 265, 273], ["lower trachea", "MULTI-TISSUE_STRUCTURE", 118, 131], ["bronchi", "MULTI-TISSUE_STRUCTURE", 135, 142], ["mucus", "ORGANISM_SUBSTANCE", 155, 160], ["upper respiratory", "ORGANISM_SUBDIVISION", 186, 203], ["tract", "ORGANISM_SUBDIVISION", 204, 209], ["IBV", "ORGANISM", 230, 233], ["tissues", "TISSUE", 329, 336], ["IBV", "SPECIES", 230, 233], ["asphyxiation", "PROBLEM", 82, 94], ["blocking of the lower trachea", "PROBLEM", 102, 131], ["plugs of mucus", "PROBLEM", 146, 160], ["RESPIRATORY INFECTION", "PROBLEM", 161, 182], ["IBV replication", "TREATMENT", 230, 245], ["a viraemia", "PROBLEM", 263, 273], ["the virus", "PROBLEM", 285, 294], ["uncomplicated", "OBSERVATION_MODIFIER", 3, 16], ["asphyxiation", "OBSERVATION", 82, 94], ["lower", "ANATOMY_MODIFIER", 118, 123], ["trachea", "ANATOMY", 124, 131], ["bronchi", "ANATOMY", 135, 142], ["plugs", "OBSERVATION", 146, 151], ["mucus", "OBSERVATION", 155, 160], ["INFECTION", "OBSERVATION", 173, 182], ["upper", "ANATOMY_MODIFIER", 186, 191], ["respiratory tract", "ANATOMY", 192, 209], ["main", "OBSERVATION_MODIFIER", 217, 221], ["IBV replication", "OBSERVATION", 230, 245], ["viraemia", "OBSERVATION", 265, 273]]], ["The virus is primarily epitheliotropic and enters the epithelial cells by viropexis (Patterson & Bingham, 1976) .", [["epithelial cells", "ANATOMY", 54, 70], ["epithelial cells", "CELL", 54, 70], ["epithelial cells", "CELL_TYPE", 54, 70], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["primarily", "OBSERVATION_MODIFIER", 13, 22], ["epitheliotropic", "OBSERVATION_MODIFIER", 23, 38], ["epithelial cells", "OBSERVATION", 54, 70]]], ["Studies using immunofluorescence (IF) Qones & Jordan, 1972; Yagyu & Ohta, 1990) , immunoperoxidase (IP) (Nakamura et al, 1991; Owen et al, 1991) and electron microscopy (Purcell & Clarke, 1972; Nakamura et al, 1991) have shown virus replication in ciliated epithelial and mucus-secreting cells.", [["ciliated epithelial", "ANATOMY", 248, 267], ["mucus", "ANATOMY", 272, 277], ["cells", "ANATOMY", 288, 293], ["immunoperoxidase", "GENE_OR_GENE_PRODUCT", 82, 98], ["ciliated epithelial", "CELL", 248, 267], ["mucus-secreting cells", "CELL", 272, 293], ["ciliated epithelial and mucus-secreting cells", "CELL_TYPE", 248, 293], ["immunofluorescence", "TEST", 14, 32], ["electron microscopy", "TEST", 149, 168], ["virus replication", "PROBLEM", 227, 244], ["ciliated", "ANATOMY_MODIFIER", 248, 256], ["epithelial", "ANATOMY", 257, 267], ["mucus", "ANATOMY", 272, 277], ["secreting cells", "OBSERVATION", 278, 293]]], ["During the clinical phase of the disease, maximum virus titres are recorded in the trachea between 5 and 10 days post-infection (p.i.)", [["trachea", "ANATOMY", 83, 90], ["trachea", "ORGAN", 83, 90], ["the disease", "PROBLEM", 29, 40], ["maximum virus titres", "PROBLEM", 42, 62], ["disease", "OBSERVATION", 33, 40], ["maximum", "OBSERVATION_MODIFIER", 42, 49], ["virus titres", "OBSERVATION", 50, 62], ["trachea", "ANATOMY", 83, 90]]], ["(Ambali & Jones, 1990; Otsuki et al, 1990 ), but occasionally virus may be present for up to 28 days p.i.", [["occasionally virus", "PROBLEM", 49, 67]]], ["Cook, 1968) .RESPIRATORY INFECTIONVirus also replicates in the epithelial cells of lungs (Janse et al, 1994 ) and airsacs (Nauwynck & Pensaert, 1988) .", [["epithelial cells", "ANATOMY", 63, 79], ["lungs", "ANATOMY", 83, 88], ["epithelial cells", "CELL", 63, 79], ["lungs", "ORGAN", 83, 88], ["epithelial cells", "CELL_TYPE", 63, 79], ["RESPIRATORY INFECTIONVirus", "PROBLEM", 13, 39], ["INFECTIONVirus", "OBSERVATION", 25, 39], ["epithelial cells", "OBSERVATION", 63, 79], ["lungs", "ANATOMY", 83, 88]]], ["High virus titres are seen in these tissues between 4 to 11 days p.i.", [["tissues", "ANATOMY", 36, 43], ["tissues", "TISSUE", 36, 43], ["High virus titres", "PROBLEM", 0, 17], ["virus titres", "OBSERVATION", 5, 17]]], ["(Nauwynck & Pensaert, 1988; Otsuki et al, 1990) .RESPIRATORY INFECTIONInfected chickens have mucosal thickening with serous or catarrhal exudate in the nasal passages, sinuses and trachea.", [["mucosal", "ANATOMY", 93, 100], ["serous", "ANATOMY", 117, 123], ["catarrhal exudate", "ANATOMY", 127, 144], ["nasal passages", "ANATOMY", 152, 166], ["sinuses", "ANATOMY", 168, 175], ["trachea", "ANATOMY", 180, 187], ["chickens", "ORGANISM", 79, 87], ["mucosal", "PATHOLOGICAL_FORMATION", 93, 100], ["serous", "ORGANISM_SUBSTANCE", 117, 123], ["nasal passages", "MULTI-TISSUE_STRUCTURE", 152, 166], ["sinuses", "MULTI-TISSUE_STRUCTURE", 168, 175], ["trachea", "ORGAN", 180, 187], ["chickens", "SPECIES", 79, 87], ["chickens", "SPECIES", 79, 87], ["RESPIRATORY INFECTIONInfected chickens", "PROBLEM", 49, 87], ["mucosal thickening", "PROBLEM", 93, 111], ["serous or catarrhal exudate in the nasal passages, sinuses and trachea", "PROBLEM", 117, 187], ["mucosal", "ANATOMY", 93, 100], ["thickening", "OBSERVATION", 101, 111], ["serous", "OBSERVATION_MODIFIER", 117, 123], ["catarrhal exudate", "OBSERVATION", 127, 144], ["nasal passages", "ANATOMY", 152, 166], ["sinuses", "ANATOMY", 168, 175], ["trachea", "ANATOMY", 180, 187]]], ["The incidence of nasal exudate in experimentally-infected chickens has been used to assess the severity of disease in different inbred lines (Parsons et al, 1992) and in bursectomised birds (Cook et al, 1991a) .", [["nasal exudate", "ANATOMY", 17, 30], ["nasal exudate", "MULTI-TISSUE_STRUCTURE", 17, 30], ["chickens", "ORGANISM", 58, 66], ["birds", "ORGANISM", 184, 189], ["inbred lines", "CELL_LINE", 128, 140], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 58, 66], ["nasal exudate", "PROBLEM", 17, 30], ["infected chickens", "TREATMENT", 49, 66], ["disease", "PROBLEM", 107, 114], ["nasal", "ANATOMY", 17, 22], ["exudate", "OBSERVATION", 23, 30], ["infected", "OBSERVATION", 49, 57], ["disease", "OBSERVATION", 107, 114], ["different", "OBSERVATION_MODIFIER", 118, 127], ["inbred lines", "OBSERVATION", 128, 140]]], ["Small areas of pneumonia may be observed in the lungs.", [["lungs", "ANATOMY", 48, 53], ["pneumonia", "DISEASE", 15, 24], ["lungs", "ORGAN", 48, 53], ["pneumonia", "PROBLEM", 15, 24], ["areas", "OBSERVATION_MODIFIER", 6, 11], ["pneumonia", "OBSERVATION", 15, 24], ["lungs", "ANATOMY", 48, 53]]], ["The air sacs may appear cloudy or contain a yellow caseous exudate (King & Cavanagh, 1991) .RESPIRATORY INFECTIONThe progression of lesions in the trachea has been divided into three stages, degenerative, hyperplastic and recovery (Nakamura et al, 1991; Purcell & Mc-Ferran, 1972) .", [["air sacs", "ANATOMY", 4, 12], ["lesions", "ANATOMY", 132, 139], ["trachea", "ANATOMY", 147, 154], ["air sacs", "MULTI-TISSUE_STRUCTURE", 4, 12], ["exudate", "ORGANISM_SUBSTANCE", 59, 66], ["lesions", "CANCER", 132, 139], ["trachea", "ORGAN", 147, 154], ["The air sacs", "PROBLEM", 0, 12], ["cloudy", "PROBLEM", 24, 30], ["a yellow caseous exudate", "PROBLEM", 42, 66], ["RESPIRATORY INFECTION", "PROBLEM", 92, 113], ["lesions in the trachea", "PROBLEM", 132, 154], ["degenerative, hyperplastic", "PROBLEM", 191, 217], ["air sacs", "OBSERVATION", 4, 12], ["may appear", "UNCERTAINTY", 13, 23], ["cloudy", "OBSERVATION", 24, 30], ["yellow", "OBSERVATION_MODIFIER", 44, 50], ["caseous", "OBSERVATION_MODIFIER", 51, 58], ["exudate", "OBSERVATION_MODIFIER", 59, 66], ["INFECTION", "OBSERVATION", 104, 113], ["progression", "OBSERVATION_MODIFIER", 117, 128], ["lesions", "OBSERVATION", 132, 139], ["trachea", "ANATOMY", 147, 154], ["three stages", "OBSERVATION_MODIFIER", 177, 189], ["degenerative", "OBSERVATION_MODIFIER", 191, 203], ["hyperplastic", "OBSERVATION_MODIFIER", 205, 217], ["recovery", "OBSERVATION_MODIFIER", 222, 230]]], ["Deciliation and desquamation of epithelial and mucous-secreting cells occur in the first 1 or 2 days with a mild infiltration of heterophils and lymphocytes in the lamina propria.", [["epithelial", "ANATOMY", 32, 42], ["mucous-secreting cells", "ANATOMY", 47, 69], ["heterophils", "ANATOMY", 129, 140], ["lymphocytes", "ANATOMY", 145, 156], ["lamina propria", "ANATOMY", 164, 178], ["Deciliation", "DISEASE", 0, 11], ["epithelial", "CELL", 32, 42], ["mucous-secreting cells", "CELL", 47, 69], ["heterophils", "CELL", 129, 140], ["lymphocytes", "CELL", 145, 156], ["lamina propria", "TISSUE", 164, 178], ["epithelial and mucous-secreting cells", "CELL_TYPE", 32, 69], ["heterophils", "CELL_TYPE", 129, 140], ["lymphocytes", "CELL_TYPE", 145, 156], ["Deciliation", "TEST", 0, 11], ["desquamation", "PROBLEM", 16, 28], ["epithelial and mucous-secreting cells", "PROBLEM", 32, 69], ["a mild infiltration of heterophils", "PROBLEM", 106, 140], ["lymphocytes in the lamina propria", "PROBLEM", 145, 178], ["desquamation", "OBSERVATION_MODIFIER", 16, 28], ["epithelial", "ANATOMY_MODIFIER", 32, 42], ["mucous", "ANATOMY", 47, 53], ["secreting cells", "OBSERVATION", 54, 69], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["infiltration", "OBSERVATION", 113, 125], ["heterophils", "OBSERVATION", 129, 140], ["lymphocytes", "OBSERVATION", 145, 156], ["lamina propria", "ANATOMY", 164, 178]]], ["Heterophils are often seen infiltrating between ciliated epithelial cells and occasionally in the lumen of the trachea.", [["Heterophils", "ANATOMY", 0, 11], ["ciliated epithelial cells", "ANATOMY", 48, 73], ["lumen", "ANATOMY", 98, 103], ["trachea", "ANATOMY", 111, 118], ["Heterophils", "GENE_OR_GENE_PRODUCT", 0, 11], ["ciliated epithelial cells", "CELL", 48, 73], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 103], ["trachea", "ORGAN", 111, 118], ["ciliated epithelial cells", "CELL_TYPE", 48, 73], ["Heterophils", "PROBLEM", 0, 11], ["ciliated", "ANATOMY_MODIFIER", 48, 56], ["epithelial cells", "OBSERVATION", 57, 73], ["occasionally", "OBSERVATION_MODIFIER", 78, 90], ["lumen", "ANATOMY_MODIFIER", 98, 103], ["trachea", "ANATOMY", 111, 118]]], ["During the hyperplastic stage, newly-formed epithelial cells are observed which usually have no cilia.", [["epithelial cells", "ANATOMY", 44, 60], ["cilia", "ANATOMY", 96, 101], ["epithelial cells", "CELL", 44, 60], ["cilia", "CELLULAR_COMPONENT", 96, 101], ["epithelial cells", "CELL_TYPE", 44, 60], ["the hyperplastic stage", "PROBLEM", 7, 29], ["newly-formed epithelial cells", "PROBLEM", 31, 60], ["cilia", "PROBLEM", 96, 101], ["hyperplastic", "OBSERVATION_MODIFIER", 11, 23], ["newly", "OBSERVATION_MODIFIER", 31, 36], ["-formed", "OBSERVATION_MODIFIER", 36, 43], ["epithelial cells", "OBSERVATION", 44, 60], ["no", "UNCERTAINTY", 93, 95], ["cilia", "ANATOMY_MODIFIER", 96, 101]]], ["By 4 to 6 days the reparative processes begin with complete recovery by 10 to 20 days (Chen et al, 1996) .", [["the reparative processes", "TREATMENT", 15, 39]]], ["In affected airsacs, epithelial cell desquamation, oedema and some fibrinous exudate may be seen (King & Cavanagh, 1991) .Variation in virulence for respiratory tract between IBV strainsDifficulty in quantifying severity of respiratory infection caused by IBV has always been a problem in studying its pathogenicity .", [["airsacs", "ANATOMY", 12, 19], ["epithelial cell", "ANATOMY", 21, 36], ["fibrinous exudate", "ANATOMY", 67, 84], ["respiratory tract", "ANATOMY", 149, 166], ["respiratory", "ANATOMY", 224, 235], ["airsacs", "DISEASE", 12, 19], ["oedema", "DISEASE", 51, 57], ["respiratory infection", "DISEASE", 224, 245], ["airsacs", "CELL", 12, 19], ["epithelial cell", "CELL", 21, 36], ["respiratory tract", "ORGANISM_SUBDIVISION", 149, 166], ["IBV", "ORGANISM", 175, 178], ["IBV", "ORGANISM", 256, 259], ["IBV", "SPECIES", 175, 178], ["IBV", "SPECIES", 256, 259], ["affected airsacs", "PROBLEM", 3, 19], ["epithelial cell desquamation", "PROBLEM", 21, 49], ["oedema", "PROBLEM", 51, 57], ["some fibrinous exudate", "PROBLEM", 62, 84], ["Variation in virulence", "PROBLEM", 122, 144], ["respiratory tract", "PROBLEM", 149, 166], ["IBV strains", "PROBLEM", 175, 186], ["respiratory infection", "PROBLEM", 224, 245], ["IBV", "PROBLEM", 256, 259], ["affected", "OBSERVATION_MODIFIER", 3, 11], ["airsacs", "OBSERVATION_MODIFIER", 12, 19], ["epithelial cell desquamation", "OBSERVATION", 21, 49], ["oedema", "OBSERVATION", 51, 57], ["some", "OBSERVATION_MODIFIER", 62, 66], ["fibrinous", "OBSERVATION_MODIFIER", 67, 76], ["exudate", "OBSERVATION", 77, 84], ["respiratory tract", "ANATOMY", 149, 166], ["respiratory", "ANATOMY", 224, 235], ["infection", "OBSERVATION", 236, 245], ["IBV", "OBSERVATION", 256, 259]]], ["The virus causes stasis of tracheal cilia both in vivo and in vitro, and this parameter has been used to assess severity of respiratory infection.", [["tracheal cilia", "ANATOMY", 27, 41], ["respiratory", "ANATOMY", 124, 135], ["respiratory infection", "DISEASE", 124, 145], ["tracheal cilia", "MULTI-TISSUE_STRUCTURE", 27, 41], ["The virus", "PROBLEM", 0, 9], ["stasis of tracheal cilia", "PROBLEM", 17, 41], ["respiratory infection", "PROBLEM", 124, 145], ["virus", "OBSERVATION", 4, 9], ["stasis", "OBSERVATION", 17, 23], ["tracheal cilia", "ANATOMY", 27, 41], ["respiratory", "ANATOMY", 124, 135], ["infection", "OBSERVATION", 136, 145]]], ["Otsuki et al. (1990) found that following infection with the M41 strain, the duration and severity of tracheal ciliary damage was longer in a susceptible line of chicken (151) than in a resistant line (C).", [["tracheal ciliary", "ANATOMY", 102, 118], ["infection", "DISEASE", 42, 51], ["ciliary damage", "DISEASE", 111, 125], ["tracheal ciliary", "MULTI-TISSUE_STRUCTURE", 102, 118], ["chicken", "ORGANISM", 162, 169], ["C", "CELL", 202, 203], ["chicken", "SPECIES", 162, 169], ["chicken", "SPECIES", 162, 169], ["infection", "PROBLEM", 42, 51], ["the M41 strain", "PROBLEM", 57, 71], ["tracheal ciliary damage", "PROBLEM", 102, 125], ["infection", "OBSERVATION", 42, 51], ["tracheal", "ANATOMY", 102, 110], ["ciliary damage", "OBSERVATION", 111, 125], ["resistant line", "OBSERVATION", 186, 200]]], ["The authors proposed that this method could be used to compare the pathogenicity of different strains or susceptibility of different breeds to IBV.", [["IBV", "ORGANISM", 143, 146], ["IBV", "SPECIES", 143, 146], ["this method", "TREATMENT", 26, 37], ["different strains", "PROBLEM", 84, 101], ["IBV", "PROBLEM", 143, 146]]], ["Cubillos et al. (1991) found that in unvaccinated chickens challenged with four IBV isolates from Chile (one belonging to the Massachusetts serotype and three variants), the tracheal damage in terms of ciliary activity was variable, suggesting differences in virulence of IBV strains for the trachea.Variation in virulence for respiratory tract between IBV strainsWhile tracheal organ cultures (TOC) have been used extensively for cultivation and assay of IBV, distinct differences in virulence among IBV strains have not been observed in this in vitro system.", [["tracheal", "ANATOMY", 174, 182], ["ciliary", "ANATOMY", 202, 209], ["trachea", "ANATOMY", 292, 299], ["respiratory tract", "ANATOMY", 327, 344], ["tracheal organ cultures", "ANATOMY", 370, 393], ["tracheal damage", "DISEASE", 174, 189], ["chickens", "ORGANISM", 50, 58], ["IBV", "ORGANISM", 80, 83], ["tracheal", "ORGAN", 174, 182], ["ciliary", "MULTI-TISSUE_STRUCTURE", 202, 209], ["IBV", "ORGANISM", 272, 275], ["trachea", "ORGAN", 292, 299], ["respiratory tract", "ORGANISM_SUBDIVISION", 327, 344], ["IBV", "ORGANISM", 353, 356], ["tracheal organ cultures", "CELL", 370, 393], ["IBV", "ORGANISM", 456, 459], ["IBV", "ORGANISM", 501, 504], ["tracheal organ cultures", "CELL_LINE", 370, 393], ["chickens", "SPECIES", 50, 58], ["chickens", "SPECIES", 50, 58], ["IBV", "SPECIES", 80, 83], ["IBV", "SPECIES", 272, 275], ["IBV", "SPECIES", 353, 356], ["IBV", "SPECIES", 456, 459], ["IBV", "SPECIES", 501, 504], ["four IBV isolates", "TREATMENT", 75, 92], ["the tracheal damage", "PROBLEM", 170, 189], ["IBV strains for the trachea", "PROBLEM", 272, 299], ["Variation in virulence", "PROBLEM", 300, 322], ["respiratory tract", "PROBLEM", 327, 344], ["IBV strains", "PROBLEM", 353, 364], ["tracheal organ cultures", "TEST", 370, 393], ["cultivation", "TEST", 431, 442], ["assay", "TEST", 447, 452], ["IBV", "PROBLEM", 456, 459], ["virulence", "PROBLEM", 485, 494], ["IBV strains", "PROBLEM", 501, 512], ["tracheal", "ANATOMY", 174, 182], ["damage", "OBSERVATION", 183, 189], ["ciliary activity", "OBSERVATION", 202, 218], ["IBV strains", "OBSERVATION", 272, 283], ["trachea", "ANATOMY", 292, 299], ["respiratory tract", "ANATOMY", 327, 344], ["tracheal organ", "ANATOMY", 370, 384]]], ["Cook et al. (1976) , while standardizing TOC for the isolation and assay of IBV, compared three strains of IBV on the basis of their effect on tracheal cilia, but found no marked differences.", [["tracheal cilia", "ANATOMY", 143, 157], ["TOC", "CHEMICAL", 41, 44], ["IBV", "ORGANISM", 76, 79], ["IBV", "ORGANISM", 107, 110], ["tracheal cilia", "MULTI-TISSUE_STRUCTURE", 143, 157], ["IBV", "SPECIES", 76, 79], ["IBV", "SPECIES", 107, 110], ["the isolation", "TREATMENT", 49, 62], ["IBV", "TREATMENT", 76, 79], ["IBV", "PROBLEM", 107, 110], ["tracheal cilia", "ANATOMY", 143, 157], ["no", "UNCERTAINTY", 169, 171], ["marked", "OBSERVATION_MODIFIER", 172, 178]]], ["Dhinakar Raj & Jones (1996c) also reported little difference among seven IBV strains using measurement of ciliary activity as a criterion for damage to the tracheal epithelium.", [["ciliary", "ANATOMY", 106, 113], ["tracheal epithelium", "ANATOMY", 156, 175], ["IBV", "ORGANISM", 73, 76], ["ciliary", "MULTI-TISSUE_STRUCTURE", 106, 113], ["tracheal epithelium", "TISSUE", 156, 175], ["IBV", "SPECIES", 73, 76], ["seven IBV strains", "PROBLEM", 67, 84], ["damage to the tracheal epithelium", "PROBLEM", 142, 175], ["tracheal epithelium", "ANATOMY", 156, 175]]], ["Of nine strains compared in TOC by Cubillos et al (1991) , the hyperplasia caused by two viruses was the only histological difference.", [["TOC", "CHEMICAL", 28, 31], ["hyperplasia", "DISEASE", 63, 74], ["hyperplasia", "PATHOLOGICAL_FORMATION", 63, 74], ["nine strains", "PROBLEM", 3, 15], ["the hyperplasia", "PROBLEM", 59, 74], ["two viruses", "PROBLEM", 85, 96], ["strains", "OBSERVATION_MODIFIER", 8, 15], ["hyperplasia", "OBSERVATION", 63, 74], ["viruses", "OBSERVATION", 89, 96]]], ["IBV infections may not occur as a single entity in the field.", [["IBV infections", "DISEASE", 0, 14], ["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["IBV infections", "PROBLEM", 0, 14], ["infections", "OBSERVATION", 4, 14]]], ["With the presence of several respiratory diseases in chickens caused by bacteria and viruses, the role of these agents in increasing the severity of IBV or otherwise is an important contributory factor in influencing the pathogenesis of the disease (see later).Laying hensIn layers, IB can cause a severe decline in egg production, and later, a deterioration in shell and internal quality (McDougall, 1968; Sevoian & Levine, 1957) .", [["egg", "ANATOMY", 316, 319], ["respiratory diseases", "DISEASE", 29, 49], ["IBV", "DISEASE", 149, 152], ["chickens", "ORGANISM", 53, 61], ["IBV", "ORGANISM", 149, 152], ["egg", "ORGANISM_SUBSTANCE", 316, 319], ["chickens", "SPECIES", 53, 61], ["chickens", "SPECIES", 53, 61], ["IBV", "SPECIES", 149, 152], ["several respiratory diseases", "PROBLEM", 21, 49], ["bacteria", "PROBLEM", 72, 80], ["viruses", "PROBLEM", 85, 92], ["these agents", "TREATMENT", 106, 118], ["IBV", "PROBLEM", 149, 152], ["the disease", "PROBLEM", 237, 248], ["a severe decline in egg production", "PROBLEM", 296, 330], ["a deterioration in shell", "PROBLEM", 343, 367], ["several", "OBSERVATION_MODIFIER", 21, 28], ["respiratory diseases", "OBSERVATION", 29, 49], ["bacteria", "OBSERVATION", 72, 80], ["viruses", "OBSERVATION", 85, 92], ["disease", "OBSERVATION", 241, 248], ["severe", "OBSERVATION_MODIFIER", 298, 304], ["decline", "OBSERVATION", 305, 312]]], ["Such effects may be accompanied by mild (Muneer et al, 1986 (Muneer et al, , 1988 or no respiratory signs (Cook, 1984; .", [["mild", "OBSERVATION_MODIFIER", 35, 39]]], ["Some strains produce only a loss in shell colour .", [["Some strains", "PROBLEM", 0, 12], ["a loss in shell colour", "PROBLEM", 26, 48], ["strains", "OBSERVATION", 5, 12], ["loss", "OBSERVATION_MODIFIER", 28, 32], ["shell colour", "OBSERVATION", 36, 48]]], ["The severity of production decline varies with the period of lay, the virulence of the virus involved and other non-specific factors.", [["production decline", "PROBLEM", 16, 34], ["the virus", "PROBLEM", 83, 92], ["other non-specific factors", "PROBLEM", 106, 132], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["production", "OBSERVATION_MODIFIER", 16, 26], ["decline", "OBSERVATION", 27, 34]]], ["The response of individual hens varies greatly (McMartin, 1968) .", [["hens", "ORGANISM", 27, 31]]], ["Production may start to increase after 2 to 3 weeks, but reaches only sub-optimal levels.", [["increase", "OBSERVATION_MODIFIER", 24, 32]]], ["When laying is resumed, some eggs have soft-shells, while others are mis-shapen or rough-shelled.Laying hensWhen laying hens were infected with IBV strain M41, viral antigen was demonstrated in the epithelium of the oviducts between 6 and 9 days p.i.", [["epithelium", "ANATOMY", 198, 208], ["oviducts", "ANATOMY", 216, 224], ["hens", "ORGANISM", 104, 108], ["hens", "ORGANISM", 120, 124], ["IBV strain M41", "ORGANISM", 144, 158], ["epithelium", "TISSUE", 198, 208], ["oviducts", "ORGAN", 216, 224], ["viral antigen", "PROTEIN", 160, 173], ["IBV", "SPECIES", 144, 147], ["M41", "SPECIES", 155, 158], ["IBV strain M41", "TEST", 144, 158], ["viral antigen", "TEST", 160, 173], ["epithelium", "ANATOMY_MODIFIER", 198, 208]]], ["Areas of glandular hypoplasia caused by IBV leads to reduction in the synthesis of albumen proteins especially ovomucin, lysozyme and other major proteins which constitute the structural matrix of the thick albumen (Butler et al, 1972) .", [["glandular", "ANATOMY", 9, 18], ["albumen", "ANATOMY", 207, 214], ["glandular hypoplasia", "DISEASE", 9, 29], ["ovomucin", "CHEMICAL", 111, 119], ["glandular hypoplasia", "PATHOLOGICAL_FORMATION", 9, 29], ["IBV", "ORGANISM", 40, 43], ["albumen", "GENE_OR_GENE_PRODUCT", 83, 90], ["ovomucin", "GENE_OR_GENE_PRODUCT", 111, 119], ["lysozyme", "GENE_OR_GENE_PRODUCT", 121, 129], ["matrix", "CELLULAR_COMPONENT", 187, 193], ["albumen", "ORGANISM_SUBSTANCE", 207, 214], ["albumen proteins", "PROTEIN", 83, 99], ["ovomucin", "PROTEIN", 111, 119], ["lysozyme", "PROTEIN", 121, 129], ["major proteins", "PROTEIN", 140, 154], ["IBV", "SPECIES", 40, 43], ["glandular hypoplasia", "PROBLEM", 9, 29], ["IBV", "PROBLEM", 40, 43], ["the synthesis of albumen proteins", "TREATMENT", 66, 99], ["lysozyme", "TREATMENT", 121, 129], ["other major proteins", "PROBLEM", 134, 154], ["glandular", "ANATOMY_MODIFIER", 9, 18], ["hypoplasia", "OBSERVATION", 19, 29], ["IBV", "OBSERVATION", 40, 43], ["reduction", "OBSERVATION_MODIFIER", 53, 62]]], ["Hence, there is a decrease in the proportion of both thick and inner thin albumen, and an increase in the amount of outer thin albumen causing 'watery-whites'.", [["inner thin albumen", "ANATOMY", 63, 81], ["albumen", "ANATOMY", 127, 134], ["albumen", "ORGAN", 74, 81], ["albumen", "ORGANISM_SUBSTANCE", 127, 134], ["both thick and inner thin albumen", "TREATMENT", 48, 81], ["outer thin albumen", "TREATMENT", 116, 134], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["inner", "OBSERVATION_MODIFIER", 63, 68], ["thin", "OBSERVATION_MODIFIER", 69, 73], ["albumen", "OBSERVATION_MODIFIER", 74, 81], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["amount", "OBSERVATION_MODIFIER", 106, 112], ["outer", "OBSERVATION_MODIFIER", 116, 121], ["thin albumen", "OBSERVATION_MODIFIER", 122, 134], ["watery", "OBSERVATION_MODIFIER", 144, 150]]], ["Presence of blood or meat spots in the egg albumen has also been reported (McDougall, 1968; Muneer et al, 1987) .Laying hensInspissated yolk material may be seen in the abdominal cavity of infected layers.", [["blood", "ANATOMY", 12, 17], ["meat spots", "ANATOMY", 21, 31], ["egg albumen", "ANATOMY", 39, 50], ["yolk material", "ANATOMY", 136, 149], ["abdominal cavity", "ANATOMY", 169, 185], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["meat", "ORGANISM_SUBDIVISION", 21, 25], ["egg albumen", "ORGAN", 39, 50], ["yolk material", "MULTI-TISSUE_STRUCTURE", 136, 149], ["abdominal cavity", "ORGANISM_SUBDIVISION", 169, 185], ["layers", "TISSUE", 198, 204], ["hens", "SPECIES", 120, 124], ["blood or meat spots in the egg albumen", "PROBLEM", 12, 50], ["Inspissated yolk material", "PROBLEM", 124, 149], ["blood", "ANATOMY", 12, 17], ["meat spots", "OBSERVATION", 21, 31], ["Inspissated yolk material", "OBSERVATION", 124, 149], ["may be seen", "UNCERTAINTY", 150, 161], ["abdominal", "ANATOMY", 169, 178], ["cavity", "ANATOMY_MODIFIER", 179, 185], ["infected", "OBSERVATION", 189, 197], ["layers", "OBSERVATION_MODIFIER", 198, 204]]], ["Microscopic changes in the oviduct include reduction in the height of the epithelial cells, reduction in number or complete absence of cilia, dilation of glands, lymphocytic foci and cellular infiltration in the lamina propria and inter tubular stroma (Sevoian & Levine, 1957) .Laying hensThe mechanisms whereby IBV infection causes egg production of some birds to cease and for varying periods of time have not been elucidated.Young chicksIBV infection of female chicks of less than 2 weeks of age can cause permanent damage to the developing reproductive tract, resulting in 'false layers' that do not lay normally at sexual maturity (Broadfoot et al, 1956; Jones & Jordan, 1970) .", [["oviduct", "ANATOMY", 27, 34], ["epithelial cells", "ANATOMY", 74, 90], ["cilia", "ANATOMY", 135, 140], ["glands", "ANATOMY", 154, 160], ["lymphocytic foci", "ANATOMY", 162, 178], ["cellular", "ANATOMY", 183, 191], ["lamina propria", "ANATOMY", 212, 226], ["tubular stroma", "ANATOMY", 237, 251], ["egg", "ANATOMY", 333, 336], ["reproductive tract", "ANATOMY", 544, 562], ["IBV infection", "DISEASE", 312, 325], ["infection", "DISEASE", 444, 453], ["damage to the developing reproductive tract", "DISEASE", 519, 562], ["oviduct", "ORGAN", 27, 34], ["epithelial cells", "CELL", 74, 90], ["cilia", "CELLULAR_COMPONENT", 135, 140], ["glands", "ORGAN", 154, 160], ["lymphocytic foci", "CELL", 162, 178], ["cellular", "CELL", 183, 191], ["lamina propria", "TISSUE", 212, 226], ["inter tubular stroma", "TISSUE", 231, 251], ["hens", "ORGANISM", 285, 289], ["IBV", "ORGANISM", 312, 315], ["egg", "ORGANISM_SUBSTANCE", 333, 336], ["chicks", "ORGANISM", 464, 470], ["reproductive tract", "ORGANISM_SUBDIVISION", 544, 562], ["epithelial cells", "CELL_TYPE", 74, 90], ["chicks", "SPECIES", 464, 470], ["IBV", "SPECIES", 312, 315], ["Microscopic changes in the oviduct", "PROBLEM", 0, 34], ["the epithelial cells", "PROBLEM", 70, 90], ["cilia, dilation of glands", "PROBLEM", 135, 160], ["lymphocytic foci", "PROBLEM", 162, 178], ["cellular infiltration in the lamina propria", "PROBLEM", 183, 226], ["IBV infection", "PROBLEM", 312, 325], ["egg production", "PROBLEM", 333, 347], ["Young chicksIBV infection", "PROBLEM", 428, 453], ["permanent damage", "PROBLEM", 509, 525], ["the developing reproductive tract", "PROBLEM", 529, 562], ["oviduct", "ANATOMY", 27, 34], ["reduction", "OBSERVATION_MODIFIER", 43, 52], ["height", "OBSERVATION_MODIFIER", 60, 66], ["epithelial cells", "OBSERVATION", 74, 90], ["reduction", "OBSERVATION_MODIFIER", 92, 101], ["number", "OBSERVATION_MODIFIER", 105, 111], ["cilia", "ANATOMY_MODIFIER", 135, 140], ["dilation", "OBSERVATION", 142, 150], ["glands", "ANATOMY", 154, 160], ["lymphocytic foci", "OBSERVATION", 162, 178], ["cellular infiltration", "OBSERVATION", 183, 204], ["lamina", "ANATOMY_MODIFIER", 212, 218], ["propria", "ANATOMY", 219, 226], ["inter", "ANATOMY_MODIFIER", 231, 236], ["tubular stroma", "ANATOMY", 237, 251], ["IBV", "OBSERVATION_MODIFIER", 312, 315], ["infection", "OBSERVATION", 316, 325], ["egg production", "OBSERVATION", 333, 347], ["infection", "OBSERVATION", 444, 453], ["false layers", "OBSERVATION", 578, 590]]], ["Following infection of day-old chicks with IBV strain M41, virus was isolated between days 5 and 11 p.i.", [["infection", "DISEASE", 10, 19], ["chicks", "ORGANISM", 31, 37], ["IBV strain M41", "ORGANISM", 43, 57], ["chicks", "SPECIES", 31, 37], ["IBV strain M41", "SPECIES", 43, 57], ["infection", "PROBLEM", 10, 19], ["IBV strain M41", "TREATMENT", 43, 57], ["virus", "PROBLEM", 59, 64], ["infection", "OBSERVATION", 10, 19]]], ["(Jones & Jordan, 1972) and was also found to replicate in the epithelium of the oviducts (Crinion & Hofstad, 1972a,b; Jones & Jordan, 1972) .Young chicksGross changes in the oviduct caused by early infection may vary from the presence of a continuous patent but underdeveloped structure to a blind sac projecting forward from the cloaca (Jones & Jordan, 1970 .", [["epithelium", "ANATOMY", 62, 72], ["oviducts", "ANATOMY", 80, 88], ["oviduct", "ANATOMY", 174, 181], ["sac", "ANATOMY", 298, 301], ["cloaca", "ANATOMY", 330, 336], ["infection", "DISEASE", 198, 207], ["epithelium", "TISSUE", 62, 72], ["oviducts", "ORGAN", 80, 88], ["chicks", "ORGANISM", 147, 153], ["oviduct", "ORGAN", 174, 181], ["sac", "TISSUE", 298, 301], ["cloaca", "ORGAN", 330, 336], ["chicks", "SPECIES", 147, 153], ["Gross changes in the oviduct", "PROBLEM", 153, 181], ["early infection", "PROBLEM", 192, 207], ["a continuous patent but underdeveloped structure", "PROBLEM", 238, 286], ["epithelium", "ANATOMY_MODIFIER", 62, 72], ["oviducts", "ANATOMY", 80, 88], ["changes", "OBSERVATION", 159, 166], ["oviduct", "ANATOMY", 174, 181], ["early", "OBSERVATION_MODIFIER", 192, 197], ["infection", "OBSERVATION", 198, 207], ["continuous", "OBSERVATION_MODIFIER", 240, 250], ["patent", "OBSERVATION", 251, 257], ["sac", "OBSERVATION_MODIFIER", 298, 301], ["cloaca", "ANATOMY", 330, 336]]], ["The middle third of the oviduct is the most severely affected with areas of localised hypoplasia seen between normal patent oviducts.", [["middle third", "ANATOMY", 4, 16], ["oviduct", "ANATOMY", 24, 31], ["oviducts", "ANATOMY", 124, 132], ["hypoplasia", "DISEASE", 86, 96], ["oviduct", "ORGAN", 24, 31], ["oviducts", "MULTI-TISSUE_STRUCTURE", 124, 132], ["localised hypoplasia", "PROBLEM", 76, 96], ["middle", "ANATOMY_MODIFIER", 4, 10], ["third", "ANATOMY_MODIFIER", 11, 16], ["oviduct", "ANATOMY", 24, 31], ["most", "OBSERVATION_MODIFIER", 39, 43], ["severely", "OBSERVATION_MODIFIER", 44, 52], ["areas", "OBSERVATION_MODIFIER", 67, 72], ["localised", "OBSERVATION_MODIFIER", 76, 85], ["hypoplasia", "OBSERVATION", 86, 96], ["normal", "OBSERVATION_MODIFIER", 110, 116], ["patent", "OBSERVATION", 117, 123], ["oviducts", "OBSERVATION_MODIFIER", 124, 132]]], ["Caudal to the hypoplastic regions, macroscopic cysts filled with a clear serous fluid may be seen (Crinion et al., 1971a) .Young chicksThe histopathological changes in the oviduct include decreased height and loss of cilia from epithelial cells, dilation of the tubular glands, infiltration of heterophils, lymphocytes and plasma cells, and oedema and fibroplasia of the lamina propria (Crinion et al, 1971a,b; Crinion & Hofstad, 1972a,b) .Young chicksThe effect of IBV on the male reproductive tract has not been reported.Variation between strainsVariations in the ability of IBV strains to cause decreases in egg production and quality were reported by Guittet et al. (1988) ; D274 was the least virulent while M41 and a variant strain PL84084 had the same degree of pathogenicity. found that some variant strains of IBV caused only small decreases in egg production, but had a marked effect on egg colour.", [["hypoplastic regions", "ANATOMY", 14, 33], ["cysts", "ANATOMY", 47, 52], ["serous fluid", "ANATOMY", 73, 85], ["oviduct", "ANATOMY", 172, 179], ["cilia", "ANATOMY", 217, 222], ["epithelial cells", "ANATOMY", 228, 244], ["tubular glands", "ANATOMY", 262, 276], ["heterophils", "ANATOMY", 294, 305], ["lymphocytes", "ANATOMY", 307, 318], ["plasma cells", "ANATOMY", 323, 335], ["lamina propria", "ANATOMY", 371, 385], ["reproductive tract", "ANATOMY", 482, 500], ["egg", "ANATOMY", 611, 614], ["egg", "ANATOMY", 854, 857], ["egg", "ANATOMY", 897, 900], ["cysts", "DISEASE", 47, 52], ["oedema", "DISEASE", 341, 347], ["fibroplasia", "DISEASE", 352, 363], ["PL84084", "CHEMICAL", 738, 745], ["IBV", "DISEASE", 819, 822], ["cysts", "CANCER", 47, 52], ["serous fluid", "ORGANISM_SUBSTANCE", 73, 85], ["chicks", "ORGANISM", 129, 135], ["oviduct", "ORGAN", 172, 179], ["cilia", "CELLULAR_COMPONENT", 217, 222], ["epithelial cells", "CELL", 228, 244], ["tubular glands", "TISSUE", 262, 276], ["heterophils", "CELL", 294, 305], ["lymphocytes", "CELL", 307, 318], ["plasma cells", "CELL", 323, 335], ["lamina propria", "TISSUE", 371, 385], ["chicks", "ORGANISM", 446, 452], ["IBV", "ORGANISM", 466, 469], ["reproductive tract", "ORGAN", 482, 500], ["IBV", "ORGANISM", 577, 580], ["egg", "ORGANISM_SUBSTANCE", 611, 614], ["IBV", "ORGANISM", 819, 822], ["egg", "ORGANISM_SUBSTANCE", 854, 857], ["egg", "ORGANISM_SUBDIVISION", 897, 900], ["epithelial cells", "CELL_TYPE", 228, 244], ["heterophils", "CELL_TYPE", 294, 305], ["lymphocytes", "CELL_TYPE", 307, 318], ["plasma cells", "CELL_TYPE", 323, 335], ["chicks", "SPECIES", 129, 135], ["chicks", "SPECIES", 446, 452], ["IBV", "SPECIES", 466, 469], ["IBV", "SPECIES", 577, 580], ["IBV", "SPECIES", 819, 822], ["macroscopic cysts", "PROBLEM", 35, 52], ["a clear serous fluid", "PROBLEM", 65, 85], ["The histopathological changes in the oviduct", "PROBLEM", 135, 179], ["decreased height", "PROBLEM", 188, 204], ["loss of cilia from epithelial cells", "PROBLEM", 209, 244], ["dilation of the tubular glands", "PROBLEM", 246, 276], ["infiltration of heterophils", "PROBLEM", 278, 305], ["lymphocytes", "PROBLEM", 307, 318], ["plasma cells", "PROBLEM", 323, 335], ["oedema", "PROBLEM", 341, 347], ["fibroplasia of the lamina propria", "PROBLEM", 352, 385], ["IBV", "TREATMENT", 466, 469], ["Variation between strains", "PROBLEM", 523, 548], ["IBV strains", "PROBLEM", 577, 588], ["decreases in egg production", "PROBLEM", 598, 625], ["a variant strain PL84084", "TEST", 721, 745], ["pathogenicity", "PROBLEM", 769, 782], ["IBV", "PROBLEM", 819, 822], ["small decreases in egg production", "PROBLEM", 835, 868], ["a marked effect on egg colour", "PROBLEM", 878, 907], ["hypoplastic", "OBSERVATION", 14, 25], ["macroscopic", "OBSERVATION_MODIFIER", 35, 46], ["cysts", "OBSERVATION", 47, 52], ["clear", "OBSERVATION_MODIFIER", 67, 72], ["serous", "OBSERVATION_MODIFIER", 73, 79], ["fluid", "OBSERVATION", 80, 85], ["histopathological", "OBSERVATION", 139, 156], ["oviduct", "ANATOMY", 172, 179], ["decreased", "OBSERVATION_MODIFIER", 188, 197], ["height", "OBSERVATION_MODIFIER", 198, 204], ["loss", "OBSERVATION_MODIFIER", 209, 213], ["cilia", "ANATOMY_MODIFIER", 217, 222], ["epithelial cells", "OBSERVATION", 228, 244], ["dilation", "OBSERVATION", 246, 254], ["tubular glands", "ANATOMY", 262, 276], ["infiltration", "OBSERVATION_MODIFIER", 278, 290], ["heterophils", "ANATOMY", 294, 305], ["lymphocytes", "ANATOMY", 307, 318], ["plasma cells", "OBSERVATION", 323, 335], ["oedema", "OBSERVATION_MODIFIER", 341, 347], ["fibroplasia", "OBSERVATION", 352, 363], ["lamina propria", "ANATOMY", 371, 385], ["IBV", "OBSERVATION", 466, 469], ["decreases", "OBSERVATION_MODIFIER", 598, 607], ["same degree", "OBSERVATION_MODIFIER", 754, 765], ["pathogenicity", "OBSERVATION", 769, 782], ["small", "OBSERVATION_MODIFIER", 835, 840], ["decreases", "OBSERVATION_MODIFIER", 841, 850], ["egg production", "OBSERVATION", 854, 868], ["marked", "OBSERVATION_MODIFIER", 880, 886]]], ["In contrast, a more recent variant (Parsons et al., 1992) caused a substantial decline in egg production with little loss of egg colour in the field, although no experimental work has been done with this virus.", [["egg", "ANATOMY", 90, 93], ["egg", "ANATOMY", 125, 128], ["egg", "ORGANISM_SUBSTANCE", 90, 93], ["egg", "ORGANISM_SUBDIVISION", 125, 128], ["a substantial decline in egg production", "PROBLEM", 65, 104], ["little loss of egg colour", "PROBLEM", 110, 135], ["this virus", "PROBLEM", 199, 209], ["substantial", "OBSERVATION_MODIFIER", 67, 78], ["decline", "OBSERVATION", 79, 86], ["egg production", "OBSERVATION", 90, 104], ["little", "OBSERVATION_MODIFIER", 110, 116], ["loss", "OBSERVATION_MODIFIER", 117, 121], ["egg colour", "OBSERVATION", 125, 135], ["no", "UNCERTAINTY", 159, 161]]], ["Differences in virulence of IBV strains for the immature chicken oviduct were reported by Crinion & Hofstad (1972a) ; Massachusetts and T strains were virulent, while Connecticut and Iowa 609 were not.", [["oviduct", "ANATOMY", 65, 72], ["IBV", "ORGANISM", 28, 31], ["chicken", "ORGANISM", 57, 64], ["oviduct", "ORGAN", 65, 72], ["T strains", "CELL", 136, 145], ["chicken", "SPECIES", 57, 64], ["IBV", "SPECIES", 28, 31], ["chicken", "SPECIES", 57, 64], ["IBV strains", "PROBLEM", 28, 39], ["IBV strains", "OBSERVATION", 28, 39]]], ["Embryo passage of IBV strain M41 reduced its virulence for the oviduct (Crinion & Hofstad, 1972b) .", [["Embryo", "ANATOMY", 0, 6], ["oviduct", "ANATOMY", 63, 70], ["M41", "CHEMICAL", 29, 32], ["Embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 0, 6], ["IBV strain M41", "ORGANISM", 18, 32], ["oviduct", "ORGAN", 63, 70], ["IBV strain M41", "SPECIES", 18, 32], ["IBV strain M41", "PROBLEM", 18, 32]]], ["In vitro, oviduct organ cultures (OOC) were highly susceptible to the H52 strain of IBV regardless of the age of the chickens and no differences in susceptibility were seen between magnum and uterus regions .", [["oviduct organ cultures", "ANATOMY", 10, 32], ["OOC", "ANATOMY", 34, 37], ["magnum", "ANATOMY", 181, 187], ["uterus", "ANATOMY", 192, 198], ["oviduct organ cultures", "CELL", 10, 32], ["OOC", "CELL", 34, 37], ["IBV", "ORGANISM", 84, 87], ["chickens", "ORGANISM", 117, 125], ["magnum", "MULTI-TISSUE_STRUCTURE", 181, 187], ["uterus", "ORGAN", 192, 198], ["oviduct organ cultures", "CELL_LINE", 10, 32], ["chickens", "SPECIES", 117, 125], ["IBV", "SPECIES", 84, 87], ["chickens", "SPECIES", 117, 125], ["oviduct organ cultures", "TEST", 10, 32], ["OOC", "TEST", 34, 37], ["IBV", "TREATMENT", 84, 87], ["the chickens", "PROBLEM", 113, 125], ["differences in susceptibility", "PROBLEM", 133, 162], ["magnum", "ANATOMY", 181, 187], ["uterus", "ANATOMY", 192, 198], ["regions", "ANATOMY_MODIFIER", 199, 206]]], ["Pradhan et al. (1984) showed that IBV strain M41 causes stasis of cilia in OOC prepared from precociously-induced oviducts in young chicks by oestrogen treatment.", [["cilia", "ANATOMY", 66, 71], ["OOC", "ANATOMY", 75, 78], ["oviducts", "ANATOMY", 114, 122], ["M41", "CHEMICAL", 45, 48], ["oestrogen", "CHEMICAL", 142, 151], ["oestrogen", "CHEMICAL", 142, 151], ["IBV strain M41", "ORGANISM", 34, 48], ["cilia", "ORGANISM_SUBSTANCE", 66, 71], ["OOC", "SIMPLE_CHEMICAL", 75, 78], ["oviducts", "ORGAN", 114, 122], ["chicks", "ORGANISM", 132, 138], ["oestrogen", "SIMPLE_CHEMICAL", 142, 151], ["IBV", "SPECIES", 34, 37], ["IBV strain M41", "TREATMENT", 34, 48], ["stasis of cilia in OOC", "PROBLEM", 56, 78], ["oestrogen treatment", "TREATMENT", 142, 161], ["stasis", "OBSERVATION", 56, 62], ["cilia", "OBSERVATION", 66, 71], ["oviducts", "ANATOMY", 114, 122]]], ["This work has been extrapolated to compare the virulence of seven strains of IBV in vitro using ciliostasis and a calmodulin assay to quantify the damage to oviduct epithelium (Dhinakar Raj & Jones, 1996c ).", [["oviduct epithelium", "ANATOMY", 157, 175], ["IBV", "ORGANISM", 77, 80], ["calmodulin", "GENE_OR_GENE_PRODUCT", 114, 124], ["oviduct epithelium", "TISSUE", 157, 175], ["calmodulin", "PROTEIN", 114, 124], ["IBV", "SPECIES", 77, 80], ["IBV", "TREATMENT", 77, 80], ["ciliostasis", "TREATMENT", 96, 107], ["a calmodulin assay", "TEST", 112, 130], ["the damage to oviduct epithelium", "PROBLEM", 143, 175]]], ["An IBV isolate belonging to serotype D207 was the most virulent while an enterotropic variant strain G was the least.NEPHRITISAlthough even those strains of IBV considered primarily to affect the respiratory tract such as M41 can occasionally cause kidney damage (Jones, 1974) , nephropathogenicity has been associated only with certain strains.", [["respiratory tract", "ANATOMY", 196, 213], ["kidney", "ANATOMY", 249, 255], ["M41", "CHEMICAL", 222, 225], ["kidney damage", "DISEASE", 249, 262], ["nephropathogenicity", "DISEASE", 279, 298], ["IBV", "ORGANISM", 3, 6], ["serotype D207", "ORGANISM", 28, 41], ["IBV", "ORGANISM", 157, 160], ["respiratory tract", "ORGANISM_SUBDIVISION", 196, 213], ["M41", "GENE_OR_GENE_PRODUCT", 222, 225], ["kidney", "ORGAN", 249, 255], ["IBV", "SPECIES", 3, 6], ["serotype D207", "SPECIES", 28, 41], ["IBV", "SPECIES", 157, 160], ["An IBV isolate", "TREATMENT", 0, 14], ["serotype D207", "TREATMENT", 28, 41], ["an enterotropic variant strain G", "TREATMENT", 70, 102], ["IBV", "PROBLEM", 157, 160], ["the respiratory tract", "PROBLEM", 192, 213], ["kidney damage", "PROBLEM", 249, 262], ["nephropathogenicity", "PROBLEM", 279, 298], ["certain strains", "PROBLEM", 329, 344], ["respiratory tract", "ANATOMY", 196, 213], ["kidney", "ANATOMY", 249, 255], ["damage", "OBSERVATION", 256, 262]]], ["Greater virulence of the virus for the kidney was first reported in Australia (Cumming, 1962) .NEPHRITISSince then, nephropathogenic IBV (NIBV) has been reported from USA and certain parts of Europe (Butcher et al., 1990; Kinde et al., 1991; Lambrechts et al, 1993; Picault et al, 1991; Zanella, 1988) .NEPHRITISNIBV strains initially cause respiratory symptoms followed by signs due to kidney damage which include increased water consumption and wet droppings (Winterfield & Hitchner, 1962; Cumming, 1963) .", [["kidney", "ANATOMY", 39, 45], ["respiratory", "ANATOMY", 341, 352], ["kidney", "ANATOMY", 387, 393], ["respiratory symptoms", "DISEASE", 341, 361], ["kidney damage", "DISEASE", 387, 400], ["kidney", "ORGAN", 39, 45], ["nephropathogenic IBV", "ORGANISM", 116, 136], ["NIBV", "CANCER", 138, 142], ["kidney", "ORGAN", 387, 393], ["IBV", "SPECIES", 133, 136], ["NIBV", "SPECIES", 138, 142], ["nephropathogenic IBV (NIBV", "TREATMENT", 116, 142], ["NEPHRITISNIBV strains", "PROBLEM", 303, 324], ["respiratory symptoms", "PROBLEM", 341, 361], ["kidney damage", "PROBLEM", 387, 400], ["increased water consumption", "PROBLEM", 415, 442], ["virus", "OBSERVATION", 25, 30], ["kidney", "ANATOMY", 39, 45], ["IBV", "OBSERVATION", 133, 136], ["kidney", "ANATOMY", 387, 393], ["damage", "OBSERVATION", 394, 400], ["increased", "OBSERVATION_MODIFIER", 415, 424], ["water consumption", "OBSERVATION", 425, 442]]], ["The first deaths usually occur around 6 days p.i., increase rapidly to a peak around 10 days with the last deaths seen around 16 days p.i.", [["deaths", "DISEASE", 10, 16], ["deaths", "DISEASE", 107, 113]]], ["However, the mortality rates depend on several intrinsic and extrinsic factors (see below).NEPHRITISVirus replication in the kidneys has been shown in the proximal convoluted tubules (Chong and Apostolov, 1982) , distal convoluted and collecting tubules (Owen et al, 1991) and collecting ducts (Chen et al, 1996) .", [["kidneys", "ANATOMY", 125, 132], ["proximal convoluted tubules", "ANATOMY", 155, 182], ["distal convoluted", "ANATOMY", 213, 230], ["collecting tubules", "ANATOMY", 235, 253], ["collecting ducts", "ANATOMY", 277, 293], ["kidneys", "ORGAN", 125, 132], ["convoluted tubules", "TISSUE", 164, 182], ["convoluted", "MULTI-TISSUE_STRUCTURE", 220, 230], ["tubules", "TISSUE", 246, 253], ["ducts", "MULTI-TISSUE_STRUCTURE", 288, 293], ["the mortality rates", "PROBLEM", 9, 28], ["several intrinsic and extrinsic factors", "PROBLEM", 39, 78], ["NEPHRITISVirus replication in the kidneys", "PROBLEM", 91, 132], ["kidneys", "ANATOMY", 125, 132], ["proximal", "ANATOMY_MODIFIER", 155, 163], ["convoluted", "ANATOMY_MODIFIER", 164, 174], ["tubules", "ANATOMY_MODIFIER", 175, 182], ["distal", "ANATOMY_MODIFIER", 213, 219], ["ducts", "ANATOMY", 288, 293]]], ["Structural alterations in the tubular epithelial cells (Condron & Marshall, 1986) caused impaired fluid and electrolyte transport leading to acute renal failure.", [["tubular epithelial cells", "ANATOMY", 30, 54], ["fluid", "ANATOMY", 98, 103], ["renal", "ANATOMY", 147, 152], ["acute renal failure", "DISEASE", 141, 160], ["tubular epithelial cells", "CELL", 30, 54], ["fluid", "ORGANISM_SUBSTANCE", 98, 103], ["electrolyte", "SIMPLE_CHEMICAL", 108, 119], ["renal", "ORGAN", 147, 152], ["tubular epithelial cells", "CELL_TYPE", 30, 54], ["Structural alterations in the tubular epithelial cells", "PROBLEM", 0, 54], ["impaired fluid", "PROBLEM", 89, 103], ["electrolyte transport", "TREATMENT", 108, 129], ["acute renal failure", "PROBLEM", 141, 160], ["tubular", "ANATOMY_MODIFIER", 30, 37], ["epithelial cells", "OBSERVATION", 38, 54], ["impaired", "OBSERVATION_MODIFIER", 89, 97], ["fluid", "OBSERVATION", 98, 103], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["renal", "ANATOMY", 147, 152], ["failure", "OBSERVATION", 153, 160]]], ["An increase in urinary water losses in chickens infected with NIBV was found to be associated with lower urine osmolality and higher rates of urinary excretion of sodium, potassium and calcium (Afanador & Roberts, 1994; Condron & Marshall, 1985; Heath, 1970) .", [["urinary", "ANATOMY", 15, 22], ["urine", "ANATOMY", 105, 110], ["urinary", "ANATOMY", 142, 149], ["NIBV", "CHEMICAL", 62, 66], ["sodium", "CHEMICAL", 163, 169], ["potassium", "CHEMICAL", 171, 180], ["calcium", "CHEMICAL", 185, 192], ["sodium", "CHEMICAL", 163, 169], ["potassium", "CHEMICAL", 171, 180], ["calcium", "CHEMICAL", 185, 192], ["urinary", "ORGANISM_SUBSTANCE", 15, 22], ["chickens", "ORGANISM", 39, 47], ["urine", "ORGANISM_SUBSTANCE", 105, 110], ["urinary", "ORGANISM_SUBSTANCE", 142, 149], ["sodium", "SIMPLE_CHEMICAL", 163, 169], ["potassium", "SIMPLE_CHEMICAL", 171, 180], ["calcium", "SIMPLE_CHEMICAL", 185, 192], ["chickens", "SPECIES", 39, 47], ["chickens", "SPECIES", 39, 47], ["NIBV", "SPECIES", 62, 66], ["An increase in urinary water losses in chickens infected with NIBV", "PROBLEM", 0, 66], ["lower urine osmolality", "PROBLEM", 99, 121], ["urinary excretion", "TEST", 142, 159], ["sodium", "TEST", 163, 169], ["potassium", "TEST", 171, 180], ["calcium", "TEST", 185, 192], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["urinary", "ANATOMY", 15, 22], ["water losses", "OBSERVATION", 23, 35], ["chickens", "OBSERVATION_MODIFIER", 39, 47], ["infected", "OBSERVATION", 48, 56], ["urinary", "ANATOMY", 142, 149]]], ["Negative sodium balance was a direct effect of increased output of sodium in the urine, while negative potassium balance was due to decreased intake.NEPHRITISThe kidneys of chickens infected with NIBV are swollen and pale, with tubules and ureters distended with urates (Cumming, 1963) .", [["urine", "ANATOMY", 81, 86], ["kidneys", "ANATOMY", 162, 169], ["tubules", "ANATOMY", 228, 235], ["ureters", "ANATOMY", 240, 247], ["sodium", "CHEMICAL", 9, 15], ["sodium", "CHEMICAL", 67, 73], ["potassium", "CHEMICAL", 103, 112], ["sodium", "CHEMICAL", 9, 15], ["sodium", "CHEMICAL", 67, 73], ["potassium", "CHEMICAL", 103, 112], ["sodium", "SIMPLE_CHEMICAL", 9, 15], ["sodium", "SIMPLE_CHEMICAL", 67, 73], ["urine", "ORGANISM_SUBSTANCE", 81, 86], ["potassium", "SIMPLE_CHEMICAL", 103, 112], ["kidneys", "ORGAN", 162, 169], ["chickens", "ORGANISM", 173, 181], ["tubules", "TISSUE", 228, 235], ["ureters", "ORGAN", 240, 247], ["chickens", "SPECIES", 173, 181], ["chickens", "SPECIES", 173, 181], ["NIBV", "SPECIES", 196, 200], ["sodium balance", "PROBLEM", 9, 23], ["increased output of sodium in the urine", "PROBLEM", 47, 86], ["potassium balance", "TEST", 103, 120], ["decreased intake", "PROBLEM", 132, 148], ["swollen", "PROBLEM", 205, 212], ["pale", "PROBLEM", 217, 221], ["tubules and ureters distended", "PROBLEM", 228, 257], ["sodium balance", "OBSERVATION", 9, 23], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["output", "OBSERVATION_MODIFIER", 57, 63], ["kidneys", "ANATOMY", 162, 169], ["chickens", "OBSERVATION_MODIFIER", 173, 181], ["infected", "OBSERVATION", 182, 190], ["swollen", "OBSERVATION", 205, 212], ["pale", "OBSERVATION", 217, 221], ["ureters", "ANATOMY", 240, 247], ["distended", "OBSERVATION", 248, 257]]], ["The relative kidney weight and kidney asymmetry are increased.", [["kidney", "ANATOMY", 13, 19], ["kidney", "ANATOMY", 31, 37], ["kidney", "ORGAN", 13, 19], ["kidney", "ORGAN", 31, 37], ["kidney asymmetry", "PROBLEM", 31, 47], ["kidney", "ANATOMY", 13, 19], ["weight", "OBSERVATION", 20, 26], ["kidney", "ANATOMY", 31, 37], ["asymmetry", "OBSERVATION", 38, 47], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["The haematocrit values of infected birds was decreased and plasma uric acid levels were increased (Afanador & Roberts, 1994) .", [["plasma", "ANATOMY", 59, 65], ["uric acid", "CHEMICAL", 66, 75], ["uric acid", "CHEMICAL", 66, 75], ["birds", "ORGANISM", 35, 40], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["uric acid", "SIMPLE_CHEMICAL", 66, 75], ["The haematocrit values", "TEST", 0, 22], ["infected birds", "PROBLEM", 26, 40], ["plasma uric acid levels", "TEST", 59, 82], ["infected", "OBSERVATION_MODIFIER", 26, 34], ["birds", "OBSERVATION_MODIFIER", 35, 40]]], ["Despite lack of gross lesions microscopic changes of nephritis may still be present (Winterfield & Albassam, 1984) .", [["gross lesions", "ANATOMY", 16, 29], ["nephritis", "DISEASE", 53, 62], ["gross lesions", "PATHOLOGICAL_FORMATION", 16, 29], ["gross lesions microscopic changes of nephritis", "PROBLEM", 16, 62], ["gross", "OBSERVATION_MODIFIER", 16, 21], ["lesions", "OBSERVATION", 22, 29], ["nephritis", "OBSERVATION", 53, 62], ["may still be", "UNCERTAINTY", 63, 75]]], ["Chen et al., (1996) proposed that IBV-induced renal lesions can be considered to be a ductotubular interstitial nephritis.", [["renal lesions", "ANATOMY", 46, 59], ["ductotubular interstitial", "ANATOMY", 86, 111], ["renal lesions", "DISEASE", 46, 59], ["interstitial nephritis", "DISEASE", 99, 121], ["IBV", "ORGANISM", 34, 37], ["renal lesions", "PATHOLOGICAL_FORMATION", 46, 59], ["IBV", "SPECIES", 34, 37], ["IBV", "PROBLEM", 34, 37], ["renal lesions", "PROBLEM", 46, 59], ["a ductotubular interstitial nephritis", "PROBLEM", 84, 121], ["IBV", "OBSERVATION", 34, 37], ["renal", "ANATOMY", 46, 51], ["lesions", "OBSERVATION", 52, 59], ["ductotubular", "OBSERVATION_MODIFIER", 86, 98], ["interstitial", "ANATOMY_MODIFIER", 99, 111], ["nephritis", "OBSERVATION", 112, 121]]], ["The virus causes granular degeneration, vacuolation and desquamation of the tubular epithelium with massive infiltration of heterophils in the interstitium in acute stages of the disease.", [["tubular epithelium", "ANATOMY", 76, 94], ["heterophils", "ANATOMY", 124, 135], ["interstitium", "ANATOMY", 143, 155], ["tubular epithelium", "TISSUE", 76, 94], ["heterophils", "CELL", 124, 135], ["interstitium", "TISSUE", 143, 155], ["heterophils", "CELL_TYPE", 124, 135], ["The virus", "PROBLEM", 0, 9], ["granular degeneration", "PROBLEM", 17, 38], ["vacuolation", "PROBLEM", 40, 51], ["desquamation of the tubular epithelium", "PROBLEM", 56, 94], ["massive infiltration of heterophils", "PROBLEM", 100, 135], ["the disease", "PROBLEM", 175, 186], ["virus", "OBSERVATION", 4, 9], ["granular degeneration", "OBSERVATION", 17, 38], ["vacuolation", "OBSERVATION_MODIFIER", 40, 51], ["desquamation", "OBSERVATION_MODIFIER", 56, 68], ["tubular", "ANATOMY_MODIFIER", 76, 83], ["epithelium", "ANATOMY_MODIFIER", 84, 94], ["massive", "OBSERVATION_MODIFIER", 100, 107], ["infiltration", "OBSERVATION", 108, 120], ["heterophils", "OBSERVATION", 124, 135], ["interstitium", "ANATOMY", 143, 155], ["acute", "OBSERVATION_MODIFIER", 159, 164], ["stages", "OBSERVATION_MODIFIER", 165, 171], ["disease", "OBSERVATION", 179, 186]]], ["The changes in the chronic phase were classified as being active or inactive types of interstitial lymphocytic nephritis (Albassam et al., 1986) .", [["interstitial lymphocytic", "ANATOMY", 86, 110], ["interstitial lymphocytic nephritis", "DISEASE", 86, 120], ["The changes in the chronic phase", "PROBLEM", 0, 32], ["interstitial lymphocytic nephritis", "PROBLEM", 86, 120], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["active", "OBSERVATION_MODIFIER", 58, 64], ["inactive", "OBSERVATION_MODIFIER", 68, 76], ["interstitial", "OBSERVATION_MODIFIER", 86, 98], ["lymphocytic nephritis", "OBSERVATION", 99, 120]]], ["The chronic inactive form of nephritis was indicative of IBV replication in the kidneys and subsequent clearance; while the chronic active type suggested a persistent viral replication and damage to epithelial cells of the kidney tubules.", [["kidneys", "ANATOMY", 80, 87], ["epithelial cells", "ANATOMY", 199, 215], ["kidney tubules", "ANATOMY", 223, 237], ["nephritis", "DISEASE", 29, 38], ["IBV", "ORGANISM", 57, 60], ["kidneys", "ORGAN", 80, 87], ["epithelial cells", "CELL", 199, 215], ["kidney tubules", "MULTI-TISSUE_STRUCTURE", 223, 237], ["epithelial cells", "CELL_TYPE", 199, 215], ["IBV", "SPECIES", 57, 60], ["The chronic inactive form of nephritis", "PROBLEM", 0, 38], ["IBV replication in the kidneys", "PROBLEM", 57, 87], ["the chronic active type", "PROBLEM", 120, 143], ["a persistent viral replication", "PROBLEM", 154, 184], ["damage to epithelial cells of the kidney tubules", "PROBLEM", 189, 237], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["inactive", "OBSERVATION", 12, 20], ["nephritis", "OBSERVATION", 29, 38], ["indicative of", "UNCERTAINTY", 43, 56], ["IBV replication", "OBSERVATION", 57, 72], ["kidneys", "ANATOMY", 80, 87], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["active", "OBSERVATION_MODIFIER", 132, 138], ["persistent", "OBSERVATION_MODIFIER", 156, 166], ["viral replication", "OBSERVATION", 167, 184], ["epithelial cells", "OBSERVATION", 199, 215], ["kidney", "ANATOMY", 223, 229], ["tubules", "ANATOMY_MODIFIER", 230, 237]]], ["Virus was isolated from 50% of the birds with chronic nephritis (Chong & Apostolov, 1982) .", [["chronic nephritis", "DISEASE", 46, 63], ["Virus", "ORGANISM", 0, 5], ["birds", "ORGANISM", 35, 40], ["Virus", "PROBLEM", 0, 5], ["chronic nephritis", "PROBLEM", 46, 63], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["nephritis", "OBSERVATION", 54, 63]]], ["The histopathological changes in the kidneys following NIBV infections have been described by several workers (Albassam et al., 1986; Chen et al., 1996; Pohl, 1974; Purcell et al, 1976; Siller & Cumming, 1974) .Variation between strainsThe type of kidney lesions produced by different NIBV strains were similar but their severity varied (Albassam et al., 1986; Chandra, 1987) .", [["kidneys", "ANATOMY", 37, 44], ["kidney lesions", "ANATOMY", 248, 262], ["infections", "DISEASE", 60, 70], ["kidney lesions", "DISEASE", 248, 262], ["kidneys", "ORGAN", 37, 44], ["kidney", "ORGAN", 248, 254], ["lesions", "PATHOLOGICAL_FORMATION", 255, 262], ["NIBV", "SPECIES", 55, 59], ["The histopathological changes in the kidneys", "PROBLEM", 0, 44], ["NIBV infections", "PROBLEM", 55, 70], ["Variation between strains", "PROBLEM", 211, 236], ["kidney lesions", "PROBLEM", 248, 262], ["different NIBV strains", "PROBLEM", 275, 297], ["histopathological", "OBSERVATION", 4, 21], ["kidneys", "ANATOMY", 37, 44], ["infections", "OBSERVATION", 60, 70], ["kidney", "ANATOMY", 248, 254], ["lesions", "OBSERVATION", 255, 262], ["different", "OBSERVATION_MODIFIER", 275, 284], ["NIBV strains", "OBSERVATION", 285, 297]]], ["The Australian strain 'T' induced the most rapid and severe lesions following both intra-venous (i.v.)", [["lesions", "ANATOMY", 60, 67], ["T'", "CELL", 23, 25], ["lesions", "PATHOLOGICAL_FORMATION", 60, 67], ["the most rapid and severe lesions", "PROBLEM", 34, 67], ["most", "OBSERVATION_MODIFIER", 38, 42], ["rapid", "OBSERVATION_MODIFIER", 43, 48], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["lesions", "OBSERVATION", 60, 67]]], ["(Chandra, 1987) or intra-ocular (Albassam et al, 1986) inoculations of susceptible chickens.", [["intra-ocular", "ANATOMY", 19, 31], ["chickens", "ORGANISM", 83, 91], ["chickens", "SPECIES", 83, 91], ["chickens", "SPECIES", 83, 91], ["intra-ocular (Albassam et al", "TREATMENT", 19, 47], ["susceptible chickens", "PROBLEM", 71, 91], ["intra-ocular", "ANATOMY", 19, 31], ["susceptible chickens", "OBSERVATION", 71, 91]]], ["The effect of IBV on the trachea is apparently independent of the effect on kidney (Ratanasethakul & Cumming, 1983) .", [["trachea", "ANATOMY", 25, 32], ["kidney", "ANATOMY", 76, 82], ["IBV", "ORGANISM", 14, 17], ["trachea", "MULTI-TISSUE_STRUCTURE", 25, 32], ["kidney", "ORGAN", 76, 82], ["IBV", "SPECIES", 14, 17], ["IBV", "PROBLEM", 14, 17], ["IBV", "OBSERVATION", 14, 17], ["trachea", "ANATOMY", 25, 32], ["kidney", "ANATOMY", 76, 82]]], ["A strain of NIBV, 'S' virus was less severe on the kidneys than 'T', but more severe on the tracheal mucosa.", [["kidneys", "ANATOMY", 51, 58], ["tracheal mucosa", "ANATOMY", 92, 107], ["NIBV", "GENE_OR_GENE_PRODUCT", 12, 16], ["'S' virus", "ORGANISM", 18, 27], ["kidneys", "ORGAN", 51, 58], ["T'", "CELL", 65, 67], ["tracheal mucosa", "MULTI-TISSUE_STRUCTURE", 92, 107], ["NIBV", "SPECIES", 12, 16], ["S' virus", "SPECIES", 19, 27], ["A strain of NIBV", "PROBLEM", 0, 16], ["'S' virus", "PROBLEM", 18, 27], ["less", "OBSERVATION_MODIFIER", 32, 36], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["kidneys", "ANATOMY", 51, 58], ["more", "OBSERVATION_MODIFIER", 73, 77], ["severe", "OBSERVATION", 78, 84], ["tracheal mucosa", "ANATOMY", 92, 107]]], ["Using an i.v. inoculation model to titrate kidney infectivity, Lambrechts et al. (1991) found no significant differences in the infectivity among Belgian field NIBV isolates, but the infectivity of egg-passaged virus was highly reduced.VIRUS IN THE INTESTINESeveral strains of IBV have been isolated from cloacal swabs, faeces and caecal tonsils Alexander et al, 1978; Cook, 1984; Lucio & Fabricant, 1990) .", [["kidney", "ANATOMY", 43, 49], ["cloacal swabs", "ANATOMY", 305, 318], ["faeces", "ANATOMY", 320, 326], ["kidney infectivity", "DISEASE", 43, 61], ["kidney", "ORGAN", 43, 49], ["egg", "ORGANISM", 198, 201], ["IBV", "ORGANISM", 277, 280], ["cloacal swabs", "MULTI-TISSUE_STRUCTURE", 305, 318], ["faeces", "ORGANISM_SUBSTANCE", 320, 326], ["Belgian field NIBV", "SPECIES", 146, 164], ["IBV", "SPECIES", 277, 280], ["an i.v. inoculation model", "TREATMENT", 6, 31], ["significant differences", "PROBLEM", 97, 120], ["the infectivity", "PROBLEM", 124, 139], ["Belgian field NIBV isolates", "TEST", 146, 173], ["the infectivity of egg", "PROBLEM", 179, 201], ["passaged virus", "PROBLEM", 202, 216], ["VIRUS", "PROBLEM", 236, 241], ["IBV", "PROBLEM", 277, 280], ["cloacal swabs", "TEST", 305, 318], ["kidney", "ANATOMY", 43, 49], ["no", "UNCERTAINTY", 94, 96], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["reduced", "OBSERVATION_MODIFIER", 228, 235], ["caecal tonsils", "ANATOMY", 331, 345]]], ["In vitro explants of several gut tissues have been shown to support the growth of IBV (Bhattacharjee, 1994; Bhattacharjee & Jones, 1997; Darbyshire et al, 1976) .", [["explants", "ANATOMY", 9, 17], ["gut tissues", "ANATOMY", 29, 40], ["gut tissues", "TISSUE", 29, 40], ["IBV", "ORGANISM", 82, 85], ["IBV", "SPECIES", 82, 85], ["gut tissues", "ANATOMY", 29, 40]]], ["In studies where virus isolation was attempted from several tissues, maximum virus isolations were obtained from the oesophagus of chickens infected with ECV2, an enteric isolate of IBV (Lucio & Fabricant, 1990) and 793/B-like virus (Dhinakar Raj & Jones, 1996a) .", [["tissues", "ANATOMY", 60, 67], ["oesophagus", "ANATOMY", 117, 127], ["tissues", "TISSUE", 60, 67], ["oesophagus", "ORGAN", 117, 127], ["chickens", "ORGANISM", 131, 139], ["ECV2", "GENE_OR_GENE_PRODUCT", 154, 158], ["IBV", "ORGANISM", 182, 185], ["793/B-like virus", "ORGANISM", 216, 232], ["chickens", "SPECIES", 131, 139], ["chickens", "SPECIES", 131, 139], ["ECV2", "SPECIES", 154, 158], ["IBV", "SPECIES", 182, 185], ["Lucio & Fabricant, 1990) and 793/B-like virus (Dhinakar Raj & Jones, 1996a)", "SPECIES", 187, 262], ["virus isolation", "TREATMENT", 17, 32], ["maximum virus isolations", "PROBLEM", 69, 93], ["ECV2", "TREATMENT", 154, 158], ["IBV", "PROBLEM", 182, 185], ["oesophagus", "ANATOMY", 117, 127]]], ["Oesophageal swabs have also been used to identify IBV using the polymerase chain reaction (D. Cavanagh, personal communication).", [["Oesophageal swabs", "ANATOMY", 0, 17], ["Oesophageal swabs", "PATHOLOGICAL_FORMATION", 0, 17], ["IBV", "ORGANISM", 50, 53], ["IBV", "SPECIES", 50, 53], ["Oesophageal swabs", "TREATMENT", 0, 17], ["IBV", "PROBLEM", 50, 53], ["the polymerase chain reaction", "PROBLEM", 60, 89]]], ["However, it is not clear whether the virus actually multiplies in the oesophagus or whether virus is swallowed after being expelled from the trachea.", [["oesophagus", "ANATOMY", 70, 80], ["trachea", "ANATOMY", 141, 148], ["oesophagus", "ORGAN", 70, 80], ["trachea", "ORGAN", 141, 148], ["the virus", "PROBLEM", 33, 42], ["virus", "PROBLEM", 92, 97], ["virus", "OBSERVATION", 37, 42], ["oesophagus", "ANATOMY", 70, 80], ["virus", "OBSERVATION", 92, 97], ["trachea", "ANATOMY", 141, 148]]], ["IBV has also been isolated from proventriculus, duodenum and jejunum (Ambali & Jones, 1990; Lucio & Fabricant, 1990) .", [["proventriculus", "ANATOMY", 32, 46], ["duodenum", "ANATOMY", 48, 56], ["jejunum", "ANATOMY", 61, 68], ["IBV", "ORGANISM", 0, 3], ["proventriculus", "ORGAN", 32, 46], ["duodenum", "ORGAN", 48, 56], ["jejunum", "ORGAN", 61, 68], ["IBV", "SPECIES", 0, 3], ["IBV", "TREATMENT", 0, 3], ["proventriculus", "ANATOMY", 32, 46], ["duodenum", "ANATOMY", 48, 56], ["jejunum", "ANATOMY", 61, 68]]], ["Darbyshire et al, (1976) have shown that proventriculus was inferior only to respiratory tissues and oviduct in supporting virus multiplication in vitro.", [["proventriculus", "ANATOMY", 41, 55], ["respiratory tissues", "ANATOMY", 77, 96], ["oviduct", "ANATOMY", 101, 108], ["proventriculus", "ORGAN", 41, 55], ["respiratory tissues", "TISSUE", 77, 96], ["oviduct", "ORGAN", 101, 108], ["respiratory tissues", "PROBLEM", 77, 96], ["proventriculus", "ANATOMY", 41, 55], ["respiratory tissues", "ANATOMY", 77, 96]]], ["However, the site of virus multiplication in these tissues has not been confirmed, but presumably occurs in the epithelial cells.VIRUS IN THE INTESTINEIn contrast, in the tissues of the lower gut, IBV replication has been described (without photographs) in cells resembling histiocytes and lymphoid cells in the caecal tonsils (Owen et al, 1991) and demonstrated by IF in apical epithelial cells of the villi in ileum and rectum (Ambali & Jones, 1990; Dhinakar Raj & Jones, 1996a) .", [["tissues", "ANATOMY", 51, 58], ["epithelial cells", "ANATOMY", 112, 128], ["tissues", "ANATOMY", 171, 178], ["lower gut", "ANATOMY", 186, 195], ["cells", "ANATOMY", 257, 262], ["histiocytes", "ANATOMY", 274, 285], ["lymphoid cells", "ANATOMY", 290, 304], ["caecal tonsils", "ANATOMY", 312, 326], ["apical epithelial cells", "ANATOMY", 372, 395], ["villi", "ANATOMY", 403, 408], ["ileum", "ANATOMY", 412, 417], ["rectum", "ANATOMY", 422, 428], ["tissues", "TISSUE", 51, 58], ["epithelial cells", "CELL", 112, 128], ["tissues", "TISSUE", 171, 178], ["lower gut", "ORGAN", 186, 195], ["IBV", "ORGANISM", 197, 200], ["cells", "CELL", 257, 262], ["histiocytes", "CELL", 274, 285], ["lymphoid cells", "CELL", 290, 304], ["caecal tonsils", "MULTI-TISSUE_STRUCTURE", 312, 326], ["IF", "GENE_OR_GENE_PRODUCT", 366, 368], ["apical epithelial cells", "CELL", 372, 395], ["villi", "MULTI-TISSUE_STRUCTURE", 403, 408], ["ileum", "MULTI-TISSUE_STRUCTURE", 412, 417], ["rectum", "ORGAN", 422, 428], ["epithelial cells", "CELL_TYPE", 112, 128], ["histiocytes and lymphoid cells", "CELL_TYPE", 274, 304], ["IF", "PROTEIN", 366, 368], ["apical epithelial cells", "CELL_TYPE", 372, 395], ["IBV", "SPECIES", 197, 200], ["virus multiplication", "PROBLEM", 21, 41], ["VIRUS IN THE INTESTINEIn contrast", "TEST", 129, 162], ["IBV replication", "TREATMENT", 197, 212], ["histiocytes", "PROBLEM", 274, 285], ["lymphoid cells in the caecal tonsils", "PROBLEM", 290, 326], ["virus multiplication", "OBSERVATION", 21, 41], ["epithelial cells", "OBSERVATION", 112, 128], ["tissues", "ANATOMY_MODIFIER", 171, 178], ["lower", "ANATOMY_MODIFIER", 186, 191], ["gut", "ANATOMY", 192, 195], ["IBV replication", "OBSERVATION", 197, 212], ["histiocytes", "OBSERVATION", 274, 285], ["lymphoid cells", "OBSERVATION", 290, 304], ["caecal tonsils", "ANATOMY", 312, 326], ["apical", "ANATOMY_MODIFIER", 372, 378], ["epithelial cells", "OBSERVATION", 379, 395], ["villi", "ANATOMY", 403, 408], ["ileum", "ANATOMY", 412, 417], ["rectum", "ANATOMY", 422, 428]]], ["Although IBV has a wide tropism for gut tissues no gross or histological changes have been reported.VIRUS IN THE INTESTINEA variant strain of IBV, strain G, was classified as being enterotropic by virtue of its prolonged persistence in the gut compared to the trachea (El Houadfi et al, 1986) .", [["gut tissues", "ANATOMY", 36, 47], ["gut", "ANATOMY", 240, 243], ["trachea", "ANATOMY", 260, 267], ["IBV", "ORGANISM", 9, 12], ["gut tissues", "TISSUE", 36, 47], ["IBV", "ORGANISM", 142, 145], ["strain G", "ORGANISM", 147, 155], ["gut", "ORGANISM_SUBDIVISION", 240, 243], ["trachea", "ORGAN", 260, 267], ["IBV", "SPECIES", 9, 12], ["IBV", "SPECIES", 142, 145], ["IBV", "PROBLEM", 9, 12], ["a wide tropism", "PROBLEM", 17, 31], ["gut tissues", "PROBLEM", 36, 47], ["gross or histological changes", "PROBLEM", 51, 80], ["IBV", "PROBLEM", 142, 145], ["wide tropism", "OBSERVATION_MODIFIER", 19, 31], ["gross", "OBSERVATION_MODIFIER", 51, 56], ["histological", "OBSERVATION", 60, 72], ["IBV", "OBSERVATION", 142, 145], ["prolonged", "OBSERVATION_MODIFIER", 211, 220], ["persistence", "OBSERVATION", 221, 232], ["gut", "ANATOMY", 240, 243], ["trachea", "ANATOMY", 260, 267]]], ["Recently, it was seen that a variant IBV strain 793/B was more enterotropic than pneumotropic and was even associated with diarrhoea in broilers (Dhinakar Raj & Jones, 1996a) .", [["diarrhoea", "DISEASE", 123, 132], ["IBV strain 793/B", "ORGANISM", 37, 53], ["broilers", "ORGANISM_SUBDIVISION", 136, 144], ["broilers", "SPECIES", 136, 144], ["IBV strain 793/B", "SPECIES", 37, 53], ["broilers", "SPECIES", 136, 144], ["a variant IBV strain", "PROBLEM", 27, 47], ["diarrhoea", "PROBLEM", 123, 132]]], ["It seems that studies on the replication of IBV in the gut have been neglected, probably because no IBV strain has been demonstrated to be enteropathogenic.", [["gut", "ANATOMY", 55, 58], ["IBV", "ORGANISM", 44, 47], ["gut", "ORGAN", 55, 58], ["IBV", "ORGANISM", 100, 103], ["IBV", "SPECIES", 44, 47], ["IBV", "SPECIES", 100, 103], ["IBV", "TREATMENT", 44, 47], ["IBV strain", "PROBLEM", 100, 110], ["enteropathogenic", "PROBLEM", 139, 155], ["enteropathogenic", "OBSERVATION", 139, 155]]], ["MacDonald et al. (1983) reported that following crop inoculation of chicks with H52 and H120 vaccines, virus was rarely isolated from the gut or any other visceral tissues and no antibody response occurred.", [["gut", "ANATOMY", 138, 141], ["visceral tissues", "ANATOMY", 155, 171], ["H52", "CHEMICAL", 80, 83], ["H120", "CHEMICAL", 88, 92], ["chicks", "ORGANISM", 68, 74], ["gut", "ORGANISM_SUBDIVISION", 138, 141], ["visceral tissues", "TISSUE", 155, 171], ["chicks", "SPECIES", 68, 74], ["H52", "SPECIES", 80, 83], ["H52", "TREATMENT", 80, 83], ["H120 vaccines", "TREATMENT", 88, 101], ["virus", "PROBLEM", 103, 108], ["antibody response", "PROBLEM", 179, 196], ["gut", "ANATOMY", 138, 141], ["visceral tissues", "ANATOMY", 155, 171], ["no", "UNCERTAINTY", 176, 178], ["antibody response", "OBSERVATION", 179, 196]]], ["However, the kidneys were found to be resistant to i.v. challenge.", [["kidneys", "ANATOMY", 13, 20], ["kidneys", "ORGAN", 13, 20], ["i.v. challenge", "TEST", 51, 65], ["kidneys", "ANATOMY", 13, 20], ["resistant", "OBSERVATION", 38, 47]]], ["More intensive studies on oral infection with enterotropic IBV strains or dual infections with the virus and other enteric pathogens, such as salmonella, coccidia or rotavirus, might yield more information on the effects of IBV replication in the gut.VIRUS IN THE INTESTINEThe ability of IBV strains to survive in the presence of low pH, digestive enzymes and bile salts may be relevant to enteric replication.", [["oral", "ANATOMY", 26, 30], ["gut", "ANATOMY", 247, 250], ["bile", "ANATOMY", 360, 364], ["infection", "DISEASE", 31, 40], ["infections", "DISEASE", 79, 89], ["enteric pathogens", "DISEASE", 115, 132], ["salmonella", "DISEASE", 142, 152], ["coccidia", "DISEASE", 154, 162], ["bile salts", "CHEMICAL", 360, 370], ["bile salts", "CHEMICAL", 360, 370], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["enterotropic IBV", "ORGANISM", 46, 62], ["IBV", "ORGANISM", 224, 227], ["gut", "ORGANISM_SUBDIVISION", 247, 250], ["IBV", "ORGANISM", 288, 291], ["bile salts", "SIMPLE_CHEMICAL", 360, 370], ["digestive enzymes", "PROTEIN", 338, 355], ["IBV", "SPECIES", 59, 62], ["rotavirus", "SPECIES", 166, 175], ["IBV", "SPECIES", 224, 227], ["IBV", "SPECIES", 288, 291], ["intensive studies", "TEST", 5, 22], ["oral infection", "PROBLEM", 26, 40], ["enterotropic IBV strains", "TREATMENT", 46, 70], ["dual infections", "PROBLEM", 74, 89], ["the virus", "PROBLEM", 95, 104], ["other enteric pathogens", "PROBLEM", 109, 132], ["salmonella", "PROBLEM", 142, 152], ["coccidia", "PROBLEM", 154, 162], ["rotavirus", "PROBLEM", 166, 175], ["IBV replication", "TREATMENT", 224, 239], ["IBV strains", "PROBLEM", 288, 299], ["low pH", "PROBLEM", 330, 336], ["digestive enzymes", "TEST", 338, 355], ["bile salts", "TREATMENT", 360, 370], ["enteric replication", "TREATMENT", 390, 409], ["enteric", "ANATOMY", 115, 122], ["pathogens", "OBSERVATION", 123, 132], ["IBV replication", "OBSERVATION", 224, 239], ["gut", "ANATOMY", 247, 250], ["IBV strains", "OBSERVATION", 288, 299], ["low pH", "OBSERVATION", 330, 336], ["bile", "ANATOMY", 360, 364]]], ["Otsuki et al (1979a) and Cowen & Hitchner (1975) showed that some strains suffer a greater loss of titre than others when kept at pH 3.0 for 3 or 4 h, but there was no indication that any of the more resistant strains were isolated from the gut.", [["gut", "ANATOMY", 241, 244], ["loss of titre", "DISEASE", 91, 104], ["gut", "ORGANISM_SUBDIVISION", 241, 244], ["some strains", "PROBLEM", 61, 73], ["a greater loss of titre", "PROBLEM", 81, 104], ["pH", "TEST", 130, 132], ["the more resistant strains", "PROBLEM", 191, 217], ["greater", "OBSERVATION_MODIFIER", 83, 90], ["loss", "OBSERVATION_MODIFIER", 91, 95], ["no indication", "UNCERTAINTY", 165, 178], ["gut", "ANATOMY", 241, 244]]], ["Ambali & Jones (1991a) compared strain M41 with an enterotropic variant (G).", [["Jones", "ANATOMY", 9, 14]]], ["Both viruses had a similar sensitivity to trypsin, but the variant showed a 50-fold greater resistance to sodium tauroglycocholate, which might partly explain its ability to replicate in the gut.PECTORAL MYOPATHYThe important variant strain of IBV, 793/B, was recently isolated from a broiler breeder flock where the affected birds had bilateral myopathy affecting both deep and superficial pectoral muscles (Gough et al, 1992) .", [["gut", "ANATOMY", 191, 194], ["superficial pectoral muscles", "ANATOMY", 379, 407], ["sodium tauroglycocholate", "CHEMICAL", 106, 130], ["myopathy", "DISEASE", 346, 354], ["sodium tauroglycocholate", "CHEMICAL", 106, 130], ["trypsin", "GENE_OR_GENE_PRODUCT", 42, 49], ["sodium tauroglycocholate", "SIMPLE_CHEMICAL", 106, 130], ["gut", "ORGANISM_SUBDIVISION", 191, 194], ["IBV", "ORGANISM", 244, 247], ["793/B", "CANCER", 249, 254], ["birds", "ORGANISM", 326, 331], ["superficial pectoral muscles", "TISSUE", 379, 407], ["trypsin", "PROTEIN", 42, 49], ["IBV", "SPECIES", 244, 247], ["trypsin", "TEST", 42, 49], ["the variant", "TEST", 55, 66], ["IBV", "PROBLEM", 244, 247], ["a broiler breeder flock", "TREATMENT", 283, 306], ["bilateral myopathy", "PROBLEM", 336, 354], ["viruses", "OBSERVATION", 5, 12], ["gut", "ANATOMY", 191, 194], ["breeder flock", "OBSERVATION", 293, 306], ["bilateral", "ANATOMY_MODIFIER", 336, 345], ["myopathy", "OBSERVATION", 346, 354], ["both", "ANATOMY_MODIFIER", 365, 369], ["deep", "ANATOMY_MODIFIER", 370, 374], ["superficial", "ANATOMY_MODIFIER", 379, 390], ["pectoral muscles", "ANATOMY", 391, 407]]], ["There was marked swelling and pallor of deep pectoral muscles together with the presence of occasional fascial haemorrhages and a layer of gelatinous oedema over its surface.", [["pectoral muscles", "ANATOMY", 45, 61], ["fascial", "ANATOMY", 103, 110], ["surface", "ANATOMY", 166, 173], ["swelling", "DISEASE", 17, 25], ["haemorrhages", "DISEASE", 111, 123], ["oedema", "DISEASE", 150, 156], ["pectoral muscles", "ORGAN", 45, 61], ["fascial haemorrhages", "PATHOLOGICAL_FORMATION", 103, 123], ["surface", "CELLULAR_COMPONENT", 166, 173], ["marked swelling", "PROBLEM", 10, 25], ["pallor of deep pectoral muscles", "PROBLEM", 30, 61], ["occasional fascial haemorrhages", "PROBLEM", 92, 123], ["gelatinous oedema", "PROBLEM", 139, 156], ["marked", "OBSERVATION_MODIFIER", 10, 16], ["swelling", "OBSERVATION", 17, 25], ["pallor", "OBSERVATION", 30, 36], ["deep", "ANATOMY_MODIFIER", 40, 44], ["pectoral muscles", "ANATOMY", 45, 61], ["occasional", "OBSERVATION_MODIFIER", 92, 102], ["fascial", "ANATOMY", 103, 110], ["haemorrhages", "OBSERVATION", 111, 123], ["layer", "OBSERVATION_MODIFIER", 130, 135], ["gelatinous", "OBSERVATION_MODIFIER", 139, 149], ["oedema", "OBSERVATION", 150, 156], ["surface", "OBSERVATION_MODIFIER", 166, 173]]], ["Experimental infection of 6 week old broilers with an isolate of IBV belonging to this group resulted in mild oedematous separation of muscle fibres but with no corresponding increase in serum creatine kinase concentrations (Dhinakar Raj & Jones, 1996a ).", [["muscle fibres", "ANATOMY", 135, 148], ["serum", "ANATOMY", 187, 192], ["infection", "DISEASE", 13, 22], ["creatine", "CHEMICAL", 193, 201], ["creatine", "CHEMICAL", 193, 201], ["broilers", "ORGANISM", 37, 45], ["IBV", "ORGANISM", 65, 68], ["muscle fibres", "TISSUE", 135, 148], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["creatine", "SIMPLE_CHEMICAL", 193, 201], ["serum creatine kinase", "PROTEIN", 187, 208], ["broilers", "SPECIES", 37, 45], ["IBV", "SPECIES", 65, 68], ["Experimental infection", "PROBLEM", 0, 22], ["IBV", "PROBLEM", 65, 68], ["mild oedematous separation of muscle fibres", "PROBLEM", 105, 148], ["corresponding increase in serum creatine kinase concentrations", "PROBLEM", 161, 223], ["infection", "OBSERVATION", 13, 22], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["oedematous", "OBSERVATION", 110, 120], ["muscle fibres", "ANATOMY", 135, 148], ["no", "UNCERTAINTY", 158, 160], ["increase", "OBSERVATION_MODIFIER", 175, 183]]], ["It has been clearly shown that the virus was not involved directly in the pathogenesis of the muscle lesions but formation and deposition of immune complexes, such as those found in the kidneys (Dhinakar Raj & Jones, 1996a) , in the capillary walls of the muscle could be a possible reason for the development of this strange lesion.VIRUS IN OTHER TISSUESIBV has been isolated from the Harderian gland (Dhinakar Raj & Jones, 1996a; Gelb et al, 1991b; Toro et al., 1996a) and IBV-positive cells have been shown in the stroma of the gland by IF staining (Toro et al, 1996a) .", [["muscle lesions", "ANATOMY", 94, 108], ["kidneys", "ANATOMY", 186, 193], ["capillary walls", "ANATOMY", 233, 248], ["muscle", "ANATOMY", 256, 262], ["lesion", "ANATOMY", 326, 332], ["Harderian gland", "ANATOMY", 386, 401], ["cells", "ANATOMY", 488, 493], ["stroma", "ANATOMY", 517, 523], ["gland", "ANATOMY", 531, 536], ["muscle lesions", "DISEASE", 94, 108], ["muscle lesions", "PATHOLOGICAL_FORMATION", 94, 108], ["kidneys", "ORGAN", 186, 193], ["capillary walls", "TISSUE", 233, 248], ["muscle", "ORGAN", 256, 262], ["Harderian gland", "ORGAN", 386, 401], ["IBV", "ORGANISM", 475, 478], ["cells", "CELL", 488, 493], ["stroma", "TISSUE", 517, 523], ["gland", "ORGAN", 531, 536], ["IF", "GENE_OR_GENE_PRODUCT", 540, 542], ["immune complexes", "PROTEIN", 141, 157], ["IBV-positive cells", "CELL_LINE", 475, 493], ["the virus", "PROBLEM", 31, 40], ["the muscle lesions", "PROBLEM", 90, 108], ["deposition of immune complexes", "PROBLEM", 127, 157], ["this strange lesion", "PROBLEM", 313, 332], ["Toro et al.", "TEST", 451, 462], ["IBV", "TEST", 475, 478], ["positive cells", "PROBLEM", 479, 493], ["virus", "OBSERVATION", 35, 40], ["muscle", "ANATOMY", 94, 100], ["lesions", "OBSERVATION", 101, 108], ["deposition", "OBSERVATION_MODIFIER", 127, 137], ["immune complexes", "OBSERVATION", 141, 157], ["kidneys", "ANATOMY", 186, 193], ["capillary", "ANATOMY_MODIFIER", 233, 242], ["walls", "ANATOMY_MODIFIER", 243, 248], ["muscle", "ANATOMY", 256, 262], ["lesion", "OBSERVATION", 326, 332], ["Harderian gland", "ANATOMY", 386, 401], ["positive cells", "OBSERVATION", 479, 493], ["gland", "ANATOMY", 531, 536]]], ["IBV vaccination by eyedrop resulted in a massive infiltration of lymphocytes, increase in plasma cell numbers (Davelaar & Kouwenhoven, 1976; Survashe et al, 1979; Montgomery et al, 1994; Toro et al, 1996a) and desquamation of tubular epithelium in the Harderian gland with restoration from 14 days after vaccination (Toro et al, 1996a) .", [["lymphocytes", "ANATOMY", 65, 76], ["plasma cell", "ANATOMY", 90, 101], ["tubular epithelium", "ANATOMY", 226, 244], ["Harderian gland", "ANATOMY", 252, 267], ["IBV", "ORGANISM", 0, 3], ["lymphocytes", "CELL", 65, 76], ["plasma cell", "CELL", 90, 101], ["tubular epithelium", "TISSUE", 226, 244], ["Harderian gland", "ORGAN", 252, 267], ["lymphocytes", "CELL_TYPE", 65, 76], ["IBV", "SPECIES", 0, 3], ["IBV vaccination", "TREATMENT", 0, 15], ["eyedrop", "TREATMENT", 19, 26], ["a massive infiltration of lymphocytes", "PROBLEM", 39, 76], ["plasma cell numbers", "TEST", 90, 109], ["desquamation of tubular epithelium in the Harderian gland", "PROBLEM", 210, 267], ["massive", "OBSERVATION_MODIFIER", 41, 48], ["infiltration", "OBSERVATION", 49, 61], ["lymphocytes", "ANATOMY", 65, 76], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["plasma cell numbers", "OBSERVATION", 90, 109], ["desquamation", "OBSERVATION", 210, 222], ["tubular", "ANATOMY_MODIFIER", 226, 233], ["epithelium", "ANATOMY_MODIFIER", 234, 244], ["Harderian gland", "ANATOMY", 252, 267], ["restoration", "OBSERVATION_MODIFIER", 273, 284]]], ["Increased numbers of plasma cells (Survashe et al, 1979) and lymphoid tissue development (Montgomery et al, 1994) were also seen in the lachrymal gland following IBV vaccination.VIRUS IN OTHER TISSUESIBV has also been isolated from the bursa of Fabricius (El Houadfi et al, 1986; Ambali & Jones, 1990) , and gross and histopathological lesions have been shown following experimental H52 and HI20 infections (MacDonald & McMartin, 1976) .", [["plasma cells", "ANATOMY", 21, 33], ["lymphoid tissue", "ANATOMY", 61, 76], ["lachrymal gland", "ANATOMY", 136, 151], ["bursa", "ANATOMY", 236, 241], ["lesions", "ANATOMY", 336, 343], ["infections", "DISEASE", 396, 406], ["plasma cells", "CELL", 21, 33], ["lymphoid tissue", "TISSUE", 61, 76], ["lachrymal gland", "ORGAN", 136, 151], ["IBV", "ORGANISM", 162, 165], ["bursa", "ORGANISM_SUBDIVISION", 236, 241], ["histopathological lesions", "CANCER", 318, 343], ["plasma cells", "CELL_TYPE", 21, 33], ["IBV", "SPECIES", 162, 165], ["H52", "SPECIES", 383, 386], ["HI20", "SPECIES", 391, 395], ["Increased numbers of plasma cells", "PROBLEM", 0, 33], ["lymphoid tissue development", "PROBLEM", 61, 88], ["IBV vaccination", "TREATMENT", 162, 177], ["gross and histopathological lesions", "PROBLEM", 308, 343], ["HI20 infections", "PROBLEM", 391, 406], ["numbers", "OBSERVATION_MODIFIER", 10, 17], ["plasma cells", "OBSERVATION", 21, 33], ["lymphoid tissue", "OBSERVATION", 61, 76], ["lachrymal gland", "ANATOMY", 136, 151], ["bursa", "ANATOMY", 236, 241], ["Fabricius", "ANATOMY", 245, 254], ["lesions", "OBSERVATION", 336, 343]]], ["Although IBV has been isolated from a variety of other tissues such as liver Ambali & Jones, 1990 ) and spleen (Otsuki et al, 1990) it has not been documented to be involved with any functional damage.", [["tissues", "ANATOMY", 55, 62], ["liver", "ANATOMY", 71, 76], ["spleen", "ANATOMY", 104, 110], ["IBV", "ORGANISM", 9, 12], ["tissues", "TISSUE", 55, 62], ["liver", "ORGAN", 71, 76], ["spleen", "ORGAN", 104, 110], ["IBV", "SPECIES", 9, 12], ["IBV", "PROBLEM", 9, 12], ["any functional damage", "PROBLEM", 179, 200], ["liver", "ANATOMY", 71, 76], ["spleen", "ANATOMY", 104, 110]]], ["IBV has been isolated from semen and eggs of infected chickens (Cook, 1971 ), but vertical transmission appears to be of little importance.FACTORS INFLUENCING PATHOGENESISSeveral intrinsic (age and breed of chickens) and extrinsic (nutrition, environment and intercurrent infections) factors influence the pathogenesis of IBV infections.AgeAll ages are susceptible, but the clinical disease is more severe in young chicks (Animas et al., 1994b) although recovery of the virus from the trachea was similar compared to 6-week old infected chickens (Animas et al., 1994a) .", [["semen", "ANATOMY", 27, 32], ["eggs", "ANATOMY", 37, 41], ["trachea", "ANATOMY", 485, 492], ["infections", "DISEASE", 272, 282], ["IBV infections", "DISEASE", 322, 336], ["IBV", "ORGANISM", 0, 3], ["semen", "ORGANISM_SUBSTANCE", 27, 32], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 41], ["chickens", "ORGANISM", 54, 62], ["chickens", "ORGANISM", 207, 215], ["IBV", "ORGANISM", 322, 325], ["trachea", "ORGAN", 485, 492], ["chickens", "ORGANISM", 537, 545], ["chickens", "SPECIES", 54, 62], ["chickens", "SPECIES", 207, 215], ["chickens", "SPECIES", 537, 545], ["IBV", "SPECIES", 0, 3], ["chickens", "SPECIES", 54, 62], ["chickens", "SPECIES", 207, 215], ["IBV", "SPECIES", 322, 325], ["chickens", "SPECIES", 537, 545], ["IBV", "PROBLEM", 0, 3], ["extrinsic (nutrition", "TREATMENT", 221, 241], ["intercurrent infections)", "PROBLEM", 259, 283], ["IBV infections", "PROBLEM", 322, 336], ["susceptible", "PROBLEM", 353, 364], ["the clinical disease", "PROBLEM", 370, 390], ["the virus", "PROBLEM", 466, 475], ["infected", "OBSERVATION_MODIFIER", 45, 53], ["chickens", "OBSERVATION", 54, 62], ["appears to be", "UNCERTAINTY", 104, 117], ["IBV infections", "OBSERVATION", 322, 336], ["susceptible", "OBSERVATION_MODIFIER", 353, 364], ["severe", "OBSERVATION_MODIFIER", 399, 405], ["virus", "OBSERVATION", 470, 475], ["trachea", "ANATOMY", 485, 492], ["infected", "OBSERVATION_MODIFIER", 528, 536], ["chickens", "OBSERVATION", 537, 545]]], ["However, the duration of virus excretion in the faeces was longer in 2-week old infected chicks compared to 4-and 6-week-old chickens.", [["faeces", "ANATOMY", 48, 54], ["faeces", "ORGANISM_SUBDIVISION", 48, 54], ["chicks", "ORGANISM", 89, 95], ["chickens", "ORGANISM", 125, 133], ["chicks", "SPECIES", 89, 95], ["chickens", "SPECIES", 125, 133], ["chickens", "SPECIES", 125, 133], ["virus excretion", "TEST", 25, 40], ["infected chicks", "PROBLEM", 80, 95], ["infected", "OBSERVATION", 80, 88]]], ["As age increases chicks become more resistant to IBV-induced mortality (Smith et al., 1985) , nephropathic effects (Albassam et al., 1986) and oviduct lesions (Crinion & Hofstad, 1972a) .", [["oviduct lesions", "ANATOMY", 143, 158], ["oviduct lesions", "DISEASE", 143, 158], ["IBV", "ORGANISM", 49, 52], ["oviduct lesions", "CANCER", 143, 158], ["chicks", "SPECIES", 17, 23], ["IBV", "SPECIES", 49, 52], ["IBV", "PROBLEM", 49, 52], ["nephropathic effects", "PROBLEM", 94, 114], ["oviduct lesions", "PROBLEM", 143, 158], ["more resistant", "OBSERVATION_MODIFIER", 31, 45], ["nephropathic", "OBSERVATION", 94, 106], ["oviduct", "ANATOMY", 143, 150], ["lesions", "OBSERVATION", 151, 158]]], ["Mac-Donald et al. (1980) described fewer pathological changes in kidneys of chickens infected at 3 weeks of age than those infected at day-old or 10 weeks of age, although the virus was inoculated i.v., which is an unnatural route of infection.", [["kidneys", "ANATOMY", 65, 72], ["infection", "DISEASE", 234, 243], ["kidneys", "ORGAN", 65, 72], ["chickens", "ORGANISM", 76, 84], ["chickens", "SPECIES", 76, 84], ["chickens", "SPECIES", 76, 84], ["pathological changes in kidneys of chickens infected", "PROBLEM", 41, 93], ["the virus", "PROBLEM", 172, 181], ["infection", "PROBLEM", 234, 243], ["fewer", "OBSERVATION_MODIFIER", 35, 40], ["pathological", "OBSERVATION", 41, 53], ["kidneys", "ANATOMY", 65, 72], ["chickens", "OBSERVATION_MODIFIER", 76, 84], ["infected", "OBSERVATION", 85, 93], ["infection", "OBSERVATION", 234, 243]]], ["Purchase et al. (1966) demonstrated variation in mortality following IBV inoculation of embryos from different inbred lines.", [["embryos", "ANATOMY", 88, 95], ["IBV", "ORGANISM", 69, 72], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 88, 95], ["inbred lines", "CELL", 111, 123], ["inbred lines", "CELL_LINE", 111, 123], ["IBV", "SPECIES", 69, 72], ["variation in mortality", "PROBLEM", 36, 58], ["IBV inoculation", "TREATMENT", 69, 84], ["embryos", "PROBLEM", 88, 95], ["different inbred lines", "TREATMENT", 101, 123], ["inbred lines", "OBSERVATION", 111, 123]]], ["Bumstead et al. (1989) compared mortalities in several inbred lines of chickens following inoculation with a pool of strains of IBV and/or Escherichia coli and found marked differences among them.", [["inbred lines", "CELL", 55, 67], ["chickens", "ORGANISM", 71, 79], ["IBV", "ORGANISM", 128, 131], ["Escherichia coli", "ORGANISM", 139, 155], ["inbred lines", "CELL_LINE", 55, 67], ["chickens", "SPECIES", 71, 79], ["IBV", "SPECIES", 128, 131], ["Escherichia coli", "SPECIES", 139, 155], ["chickens", "SPECIES", 71, 79], ["IBV", "SPECIES", 128, 131], ["Escherichia coli", "SPECIES", 139, 155], ["inoculation", "PROBLEM", 90, 101], ["IBV", "PROBLEM", 128, 131], ["Escherichia coli", "PROBLEM", 139, 155], ["Escherichia coli", "OBSERVATION", 139, 155], ["marked", "OBSERVATION_MODIFIER", 166, 172]]], ["On this basis, the lines of chickens were classified as being resistant or sensitive to IBV.", [["chickens", "ORGANISM", 28, 36], ["IBV", "ORGANISM", 88, 91], ["chickens", "SPECIES", 28, 36], ["chickens", "SPECIES", 28, 36], ["IBV", "SPECIES", 88, 91], ["the lines of chickens", "TREATMENT", 15, 36], ["IBV", "TREATMENT", 88, 91]]], ["However, these inbred lines did not show marked differences in susceptibility to the variant strain of IBV, 793/B (Parsons et al, 1992) .BreedGenetic differences in susceptibility to nephritis are also marked, with light breeds being more susceptible than heavy breeds (Cumming & Chubb, 1988) .", [["nephritis", "DISEASE", 183, 192], ["inbred lines", "CELL", 15, 27], ["IBV", "ORGANISM", 103, 106], ["inbred lines", "CELL_LINE", 15, 27], ["IBV", "SPECIES", 103, 106], ["BreedGenetic differences", "PROBLEM", 137, 161], ["nephritis", "PROBLEM", 183, 192], ["light breeds", "PROBLEM", 215, 227], ["marked", "OBSERVATION_MODIFIER", 41, 47], ["susceptibility", "OBSERVATION_MODIFIER", 165, 179], ["nephritis", "OBSERVATION", 183, 192], ["marked", "OBSERVATION_MODIFIER", 202, 208]]], ["The mortalities in 4-week-old cockerels of 10 Australian commercial egg-laying strains varied from 11 to 59%.", [["cockerels", "ORGANISM", 30, 39], ["egg", "ORGANISM", 68, 71]]], ["NIBV has been shown to cause higher mortalities in broilers than layers (Ignjatovic, 1988; Zanella, 1988) although the virus multiplies to the same extent in both types of birds (Lambrechts et al., 1993) .", [["NIBV", "CHEMICAL", 0, 4], ["birds", "ORGANISM", 172, 177], ["NIBV", "PROTEIN", 0, 4], ["broilers", "SPECIES", 51, 59], ["NIBV", "SPECIES", 0, 4], ["the virus", "PROBLEM", 115, 124], ["shown to cause", "UNCERTAINTY", 14, 28], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["mortalities", "OBSERVATION", 36, 47], ["virus", "OBSERVATION", 119, 124], ["both", "ANATOMY_MODIFIER", 158, 162]]], ["Male chicks are twice as susceptible as females to nephritis (Cumming, 1969) .NutritionHigh protein diets increase mortality from IBV-induced nephrosis; chickens fed meat meal or poultry by-product meal-based diets experience higher mortality than those fed soybean based diets (Cumming, 1969; Cumming & Chubb, 1988) .EnvironmentLow temperatures have a dramatic effect on mortality due to NIBV.", [["meat", "ANATOMY", 166, 170], ["nephritis", "DISEASE", 51, 60], ["nephrosis", "DISEASE", 142, 151], ["chicks", "ORGANISM", 5, 11], ["IBV", "ORGANISM", 130, 133], ["chickens", "ORGANISM", 153, 161], ["meat", "ORGANISM_SUBDIVISION", 166, 170], ["chicks", "SPECIES", 5, 11], ["chickens", "SPECIES", 153, 161], ["IBV", "SPECIES", 130, 133], ["chickens", "SPECIES", 153, 161], ["poultry", "SPECIES", 179, 186], ["soybean", "SPECIES", 258, 265], ["NIBV", "SPECIES", 389, 393], ["nephritis", "PROBLEM", 51, 60], ["NutritionHigh protein diets", "TREATMENT", 78, 105], ["IBV", "PROBLEM", 130, 133], ["nephrosis", "PROBLEM", 142, 151], ["NIBV", "TREATMENT", 389, 393], ["nephritis", "OBSERVATION", 51, 60], ["nephrosis", "OBSERVATION", 142, 151], ["dramatic", "OBSERVATION_MODIFIER", 353, 361]]], ["Reduction in temperature from 20\u00b0C to 16\u00b0C increased mortality from 8 to 50% (Cumming, 1969) with greater severity of histopathological lesions in kidneys (Ratanasethakul & Cumming, 1983) .", [["lesions", "ANATOMY", 136, 143], ["kidneys", "ANATOMY", 147, 154], ["histopathological lesions", "PATHOLOGICAL_FORMATION", 118, 143], ["kidneys", "ORGAN", 147, 154], ["Reduction in temperature", "PROBLEM", 0, 24], ["increased mortality", "PROBLEM", 43, 62], ["histopathological lesions in kidneys", "PROBLEM", 118, 154], ["temperature", "OBSERVATION_MODIFIER", 13, 24], ["histopathological", "OBSERVATION_MODIFIER", 118, 135], ["lesions", "OBSERVATION", 136, 143], ["kidneys", "ANATOMY", 147, 154]]], ["Exposure to cold stress has been used to increase the severity of challenge for assessing protection afforded by IBV vaccines (Klieve & Cumming, 1990) .", [["IBV", "ORGANISM", 113, 116], ["IBV", "SPECIES", 113, 116], ["cold stress", "PROBLEM", 12, 23], ["assessing protection", "TREATMENT", 80, 100], ["IBV vaccines", "TREATMENT", 113, 125]]], ["Cold stress also increased the severity of IBV-induced tracheal lesions (Ratanasethakul & Cumming, 1983) and promoted more extensive air sacculitis after combined infections with IBV and Mycoplasma synoviae (MS) (Yoder et al, 1977) .Intercurrent infectionsMycoplasmas Adler et al. (1962) found that intranasal inoculation of either the Massachusetts strain of IBV or M. gallisepticum (MG) given alone produced little by way of clinical signs, but dual infections resulted in coryza, tracheitis and airsacculitis.", [["tracheal lesions", "ANATOMY", 55, 71], ["tracheal lesions", "DISEASE", 55, 71], ["air sacculitis", "DISEASE", 133, 147], ["infections", "DISEASE", 163, 173], ["Mycoplasma synoviae", "DISEASE", 187, 206], ["infections", "DISEASE", 246, 256], ["MG", "CHEMICAL", 385, 387], ["infections", "DISEASE", 452, 462], ["tracheitis", "DISEASE", 483, 493], ["airsacculitis", "DISEASE", 498, 511], ["IBV", "ORGANISM", 43, 46], ["tracheal lesions", "PATHOLOGICAL_FORMATION", 55, 71], ["IBV", "ORGANISM", 179, 182], ["Mycoplasma synoviae", "ORGANISM", 187, 206], ["IBV", "ORGANISM", 360, 363], ["M. gallisepticum", "ORGANISM", 367, 383], ["MG", "MULTI-TISSUE_STRUCTURE", 385, 387], ["IBV", "SPECIES", 179, 182], ["Mycoplasma synoviae", "SPECIES", 187, 206], ["M. gallisepticum", "SPECIES", 367, 383], ["IBV", "SPECIES", 43, 46], ["IBV", "SPECIES", 179, 182], ["Mycoplasma synoviae", "SPECIES", 187, 206], ["IBV", "SPECIES", 360, 363], ["M. gallisepticum", "SPECIES", 367, 383], ["Cold stress", "PROBLEM", 0, 11], ["IBV", "PROBLEM", 43, 46], ["tracheal lesions", "PROBLEM", 55, 71], ["extensive air sacculitis", "PROBLEM", 123, 147], ["combined infections", "PROBLEM", 154, 173], ["IBV", "PROBLEM", 179, 182], ["Mycoplasma synoviae", "PROBLEM", 187, 206], ["Intercurrent infections", "PROBLEM", 233, 256], ["intranasal inoculation", "TREATMENT", 299, 321], ["IBV", "PROBLEM", 360, 363], ["M. gallisepticum (MG)", "TREATMENT", 367, 388], ["clinical signs", "PROBLEM", 427, 441], ["dual infections", "PROBLEM", 447, 462], ["coryza", "PROBLEM", 475, 481], ["tracheitis", "PROBLEM", 483, 493], ["airsacculitis", "PROBLEM", 498, 511], ["stress", "OBSERVATION", 5, 11], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["IBV", "OBSERVATION", 43, 46], ["tracheal", "ANATOMY", 55, 63], ["lesions", "OBSERVATION", 64, 71], ["extensive", "OBSERVATION_MODIFIER", 123, 132], ["air sacculitis", "OBSERVATION", 133, 147], ["infections", "OBSERVATION", 163, 173], ["Mycoplasma synoviae", "OBSERVATION", 187, 206], ["infections", "OBSERVATION", 246, 256], ["coryza", "OBSERVATION", 475, 481], ["tracheitis", "OBSERVATION", 483, 493]]], ["The incidence of airsacculitis was highest in chickens infected with IBV 1 week after MG inoculation.", [["airsacculitis", "DISEASE", 17, 30], ["MG", "CHEMICAL", 86, 88], ["airsacculitis", "CANCER", 17, 30], ["chickens", "ORGANISM", 46, 54], ["IBV", "ORGANISM", 69, 72], ["chickens", "SPECIES", 46, 54], ["chickens", "SPECIES", 46, 54], ["IBV", "SPECIES", 69, 72], ["airsacculitis", "PROBLEM", 17, 30], ["IBV", "TREATMENT", 69, 72], ["MG inoculation", "TREATMENT", 86, 100], ["airsacculitis", "OBSERVATION", 17, 30], ["highest", "OBSERVATION_MODIFIER", 35, 42], ["chickens", "OBSERVATION_MODIFIER", 46, 54], ["infected", "OBSERVATION", 55, 63]]], ["In adult chickens combined infections with IBV and MG has been shown to cause a more severe effect on egg production and quality than inoculation with either agent alone (Blake, 1962) .Intercurrent infectionsOlson et al, (1964) exposed chickens to IBV and MS but found that dual infections were not synergistic.", [["egg", "ANATOMY", 102, 105], ["infections", "DISEASE", 27, 37], ["MG", "CHEMICAL", 51, 53], ["infections", "DISEASE", 198, 208], ["MS", "DISEASE", 256, 258], ["infections", "DISEASE", 279, 289], ["chickens", "ORGANISM", 9, 17], ["IBV", "ORGANISM", 43, 46], ["egg", "ORGANISM_SUBDIVISION", 102, 105], ["chickens", "ORGANISM", 236, 244], ["IBV", "ORGANISM", 248, 251], ["chickens", "SPECIES", 9, 17], ["chickens", "SPECIES", 236, 244], ["chickens", "SPECIES", 9, 17], ["IBV", "SPECIES", 43, 46], ["chickens", "SPECIES", 236, 244], ["IBV", "SPECIES", 248, 251], ["adult chickens combined infections", "PROBLEM", 3, 37], ["IBV", "TREATMENT", 43, 46], ["MG", "TREATMENT", 51, 53], ["egg production", "PROBLEM", 102, 116], ["Intercurrent infections", "PROBLEM", 185, 208], ["IBV", "PROBLEM", 248, 251], ["MS", "PROBLEM", 256, 258], ["dual infections", "PROBLEM", 274, 289], ["synergistic", "PROBLEM", 299, 310], ["infections", "OBSERVATION", 27, 37], ["more severe", "OBSERVATION_MODIFIER", 80, 91], ["infections", "OBSERVATION", 198, 208], ["infections", "OBSERVATION", 279, 289]]], ["In contrast, later work by Kleven et al, (1972) found that airsacculitis resulted when chickens were infected with IB and Newcastle disease (ND) vaccines after MS infection.", [["airsacculitis", "DISEASE", 59, 72], ["Newcastle disease", "DISEASE", 122, 139], ["ND", "DISEASE", 141, 143], ["MS infection", "DISEASE", 160, 172], ["chickens", "ORGANISM", 87, 95], ["Newcastle disease", "ORGANISM", 122, 139], ["chickens", "SPECIES", 87, 95], ["chickens", "SPECIES", 87, 95], ["airsacculitis", "PROBLEM", 59, 72], ["IB", "PROBLEM", 115, 117], ["Newcastle disease (ND) vaccines", "TREATMENT", 122, 153], ["MS infection", "PROBLEM", 160, 172], ["infection", "OBSERVATION", 163, 172]]], ["Hopkins & Yoder (1982) , in similar experiments with MS, gave different strains of IBV 2 to 5 days before the mycoplasma.", [["mycoplasma", "DISEASE", 110, 120], ["IBV", "ORGANISM", 83, 86], ["IBV", "SPECIES", 83, 86], ["IBV", "TREATMENT", 83, 86], ["the mycoplasma", "PROBLEM", 106, 120], ["mycoplasma", "OBSERVATION", 110, 120]]], ["They showed that different strains of IBV had differing abilities to induce airsacculitis.", [["airsacculitis", "DISEASE", 76, 89], ["IBV", "ORGANISM", 38, 41], ["IBV", "SPECIES", 38, 41], ["different strains of IBV", "PROBLEM", 17, 41], ["airsacculitis", "PROBLEM", 76, 89]]], ["Field isolates of IBV had the most severe effects.", [["IBV", "ORGANISM", 18, 21], ["IBV", "SPECIES", 18, 21], ["IBV", "TREATMENT", 18, 21], ["most severe", "OBSERVATION_MODIFIER", 30, 41]]], ["Vaccines of high passage produced very mild lesions while those of low passage caused intermediate lesions.", [["lesions", "ANATOMY", 44, 51], ["lesions", "ANATOMY", 99, 106], ["lesions", "PATHOLOGICAL_FORMATION", 44, 51], ["intermediate lesions", "PATHOLOGICAL_FORMATION", 86, 106], ["Vaccines", "TREATMENT", 0, 8], ["high passage", "PROBLEM", 12, 24], ["very mild lesions", "PROBLEM", 34, 51], ["intermediate lesions", "PROBLEM", 86, 106], ["high passage", "OBSERVATION_MODIFIER", 12, 24], ["very", "OBSERVATION_MODIFIER", 34, 38], ["mild", "OBSERVATION_MODIFIER", 39, 43], ["lesions", "OBSERVATION", 44, 51], ["low passage", "OBSERVATION_MODIFIER", 67, 78], ["intermediate", "OBSERVATION_MODIFIER", 86, 98], ["lesions", "OBSERVATION", 99, 106]]], ["Gross (1958) , in one of the first studies, infected 5-week-old chickens with IBV and gave pathogenic E. coli by aerosol at intervals afterwards.", [["chickens", "ORGANISM", 64, 72], ["IBV", "ORGANISM", 78, 81], ["E. coli", "ORGANISM", 102, 109], ["chickens", "SPECIES", 64, 72], ["E. coli", "SPECIES", 102, 109], ["chickens", "SPECIES", 64, 72], ["IBV", "SPECIES", 78, 81], ["E. coli", "SPECIES", 102, 109], ["IBV", "TREATMENT", 78, 81], ["pathogenic E. coli", "PROBLEM", 91, 109], ["infected", "OBSERVATION", 44, 52], ["E. coli", "OBSERVATION", 102, 109]]], ["The most severe pericarditis was seen when the bacteria were given 11 to 22 days after the virus.", [["pericarditis", "DISEASE", 16, 28], ["The most severe pericarditis", "PROBLEM", 0, 28], ["the bacteria", "PROBLEM", 43, 55], ["the virus", "PROBLEM", 87, 96], ["most", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["pericarditis", "OBSERVATION", 16, 28]]], ["Smith et al. (1985) , using a combined inoculation of a pool of strains of IBV and E. coli, developed an experimental model for IBV which closely resembled natural outbreaks of the disease.", [["IBV", "ORGANISM", 75, 78], ["E. coli", "ORGANISM", 83, 90], ["IBV", "ORGANISM", 128, 131], ["E. coli", "SPECIES", 83, 90], ["IBV", "SPECIES", 75, 78], ["E. coli", "SPECIES", 83, 90], ["IBV", "SPECIES", 128, 131], ["a combined inoculation", "TREATMENT", 28, 50], ["IBV", "PROBLEM", 75, 78], ["E. coli", "PROBLEM", 83, 90], ["IBV", "PROBLEM", 128, 131], ["the disease", "PROBLEM", 177, 188], ["E. coli", "OBSERVATION", 83, 90], ["natural outbreaks", "OBSERVATION", 156, 173], ["disease", "OBSERVATION", 181, 188]]], ["The damage to tracheal epithelium caused by IBV facilitates E. coli invasion and multiplication leading to death or lesions in surviving chickens.", [["tracheal epithelium", "ANATOMY", 14, 33], ["lesions", "ANATOMY", 116, 123], ["death", "DISEASE", 107, 112], ["tracheal epithelium", "TISSUE", 14, 33], ["IBV", "ORGANISM", 44, 47], ["E. coli", "ORGANISM", 60, 67], ["lesions", "PATHOLOGICAL_FORMATION", 116, 123], ["chickens", "ORGANISM", 137, 145], ["E. coli", "SPECIES", 60, 67], ["chickens", "SPECIES", 137, 145], ["IBV", "SPECIES", 44, 47], ["E. coli", "SPECIES", 60, 67], ["chickens", "SPECIES", 137, 145], ["The damage to tracheal epithelium", "PROBLEM", 0, 33], ["IBV", "PROBLEM", 44, 47], ["E. coli invasion", "PROBLEM", 60, 76], ["multiplication", "PROBLEM", 81, 95], ["death", "PROBLEM", 107, 112], ["lesions", "PROBLEM", 116, 123], ["tracheal epithelium", "ANATOMY", 14, 33], ["coli invasion", "OBSERVATION", 63, 76], ["lesions", "OBSERVATION", 116, 123]]], ["Using this model, several reports have described differences in virulence of IBV strains, differences in susceptibility between genetic lines of chickens and detailed interactions between the agents (Avellanda et al., 1994; Bumstead et al, 1989; Cook et al, , 1991b Cubillos et al, 1991; Smith et al, 1985) .", [["IBV", "ORGANISM", 77, 80], ["chickens", "ORGANISM", 145, 153], ["chickens", "SPECIES", 145, 153], ["IBV", "SPECIES", 77, 80], ["chickens", "SPECIES", 145, 153], ["IBV strains", "PROBLEM", 77, 88]]], ["Raggi et al. (1967b) showed that when IBV and Haemophilus paragallinarum were given together intra-nasally, the incubation period was shorter, there was higher mortality and lesions were more severe.BacteriaThere is no reported evidence of dual infections with IBV and Pasteurella multocida, the causative agent of fowl cholera.", [["lesions", "ANATOMY", 174, 181], ["infections", "DISEASE", 245, 255], ["Pasteurella multocida", "DISEASE", 269, 290], ["fowl cholera", "DISEASE", 315, 327], ["IBV", "ORGANISM", 38, 41], ["Haemophilus paragallinarum", "ORGANISM", 46, 72], ["lesions", "PATHOLOGICAL_FORMATION", 174, 181], ["IBV", "ORGANISM", 261, 264], ["Pasteurella multocida", "ORGANISM", 269, 290], ["fowl cholera", "ORGANISM", 315, 327], ["IBV", "SPECIES", 38, 41], ["Haemophilus paragallinarum", "SPECIES", 46, 72], ["Pasteurella multocida", "SPECIES", 269, 290], ["fowl", "SPECIES", 315, 319], ["IBV", "SPECIES", 38, 41], ["Haemophilus paragallinarum", "SPECIES", 46, 72], ["IBV", "SPECIES", 261, 264], ["Pasteurella multocida", "SPECIES", 269, 290], ["fowl", "SPECIES", 315, 319], ["IBV", "PROBLEM", 38, 41], ["Haemophilus paragallinarum", "PROBLEM", 46, 72], ["higher mortality", "PROBLEM", 153, 169], ["lesions", "PROBLEM", 174, 181], ["dual infections", "PROBLEM", 240, 255], ["IBV", "PROBLEM", 261, 264], ["Pasteurella multocida", "PROBLEM", 269, 290], ["fowl cholera", "PROBLEM", 315, 327], ["higher", "OBSERVATION_MODIFIER", 153, 159], ["mortality", "OBSERVATION_MODIFIER", 160, 169], ["lesions", "OBSERVATION", 174, 181], ["more severe", "OBSERVATION_MODIFIER", 187, 198], ["no reported evidence of", "UNCERTAINTY", 216, 239], ["dual", "OBSERVATION_MODIFIER", 240, 244], ["infections", "OBSERVATION", 245, 255]]], ["However, Bisgaard (1977) , in a study of chickens in the field, found that where the bacterium P. haemolytica was present with IBV, there was no apparent exacerbation of the viral infection.Other respiratory virusesIBV is known to interfere with the replication of NDV in eggs and Raggi & Lee (1964) have shown that interference also occurs in chickens, but this is only one way.", [["viral infection", "DISEASE", 174, 189], ["chickens", "ORGANISM", 41, 49], ["P. haemolytica", "ORGANISM", 95, 109], ["IBV", "ORGANISM", 127, 130], ["NDV", "ORGANISM", 265, 268], ["chickens", "ORGANISM", 344, 352], ["chickens", "SPECIES", 41, 49], ["P. haemolytica", "SPECIES", 95, 109], ["chickens", "SPECIES", 344, 352], ["chickens", "SPECIES", 41, 49], ["P. haemolytica", "SPECIES", 95, 109], ["IBV", "SPECIES", 127, 130], ["NDV", "SPECIES", 265, 268], ["chickens", "SPECIES", 344, 352], ["the bacterium", "PROBLEM", 81, 94], ["haemolytica", "PROBLEM", 98, 109], ["IBV", "PROBLEM", 127, 130], ["the viral infection", "PROBLEM", 170, 189], ["NDV", "PROBLEM", 265, 268], ["no apparent", "UNCERTAINTY", 142, 153], ["exacerbation", "OBSERVATION_MODIFIER", 154, 166], ["viral", "OBSERVATION_MODIFIER", 174, 179], ["infection", "OBSERVATION", 180, 189], ["respiratory virusesIBV", "OBSERVATION", 196, 218]]], ["They found that when IBV was given to chickens with NDB1 vaccine, there was subsequently no production of haemagglutination-inhibition (HI) antibodies to NDV, but NDV did not interfere with IBV infection.", [["IBV infection", "DISEASE", 190, 203], ["IBV", "ORGANISM", 21, 24], ["chickens", "ORGANISM", 38, 46], ["NDB1", "GENE_OR_GENE_PRODUCT", 52, 56], ["NDV", "ORGANISM", 154, 157], ["NDV", "ORGANISM", 163, 166], ["IBV", "ORGANISM", 190, 193], ["haemagglutination-inhibition (HI) antibodies", "PROTEIN", 106, 150], ["chickens", "SPECIES", 38, 46], ["IBV", "SPECIES", 21, 24], ["chickens", "SPECIES", 38, 46], ["NDB1", "SPECIES", 52, 56], ["NDV", "SPECIES", 154, 157], ["NDV", "SPECIES", 163, 166], ["IBV", "SPECIES", 190, 193], ["IBV", "TREATMENT", 21, 24], ["NDB1 vaccine", "TREATMENT", 52, 64], ["production of haemagglutination", "PROBLEM", 92, 123], ["NDV", "PROBLEM", 154, 157], ["NDV", "PROBLEM", 163, 166], ["IBV infection", "PROBLEM", 190, 203], ["infection", "OBSERVATION", 194, 203]]], ["Raggi et al. (1967a) found no synergism between IBV and infectious laryngotracheitis virus (ILTV), but Pattison et al. (1971) reported that aerosol vaccination with IBV increased the mortalities due to ILTV.", [["infectious laryngotracheitis virus", "DISEASE", 56, 90], ["ILTV", "DISEASE", 202, 206], ["IBV", "ORGANISM", 48, 51], ["infectious laryngotracheitis virus", "ORGANISM", 56, 90], ["IBV", "ORGANISM", 165, 168], ["infectious laryngotracheitis virus", "SPECIES", 56, 90], ["IBV", "SPECIES", 48, 51], ["infectious laryngotracheitis virus", "SPECIES", 56, 90], ["ILTV", "SPECIES", 92, 96], ["IBV", "SPECIES", 165, 168], ["ILTV", "SPECIES", 202, 206], ["synergism", "PROBLEM", 30, 39], ["IBV", "PROBLEM", 48, 51], ["infectious laryngotracheitis virus", "PROBLEM", 56, 90], ["aerosol vaccination", "TREATMENT", 140, 159], ["IBV", "TREATMENT", 165, 168], ["ILTV", "PROBLEM", 202, 206], ["no", "UNCERTAINTY", 27, 29], ["infectious", "OBSERVATION_MODIFIER", 56, 66], ["laryngotracheitis", "OBSERVATION", 67, 84]]], ["APV, the cause of TRT and mild respiratory disease in chickens may also occur in respiratory outbreaks involving IBV, but the significance of these two agents being present together is yet to be reported.", [["respiratory", "ANATOMY", 31, 42], ["APV", "CHEMICAL", 0, 3], ["respiratory disease", "DISEASE", 31, 50], ["APV", "CHEMICAL", 0, 3], ["APV", "SIMPLE_CHEMICAL", 0, 3], ["chickens", "ORGANISM", 54, 62], ["IBV", "ORGANISM", 113, 116], ["chickens", "SPECIES", 54, 62], ["chickens", "SPECIES", 54, 62], ["IBV", "SPECIES", 113, 116], ["APV", "TREATMENT", 0, 3], ["TRT", "PROBLEM", 18, 21], ["mild respiratory disease", "PROBLEM", 26, 50], ["IBV", "PROBLEM", 113, 116], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["respiratory disease", "OBSERVATION", 31, 50]]], ["Fabricant & Levine (1962) examined triple infections involving IBV, MG and pathogenic E. coli.", [["infections", "DISEASE", 42, 52], ["MG", "DISEASE", 68, 70], ["IBV", "ORGANISM", 63, 66], ["E. coli", "ORGANISM", 86, 93], ["E. coli", "SPECIES", 86, 93], ["IBV", "SPECIES", 63, 66], ["E. coli", "SPECIES", 86, 93], ["triple infections", "PROBLEM", 35, 52], ["IBV", "PROBLEM", 63, 66], ["MG", "TREATMENT", 68, 70], ["pathogenic E. coli", "PROBLEM", 75, 93], ["infections", "OBSERVATION", 42, 52], ["E. coli", "OBSERVATION", 86, 93]]], ["They reported that with regard to disease lesions the descending order of severity was IBV, MG and E. coli; MG and E. coli; IBV and E. coli; and E. coli alone.", [["lesions", "ANATOMY", 42, 49], ["MG", "DISEASE", 92, 94], ["lesions", "PATHOLOGICAL_FORMATION", 42, 49], ["IBV", "ORGANISM", 87, 90], ["E. coli", "ORGANISM", 99, 106], ["MG", "CANCER", 108, 110], ["E. coli", "ORGANISM", 115, 122], ["IBV", "ORGANISM", 124, 127], ["E. coli", "ORGANISM", 132, 139], ["E. coli", "ORGANISM", 145, 152], ["E. coli", "SPECIES", 99, 106], ["E. coli", "SPECIES", 115, 122], ["E. coli", "SPECIES", 132, 139], ["E. coli", "SPECIES", 145, 152], ["IBV", "SPECIES", 87, 90], ["E. coli", "SPECIES", 99, 106], ["E. coli", "SPECIES", 115, 122], ["IBV", "SPECIES", 124, 127], ["E. coli", "SPECIES", 132, 139], ["E. coli", "SPECIES", 145, 152], ["disease lesions", "PROBLEM", 34, 49], ["severity", "PROBLEM", 74, 82], ["IBV", "PROBLEM", 87, 90], ["MG", "TREATMENT", 92, 94], ["E. coli", "PROBLEM", 99, 106], ["MG", "TEST", 108, 110], ["E. coli", "PROBLEM", 115, 122], ["IBV", "PROBLEM", 124, 127], ["E. coli", "PROBLEM", 132, 139], ["E. coli", "PROBLEM", 145, 152], ["descending", "ANATOMY_MODIFIER", 54, 64], ["E. coli", "OBSERVATION", 132, 139]]], ["A similar study by Nakamura et al. (1994) was performed with live IB and ND vaccines given to young chicks with MG and/or E. coli or both.", [["MG", "CHEMICAL", 112, 114], ["chicks", "ORGANISM", 100, 106], ["E. coli", "ORGANISM", 122, 129], ["chicks", "SPECIES", 100, 106], ["E. coli", "SPECIES", 122, 129], ["E. coli", "SPECIES", 122, 129], ["A similar study", "TEST", 0, 15], ["live IB", "TREATMENT", 61, 68], ["ND vaccines", "TREATMENT", 73, 84], ["MG", "TREATMENT", 112, 114], ["E. coli", "PROBLEM", 122, 129], ["coli", "OBSERVATION", 125, 129]]], ["Again, the most severe combination was when vaccine, E. coli and MG were given together.Triple infectionsThus, it is clear that several respiratory pathogens interact synergistically with IBV or IB vaccines and enhance the severity and duration of the disease.", [["MG", "CHEMICAL", 65, 67], ["infections", "DISEASE", 95, 105], ["E. coli", "ORGANISM", 53, 60], ["MG", "SIMPLE_CHEMICAL", 65, 67], ["IBV", "ORGANISM", 188, 191], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["IBV", "SPECIES", 188, 191], ["vaccine", "TREATMENT", 44, 51], ["E. coli", "TREATMENT", 53, 60], ["MG", "TREATMENT", 65, 67], ["Triple infections", "PROBLEM", 88, 105], ["several respiratory pathogens", "PROBLEM", 128, 157], ["IBV", "PROBLEM", 188, 191], ["IB vaccines", "TREATMENT", 195, 206], ["the disease", "PROBLEM", 248, 259], ["most severe", "OBSERVATION_MODIFIER", 11, 22], ["infections", "OBSERVATION", 95, 105], ["disease", "OBSERVATION", 252, 259]]], ["In many instances, the interval between infections is important, as are the challenge doses.", [["infections", "DISEASE", 40, 50], ["infections", "PROBLEM", 40, 50], ["many", "OBSERVATION_MODIFIER", 3, 7], ["instances", "OBSERVATION", 8, 17], ["infections", "OBSERVATION", 40, 50]]], ["However, with few exceptions (e.g. Nakamura et al., 1992) , it is not known whether the synergisms are due to immunosuppression or simply that the epithelial damage caused by one agent permits greater penetration by others.IBV and immunosuppressive agentsThe two classical examples of immunosuppressive viruses of chickens are infectious bursal disease (II3D) which principally affects the B-cells and chicken anaemia virus (CAV) which affects the T-cells.IBV and immunosuppressive agentsThere is abundant evidence that IBDV infection impairs the humoral response to IBV.", [["epithelial", "ANATOMY", 147, 157], ["bursal", "ANATOMY", 338, 344], ["B-cells", "ANATOMY", 390, 397], ["T-cells", "ANATOMY", 448, 455], ["epithelial damage", "DISEASE", 147, 164], ["infectious bursal disease", "DISEASE", 327, 352], ["anaemia", "DISEASE", 410, 417], ["CAV", "DISEASE", 425, 428], ["IBDV infection", "DISEASE", 520, 534], ["epithelial", "TISSUE", 147, 157], ["IBV", "ORGANISM", 223, 226], ["chickens", "ORGANISM", 314, 322], ["bursal", "ORGAN", 338, 344], ["II3D", "CANCER", 354, 358], ["B-cells", "CELL", 390, 397], ["chicken anaemia virus", "ORGANISM", 402, 423], ["CAV", "ORGANISM", 425, 428], ["T-cells", "CELL", 448, 455], ["IBV", "ORGANISM", 456, 459], ["IBDV", "ORGANISM", 520, 524], ["IBV", "ORGANISM", 567, 570], ["B-cells", "CELL_TYPE", 390, 397], ["T-cells", "CELL_TYPE", 448, 455], ["chickens", "SPECIES", 314, 322], ["chicken anaemia virus", "SPECIES", 402, 423], ["IBV", "SPECIES", 223, 226], ["chickens", "SPECIES", 314, 322], ["chicken anaemia virus", "SPECIES", 402, 423], ["CAV", "SPECIES", 425, 428], ["IBV", "SPECIES", 456, 459], ["IBDV", "SPECIES", 520, 524], ["IBV", "SPECIES", 567, 570], ["the synergisms", "PROBLEM", 84, 98], ["immunosuppression", "TREATMENT", 110, 127], ["the epithelial damage", "PROBLEM", 143, 164], ["IBV", "TREATMENT", 223, 226], ["immunosuppressive agents", "TREATMENT", 231, 255], ["immunosuppressive viruses", "TREATMENT", 285, 310], ["infectious bursal disease", "PROBLEM", 327, 352], ["chicken anaemia virus", "PROBLEM", 402, 423], ["IBV", "TREATMENT", 456, 459], ["immunosuppressive agents", "TREATMENT", 464, 488], ["IBDV infection", "PROBLEM", 520, 534], ["IBV", "PROBLEM", 567, 570], ["epithelial damage", "OBSERVATION", 147, 164], ["immunosuppressive viruses", "OBSERVATION", 285, 310], ["infectious", "OBSERVATION_MODIFIER", 327, 337], ["B-cells", "OBSERVATION_MODIFIER", 390, 397], ["anaemia virus", "OBSERVATION", 410, 423], ["abundant evidence that", "UNCERTAINTY", 497, 519], ["IBDV", "OBSERVATION_MODIFIER", 520, 524], ["infection", "OBSERVATION", 525, 534], ["humoral response to IBV", "OBSERVATION", 547, 570]]], ["Giambrone et al. (1977) infected chicks with IBDV at day-old and IBV at 14 days.", [["chicks", "ORGANISM", 33, 39], ["IBDV", "ORGANISM", 45, 49], ["IBV", "ORGANISM", 65, 68], ["chicks", "SPECIES", 33, 39], ["IBDV", "SPECIES", 45, 49], ["IBDV", "SPECIES", 45, 49], ["IBV", "SPECIES", 65, 68], ["IBDV", "TREATMENT", 45, 49], ["IBV", "TREATMENT", 65, 68]]], ["Compared to single IBV infection with both viruses, antibody titres were lower and airsac lesions greater.", [["airsac lesions", "ANATOMY", 83, 97], ["IBV infection", "DISEASE", 19, 32], ["IBV", "ORGANISM", 19, 22], ["airsac lesions", "PATHOLOGICAL_FORMATION", 83, 97], ["IBV", "SPECIES", 19, 22], ["single IBV infection", "PROBLEM", 12, 32], ["both viruses", "PROBLEM", 38, 50], ["antibody titres", "TEST", 52, 67], ["airsac lesions", "PROBLEM", 83, 97], ["infection", "OBSERVATION", 23, 32], ["both", "OBSERVATION_MODIFIER", 38, 42], ["viruses", "OBSERVATION", 43, 50], ["lower", "OBSERVATION_MODIFIER", 73, 78], ["airsac", "OBSERVATION_MODIFIER", 83, 89], ["lesions", "OBSERVATION", 90, 97], ["greater", "OBSERVATION_MODIFIER", 98, 105]]], ["Rosenberger & Gelb (1978) also showed that IBDV at day-old affected the response to IB vaccines so that there was lowered resistance to challenge.", [["IBDV", "ORGANISM", 43, 47], ["IBDV", "SPECIES", 43, 47], ["IBDV", "PROBLEM", 43, 47], ["IB vaccines", "TREATMENT", 84, 95], ["IBDV", "OBSERVATION", 43, 47]]], ["Furthermore, Winterfield et al. (1978) showed that IBDV increased susceptibility to IBV, reduced IBV antibody levels and explained unsatisfactory immunity when replacement and broilers were vaccinated at an early age.IBV and immunosuppressive agentsThere are no reports of dual infection of chickens with IBV and CAV.", [["infection", "DISEASE", 278, 287], ["CAV", "DISEASE", 313, 316], ["IBDV", "ORGANISM", 51, 55], ["IBV", "ORGANISM", 84, 87], ["IBV", "ORGANISM", 97, 100], ["broilers", "ORGANISM", 176, 184], ["IBV", "ORGANISM", 217, 220], ["chickens", "ORGANISM", 291, 299], ["IBV", "ORGANISM", 305, 308], ["IBV antibody", "PROTEIN", 97, 109], ["broilers", "SPECIES", 176, 184], ["chickens", "SPECIES", 291, 299], ["IBDV", "SPECIES", 51, 55], ["IBV", "SPECIES", 84, 87], ["IBV", "SPECIES", 97, 100], ["broilers", "SPECIES", 176, 184], ["IBV", "SPECIES", 217, 220], ["chickens", "SPECIES", 291, 299], ["IBV", "SPECIES", 305, 308], ["CAV", "SPECIES", 313, 316], ["IBDV increased susceptibility", "PROBLEM", 51, 80], ["IBV", "PROBLEM", 84, 87], ["reduced IBV antibody levels", "PROBLEM", 89, 116], ["replacement and broilers", "TREATMENT", 160, 184], ["IBV", "TREATMENT", 217, 220], ["immunosuppressive agents", "TREATMENT", 225, 249], ["dual infection of chickens", "PROBLEM", 273, 299], ["IBV", "TREATMENT", 305, 308], ["CAV", "TREATMENT", 313, 316], ["IBDV", "OBSERVATION", 51, 55], ["no reports of", "UNCERTAINTY", 259, 272], ["dual", "OBSERVATION_MODIFIER", 273, 277], ["infection", "OBSERVATION", 278, 287], ["CAV", "ANATOMY", 313, 316]]], ["Goodwin et al. (1992) reported that there were no significant differences in IBV-specific antibody titres between chicken flocks positive or negative for CAV antibodies.", [["IBV", "ORGANISM", 77, 80], ["chicken", "ORGANISM", 114, 121], ["CAV antibodies", "PROTEIN", 154, 168], ["chicken", "SPECIES", 114, 121], ["IBV", "SPECIES", 77, 80], ["chicken", "SPECIES", 114, 121], ["CAV", "SPECIES", 154, 157], ["significant differences", "PROBLEM", 50, 73], ["IBV", "TEST", 77, 80], ["specific antibody titres", "TEST", 81, 105], ["chicken flocks", "TEST", 114, 128], ["CAV antibodies", "PROBLEM", 154, 168], ["no", "UNCERTAINTY", 47, 49], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["negative for", "UNCERTAINTY", 141, 153]]], ["However, when chicks infected with IBV strain M41 were treated with the T-cell immunosuppressor drug cyclosporin A (CSA), the clinical signs in these birds were more severe and virus titres in tissues, especially kidneys, were greater than in infected but untreated birds, although the persistence of the virus was not increased (Dhinakar Raj & Jones, 1997a).", [["T-cell", "ANATOMY", 72, 78], ["tissues", "ANATOMY", 193, 200], ["kidneys", "ANATOMY", 213, 220], ["cyclosporin A", "CHEMICAL", 101, 114], ["cyclosporin A", "CHEMICAL", 101, 114], ["chicks", "ORGANISM", 14, 20], ["IBV strain M41", "ORGANISM", 35, 49], ["T-cell", "CELL", 72, 78], ["cyclosporin A", "SIMPLE_CHEMICAL", 101, 114], ["CSA", "SIMPLE_CHEMICAL", 116, 119], ["birds", "ORGANISM", 150, 155], ["tissues", "TISSUE", 193, 200], ["kidneys", "ORGAN", 213, 220], ["birds", "ORGANISM", 266, 271], ["chicks", "SPECIES", 14, 20], ["IBV", "SPECIES", 35, 38], ["IBV strain M41", "SPECIES", 35, 49], ["chicks infected", "PROBLEM", 14, 29], ["IBV strain M41", "PROBLEM", 35, 49], ["the T-cell immunosuppressor drug cyclosporin", "TREATMENT", 68, 112], ["the clinical signs", "TEST", 122, 140], ["virus titres in tissues", "PROBLEM", 177, 200], ["the virus", "PROBLEM", 301, 310], ["virus titres", "OBSERVATION", 177, 189], ["kidneys", "ANATOMY", 213, 220], ["greater", "OBSERVATION_MODIFIER", 227, 234], ["untreated", "OBSERVATION", 256, 265], ["virus", "OBSERVATION", 305, 310], ["increased", "OBSERVATION_MODIFIER", 319, 328]]], ["IBV-induced mortality was also increased.", [["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3], ["mortality", "OBSERVATION", 12, 21], ["increased", "OBSERVATION_MODIFIER", 31, 40]]], ["It seems possible that infection with CAV at a critical time might induce some of these effects on IB.IMMUNOSUPPRESSION BY IBVAlthough IBV has been isolated from lymphoid tissues such as bursa of Fabricius and Harderian gland, the evidence for a direct immunosuppression is limited.", [["lymphoid tissues", "ANATOMY", 162, 178], ["bursa", "ANATOMY", 187, 192], ["Fabricius", "ANATOMY", 196, 205], ["Harderian gland", "ANATOMY", 210, 225], ["infection", "DISEASE", 23, 32], ["CAV", "DISEASE", 38, 41], ["IBV", "ORGANISM", 135, 138], ["lymphoid tissues", "TISSUE", 162, 178], ["bursa", "ORGAN", 187, 192], ["Fabricius", "TISSUE", 196, 205], ["Harderian gland", "ORGAN", 210, 225], ["IBV", "SPECIES", 135, 138], ["infection", "PROBLEM", 23, 32], ["CAV", "TREATMENT", 38, 41], ["IMMUNOSUPPRESSION", "TREATMENT", 102, 119], ["IBVAlthough IBV", "TREATMENT", 123, 138], ["lymphoid tissues", "PROBLEM", 162, 178], ["Fabricius and Harderian gland", "PROBLEM", 196, 225], ["a direct immunosuppression", "TREATMENT", 244, 270], ["seems possible", "UNCERTAINTY", 3, 17], ["infection", "OBSERVATION", 23, 32], ["IBV", "OBSERVATION", 135, 138], ["lymphoid tissues", "OBSERVATION", 162, 178], ["bursa", "ANATOMY", 187, 192], ["Fabricius", "ANATOMY", 196, 205], ["Harderian gland", "ANATOMY", 210, 225]]], ["It is not clear whether IBV multiplies in the lymphocytes but cultured macrophages were found to be resistant (von Bulow & Klasen, 1983) .", [["lymphocytes", "ANATOMY", 46, 57], ["macrophages", "ANATOMY", 71, 82], ["IBV", "ORGANISM", 24, 27], ["lymphocytes", "CELL", 46, 57], ["macrophages", "CELL", 71, 82], ["lymphocytes", "CELL_TYPE", 46, 57], ["cultured macrophages", "CELL_TYPE", 62, 82], ["IBV", "SPECIES", 24, 27], ["IBV", "PROBLEM", 24, 27], ["cultured macrophages", "PROBLEM", 62, 82], ["not clear", "UNCERTAINTY", 6, 15], ["IBV", "OBSERVATION", 24, 27], ["lymphocytes", "ANATOMY", 46, 57]]], ["A virulent IBV has been shown to induce transitory reduction in proliferative responses of whole blood lymphocytes to T-cell mitogens, PHA (Wakenell et ah, 1995) and concanavalin A (Dhinakar Raj & Jones, 1997a).", [["whole blood lymphocytes", "ANATOMY", 91, 114], ["T-cell", "ANATOMY", 118, 124], ["concanavalin A", "CHEMICAL", 166, 180], ["IBV", "ORGANISM", 11, 14], ["blood lymphocytes", "CELL", 97, 114], ["T-cell mitogens", "CELL", 118, 133], ["PHA", "SIMPLE_CHEMICAL", 135, 138], ["concanavalin A", "SIMPLE_CHEMICAL", 166, 180], ["whole blood lymphocytes", "CELL_TYPE", 91, 114], ["PHA", "PROTEIN", 135, 138], ["IBV", "SPECIES", 11, 14], ["A virulent IBV", "PROBLEM", 0, 14], ["transitory reduction", "PROBLEM", 40, 60], ["whole blood lymphocytes", "PROBLEM", 91, 114], ["PHA", "TEST", 135, 138], ["virulent", "OBSERVATION_MODIFIER", 2, 10], ["IBV", "OBSERVATION", 11, 14], ["transitory", "OBSERVATION_MODIFIER", 40, 50], ["reduction", "OBSERVATION_MODIFIER", 51, 60], ["proliferative responses", "OBSERVATION", 64, 87]]], ["IBV vaccines were found to depress the Harderian gland responses to killed Brucella abortus (Montgomery et al., 1991 (Montgomery et al., , 1994 .", [["Harderian gland", "ANATOMY", 39, 54], ["IBV", "ORGANISM", 0, 3], ["Harderian gland", "ORGAN", 39, 54], ["Brucella abortus", "ORGANISM", 75, 91], ["Brucella abortus", "SPECIES", 75, 91], ["IBV", "SPECIES", 0, 3], ["Brucella abortus", "SPECIES", 75, 91], ["IBV vaccines", "TREATMENT", 0, 12], ["Harderian gland", "ANATOMY", 39, 54]]], ["However, no correlation between histological responses and HI titres to IBV were found with depression of responses to Br. abortus.Immunogenic proteins of IBVIBV is a positive-stranded RNA virus and is the prototype of the Family Coronaviradae.", [["depression", "DISEASE", 92, 102], ["IBVIBV", "CHEMICAL", 155, 161], ["IBV", "ORGANISM", 72, 75], ["Br. abortus", "ORGANISM", 119, 130], ["IBVIBV", "GENE_OR_GENE_PRODUCT", 155, 161], ["Immunogenic proteins", "PROTEIN", 131, 151], ["IBVIBV", "PROTEIN", 155, 161], ["Br. abortus", "SPECIES", 119, 130], ["IBV", "SPECIES", 72, 75], ["Br. abortus", "SPECIES", 119, 130], ["IBVIBV", "SPECIES", 155, 161], ["histological responses", "TEST", 32, 54], ["HI titres", "TEST", 59, 68], ["IBV", "PROBLEM", 72, 75], ["depression of responses", "PROBLEM", 92, 115], ["Immunogenic proteins", "TEST", 131, 151], ["IBVIBV", "TEST", 155, 161], ["a positive-stranded RNA virus", "PROBLEM", 165, 194], ["positive", "OBSERVATION_MODIFIER", 167, 175], ["stranded RNA virus", "OBSERVATION", 176, 194]]], ["It has three structural proteins.", [["structural proteins", "PROTEIN", 13, 32], ["structural proteins", "OBSERVATION", 13, 32]]], ["The spike 'S' glycoprotein is located at the surface of the virion, and consists of two subunits, SI and S2, with molecular weights of 92 and 84 K, respectively.", [["surface", "ANATOMY", 45, 52], ["virion", "ANATOMY", 60, 66], ["S' glycoprotein", "GENE_OR_GENE_PRODUCT", 11, 26], ["surface", "CELLULAR_COMPONENT", 45, 52], ["virion", "CELLULAR_COMPONENT", 60, 66], ["S2", "GENE_OR_GENE_PRODUCT", 105, 107], ["spike 'S' glycoprotein", "PROTEIN", 4, 26], ["SI", "PROTEIN", 98, 100], ["S2", "PROTEIN", 105, 107], ["The spike 'S' glycoprotein", "PROBLEM", 0, 26], ["molecular weights", "TEST", 114, 131], ["spike", "OBSERVATION_MODIFIER", 4, 9], ["surface", "ANATOMY_MODIFIER", 45, 52], ["virion", "ANATOMY", 60, 66], ["S2", "ANATOMY", 105, 107]]], ["The membrane 'M' glycoprotein is partially exposed at the surface of the virion with molecular weights ranging from 27 to 36 K, and the nucleocapsid 'N' protein is internally located with a molecular weight of 52 K (Wadey & Westaway, 1981; Cavanagh, 1983a,b,c) .Immunogenic proteins of IBVThe SI glycoprotein of IBV induces virus neutralizing (VN) and HI antibodies (Cavanagh et al, , 1986 Kant et al, 1992; Koch et al, 1990; Mockett et al, 1984; Niesters et al, 1987) and has been considered as the most likely inducer of protection (Cavanagh et al, 1986; Ignjatovic & Galli, 1994) , but S2 and N proteins may also be important since they carried epitopes for induction of cross-reactive antibodies (Ignjatovic & Galli, 1995) .", [["membrane", "ANATOMY", 4, 12], ["surface", "ANATOMY", 58, 65], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["M' glycoprotein", "GENE_OR_GENE_PRODUCT", 14, 29], ["surface", "CELLULAR_COMPONENT", 58, 65], ["virion", "CELLULAR_COMPONENT", 73, 79], ["nucleocapsid", "CELLULAR_COMPONENT", 136, 148], ["IBVThe SI glycoprotein", "GENE_OR_GENE_PRODUCT", 286, 308], ["IBV", "ORGANISM", 312, 315], ["VN", "GENE_OR_GENE_PRODUCT", 344, 346], ["HI antibodies", "GENE_OR_GENE_PRODUCT", 352, 365], ["S2", "GENE_OR_GENE_PRODUCT", 589, 591], ["N proteins", "GENE_OR_GENE_PRODUCT", 596, 606], ["membrane 'M' glycoprotein", "PROTEIN", 4, 29], ["nucleocapsid 'N' protein", "PROTEIN", 136, 160], ["Immunogenic proteins", "PROTEIN", 262, 282], ["IBVThe SI glycoprotein", "PROTEIN", 286, 308], ["VN", "PROTEIN", 344, 346], ["HI antibodies", "PROTEIN", 352, 365], ["S2 and N proteins", "PROTEIN", 589, 606], ["epitopes", "PROTEIN", 648, 656], ["cross-reactive antibodies", "PROTEIN", 674, 699], ["IBV", "SPECIES", 312, 315], ["HI", "SPECIES", 352, 354], ["The membrane 'M' glycoprotein", "TREATMENT", 0, 29], ["molecular weights", "TEST", 85, 102], ["the nucleocapsid 'N' protein", "TEST", 132, 160], ["a molecular weight", "TEST", 188, 206], ["Cavanagh", "TEST", 240, 248], ["Immunogenic proteins", "PROBLEM", 262, 282], ["IBVThe SI glycoprotein", "TREATMENT", 286, 308], ["IBV induces virus neutralizing", "PROBLEM", 312, 342], ["HI antibodies", "TEST", 352, 365], ["S2 and N proteins", "PROBLEM", 589, 606], ["cross-reactive antibodies", "PROBLEM", 674, 699], ["IBVThe SI", "OBSERVATION_MODIFIER", 286, 295], ["Galli", "ANATOMY", 570, 575]]], ["The time of appearance of SI, S2 and N ELJSA-antibodies have been shown to be similar, being detected 2 weeks after live IBV vaccination (Ignjatovic & Galli, 1995) .", [["S2", "GENE_OR_GENE_PRODUCT", 30, 32], ["ELJSA", "GENE_OR_GENE_PRODUCT", 39, 44], ["IBV", "ORGANISM", 121, 124], ["S2", "PROTEIN", 30, 32], ["ELJSA", "PROTEIN", 39, 44], ["antibodies", "PROTEIN", 45, 55], ["IBV", "SPECIES", 121, 124], ["N ELJSA-antibodies", "TEST", 37, 55], ["live IBV vaccination", "TREATMENT", 116, 136]]], ["This coincides with the appearance of VN antibodies Mockett & Darbyshire, 1981; Darbyshire and Peters, 1984) .", [["VN antibodies", "PROTEIN", 38, 51]]], ["Epitopes on N and S2 proteins that gave rise to cross-reactive antibodies showed the same degree of conservation while SI epitopes were shown to be marginally less conserved (Ignjatovic & Galli, 1995) .Immunogenic proteins of IBVA T-cell epitope has been identified in the IBV 'N' protein (Boots et al, 1991) and has been shown to induce anti-viral responses (Boots et al, 1992) .", [["IBVA T-cell", "ANATOMY", 226, 237], ["IBVA T-cell epitope", "GENE_OR_GENE_PRODUCT", 226, 245], ["IBV", "ORGANISM", 273, 276], ["N and S2 proteins", "PROTEIN", 12, 29], ["cross-reactive antibodies", "PROTEIN", 48, 73], ["SI epitopes", "PROTEIN", 119, 130], ["Immunogenic proteins", "PROTEIN", 202, 222], ["IBVA T-cell epitope", "PROTEIN", 226, 245], ["IBV", "SPECIES", 273, 276], ["Epitopes on N and S2 proteins", "TEST", 0, 29], ["cross-reactive antibodies", "TEST", 48, 73], ["SI epitopes", "TEST", 119, 130], ["Immunogenic proteins", "TEST", 202, 222], ["IBVA T-cell epitope", "TREATMENT", 226, 245], ["cell epitope", "OBSERVATION", 233, 245]]], ["Cellular immune responses elicited by a live IBV vaccine have also been found to be cross-reactive and the responses varied in magnitude with the serotype of IBV used for in vitro stimulation (Dhinakar Raj & Jones, 1997b) .Innate immunityImmunity can be considered to be either innate or acquired.", [["Cellular", "ANATOMY", 0, 8], ["Cellular", "CELL", 0, 8], ["IBV", "ORGANISM", 45, 48], ["IBV", "ORGANISM", 158, 161], ["IBV", "SPECIES", 45, 48], ["IBV", "SPECIES", 158, 161], ["a live IBV vaccine", "TREATMENT", 38, 56], ["the serotype of IBV", "TREATMENT", 142, 161], ["cross-reactive", "OBSERVATION", 84, 98]]], ["Innate immunity comprises a collection of factors which resist invasion by external agents, such as physical barriers provided by skin and mucous membranes, soluble factors like lysozyme, complement and acute phase proteins, and cells such as granulocytes, macrophages and natural killer (NK) cells.", [["skin", "ANATOMY", 130, 134], ["mucous membranes", "ANATOMY", 139, 155], ["cells", "ANATOMY", 229, 234], ["granulocytes", "ANATOMY", 243, 255], ["macrophages", "ANATOMY", 257, 268], ["natural killer (NK) cells", "ANATOMY", 273, 298], ["skin", "ORGAN", 130, 134], ["mucous membranes", "CELLULAR_COMPONENT", 139, 155], ["lysozyme", "GENE_OR_GENE_PRODUCT", 178, 186], ["cells", "CELL", 229, 234], ["granulocytes", "CELL", 243, 255], ["macrophages", "CELL", 257, 268], ["natural killer (NK) cells", "CELL", 273, 298], ["soluble factors", "PROTEIN", 157, 172], ["lysozyme", "PROTEIN", 178, 186], ["complement and acute phase proteins", "PROTEIN", 188, 223], ["granulocytes", "CELL_TYPE", 243, 255], ["macrophages", "CELL_TYPE", 257, 268], ["natural killer (NK) cells", "CELL_TYPE", 273, 298], ["external agents", "TREATMENT", 75, 90], ["physical barriers", "TREATMENT", 100, 117], ["lysozyme", "TREATMENT", 178, 186], ["acute phase proteins", "PROBLEM", 203, 223], ["granulocytes", "TEST", 243, 255], ["macrophages", "TEST", 257, 268], ["skin", "ANATOMY", 130, 134], ["mucous membranes", "ANATOMY", 139, 155], ["acute phase", "OBSERVATION_MODIFIER", 203, 214], ["natural killer", "OBSERVATION", 273, 287]]], ["The main features of innate immunity are lack of specificity and immunological memory.Innate immunityHeterophils (neutrophils) constitute the 'first line of defence' against infectious agents and are the first cells to be recruited to the site of infection, following initiation of an inflammatory response.", [["neutrophils", "ANATOMY", 114, 125], ["cells", "ANATOMY", 210, 215], ["infection", "DISEASE", 247, 256], ["Heterophils", "GENE_OR_GENE_PRODUCT", 101, 112], ["neutrophils", "CELL", 114, 125], ["cells", "CELL", 210, 215], ["Heterophils", "CELL_TYPE", 101, 112], ["neutrophils", "CELL_TYPE", 114, 125], ["neutrophils", "TEST", 114, 125], ["infectious agents", "TREATMENT", 174, 191], ["the first cells", "PROBLEM", 200, 215], ["infection", "PROBLEM", 247, 256], ["an inflammatory response", "PROBLEM", 282, 306], ["main", "OBSERVATION_MODIFIER", 4, 8], ["innate immunity", "OBSERVATION", 21, 36], ["immunityHeterophils", "OBSERVATION", 93, 112], ["infection", "OBSERVATION", 247, 256], ["inflammatory", "OBSERVATION", 285, 297]]], ["In IBV-infected chickens, heterophils are the most numerous early inflammatory cells in respiratory lavage fluids (Fulton et al, 1993) .", [["heterophils", "ANATOMY", 26, 37], ["early inflammatory cells", "ANATOMY", 60, 84], ["respiratory lavage fluids", "ANATOMY", 88, 113], ["IBV-infected", "DISEASE", 3, 15], ["IBV", "ORGANISM", 3, 6], ["chickens", "ORGANISM", 16, 24], ["heterophils", "CELL", 26, 37], ["inflammatory cells", "CELL", 66, 84], ["lavage fluids", "ORGANISM_SUBSTANCE", 100, 113], ["heterophils", "CELL_TYPE", 26, 37], ["inflammatory cells", "CELL_TYPE", 66, 84], ["chickens", "SPECIES", 16, 24], ["IBV", "SPECIES", 3, 6], ["chickens", "SPECIES", 16, 24], ["IBV", "PROBLEM", 3, 6], ["infected chickens", "PROBLEM", 7, 24], ["heterophils", "PROBLEM", 26, 37], ["respiratory lavage fluids", "TREATMENT", 88, 113], ["IBV", "OBSERVATION", 3, 6], ["infected chickens", "OBSERVATION", 7, 24], ["most numerous", "OBSERVATION_MODIFIER", 46, 59], ["early", "OBSERVATION_MODIFIER", 60, 65], ["inflammatory cells", "OBSERVATION", 66, 84], ["respiratory lavage", "OBSERVATION", 88, 106]]], ["Using a heteropaenic chicken model (Kogut et al, 1993) the importance of these cells in limiting IBV replication was studied (Dhinakar Raj et al., 1997c) .", [["cells", "ANATOMY", 79, 84], ["chicken", "ORGANISM", 21, 28], ["cells", "CELL", 79, 84], ["IBV", "ORGANISM", 97, 100], ["chicken", "SPECIES", 21, 28], ["chicken", "SPECIES", 21, 28], ["IBV", "SPECIES", 97, 100], ["a heteropaenic chicken model", "TREATMENT", 6, 34], ["these cells", "TREATMENT", 73, 84], ["IBV replication", "TREATMENT", 97, 112]]], ["It was found that they had no effect on virus multiplication and, in fact, contributed to the damage in the tracheal epithelium.Innate immunityThe role of macrophages in IBV infections is unknown, while no alterations in NK cell activity has been found following IBV infection (Wakenell et al, 1995) .", [["tracheal epithelium", "ANATOMY", 108, 127], ["macrophages", "ANATOMY", 155, 166], ["NK cell", "ANATOMY", 221, 228], ["IBV infections", "DISEASE", 170, 184], ["IBV infection", "DISEASE", 263, 276], ["tracheal epithelium", "TISSUE", 108, 127], ["macrophages", "CELL", 155, 166], ["IBV", "ORGANISM", 170, 173], ["NK cell", "CELL", 221, 228], ["IBV", "ORGANISM", 263, 266], ["macrophages", "CELL_TYPE", 155, 166], ["IBV", "SPECIES", 170, 173], ["IBV", "SPECIES", 263, 266], ["virus multiplication", "PROBLEM", 40, 60], ["the damage in the tracheal epithelium", "PROBLEM", 90, 127], ["macrophages", "PROBLEM", 155, 166], ["IBV infections", "PROBLEM", 170, 184], ["alterations in NK cell activity", "PROBLEM", 206, 237], ["IBV infection", "PROBLEM", 263, 276], ["virus", "OBSERVATION", 40, 45], ["damage", "OBSERVATION", 94, 100], ["tracheal epithelium", "ANATOMY", 108, 127], ["macrophages", "OBSERVATION", 155, 166], ["IBV", "OBSERVATION_MODIFIER", 170, 173], ["infections", "OBSERVATION", 174, 184], ["NK cell activity", "OBSERVATION", 221, 237], ["infection", "OBSERVATION", 267, 276]]], ["Serum levels of an acute phase protein, \u00b0\u00b0 i acid glycoprotein, have been found to peak on day 6 following IBV infection (Nakamura et al, 1996) .Acquired immunityAcquired immunity results in the activation of antigen-specific effector mechanisms including B-cells (humoral), T-cells (cellular) and macrophages, and the production of memory cells.Upon receiving proper stimuli, B-cells differentiate into plasma cells to secrete antibodies either in the presence (T-dependent antigen) or absence (T-independent antigen) of T-helper (T n ) cells.", [["Serum", "ANATOMY", 0, 5], ["B-cells", "ANATOMY", 256, 263], ["T-cells", "ANATOMY", 275, 282], ["cellular", "ANATOMY", 284, 292], ["macrophages", "ANATOMY", 298, 309], ["memory cells", "ANATOMY", 333, 345], ["B-cells", "ANATOMY", 377, 384], ["plasma cells", "ANATOMY", 404, 416], ["T-helper (T n ) cells", "ANATOMY", 522, 543], ["IBV infection", "DISEASE", 107, 120], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["\u00b0\u00b0 i acid glycoprotein", "GENE_OR_GENE_PRODUCT", 40, 62], ["IBV", "ORGANISM", 107, 110], ["antigen", "GENE_OR_GENE_PRODUCT", 209, 216], ["B-cells", "CELL", 256, 263], ["humoral", "CELL", 265, 272], ["T-cells", "CELL", 275, 282], ["cellular", "CELL", 284, 292], ["macrophages", "CELL", 298, 309], ["memory cells", "CELL", 333, 345], ["B-cells", "CELL", 377, 384], ["plasma cells", "CELL", 404, 416], ["T-dependent antigen", "GENE_OR_GENE_PRODUCT", 463, 482], ["T-independent antigen", "GENE_OR_GENE_PRODUCT", 496, 517], ["T-helper (T n ) cells", "CELL", 522, 543], ["acute phase protein", "PROTEIN", 19, 38], ["\u00b0\u00b0 i acid glycoprotein", "PROTEIN", 40, 62], ["B-cells", "CELL_TYPE", 256, 263], ["T-cells", "CELL_TYPE", 275, 282], ["macrophages", "CELL_TYPE", 298, 309], ["memory cells", "CELL_TYPE", 333, 345], ["B-cells", "CELL_TYPE", 377, 384], ["plasma cells", "CELL_TYPE", 404, 416], ["antibodies", "PROTEIN", 428, 438], ["T-dependent antigen", "PROTEIN", 463, 482], ["T-independent antigen", "PROTEIN", 496, 517], ["T-helper (T n ) cells", "CELL_TYPE", 522, 543], ["IBV", "SPECIES", 107, 110], ["Serum levels", "TEST", 0, 12], ["an acute phase protein", "TEST", 16, 38], ["\u00b0\u00b0 i acid glycoprotein", "PROBLEM", 40, 62], ["IBV infection", "PROBLEM", 107, 120], ["antigen", "TEST", 209, 216], ["B-cells", "TEST", 256, 263], ["macrophages", "PROBLEM", 298, 309], ["proper stimuli", "TEST", 361, 375], ["B-cells", "TEST", 377, 384], ["plasma cells", "TEST", 404, 416], ["secrete antibodies", "TEST", 420, 438], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 111, 120], ["macrophages", "ANATOMY", 298, 309], ["memory cells", "OBSERVATION", 333, 345]]], ["Chickens develop a good humoral responseto IBV infections, measurable by enzyme-linked immunosorbent assay (ELISA), haemagglutiation inhibition (HI) or VN tests (De Wit et al, 1992; Monreal et al, 1985; Wilcox et al, 1983) .", [["IBV infections", "DISEASE", 43, 57], ["Chickens", "ORGANISM", 0, 8], ["IBV", "ORGANISM", 43, 46], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 43, 46], ["a good humoral responseto IBV infections", "PROBLEM", 17, 57], ["enzyme", "TEST", 73, 79], ["immunosorbent assay", "TEST", 87, 106], ["ELISA", "TEST", 108, 113], ["haemagglutiation inhibition", "PROBLEM", 116, 143], ["VN tests", "TEST", 152, 160], ["good", "OBSERVATION_MODIFIER", 19, 23], ["humoral responseto", "OBSERVATION", 24, 42], ["IBV infections", "OBSERVATION", 43, 57]]], ["However, there is a lack of correlation between titres of circulating antibodies and resistance to infection (Raggi & Lee, 1965; Winterfield & Fadly, 1972; .Upon receiving proper stimuli, B-cells differentiate into plasma cells to secrete antibodies either in the presence (T-dependent antigen) or absence (T-independent antigen) of T-helper (T n ) cells.", [["B-cells", "ANATOMY", 188, 195], ["plasma cells", "ANATOMY", 215, 227], ["T-helper (T n ) cells", "ANATOMY", 333, 354], ["infection", "DISEASE", 99, 108], ["B-cells", "CELL", 188, 195], ["plasma cells", "CELL", 215, 227], ["T-dependent antigen", "GENE_OR_GENE_PRODUCT", 274, 293], ["T-independent antigen", "GENE_OR_GENE_PRODUCT", 307, 328], ["T-helper (T n ) cells", "CELL", 333, 354], ["circulating antibodies", "PROTEIN", 58, 80], ["B-cells", "CELL_TYPE", 188, 195], ["plasma cells", "CELL_TYPE", 215, 227], ["antibodies", "PROTEIN", 239, 249], ["T-dependent antigen", "PROTEIN", 274, 293], ["T-independent antigen", "PROTEIN", 307, 328], ["T-helper (T n ) cells", "CELL_TYPE", 333, 354], ["Raggi & Lee, 1965; Winterfield & Fadly, 1972", "SPECIES", 110, 154], ["circulating antibodies", "PROBLEM", 58, 80], ["infection", "PROBLEM", 99, 108], ["proper stimuli", "TEST", 172, 186], ["B-cells", "TEST", 188, 195], ["plasma cells", "TEST", 215, 227], ["secrete antibodies", "TEST", 231, 249], ["infection", "OBSERVATION", 99, 108]]], ["Chickens develop a good humoral responseImmunoglobulin G (IgG), the major circulating Ig, is the antibody detected by HI and an ELISA developed to measure it is more sensitive (Mockett & Darbyshire, 1981) .", [["Chickens", "ORGANISM", 0, 8], ["responseImmunoglobulin G", "GENE_OR_GENE_PRODUCT", 32, 56], ["IgG", "GENE_OR_GENE_PRODUCT", 58, 61], ["Ig", "GENE_OR_GENE_PRODUCT", 86, 88], ["humoral responseImmunoglobulin G", "PROTEIN", 24, 56], ["IgG", "PROTEIN", 58, 61], ["major circulating Ig", "PROTEIN", 68, 88], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["the antibody", "TEST", 93, 105], ["HI", "PROBLEM", 118, 120], ["an ELISA", "TEST", 125, 133], ["good", "OBSERVATION_MODIFIER", 19, 23]]], ["Anti-IBV IgG can be detected as soon as four days pi, reaches a peak at about 21 days but can remain in high titre in the serum for many weeks (Mockett and Darbyshire, 1981) .", [["serum", "ANATOMY", 122, 127], ["Anti-IBV IgG", "GENE_OR_GENE_PRODUCT", 0, 12], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["Anti-IBV IgG", "PROTEIN", 0, 12], ["Anti-IBV", "SPECIES", 0, 8], ["Anti-IBV IgG", "TREATMENT", 0, 12]]], ["This is the antibody measured in conventional serological tests to monitor IBV infections or vaccine uptake.Upon receiving proper stimuli, B-cells differentiate into plasma cells to secrete antibodies either in the presence (T-dependent antigen) or absence (T-independent antigen) of T-helper (T n ) cells.", [["B-cells", "ANATOMY", 139, 146], ["plasma cells", "ANATOMY", 166, 178], ["T-helper (T n ) cells", "ANATOMY", 284, 305], ["IBV infections", "DISEASE", 75, 89], ["IBV", "ORGANISM", 75, 78], ["B-cells", "CELL", 139, 146], ["plasma cells", "CELL", 166, 178], ["T-dependent antigen", "GENE_OR_GENE_PRODUCT", 225, 244], ["T-independent antigen", "GENE_OR_GENE_PRODUCT", 258, 279], ["T-helper (T n ) cells", "CELL", 284, 305], ["B-cells", "CELL_TYPE", 139, 146], ["plasma cells", "CELL_TYPE", 166, 178], ["antibodies", "PROTEIN", 190, 200], ["T-dependent antigen", "PROTEIN", 225, 244], ["T-independent antigen", "PROTEIN", 258, 279], ["T-helper (T n ) cells", "CELL_TYPE", 284, 305], ["IBV", "SPECIES", 75, 78], ["the antibody", "TEST", 8, 20], ["conventional serological tests", "TEST", 33, 63], ["IBV infections", "PROBLEM", 75, 89], ["vaccine uptake", "PROBLEM", 93, 107], ["proper stimuli", "TEST", 123, 137], ["B-cells", "TEST", 139, 146], ["plasma cells", "TEST", 166, 178], ["secrete antibodies", "TEST", 182, 200]]], ["Chickens develop a good humoral responseImmunoglobulin M (IgM), present only transitorily after infection, reaches peak concentrations about 8 days after IBV infection and levels then decline (Mockett and Cook, 1986) .", [["infection", "DISEASE", 96, 105], ["IBV infection", "DISEASE", 154, 167], ["Chickens", "ORGANISM", 0, 8], ["responseImmunoglobulin M", "GENE_OR_GENE_PRODUCT", 32, 56], ["IgM", "GENE_OR_GENE_PRODUCT", 58, 61], ["IBV", "ORGANISM", 154, 157], ["IgM", "PROTEIN", 58, 61], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 154, 157], ["infection", "PROBLEM", 96, 105], ["peak concentrations", "PROBLEM", 115, 134], ["IBV infection", "PROBLEM", 154, 167], ["infection", "OBSERVATION", 96, 105], ["infection", "OBSERVATION", 158, 167]]], ["Although an IgM-specific ELISA has been shown to be useful in the diagnosis of recent infections (Martins et al., 1991) , these antibodies needed to be separated either by sucrose density gradient centrifugation (Gillette, 1974) or column chromatography (Mockett & Cook, 1986) before performing the ELISA.", [["infections", "DISEASE", 86, 96], ["sucrose", "CHEMICAL", 172, 179], ["sucrose", "CHEMICAL", 172, 179], ["IgM", "GENE_OR_GENE_PRODUCT", 12, 15], ["sucrose", "SIMPLE_CHEMICAL", 172, 179], ["IgM", "PROTEIN", 12, 15], ["antibodies", "PROTEIN", 128, 138], ["an IgM", "TEST", 9, 15], ["specific ELISA", "TEST", 16, 30], ["recent infections", "PROBLEM", 79, 96], ["these antibodies", "TEST", 122, 138], ["column chromatography", "TEST", 232, 253], ["IgM", "OBSERVATION", 12, 15], ["infections", "OBSERVATION", 86, 96]]], ["The availability of an antibody-capture ELISA for IBVspecific IgM assays would facilitate IB diagnosis where demonstration of the virus is time-consuming.Upon receiving proper stimuli, B-cells differentiate into plasma cells to secrete antibodies either in the presence (T-dependent antigen) or absence (T-independent antigen) of T-helper (T n ) cells.", [["B-cells", "ANATOMY", 185, 192], ["plasma cells", "ANATOMY", 212, 224], ["T-helper (T n ) cells", "ANATOMY", 330, 351], ["B-cells", "CELL", 185, 192], ["plasma cells", "CELL", 212, 224], ["T-dependent antigen", "GENE_OR_GENE_PRODUCT", 271, 290], ["T-independent antigen", "GENE_OR_GENE_PRODUCT", 304, 325], ["T-helper (T n ) cells", "CELL", 330, 351], ["IgM", "PROTEIN", 62, 65], ["B-cells", "CELL_TYPE", 185, 192], ["plasma cells", "CELL_TYPE", 212, 224], ["antibodies", "PROTEIN", 236, 246], ["T-dependent antigen", "PROTEIN", 271, 290], ["T-independent antigen", "PROTEIN", 304, 325], ["T-helper (T n ) cells", "CELL_TYPE", 330, 351], ["an antibody", "TEST", 20, 31], ["capture ELISA", "TEST", 32, 45], ["IBVspecific IgM assays", "TEST", 50, 72], ["the virus", "PROBLEM", 126, 135], ["proper stimuli", "TEST", 169, 183], ["B-cells", "TEST", 185, 192], ["plasma cells", "TEST", 212, 224], ["secrete antibodies", "TEST", 228, 246]]], ["Chickens develop a good humoral responseThe importance of B-cells in IBV infections has been studied by depletion experiments using the hormone testosterone propionate (Chubb, 1974) , the chemical cyclophosphamide (Chandra, 1988; Chubb, 1974) and surgical bursectomy (Cook et al, 1991a) .", [["B-cells", "ANATOMY", 58, 65], ["IBV infections", "DISEASE", 69, 83], ["testosterone propionate", "CHEMICAL", 144, 167], ["Chubb, 1974", "CHEMICAL", 169, 180], ["cyclophosphamide", "CHEMICAL", 197, 213], ["testosterone propionate", "CHEMICAL", 144, 167], ["Chubb, 1974", "CHEMICAL", 169, 180], ["cyclophosphamide", "CHEMICAL", 197, 213], ["Chickens", "ORGANISM", 0, 8], ["B-cells", "CELL", 58, 65], ["IBV", "ORGANISM", 69, 72], ["testosterone propionate", "SIMPLE_CHEMICAL", 144, 167], ["Chubb", "SIMPLE_CHEMICAL", 169, 174], ["cyclophosphamide", "SIMPLE_CHEMICAL", 197, 213], ["B-cells", "CELL_TYPE", 58, 65], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 69, 72], ["B-cells", "TREATMENT", 58, 65], ["IBV infections", "PROBLEM", 69, 83], ["the hormone testosterone propionate", "TREATMENT", 132, 167], ["the chemical cyclophosphamide", "TREATMENT", 184, 213], ["surgical bursectomy", "TREATMENT", 247, 266], ["good", "OBSERVATION_MODIFIER", 19, 23], ["humoral response", "OBSERVATION", 24, 40], ["infections", "OBSERVATION", 73, 83], ["surgical bursectomy", "OBSERVATION", 247, 266]]], ["Cyclophosphamide-treated chickens showed increased clinical signs and more severe histopathological lesions in the kidney (Chandra, 1988) attributable to the prolonged persistence of virus.", [["lesions", "ANATOMY", 100, 107], ["kidney", "ANATOMY", 115, 121], ["Cyclophosphamide", "CHEMICAL", 0, 16], ["Cyclophosphamide", "CHEMICAL", 0, 16], ["Cyclophosphamide", "SIMPLE_CHEMICAL", 0, 16], ["chickens", "ORGANISM", 25, 33], ["histopathological lesions", "PATHOLOGICAL_FORMATION", 82, 107], ["kidney", "ORGAN", 115, 121], ["chickens", "SPECIES", 25, 33], ["chickens", "SPECIES", 25, 33], ["Cyclophosphamide", "TREATMENT", 0, 16], ["increased clinical signs", "PROBLEM", 41, 65], ["more severe histopathological lesions in the kidney", "PROBLEM", 70, 121], ["the prolonged persistence of virus", "PROBLEM", 154, 188], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["more severe", "OBSERVATION_MODIFIER", 70, 81], ["histopathological", "OBSERVATION_MODIFIER", 82, 99], ["lesions", "OBSERVATION", 100, 107], ["kidney", "ANATOMY", 115, 121], ["virus", "OBSERVATION", 183, 188]]], ["IBV infection of a surgically bursectomised resistant chicken line (line C) resulted in increased severity and duration of clinical infection but not mortality (Cook et al., 1991a) .", [["IBV infection", "DISEASE", 0, 13], ["infection", "DISEASE", 132, 141], ["IBV", "ORGANISM", 0, 3], ["chicken", "ORGANISM", 54, 61], ["line C", "CELL", 68, 74], ["surgically bursectomised resistant chicken line", "CELL_LINE", 19, 66], ["line C", "CELL_LINE", 68, 74], ["chicken", "SPECIES", 54, 61], ["IBV", "SPECIES", 0, 3], ["chicken", "SPECIES", 54, 61], ["IBV infection", "PROBLEM", 0, 13], ["a surgically bursectomised resistant chicken line (line C", "TREATMENT", 17, 74], ["increased severity", "PROBLEM", 88, 106], ["clinical infection", "PROBLEM", 123, 141], ["infection", "OBSERVATION", 4, 13], ["surgically bursectomised", "OBSERVATION_MODIFIER", 19, 43], ["resistant", "OBSERVATION_MODIFIER", 44, 53], ["chicken line", "OBSERVATION", 54, 66], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["severity", "OBSERVATION_MODIFIER", 98, 106], ["infection", "OBSERVATION", 132, 141]]], ["However, humoral antibodies seemed to protect the tracheal epithelium following secondary challenge.", [["tracheal epithelium", "ANATOMY", 50, 69], ["tracheal epithelium", "TISSUE", 50, 69], ["humoral antibodies", "PROTEIN", 9, 27], ["humoral antibodies", "TEST", 9, 27], ["the tracheal epithelium", "PROBLEM", 46, 69], ["tracheal", "ANATOMY", 50, 58], ["epithelium", "ANATOMY_MODIFIER", 59, 69]]], ["Presence of high titres of humoral antibodies correlate well with the absence of virus recovery from kidneys and genital tract MacDonald et al, 1981; Yachida et al, 1985) and protection against drop in egg production (Box et al., 1988) .", [["kidneys", "ANATOMY", 101, 108], ["egg", "ANATOMY", 202, 205], ["kidneys", "ORGAN", 101, 108], ["genital", "ORGANISM_SUBDIVISION", 113, 120], ["egg", "ORGANISM_SUBSTANCE", 202, 205], ["humoral antibodies", "PROTEIN", 27, 45], ["high titres of humoral antibodies", "PROBLEM", 12, 45], ["protection", "TREATMENT", 175, 185], ["drop in egg production", "PROBLEM", 194, 216], ["high", "OBSERVATION_MODIFIER", 12, 16], ["kidneys", "ANATOMY", 101, 108], ["genital tract", "ANATOMY", 113, 126]]], ["IBV-specific antibodies probably prevent the spread of virus by viraemia from the trachea to other susceptible organs such as the kidneys and oviduct.Upon receiving proper stimuli, B-cells differentiate into plasma cells to secrete antibodies either in the presence (T-dependent antigen) or absence (T-independent antigen) of T-helper (T n ) cells.", [["trachea", "ANATOMY", 82, 89], ["organs", "ANATOMY", 111, 117], ["kidneys", "ANATOMY", 130, 137], ["oviduct", "ANATOMY", 142, 149], ["B-cells", "ANATOMY", 181, 188], ["plasma cells", "ANATOMY", 208, 220], ["T-helper (T n ) cells", "ANATOMY", 326, 347], ["viraemia", "DISEASE", 64, 72], ["IBV", "ORGANISM", 0, 3], ["trachea", "ORGAN", 82, 89], ["organs", "ORGAN", 111, 117], ["kidneys", "ORGAN", 130, 137], ["oviduct", "ORGAN", 142, 149], ["B-cells", "CELL", 181, 188], ["plasma cells", "CELL", 208, 220], ["T-dependent antigen", "GENE_OR_GENE_PRODUCT", 267, 286], ["T-independent antigen", "GENE_OR_GENE_PRODUCT", 300, 321], ["T-helper (T n ) cells", "CELL", 326, 347], ["IBV-specific antibodies", "PROTEIN", 0, 23], ["B-cells", "CELL_TYPE", 181, 188], ["plasma cells", "CELL_TYPE", 208, 220], ["antibodies", "PROTEIN", 232, 242], ["T-dependent antigen", "PROTEIN", 267, 286], ["T-independent antigen", "PROTEIN", 300, 321], ["T-helper (T n ) cells", "CELL_TYPE", 326, 347], ["IBV", "SPECIES", 0, 3], ["IBV", "TREATMENT", 0, 3], ["specific antibodies", "TREATMENT", 4, 23], ["virus", "PROBLEM", 55, 60], ["viraemia", "PROBLEM", 64, 72], ["proper stimuli", "TEST", 165, 179], ["B-cells", "TEST", 181, 188], ["plasma cells", "TEST", 208, 220], ["secrete antibodies", "TEST", 224, 242], ["virus", "OBSERVATION", 55, 60], ["viraemia", "OBSERVATION", 64, 72], ["trachea", "ANATOMY", 82, 89], ["kidneys", "ANATOMY", 130, 137], ["oviduct", "ANATOMY", 142, 149]]], ["Chickens develop a good humoral responseVaccination studies with IBV have always focussed on humoral immune responses in relation to protection.", [["Chickens", "ORGANISM", 0, 8], ["IBV", "ORGANISM", 65, 68], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 65, 68], ["IBV", "TREATMENT", 65, 68], ["humoral immune responses", "TREATMENT", 93, 117]]], ["Nevertheless, the lack of correlation between antibodies and resistance, discrepancies between in vitro strain differentiation by VN tests and in vivo cross-protection results (Darbyshire, 1985) and re-excretion of virus in the presence of high titres of circulating antibodies (Jones & Ambali, 1987) all suggest that while humoral antibodies play a role in recovery from IBV infection, other immunological mechanisms are involved.Maternal antibodiesMaternally derived antibodies (MDA) can provide protection against IBV, but they are short-lived (Darbyshire & Peters, 1985; Cook et al, 1991b) .", [["IBV infection", "DISEASE", 372, 385], ["IBV", "ORGANISM", 372, 375], ["Maternally derived antibodies", "GENE_OR_GENE_PRODUCT", 450, 479], ["MDA", "SIMPLE_CHEMICAL", 481, 484], ["IBV", "ORGANISM", 517, 520], ["antibodies", "PROTEIN", 46, 56], ["VN", "PROTEIN", 130, 132], ["circulating antibodies", "PROTEIN", 255, 277], ["humoral antibodies", "PROTEIN", 324, 342], ["Maternal antibodies", "PROTEIN", 431, 450], ["Maternally derived antibodies", "PROTEIN", 450, 479], ["MDA", "PROTEIN", 481, 484], ["IBV", "SPECIES", 372, 375], ["IBV", "SPECIES", 517, 520], ["antibodies", "TEST", 46, 56], ["VN tests", "TEST", 130, 138], ["re-excretion of virus", "PROBLEM", 199, 220], ["high titres of circulating antibodies", "PROBLEM", 240, 277], ["IBV infection", "PROBLEM", 372, 385], ["Maternal antibodies", "PROBLEM", 431, 450], ["IBV", "PROBLEM", 517, 520], ["high titres", "OBSERVATION", 240, 251], ["infection", "OBSERVATION", 376, 385]]], ["Presence of MDA has no adverse effect on the efficacy of live IBV vaccines administered at one-day of age (Davelaar & Kouwenhoven, 1977 , Cook et al, 1981 .", [["MDA", "CHEMICAL", 12, 15], ["MDA", "CHEMICAL", 12, 15], ["MDA", "SIMPLE_CHEMICAL", 12, 15], ["IBV", "ORGANISM", 62, 65], ["IBV", "SPECIES", 62, 65], ["adverse effect", "PROBLEM", 23, 37], ["IBV vaccines", "TREATMENT", 62, 74], ["MDA", "OBSERVATION", 12, 15], ["no", "UNCERTAINTY", 20, 22], ["adverse effect", "OBSERVATION_MODIFIER", 23, 37]]], ["Maternally-derived IgG has been demonstrated in tracheal washes (Mockett et al, 1987) .Local immunityLocal immunity in the respiratory tract is of fundamental importance in protection against IBV (Gomez & Raggi, 1974; Gillette, 1981; Hawkes et al, 1983) .", [["tracheal", "ANATOMY", 48, 56], ["respiratory tract", "ANATOMY", 123, 140], ["IgG", "GENE_OR_GENE_PRODUCT", 19, 22], ["tracheal", "ORGAN", 48, 56], ["respiratory tract", "ORGANISM_SUBDIVISION", 123, 140], ["IBV", "ORGANISM", 192, 195], ["IgG", "PROTEIN", 19, 22], ["IBV", "SPECIES", 192, 195], ["Gomez & Raggi, 1974; Gillette, 1981; Hawkes et al, 1983)", "SPECIES", 197, 253], ["tracheal washes", "TREATMENT", 48, 63], ["Local immunityLocal immunity", "TREATMENT", 87, 115], ["tracheal", "ANATOMY", 48, 56], ["immunityLocal immunity", "OBSERVATION", 93, 115], ["respiratory tract", "ANATOMY", 123, 140]]], ["This has been exemplified by the use of an in vitro challenge model using TOC from immunized chickens, for cross-protection studies .", [["TOC", "CHEMICAL", 74, 77], ["TOC", "CHEMICAL", 74, 77], ["TOC", "SIMPLE_CHEMICAL", 74, 77], ["chickens", "ORGANISM", 93, 101], ["chickens", "SPECIES", 93, 101], ["chickens", "SPECIES", 93, 101], ["an in vitro challenge model", "TREATMENT", 40, 67], ["immunized chickens", "TREATMENT", 83, 101], ["cross-protection studies", "TEST", 107, 131]]], ["IBVspecific IgA and IgG have been demonstrated in tracheal washes of infected chickens (Hawkes et al, 1983; Dhinakar Raj & Jones, 1996b ) and antibody-secreting cells were shown in tracheal sections (Nakamura et al, 1991) .", [["tracheal", "ANATOMY", 50, 58], ["cells", "ANATOMY", 161, 166], ["tracheal sections", "ANATOMY", 181, 198], ["IgA", "GENE_OR_GENE_PRODUCT", 12, 15], ["IgG", "GENE_OR_GENE_PRODUCT", 20, 23], ["chickens", "ORGANISM", 78, 86], ["cells", "CELL", 161, 166], ["tracheal sections", "MULTI-TISSUE_STRUCTURE", 181, 198], ["IBVspecific IgA", "PROTEIN", 0, 15], ["IgG", "PROTEIN", 20, 23], ["antibody-secreting cells", "CELL_TYPE", 142, 166], ["chickens", "SPECIES", 78, 86], ["chickens", "SPECIES", 78, 86], ["IBVspecific IgA", "TEST", 0, 15], ["IgG", "TEST", 20, 23], ["tracheal washes", "TREATMENT", 50, 65], ["infected chickens", "PROBLEM", 69, 86], ["antibody", "TEST", 142, 150], ["secreting cells", "PROBLEM", 151, 166], ["IgA", "OBSERVATION", 12, 15], ["IgG", "OBSERVATION", 20, 23], ["tracheal", "ANATOMY", 50, 58], ["washes", "OBSERVATION_MODIFIER", 59, 65], ["infected", "OBSERVATION_MODIFIER", 69, 77], ["chickens", "OBSERVATION_MODIFIER", 78, 86], ["secreting cells", "OBSERVATION", 151, 166], ["tracheal", "ANATOMY", 181, 189]]], ["Local immunity at the oviduct level has been shown by demonstration of virus-specific IgG and IgA in the oviduct washes of infected hens (Dhinakar Raj & Jones, 1996b) .", [["oviduct", "ANATOMY", 22, 29], ["oviduct", "ANATOMY", 105, 112], ["oviduct", "ORGAN", 22, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 86, 89], ["IgA", "GENE_OR_GENE_PRODUCT", 94, 97], ["oviduct", "ORGAN", 105, 112], ["hens", "ORGANISM", 132, 136], ["IgG", "PROTEIN", 86, 89], ["IgA", "PROTEIN", 94, 97], ["hens", "SPECIES", 132, 136], ["Dhinakar Raj & Jones, 1996b", "SPECIES", 138, 165], ["virus", "PROBLEM", 71, 76], ["specific IgG", "TEST", 77, 89], ["IgA", "TEST", 94, 97], ["infected", "OBSERVATION", 123, 131]]], ["It was found that in addition to local production, antibodies also transuded from the serum later in the course of infection, but their value in protection of the oviduct has not been determined.", [["serum", "ANATOMY", 86, 91], ["oviduct", "ANATOMY", 163, 170], ["infection", "DISEASE", 115, 124], ["serum", "ORGANISM_SUBSTANCE", 86, 91], ["oviduct", "ORGAN", 163, 170], ["antibodies", "PROTEIN", 51, 61], ["local production, antibodies", "PROBLEM", 33, 61], ["the serum", "TEST", 82, 91], ["infection", "PROBLEM", 115, 124], ["local production", "OBSERVATION", 33, 49], ["infection", "OBSERVATION", 115, 124], ["oviduct", "ANATOMY", 163, 170]]], ["In young chicks, local antibodies in the oviduct were found to be less protective compared to those in the trachea using in vitro challenge of OOC prepared from vaccinated chickens (Dhinakar Raj & Jones, 1996d) .Local immunityAlthough IBV has been shown to multiply in the gut (Lucio & Fabricant, 1990; Ambali & Jones, 1990) , Lutticken et al. (1988) could not detect any antibodies in gut washings following vaccination of day-old chicks with HI20 vaccine and revaccination at 4 weeks of age with live H52 vaccine, inactivated M41 in an oil emulsion or inactivated M41 adjuvanted with avridine.", [["oviduct", "ANATOMY", 41, 48], ["trachea", "ANATOMY", 107, 114], ["OOC", "ANATOMY", 143, 146], ["gut", "ANATOMY", 273, 276], ["gut", "ANATOMY", 386, 389], ["oil", "ANATOMY", 538, 541], ["OOC", "CHEMICAL", 143, 146], ["HI20", "CHEMICAL", 444, 448], ["H52", "CHEMICAL", 503, 506], ["M41", "CHEMICAL", 528, 531], ["M41", "CHEMICAL", 566, 569], ["avridine", "CHEMICAL", 586, 594], ["avridine", "CHEMICAL", 586, 594], ["oviduct", "ORGAN", 41, 48], ["trachea", "ORGAN", 107, 114], ["OOC", "SIMPLE_CHEMICAL", 143, 146], ["chickens", "ORGANISM", 172, 180], ["IBV", "ORGANISM", 235, 238], ["gut", "ORGANISM_SUBDIVISION", 273, 276], ["gut", "ORGANISM_SUBDIVISION", 386, 389], ["chicks", "ORGANISM", 432, 438], ["HI20", "ORGANISM", 444, 448], ["oil", "ORGANISM_SUBSTANCE", 538, 541], ["avridine", "SIMPLE_CHEMICAL", 586, 594], ["local antibodies", "PROTEIN", 17, 33], ["antibodies", "PROTEIN", 372, 382], ["chicks", "SPECIES", 9, 15], ["chickens", "SPECIES", 172, 180], ["chickens", "SPECIES", 172, 180], ["Dhinakar Raj & Jones, 1996d", "SPECIES", 182, 209], ["IBV", "SPECIES", 235, 238], ["HI20", "SPECIES", 444, 448], ["M41", "SPECIES", 566, 569], ["local antibodies", "TEST", 17, 33], ["IBV", "PROBLEM", 235, 238], ["any antibodies", "PROBLEM", 368, 382], ["HI20 vaccine", "TREATMENT", 444, 456], ["revaccination", "TREATMENT", 461, 474], ["live H52 vaccine", "TREATMENT", 498, 514], ["an oil emulsion", "TREATMENT", 535, 550], ["avridine", "TREATMENT", 586, 594], ["oviduct", "ANATOMY", 41, 48], ["trachea", "ANATOMY", 107, 114], ["gut", "ANATOMY", 273, 276]]], ["In contrast, Dhinakar Raj & Jones (1996b) demonstrated local antibody production in the duodenum and caecal tonsils of 16-week-old hens infected with an enterotropic strain of IBV (strain G).", [["duodenum", "ANATOMY", 88, 96], ["caecal tonsils", "ANATOMY", 101, 115], ["duodenum", "ORGAN", 88, 96], ["caecal tonsils", "MULTI-TISSUE_STRUCTURE", 101, 115], ["hens", "ORGANISM", 131, 135], ["IBV", "ORGANISM", 176, 179], ["IBV", "SPECIES", 176, 179], ["local antibody production in the duodenum", "PROBLEM", 55, 96], ["IBV", "PROBLEM", 176, 179], ["antibody production", "OBSERVATION", 61, 80], ["duodenum", "ANATOMY", 88, 96], ["caecal tonsils", "ANATOMY", 101, 115]]], ["It is not clear whether the induction of these antibodies is strain-related and their role in limiting the replication of IBV in the gut needs to be investigated.Local immunityThe Harderian gland of the chicken contains a large age-dependent population of plasma cells and is the source of immunoglobulins in the lachrymal fluid (Baba et al, 1988) .", [["gut", "ANATOMY", 133, 136], ["Harderian gland", "ANATOMY", 180, 195], ["plasma cells", "ANATOMY", 256, 268], ["lachrymal fluid", "ANATOMY", 313, 328], ["IBV", "ORGANISM", 122, 125], ["gut", "ORGAN", 133, 136], ["Harderian gland", "ORGAN", 180, 195], ["chicken", "ORGANISM", 203, 210], ["plasma cells", "CELL", 256, 268], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 290, 305], ["lachrymal fluid", "ORGANISM_SUBSTANCE", 313, 328], ["antibodies", "PROTEIN", 47, 57], ["plasma cells", "CELL_TYPE", 256, 268], ["immunoglobulins", "PROTEIN", 290, 305], ["chicken", "SPECIES", 203, 210], ["IBV", "SPECIES", 122, 125], ["chicken", "SPECIES", 203, 210], ["these antibodies", "TEST", 41, 57], ["IBV", "TREATMENT", 122, 125], ["plasma cells", "PROBLEM", 256, 268], ["immunoglobulins in the lachrymal fluid", "PROBLEM", 290, 328], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["Harderian gland", "ANATOMY", 180, 195], ["large", "OBSERVATION_MODIFIER", 222, 227], ["dependent", "OBSERVATION_MODIFIER", 232, 241], ["population", "OBSERVATION_MODIFIER", 242, 252], ["plasma cells", "OBSERVATION", 256, 268], ["immunoglobulins", "OBSERVATION", 290, 305], ["lachrymal", "ANATOMY", 313, 322], ["fluid", "OBSERVATION", 323, 328]]], ["It plays an important role in the development of vaccinal immunity since vaccines are generally given by spray or eye-drop.", [["vaccinal immunity", "TREATMENT", 49, 66], ["vaccines", "TREATMENT", 73, 81]]], ["Davelaar & Kouwenhoven (1981) reported that the protection against IBV of day-old ocular-vaccinated chickens was localized mainly in the oculo-nasal mucosa and removal of the Harderian gland caused a decreased level of protection (Davelaar & Kouwenhoven, 1980) .", [["oculo-nasal mucosa", "ANATOMY", 137, 155], ["Harderian gland", "ANATOMY", 175, 190], ["IBV", "ORGANISM", 67, 70], ["ocular", "ORGAN", 82, 88], ["chickens", "ORGANISM", 100, 108], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 143, 155], ["Harderian gland", "ORGAN", 175, 190], ["chickens", "SPECIES", 100, 108], ["IBV", "SPECIES", 67, 70], ["chickens", "SPECIES", 100, 108], ["old ocular-vaccinated chickens", "PROBLEM", 78, 108], ["removal", "TREATMENT", 160, 167], ["the Harderian gland", "PROBLEM", 171, 190], ["ocular", "ANATOMY", 82, 88], ["nasal mucosa", "ANATOMY", 143, 155], ["Harderian gland", "ANATOMY", 175, 190], ["decreased", "OBSERVATION_MODIFIER", 200, 209]]], ["IBV-specific IgA has been demonstrated in the lachrymal fluid Davelaar et al, 1982; and its synthesis in the Harderian gland has been shown (Davelaar et al, 1982) .", [["Harderian gland", "ANATOMY", 109, 124], ["IBV", "ORGANISM", 0, 3], ["IgA", "GENE_OR_GENE_PRODUCT", 13, 16], ["Harderian gland", "ORGAN", 109, 124], ["IgA", "PROTEIN", 13, 16], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3], ["its synthesis in the Harderian gland", "PROBLEM", 88, 124], ["specific", "OBSERVATION_MODIFIER", 4, 12], ["IgA", "OBSERVATION", 13, 16], ["lachrymal", "ANATOMY", 46, 55], ["fluid", "OBSERVATION", 56, 61], ["Harderian gland", "ANATOMY", 109, 124]]], ["IgG in tears was mainly serum-derived (Davelaar et al, 1982; Toro et al., 1993) .", [["tears", "ANATOMY", 7, 12], ["serum", "ANATOMY", 24, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["tears", "PATHOLOGICAL_FORMATION", 7, 12], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["IgG", "PROTEIN", 0, 3], ["IgG in tears", "PROBLEM", 0, 12]]], ["IgA levels in tears appeared to be better correlated with resistance to IBV re-infection (Toro & Fernandez, 1994) than levels of serum antibody (Yachida et al, 1985) and their measurement was recommended for antibody profiling of chicken flocks.", [["serum", "ANATOMY", 129, 134], ["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["tears", "PATHOLOGICAL_FORMATION", 14, 19], ["IBV", "ORGANISM", 72, 75], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["chicken", "ORGANISM", 230, 237], ["IgA", "PROTEIN", 0, 3], ["serum antibody", "PROTEIN", 129, 143], ["chicken", "SPECIES", 230, 237], ["IBV", "SPECIES", 72, 75], ["chicken", "SPECIES", 230, 237], ["IgA levels", "TEST", 0, 10], ["tears", "PROBLEM", 14, 19], ["IBV re-infection", "PROBLEM", 72, 88], ["serum antibody", "TEST", 129, 143], ["their measurement", "TEST", 170, 187], ["antibody profiling", "TEST", 208, 226], ["chicken flocks", "PROBLEM", 230, 244], ["tears", "OBSERVATION", 14, 19], ["chicken flocks", "OBSERVATION", 230, 244]]], ["Cook et al. (1992) found more IBV-specific IgA in the lachrymal fluids of chicken lines resistant to IBV while antibody titres in tracheal washes were similar.", [["lachrymal fluids", "ANATOMY", 54, 70], ["lines", "ANATOMY", 82, 87], ["tracheal", "ANATOMY", 130, 138], ["IBV", "ORGANISM", 30, 33], ["IgA", "GENE_OR_GENE_PRODUCT", 43, 46], ["lachrymal fluids", "ORGANISM_SUBSTANCE", 54, 70], ["chicken", "ORGANISM", 74, 81], ["lines", "CELL", 82, 87], ["IBV", "ORGANISM", 101, 104], ["tracheal", "ORGAN", 130, 138], ["IgA", "PROTEIN", 43, 46], ["chicken lines", "CELL_LINE", 74, 87], ["chicken", "SPECIES", 74, 81], ["IBV", "SPECIES", 30, 33], ["chicken", "SPECIES", 74, 81], ["IBV", "SPECIES", 101, 104], ["IBV", "PROBLEM", 30, 33], ["chicken lines", "TREATMENT", 74, 87], ["IBV", "TREATMENT", 101, 104], ["antibody titres", "TEST", 111, 126], ["tracheal washes", "TREATMENT", 130, 145], ["IBV", "OBSERVATION", 30, 33], ["specific", "OBSERVATION_MODIFIER", 34, 42], ["IgA", "OBSERVATION", 43, 46], ["lachrymal", "ANATOMY", 54, 63], ["chicken lines", "OBSERVATION", 74, 87], ["tracheal", "ANATOMY", 130, 138], ["washes", "OBSERVATION", 139, 145]]], ["Variation in IBV-specific IgG levels in serum and IgA levels in lachrymal fluids has also been demonstrated in different chicken lines after ocular vaccination with IBV (Toro et al, 1996b) .", [["serum", "ANATOMY", 40, 45], ["lachrymal fluids", "ANATOMY", 64, 80], ["ocular", "ANATOMY", 141, 147], ["IBV", "ORGANISM", 13, 16], ["IgG", "GENE_OR_GENE_PRODUCT", 26, 29], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["IgA", "GENE_OR_GENE_PRODUCT", 50, 53], ["chicken", "ORGANISM", 121, 128], ["lines", "CELL", 129, 134], ["ocular", "ORGAN", 141, 147], ["IBV", "ORGANISM", 165, 168], ["IgG", "PROTEIN", 26, 29], ["IgA", "PROTEIN", 50, 53], ["chicken lines", "CELL_LINE", 121, 134], ["chicken", "SPECIES", 121, 128], ["IBV", "SPECIES", 13, 16], ["chicken", "SPECIES", 121, 128], ["IBV", "SPECIES", 165, 168], ["Variation", "TEST", 0, 9], ["IBV", "TEST", 13, 16], ["specific IgG levels", "TEST", 17, 36], ["serum", "TEST", 40, 45], ["IgA levels", "TEST", 50, 60], ["lachrymal fluids", "PROBLEM", 64, 80], ["different chicken lines", "TREATMENT", 111, 134], ["ocular vaccination", "TREATMENT", 141, 159], ["IBV (Toro et al", "TREATMENT", 165, 180], ["IBV", "OBSERVATION", 13, 16], ["lachrymal", "ANATOMY", 64, 73], ["fluids", "OBSERVATION", 74, 80], ["different chicken lines", "OBSERVATION", 111, 134]]], ["It was found that light layer (white leghorn) chickens had a significantly higher and more homogenous serum IgG response between days 5 and 9 p.i., and lachrymal IgA response between days 5 and 14 p.i. than broiler or brown-egg (heavy) layer chicks.Cellular immunityReports concerning a role for cell-mediated immunity in protection against IBV are limited.", [["serum", "ANATOMY", 102, 107], ["cell", "ANATOMY", 296, 300], ["chickens", "ORGANISM", 46, 54], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["IgG", "GENE_OR_GENE_PRODUCT", 108, 111], ["IgA", "GENE_OR_GENE_PRODUCT", 162, 165], ["egg", "ORGANISM_SUBSTANCE", 224, 227], ["cell", "CELL", 296, 300], ["IBV", "ORGANISM", 341, 344], ["serum IgG", "PROTEIN", 102, 111], ["IgA", "PROTEIN", 162, 165], ["chickens", "SPECIES", 46, 54], ["chickens", "SPECIES", 46, 54], ["IBV", "SPECIES", 341, 344], ["light layer (white leghorn) chickens", "PROBLEM", 18, 54], ["lachrymal IgA response", "TEST", 152, 174], ["Cellular immunityReports", "TREATMENT", 249, 273], ["cell-mediated immunity in protection", "TREATMENT", 296, 332], ["IBV", "PROBLEM", 341, 344], ["light", "OBSERVATION_MODIFIER", 18, 23], ["layer", "OBSERVATION_MODIFIER", 24, 29], ["significantly", "OBSERVATION_MODIFIER", 61, 74], ["higher", "OBSERVATION_MODIFIER", 75, 81], ["egg", "ANATOMY", 224, 227]]], ["Antigen-specific proliferation of T-lymphocytes in IBV-infected or vaccinated chickens has been demonstrated (Timms et al, 1980; Timms & Bracewell, 1981 .", [["T-lymphocytes", "ANATOMY", 34, 47], ["IBV-infected", "DISEASE", 51, 63], ["T-lymphocytes", "CELL", 34, 47], ["IBV", "ORGANISM", 51, 54], ["chickens", "ORGANISM", 78, 86], ["T-lymphocytes", "CELL_TYPE", 34, 47], ["chickens", "SPECIES", 78, 86], ["IBV", "SPECIES", 51, 54], ["chickens", "SPECIES", 78, 86], ["Antigen", "TEST", 0, 7], ["T-lymphocytes", "PROBLEM", 34, 47], ["IBV", "PROBLEM", 51, 54], ["infected", "PROBLEM", 55, 63], ["vaccinated chickens", "PROBLEM", 67, 86], ["specific", "OBSERVATION_MODIFIER", 8, 16], ["proliferation", "OBSERVATION_MODIFIER", 17, 30], ["T-lymphocytes", "OBSERVATION_MODIFIER", 34, 47], ["infected", "OBSERVATION_MODIFIER", 55, 63]]], ["In some chickens, a positive correlation between lymphoproliferative responses and resistance to challenge has been shown (Timms & Bracewell, 1981) .Cellular immunityMouse monoclonal antibodies (Mab) that distinguish between chicken Tlymphocytes have been described (Chan et al., 1988; Iillehoj et al, 1988) .", [["Cellular", "ANATOMY", 149, 157], ["Tlymphocytes", "ANATOMY", 233, 245], ["chickens", "ORGANISM", 8, 16], ["Mouse", "ORGANISM", 166, 171], ["Mab", "GENE_OR_GENE_PRODUCT", 195, 198], ["chicken", "ORGANISM", 225, 232], ["Tlymphocytes", "CELL", 233, 245], ["Mouse monoclonal antibodies", "PROTEIN", 166, 193], ["Mab", "PROTEIN", 195, 198], ["chickens", "SPECIES", 8, 16], ["Mouse", "SPECIES", 166, 171], ["chicken", "SPECIES", 225, 232], ["chickens", "SPECIES", 8, 16], ["Mouse", "SPECIES", 166, 171], ["chicken", "SPECIES", 225, 232], ["Mouse monoclonal antibodies (Mab", "TEST", 166, 198], ["chicken Tlymphocytes", "PROBLEM", 225, 245], ["some", "OBSERVATION_MODIFIER", 3, 7], ["chickens", "OBSERVATION", 8, 16], ["immunity", "OBSERVATION", 158, 166]]], ["The CD4 and CD8 antigens are found on two main populations of T-cells, T-helper (T n ) and T-cytotoxic / suppresser (Tc/ S ) cells, respectively.", [["T-cells", "ANATOMY", 62, 69], ["T-cytotoxic / suppresser (Tc/ S ) cells", "ANATOMY", 91, 130], ["CD4", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD8 antigens", "GENE_OR_GENE_PRODUCT", 12, 24], ["T-cells", "CELL", 62, 69], ["T-helper", "CELL", 71, 79], ["Tc/ S ) cells", "CELL", 117, 130], ["CD4", "PROTEIN", 4, 7], ["CD8 antigens", "PROTEIN", 12, 24], ["T-cells", "CELL_TYPE", 62, 69], ["T-helper (T n ) and T-cytotoxic / suppresser (Tc/ S ) cells", "CELL_TYPE", 71, 130], ["The CD4", "TEST", 0, 7], ["CD8 antigens", "TEST", 12, 24], ["T", "TEST", 71, 72], ["T", "TEST", 91, 92], ["CD4", "OBSERVATION", 4, 7]]], ["Janse et al. (1994) contended that local immunity to IBV in the trachea is mediated by T-cells.", [["trachea", "ANATOMY", 64, 71], ["T-cells", "ANATOMY", 87, 94], ["IBV", "ORGANISM", 53, 56], ["trachea", "ORGAN", 64, 71], ["T-cells", "CELL", 87, 94], ["T-cells", "CELL_TYPE", 87, 94], ["IBV", "SPECIES", 53, 56], ["trachea", "ANATOMY", 64, 71]]], ["CD4 and CD8 cells were shown in sections of trachea and lung of chickens infected with IBV (Janse et al, 1994; Dhinakar Raj & Jones, 1996a) .", [["CD4", "ANATOMY", 0, 3], ["CD8 cells", "ANATOMY", 8, 17], ["sections", "ANATOMY", 32, 40], ["trachea", "ANATOMY", 44, 51], ["lung", "ANATOMY", 56, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 8, 11], ["trachea", "ORGAN", 44, 51], ["lung", "ORGAN", 56, 60], ["chickens", "ORGANISM", 64, 72], ["IBV", "ORGANISM", 87, 90], ["CD4", "PROTEIN", 0, 3], ["CD8 cells", "CELL_TYPE", 8, 17], ["chickens", "SPECIES", 64, 72], ["chickens", "SPECIES", 64, 72], ["IBV", "SPECIES", 87, 90], ["CD4", "TEST", 0, 3], ["CD8 cells", "TEST", 8, 17], ["CD8 cells", "OBSERVATION", 8, 17], ["trachea", "ANATOMY", 44, 51], ["lung", "ANATOMY", 56, 60]]], ["However, it is not clear which of these cells are more important in virus clearance, since Janse et al. (1994) found an increase in CD4 cells, while Dhinakar Raj & Jones (1996a) found higher proportions of CD8 cells.", [["cells", "ANATOMY", 40, 45], ["CD4 cells", "ANATOMY", 132, 141], ["CD8 cells", "ANATOMY", 206, 215], ["cells", "CELL", 40, 45], ["CD4 cells", "CELL", 132, 141], ["CD8 cells", "CELL", 206, 215], ["CD4 cells", "CELL_TYPE", 132, 141], ["CD8 cells", "CELL_TYPE", 206, 215], ["these cells", "PROBLEM", 34, 45], ["an increase in CD4 cells", "PROBLEM", 117, 141], ["CD8 cells", "PROBLEM", 206, 215], ["not", "UNCERTAINTY", 15, 18], ["clear", "OBSERVATION", 19, 24], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["CD4 cells", "OBSERVATION", 132, 141], ["CD8 cells", "OBSERVATION", 206, 215]]], ["The differences may be related to the strains of IBV used.Cellular immunityWhen chickens were treated with CSA to suppress the T-cells, virus titres in the kidneys were 1 to 3 logio median ciliostatic doses (CD 50 ) higher than in intact birds (Dhinakar Raj & Jones, 1997a) .", [["Cellular", "ANATOMY", 58, 66], ["T-cells", "ANATOMY", 127, 134], ["kidneys", "ANATOMY", 156, 163], ["CSA", "CHEMICAL", 107, 110], ["IBV", "ORGANISM", 49, 52], ["chickens", "ORGANISM", 80, 88], ["CSA", "SIMPLE_CHEMICAL", 107, 110], ["T-cells", "CELL", 127, 134], ["kidneys", "ORGAN", 156, 163], ["T-cells", "CELL_TYPE", 127, 134], ["chickens", "SPECIES", 80, 88], ["IBV", "SPECIES", 49, 52], ["chickens", "SPECIES", 80, 88], ["IBV", "TREATMENT", 49, 52], ["CSA", "TREATMENT", 107, 110], ["virus titres", "TEST", 136, 148], ["may be related to", "UNCERTAINTY", 16, 33], ["immunity", "OBSERVATION", 67, 75], ["kidneys", "ANATOMY", 156, 163]]], ["Thus, T-cells may also play an important role in limiting virus replication in the kidneys.", [["T-cells", "ANATOMY", 6, 13], ["kidneys", "ANATOMY", 83, 90], ["T-cells", "CELL", 6, 13], ["kidneys", "ORGAN", 83, 90], ["T-cells", "CELL_TYPE", 6, 13], ["kidneys", "ANATOMY", 83, 90]]], ["Chubb et al (1987) demonstrated the presence of cytotoxic lymphocytes (CTL) in the spleen and peripheral blood following IBV infection using adherent cells as target cells and neutral red as indicator of lysis.", [["cytotoxic lymphocytes", "ANATOMY", 48, 69], ["CTL", "ANATOMY", 71, 74], ["spleen", "ANATOMY", 83, 89], ["peripheral blood", "ANATOMY", 94, 110], ["cells", "ANATOMY", 150, 155], ["cells", "ANATOMY", 166, 171], ["IBV infection", "DISEASE", 121, 134], ["cytotoxic lymphocytes", "CELL", 48, 69], ["CTL", "CELL", 71, 74], ["spleen", "ORGAN", 83, 89], ["peripheral blood", "ORGANISM_SUBSTANCE", 94, 110], ["IBV", "ORGANISM", 121, 124], ["cells", "CELL", 150, 155], ["cells", "CELL", 166, 171], ["cytotoxic lymphocytes", "CELL_TYPE", 48, 69], ["CTL", "CELL_TYPE", 71, 74], ["adherent cells", "CELL_TYPE", 141, 155], ["target cells", "CELL_TYPE", 159, 171], ["IBV", "SPECIES", 121, 124], ["cytotoxic lymphocytes (CTL) in the spleen", "PROBLEM", 48, 89], ["peripheral blood", "PROBLEM", 94, 110], ["IBV infection", "PROBLEM", 121, 134], ["adherent cells", "TREATMENT", 141, 155], ["lysis", "TREATMENT", 204, 209], ["cytotoxic lymphocytes", "OBSERVATION", 48, 69], ["spleen", "ANATOMY", 83, 89], ["peripheral", "ANATOMY_MODIFIER", 94, 104], ["blood", "ANATOMY", 105, 110], ["IBV", "OBSERVATION_MODIFIER", 121, 124], ["infection", "OBSERVATION", 125, 134], ["adherent cells", "OBSERVATION", 141, 155], ["lysis", "OBSERVATION", 204, 209]]], ["However, Wakenell et al. (1995) could not demonstrate CTL using kidney cells as targets and the conven-tional chromium-release assay.", [["kidney cells", "ANATOMY", 64, 76], ["chromium", "CHEMICAL", 110, 118], ["chromium", "CHEMICAL", 110, 118], ["CTL", "CELL", 54, 57], ["kidney cells", "CELL", 64, 76], ["chromium", "SIMPLE_CHEMICAL", 110, 118], ["CTL", "CELL_TYPE", 54, 57], ["kidney cells", "CELL_TYPE", 64, 76], ["the conven-tional chromium", "TREATMENT", 92, 118], ["kidney", "ANATOMY", 64, 70]]], ["Delayed-type hypersensitivity (DTH) responses were induced in response to live IBV and to affinity-purified SI, S2, N and M proteins (Igjnatovic & Galli, 1995) .CytokinesCytokines secreted in response to a general stimulus such as concanavalin A (Con A) or by specific antigen are important mediators of cellular immunity.", [["cellular", "ANATOMY", 304, 312], ["Delayed-type hypersensitivity", "DISEASE", 0, 29], ["concanavalin A", "CHEMICAL", 231, 245], ["Con A", "CHEMICAL", 247, 252], ["IBV", "ORGANISM", 79, 82], ["SI", "CELL", 108, 110], ["S2", "CELL", 112, 114], ["concanavalin A", "SIMPLE_CHEMICAL", 231, 245], ["Con A", "SIMPLE_CHEMICAL", 247, 252], ["cellular", "CELL", 304, 312], ["affinity-purified SI, S2, N and M proteins", "PROTEIN", 90, 132], ["Cytokines", "PROTEIN", 161, 170], ["Cytokines", "PROTEIN", 170, 179], ["IBV", "SPECIES", 79, 82], ["Delayed-type hypersensitivity", "PROBLEM", 0, 29], ["affinity", "TEST", 90, 98], ["CytokinesCytokines", "PROBLEM", 161, 179], ["a general stimulus", "TREATMENT", 204, 222], ["concanavalin A (Con A)", "TREATMENT", 231, 253], ["-type", "OBSERVATION_MODIFIER", 7, 12], ["hypersensitivity", "OBSERVATION_MODIFIER", 13, 29], ["Galli", "ANATOMY", 147, 152], ["cellular immunity", "OBSERVATION", 304, 321]]], ["T-cell growth factor (TCGF) or IL-2 and IFN-y are among the most important soluble factors produced by lymphocytes.", [["lymphocytes", "ANATOMY", 103, 114], ["T-cell growth factor", "GENE_OR_GENE_PRODUCT", 0, 20], ["TCGF", "GENE_OR_GENE_PRODUCT", 22, 26], ["IL-2", "GENE_OR_GENE_PRODUCT", 31, 35], ["IFN-y", "GENE_OR_GENE_PRODUCT", 40, 45], ["lymphocytes", "CELL", 103, 114], ["T-cell growth factor", "PROTEIN", 0, 20], ["TCGF", "PROTEIN", 22, 26], ["IL-2", "PROTEIN", 31, 35], ["IFN", "PROTEIN", 40, 43], ["soluble factors", "PROTEIN", 75, 90], ["lymphocytes", "CELL_TYPE", 103, 114], ["T-cell growth factor", "TEST", 0, 20], ["TCGF", "TEST", 22, 26], ["IL", "TEST", 31, 33], ["IFN-y", "PROBLEM", 40, 45]]], ["Only IFN-y has been studied in relation to IBV but results are conflicting.", [["IFN-y", "GENE_OR_GENE_PRODUCT", 5, 10], ["IBV", "ORGANISM", 43, 46], ["IFN", "PROTEIN", 5, 8], ["IBV", "SPECIES", 43, 46], ["IBV", "TREATMENT", 43, 46]]], ["Otsuki et al (1988) detected variable levels of IFN-y in chickens with various strains of IBV whereas other workers (Lomniczi, 1974; Holmes & Darbyshire, 1978) could not detect IFN-y in serum or organ cultures of chickens infected with IBV.", [["serum", "ANATOMY", 186, 191], ["organ cultures", "ANATOMY", 195, 209], ["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["chickens", "ORGANISM", 57, 65], ["IBV", "ORGANISM", 90, 93], ["IFN", "GENE_OR_GENE_PRODUCT", 177, 180], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["organ cultures", "CELL", 195, 209], ["chickens", "ORGANISM", 213, 221], ["IBV", "ORGANISM", 236, 239], ["IFN", "PROTEIN", 48, 51], ["IFN", "PROTEIN", 177, 180], ["chickens", "SPECIES", 57, 65], ["chickens", "SPECIES", 213, 221], ["chickens", "SPECIES", 57, 65], ["IBV", "SPECIES", 90, 93], ["chickens", "SPECIES", 213, 221], ["IBV", "SPECIES", 236, 239], ["IFN-y in serum", "TEST", 177, 191], ["organ cultures", "TEST", 195, 209], ["chickens", "PROBLEM", 213, 221], ["IBV", "PROBLEM", 236, 239], ["organ", "ANATOMY", 195, 200]]], ["Furthermore, whether IBV is susceptible to anti-viral effects of IFN-y is controversial (Holmes & Darbyshire, 1978; Otsuki et al, 1979b) .", [["IFN", "CHEMICAL", 65, 68], ["IBV", "ORGANISM", 21, 24], ["IFN", "GENE_OR_GENE_PRODUCT", 65, 68], ["IFN", "PROTEIN", 65, 68], ["IBV", "SPECIES", 21, 24], ["IBV", "PROBLEM", 21, 24]]], ["Otsuki et al. (1991) found no differences in IFN-y levels of IBV-resistant and IBV-sensitive lines of chickens.Resistance to IBVThe identification of resistant and sensitive inbred lines of chickens to IBV (Bumstead et al, 1989) has provided an excellent model to study immune mechanisms in relation to resistance of chickens to IBV.", [["lines", "ANATOMY", 93, 98], ["IFN-y", "GENE_OR_GENE_PRODUCT", 45, 50], ["IBV", "ORGANISM", 61, 64], ["IBV", "ORGANISM", 79, 82], ["lines", "CELL", 93, 98], ["chickens", "ORGANISM", 102, 110], ["inbred lines", "CELL", 174, 186], ["chickens", "ORGANISM", 190, 198], ["IBV", "ORGANISM", 202, 205], ["chickens", "ORGANISM", 317, 325], ["IBV", "ORGANISM", 329, 332], ["IFN", "PROTEIN", 45, 48], ["inbred lines", "CELL_LINE", 174, 186], ["chickens", "SPECIES", 102, 110], ["chickens", "SPECIES", 190, 198], ["chickens", "SPECIES", 317, 325], ["IBV", "SPECIES", 61, 64], ["IBV", "SPECIES", 79, 82], ["chickens", "SPECIES", 102, 110], ["chickens", "SPECIES", 190, 198], ["IBV", "SPECIES", 202, 205], ["chickens", "SPECIES", 317, 325], ["IBV", "SPECIES", 329, 332], ["IFN-y levels", "TEST", 45, 57], ["IBV", "PROBLEM", 61, 64], ["IBV", "PROBLEM", 79, 82], ["chickens", "PROBLEM", 102, 110], ["resistant and sensitive inbred lines", "PROBLEM", 150, 186], ["IBV", "TREATMENT", 329, 332], ["no", "UNCERTAINTY", 27, 29], ["sensitive lines", "OBSERVATION", 83, 98], ["resistant", "OBSERVATION_MODIFIER", 150, 159]]], ["Otsuki et al, (1990) found that although a resistant line (C) and a sensitive line (151) were equally susceptible to infection initially, recovery was more rapid in the resistant line.", [["infection", "DISEASE", 117, 126], ["C", "CELL", 59, 60], ["resistant line", "CELL_LINE", 43, 57], ["a resistant line (C)", "PROBLEM", 41, 61], ["a sensitive line", "PROBLEM", 66, 82], ["infection", "PROBLEM", 117, 126], ["the resistant line", "PROBLEM", 165, 183], ["infection", "OBSERVATION", 117, 126], ["resistant line", "OBSERVATION", 169, 183]]], ["Ultrastructural and histochemical studies showed that though the type of damage to the tracheal epithelium following IBV infection was similar in both lines of chickens, lesions were more severe and longer lasting in the sensitive line (Nakamura et al, 1991) .", [["tracheal epithelium", "ANATOMY", 87, 106], ["lesions", "ANATOMY", 170, 177], ["IBV infection", "DISEASE", 117, 130], ["tracheal epithelium", "MULTI-TISSUE_STRUCTURE", 87, 106], ["IBV", "ORGANISM", 117, 120], ["chickens", "ORGANISM", 160, 168], ["lesions", "PATHOLOGICAL_FORMATION", 170, 177], ["chickens", "SPECIES", 160, 168], ["IBV", "SPECIES", 117, 120], ["chickens", "SPECIES", 160, 168], ["Ultrastructural and histochemical studies", "TEST", 0, 41], ["damage to the tracheal epithelium", "PROBLEM", 73, 106], ["IBV infection", "PROBLEM", 117, 130], ["chickens", "PROBLEM", 160, 168], ["lesions", "PROBLEM", 170, 177], ["damage", "OBSERVATION", 73, 79], ["tracheal", "ANATOMY", 87, 95], ["epithelium", "ANATOMY_MODIFIER", 96, 106], ["IBV", "OBSERVATION_MODIFIER", 117, 120], ["infection", "OBSERVATION", 121, 130], ["both", "OBSERVATION_MODIFIER", 146, 150], ["lines", "OBSERVATION_MODIFIER", 151, 156], ["chickens", "OBSERVATION_MODIFIER", 160, 168], ["lesions", "OBSERVATION", 170, 177], ["more severe", "OBSERVATION_MODIFIER", 183, 194]]], ["The severity and duration of clinical infection in bursectomised line C chickens were similar to those seen in the sensitive line (Cook et al, 1991a) .", [["infection", "DISEASE", 38, 47], ["chickens", "ORGANISM", 72, 80], ["chickens", "SPECIES", 72, 80], ["C chickens", "SPECIES", 70, 80], ["The severity", "PROBLEM", 0, 12], ["clinical infection", "PROBLEM", 29, 47], ["bursectomised line C chickens", "TREATMENT", 51, 80], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 38, 47]]], ["However, no increase in mortality was observed, in contrast to high mortality recorded in line 151 chickens.", [["chickens", "ORGANISM", 99, 107], ["chickens", "SPECIES", 99, 107], ["chickens", "SPECIES", 99, 107], ["increase in mortality", "PROBLEM", 12, 33], ["no", "UNCERTAINTY", 9, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["mortality", "OBSERVATION", 24, 33]]], ["Comparisons of secretory antibody responses between the two lines of chickens revealed increased local antibody secretion in the saliva and lachrymal fluid of the resistant line .Resistance to IBVSuppression of T-cells by CSA in a line of chickens resistant to IBV (brown leghorn; BLH), induced them to behave like a sensitive line, in terms of mortality (Dhinakar Raj & Jones, 1997a) .", [["saliva", "ANATOMY", 129, 135], ["lachrymal fluid", "ANATOMY", 140, 155], ["T-cells", "ANATOMY", 211, 218], ["CSA", "CHEMICAL", 222, 225], ["secretory antibody", "GENE_OR_GENE_PRODUCT", 15, 33], ["chickens", "ORGANISM", 69, 77], ["saliva", "ORGANISM_SUBSTANCE", 129, 135], ["lachrymal fluid", "ORGANISM_SUBSTANCE", 140, 155], ["T-cells", "CELL", 211, 218], ["CSA", "SIMPLE_CHEMICAL", 222, 225], ["chickens", "ORGANISM", 239, 247], ["IBV", "ORGANISM", 261, 264], ["brown leghorn", "ORGANISM", 266, 279], ["T-cells", "CELL_TYPE", 211, 218], ["chickens", "SPECIES", 69, 77], ["chickens", "SPECIES", 239, 247], ["chickens", "SPECIES", 69, 77], ["chickens", "SPECIES", 239, 247], ["IBV", "SPECIES", 261, 264], ["secretory antibody responses", "TEST", 15, 43], ["increased local antibody secretion in the saliva", "PROBLEM", 87, 135], ["the resistant line", "TREATMENT", 159, 177], ["T-cells", "PROBLEM", 211, 218], ["CSA", "PROBLEM", 222, 225], ["IBV", "PROBLEM", 261, 264], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["local", "OBSERVATION_MODIFIER", 97, 102], ["antibody secretion", "OBSERVATION", 103, 121], ["saliva", "ANATOMY", 129, 135], ["lachrymal", "ANATOMY", 140, 149], ["fluid", "OBSERVATION", 150, 155], ["resistant line", "OBSERVATION", 163, 177], ["sensitive line", "OBSERVATION", 317, 331]]], ["The mortality of intact BLH chickens infected with a pool of ten IBV strains was 0% compared to 43% in CSA-treated BLH chickens.", [["CSA", "CHEMICAL", 103, 106], ["BLH chickens", "ORGANISM", 24, 36], ["IBV", "ORGANISM", 65, 68], ["CSA", "SIMPLE_CHEMICAL", 103, 106], ["BLH", "ORGANISM", 115, 118], ["chickens", "ORGANISM", 119, 127], ["chickens", "SPECIES", 28, 36], ["chickens", "SPECIES", 119, 127], ["chickens", "SPECIES", 28, 36], ["IBV", "SPECIES", 65, 68], ["chickens", "SPECIES", 119, 127], ["ten IBV strains", "PROBLEM", 61, 76], ["CSA", "TEST", 103, 106], ["intact", "OBSERVATION_MODIFIER", 17, 23]]], ["The virus titres in kidneys were much higher than in intact birds.", [["kidneys", "ANATOMY", 20, 27], ["kidneys", "ORGAN", 20, 27], ["The virus titres", "TEST", 0, 16], ["virus titres", "OBSERVATION", 4, 16], ["kidneys", "ANATOMY", 20, 27], ["much", "OBSERVATION_MODIFIER", 33, 37], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["intact", "OBSERVATION", 53, 59]]], ["The classes of T-cells involved in these effects need to be studied in further detail by analysing the kinetic changes in T-cell subsets following IBV infections using flow cytometry or by specific depletion in vivo by Mabs against T-cell subsets.VIRUS PERSISTENCEAlthough IB is generally considered as an acute respiratory disease, prolonged virus excretion has been reported (Cook, 1968; Alexander et al, 1978; Chong & Apostolov, 1982) .", [["T-cells", "ANATOMY", 15, 22], ["T-cell", "ANATOMY", 122, 128], ["T-cell", "ANATOMY", 232, 238], ["respiratory", "ANATOMY", 312, 323], ["infections", "DISEASE", 151, 161], ["respiratory disease", "DISEASE", 312, 331], ["T-cells", "CELL", 15, 22], ["T-cell", "CELL", 122, 128], ["IBV", "ORGANISM", 147, 150], ["T-cell", "CELL", 232, 238], ["T-cells", "CELL_TYPE", 15, 22], ["T-cell subsets", "CELL_TYPE", 122, 136], ["Mabs", "PROTEIN", 219, 223], ["T-cell subsets", "CELL_TYPE", 232, 246], ["IBV", "SPECIES", 147, 150], ["the kinetic changes", "PROBLEM", 99, 118], ["IBV infections", "PROBLEM", 147, 161], ["flow cytometry", "TEST", 168, 182], ["an acute respiratory disease", "PROBLEM", 303, 331], ["prolonged virus excretion", "PROBLEM", 333, 358], ["cell subsets", "OBSERVATION", 234, 246], ["generally considered", "UNCERTAINTY", 279, 299], ["acute", "OBSERVATION_MODIFIER", 306, 311], ["respiratory disease", "OBSERVATION", 312, 331]]], ["When day-old chicks were infected with an enterotropic IBV, strain G, faecal excretion could not be detected beyond day 35 p.i., but when birds reached sexual maturity re-excretion occurred (Jones & Ambali, 1987) .", [["faecal", "ANATOMY", 70, 76], ["chicks", "ORGANISM", 13, 19], ["enterotropic IBV", "ORGANISM", 42, 58], ["faecal", "ORGANISM_SUBSTANCE", 70, 76], ["chicks", "SPECIES", 13, 19], ["IBV", "SPECIES", 55, 58], ["infected", "PROBLEM", 25, 33], ["an enterotropic IBV", "TREATMENT", 39, 58], ["strain G", "TREATMENT", 60, 68], ["faecal excretion", "TEST", 70, 86]]], ["Virus re-excretion could not be induced earlier by hormone injections (Ambali & Jones, 1991b) , but it could after T-cell suppression by CSA (Bhattacharjee et al, 1995) .", [["T-cell", "ANATOMY", 115, 121], ["Virus", "ORGANISM", 0, 5], ["T-cell", "CELL", 115, 121], ["Virus re-excretion", "TREATMENT", 0, 18], ["hormone injections", "TREATMENT", 51, 69], ["T-cell suppression", "TREATMENT", 115, 133], ["could not be", "UNCERTAINTY", 19, 31]]], ["Reactivation of virus was confirmed by appearance of IBV-specific IgM in the serum (Bhattacharjee et al, 1995) .VIRUS PERSISTENCEMainly because of the prolonged or intermittent recovery of IBV from these tissues, 2 candidate sites have been proposed for virus persistence in the chicken, the kidneys (Chong & Apostolov, 1982) and/or caecal tonsils (Cook, 1968; Alexander et al, 1978) .", [["serum", "ANATOMY", 77, 82], ["tissues", "ANATOMY", 204, 211], ["kidneys", "ANATOMY", 292, 299], ["caecal tonsils", "ANATOMY", 333, 347], ["IBV", "ORGANISM", 53, 56], ["IgM", "GENE_OR_GENE_PRODUCT", 66, 69], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["IBV", "ORGANISM", 189, 192], ["tissues", "TISSUE", 204, 211], ["chicken", "ORGANISM", 279, 286], ["kidneys", "ORGAN", 292, 299], ["caecal tonsils", "MULTI-TISSUE_STRUCTURE", 333, 347], ["IgM", "PROTEIN", 66, 69], ["chicken", "SPECIES", 279, 286], ["IBV", "SPECIES", 53, 56], ["IBV", "SPECIES", 189, 192], ["chicken", "SPECIES", 279, 286], ["Reactivation of virus", "PROBLEM", 0, 21], ["IBV", "PROBLEM", 53, 56], ["specific IgM", "TEST", 57, 69], ["the serum", "TEST", 73, 82], ["IBV", "PROBLEM", 189, 192], ["virus", "PROBLEM", 254, 259], ["virus", "OBSERVATION", 16, 21], ["IBV", "OBSERVATION", 53, 56], ["prolonged", "OBSERVATION_MODIFIER", 151, 160], ["IBV", "OBSERVATION", 189, 192], ["kidneys", "ANATOMY", 292, 299], ["caecal tonsils", "ANATOMY", 333, 347]]], ["However, recent work has suggested that the kidneys are the more likely site.", [["kidneys", "ANATOMY", 44, 51], ["kidneys", "ORGAN", 44, 51], ["kidneys", "ANATOMY", 44, 51], ["more likely", "UNCERTAINTY", 60, 71]]], ["When strain M41 was used to infect day-old chickens and T-cell immunosuppression by CSA treatment was given from 5 weeks p.i., virus was recovered first from the kidneys and then from the trachea and lungs but never from the caecal tonsils (Dhinakar Raj & Jones, 1997a) .", [["T-cell", "ANATOMY", 56, 62], ["kidneys", "ANATOMY", 162, 169], ["trachea", "ANATOMY", 188, 195], ["lungs", "ANATOMY", 200, 205], ["caecal tonsils", "ANATOMY", 225, 239], ["M41", "CHEMICAL", 12, 15], ["CSA", "CHEMICAL", 84, 87], ["chickens", "ORGANISM", 43, 51], ["T-cell", "CELL", 56, 62], ["CSA", "SIMPLE_CHEMICAL", 84, 87], ["kidneys", "ORGAN", 162, 169], ["trachea", "ORGAN", 188, 195], ["lungs", "ORGAN", 200, 205], ["caecal tonsils", "MULTI-TISSUE_STRUCTURE", 225, 239], ["chickens", "SPECIES", 43, 51], ["M41", "SPECIES", 12, 15], ["chickens", "SPECIES", 43, 51], ["old chickens", "PROBLEM", 39, 51], ["T-cell immunosuppression", "TREATMENT", 56, 80], ["CSA treatment", "TREATMENT", 84, 97], ["virus", "PROBLEM", 127, 132], ["kidneys", "ANATOMY", 162, 169], ["trachea", "ANATOMY", 188, 195], ["lungs", "ANATOMY", 200, 205], ["caecal tonsils", "ANATOMY", 225, 239]]], ["The target cells of the virus in the kidneys are in the tubular epithelium (Chong & Apostolov, 1982; Ambali & Jones, 1990 ) which provides an ideal site for virus persistence because of its immunologically privileged nature (Mimms, 1988) .VIRUS PERSISTENCEOccurrence of persistence was also found to be related to the age at infection (Dhinakar Raj & Jones, 1997a) .", [["cells", "ANATOMY", 11, 16], ["kidneys", "ANATOMY", 37, 44], ["tubular epithelium", "ANATOMY", 56, 74], ["infection", "DISEASE", 325, 334], ["cells", "CELL", 11, 16], ["kidneys", "ORGAN", 37, 44], ["tubular epithelium", "TISSUE", 56, 74], ["virus persistence", "PROBLEM", 157, 174], ["the age at infection", "PROBLEM", 314, 334], ["target cells", "OBSERVATION", 4, 16], ["virus", "OBSERVATION", 24, 29], ["kidneys", "ANATOMY", 37, 44], ["tubular", "ANATOMY_MODIFIER", 56, 63], ["epithelium", "ANATOMY_MODIFIER", 64, 74], ["infection", "OBSERVATION", 325, 334]]], ["When chicks were infected at 2 weeks of age and treated with CSA from 5 weeks p.i. no virus re-excretion was observed, but when chicks were infected at day-old, virus re-excretion was successfully induced with CSA.", [["CSA", "CHEMICAL", 61, 64], ["chicks", "ORGANISM", 5, 11], ["virus", "ORGANISM", 161, 166], ["chicks", "SPECIES", 5, 11], ["chicks", "SPECIES", 128, 134], ["CSA", "TREATMENT", 61, 64], ["virus re-excretion", "PROBLEM", 86, 104], ["virus re-excretion", "TREATMENT", 161, 179], ["CSA", "PROBLEM", 210, 213]]], ["Notably, virus re-excretion was not accompanied by clinical symptoms.VIRUS PERSISTENCEThe persistence of IBV may have practical implications in the epizootiology of the disease and perhaps a role in evolution of variant strains of the virus.", [["IBV", "ORGANISM", 105, 108], ["IBV", "SPECIES", 105, 108], ["virus re-excretion", "PROBLEM", 9, 27], ["clinical symptoms", "PROBLEM", 51, 68], ["IBV", "PROBLEM", 105, 108], ["the disease", "PROBLEM", 165, 176], ["variant strains of the virus", "PROBLEM", 212, 240], ["virus", "OBSERVATION", 9, 14], ["IBV", "OBSERVATION", 105, 108], ["disease", "OBSERVATION", 169, 176]]], ["Furthermore, re-excretion of persistent virus may serve as an unnoticed source of infection to susceptible chickens.Antigenic types (serotypes)IBV does not constitute a single homogenous antigenic type.", [["infection", "DISEASE", 82, 91], ["chickens", "ORGANISM", 107, 115], ["IBV", "ORGANISM", 143, 146], ["chickens", "SPECIES", 107, 115], ["chickens", "SPECIES", 107, 115], ["IBV", "SPECIES", 143, 146], ["persistent virus", "PROBLEM", 29, 45], ["infection", "PROBLEM", 82, 91], ["susceptible chickens", "PROBLEM", 95, 115], ["Antigenic types (serotypes)IBV", "PROBLEM", 116, 146], ["persistent", "OBSERVATION_MODIFIER", 29, 39], ["virus", "OBSERVATION", 40, 45], ["infection", "OBSERVATION", 82, 91], ["homogenous", "OBSERVATION_MODIFIER", 176, 186], ["antigenic type", "OBSERVATION", 187, 201]]], ["The major virus neutralizing antibody site of IBV, which defines serotype, resides in the SI subunit of the spike protein (Mockett et al, 1984; Cavanagh et al, 1986) .", [["IBV", "ORGANISM", 46, 49], ["major virus neutralizing antibody site", "DNA", 4, 42], ["SI subunit", "PROTEIN", 90, 100], ["spike protein", "PROTEIN", 108, 121], ["IBV", "SPECIES", 46, 49], ["The major virus neutralizing antibody site", "TREATMENT", 0, 42], ["IBV", "PROBLEM", 46, 49], ["serotype", "PROBLEM", 65, 73], ["virus", "OBSERVATION_MODIFIER", 10, 15], ["neutralizing antibody", "OBSERVATION", 16, 37]]], ["Differences in only a few amino acids in the SI protein can result in different VN serotypes (Cavanagh et al, 1992a) which accounts for the plethora of IBV strains which exists today.Antigenic types (serotypes)Hence, different antigenic types identified by VN tests do not imply that the isolates have substantially different SI proteins or overall antigenic properties or greatly different evolutionary lineages.Antigenic types (serotypes)As in other RNA viruses, antigenic variation is probably facilitated by the high error rate during the transcription of RNA template and the absence of a proof-reading mechanism.", [["amino acids", "CHEMICAL", 26, 37], ["amino acids", "CHEMICAL", 26, 37], ["amino acids", "AMINO_ACID", 26, 37], ["IBV", "ORGANISM", 152, 155], ["SI protein", "PROTEIN", 45, 55], ["VN", "PROTEIN", 257, 259], ["SI proteins", "PROTEIN", 326, 337], ["RNA template", "RNA", 560, 572], ["IBV", "SPECIES", 152, 155], ["a few amino acids", "TREATMENT", 20, 37], ["different VN serotypes", "PROBLEM", 70, 92], ["IBV strains", "PROBLEM", 152, 163], ["Antigenic types (serotypes", "PROBLEM", 183, 209], ["VN tests", "TEST", 257, 265], ["the isolates", "PROBLEM", 284, 296], ["substantially different SI proteins", "PROBLEM", 302, 337], ["overall antigenic properties", "PROBLEM", 341, 369], ["Antigenic types (serotypes)", "PROBLEM", 413, 440], ["other RNA viruses", "PROBLEM", 446, 463], ["RNA template", "TREATMENT", 560, 572], ["IBV strains", "OBSERVATION", 152, 163], ["evolutionary lineages", "OBSERVATION", 391, 412], ["RNA viruses", "OBSERVATION", 452, 463], ["antigenic variation", "OBSERVATION", 465, 484]]], ["It has been shown that point mutations may lead to the generation of IBV variants in the field Qia et al, 1995) .", [["IBV", "ORGANISM", 69, 72], ["point mutations", "PROBLEM", 23, 38], ["IBV variants", "PROBLEM", 69, 81]]], ["However, both circumstantial (Cavanagh & Davis, 1988; Cavanagh et al, 1992b; Jia et al, 1995; Kusters et al, 1989 Kusters et al, , 1990 Wang et al, 1994) and experimental (Kottier et al, 1995) evidence suggest that the main mechanism of generation of variant strains of IBV is by recombination.", [["IBV", "ORGANISM", 270, 273], ["IBV", "SPECIES", 270, 273], ["variant strains of IBV", "PROBLEM", 251, 273]]], ["This could be promoted by the use of more than one strain of IBV for vaccination or by a mixture of vaccine and challenge viruses.Immunogenic types (protectotypes)Isolates of IBV shown to be distinct by the VN test can still induce partial or complete cross-immunity (Arvidson et al, 1990; Darbyshire, 1980 Darbyshire, , 1985 Hitchner et al, 1964; Raggi & Lee, 1965; Winterfield & Fadly, 1972; Winterfield et al, 1976) .", [["IBV", "ORGANISM", 61, 64], ["IBV", "ORGANISM", 175, 178], ["VN", "PROTEIN", 207, 209], ["IBV", "SPECIES", 61, 64], ["IBV", "SPECIES", 175, 178], ["IBV", "TREATMENT", 61, 64], ["vaccination", "TREATMENT", 69, 80], ["a mixture of vaccine", "TREATMENT", 87, 107], ["challenge viruses", "TREATMENT", 112, 129], ["Immunogenic types", "PROBLEM", 130, 147], ["IBV", "PROBLEM", 175, 178], ["the VN test", "TEST", 203, 214]]], ["For example, vaccination with H120 caused a 30,000-fold reduction in titres of the challenge virus, Australian 'T' strain (Darbyshire, 1985) , while on the basis of VN tests in vitro, no evidence of a serological relationship between these two viruses could be demonstrated .", [["H120", "CHEMICAL", 30, 34], ["H120", "SIMPLE_CHEMICAL", 30, 34], ["T' strain", "ORGANISM", 112, 121], ["VN", "GENE_OR_GENE_PRODUCT", 165, 167], ["VN", "PROTEIN", 165, 167], ["vaccination", "TREATMENT", 13, 24], ["H120", "TREATMENT", 30, 34], ["a 30,000-fold reduction", "TREATMENT", 42, 65], ["the challenge virus", "TREATMENT", 79, 98], ["VN tests", "TEST", 165, 173], ["a serological relationship between these two viruses", "PROBLEM", 199, 251], ["no evidence of", "UNCERTAINTY", 184, 198], ["viruses", "OBSERVATION", 244, 251]]], ["Hence, antigenic studies alone do not adequately define immunological relationships between strains.", [["antigenic studies", "TEST", 7, 24]]], ["Thus, it was suggested that cross-immunization studies could be used to classify IBV isolates into protectotypes (Lohr, 1988) as this would reduce the large number of serotypes to a smaller number of protectotypes and provide more practical information to the field.Immunogenic types (protectotypes)Cross-immunisation tests have been performed in experimental chickens (Darbyshire, 1980 (Darbyshire, , 1985 Lambrechts et al, 1993) or in in vitro conditions using TOC from immunized birds Dhinakar Raj & Jones, 1996d) to determine protective immunological relationships between IBV strains.", [["TOC", "CHEMICAL", 463, 466], ["TOC", "CHEMICAL", 463, 466], ["IBV", "ORGANISM", 81, 84], ["chickens", "ORGANISM", 360, 368], ["IBV", "ORGANISM", 577, 580], ["chickens", "SPECIES", 360, 368], ["IBV", "SPECIES", 81, 84], ["chickens", "SPECIES", 360, 368], ["IBV", "SPECIES", 577, 580], ["cross-immunization studies", "TEST", 28, 54], ["Cross-immunisation tests", "TEST", 299, 323], ["TOC", "TEST", 463, 466], ["IBV strains", "PROBLEM", 577, 588], ["large", "OBSERVATION_MODIFIER", 151, 156]]], ["Arvidson et al. (1990) have described a model to study immunogenic relationships between IBV strains based on the vaccinating dose required to prevent the multiplication of a standard challenge dose of a homologous strain in the lungs of chickens.", [["lungs", "ANATOMY", 229, 234], ["IBV", "ORGANISM", 89, 92], ["lungs", "ORGAN", 229, 234], ["chickens", "ORGANISM", 238, 246], ["chickens", "SPECIES", 238, 246], ["IBV", "SPECIES", 89, 92], ["chickens", "SPECIES", 238, 246], ["IBV strains", "PROBLEM", 89, 100], ["the vaccinating dose", "TREATMENT", 110, 130], ["a homologous strain", "TREATMENT", 202, 221], ["lungs", "ANATOMY", 229, 234]]], ["These cross-immunization tests would help to determine whether an already existing vaccine could offer protection to a new variant.", [["These cross-immunization tests", "TEST", 0, 30], ["an already existing vaccine", "TREATMENT", 63, 90], ["a new variant", "PROBLEM", 117, 130]]], ["This information is critical before embarking on a long and cumbersome process of new vaccine production.Variation in tropisms?Since tissue affinities are a function of the viral peplomer-mediated attachment of virus to cells, changes in the spike protein might lead to altered tropism of the virus.", [["tissue", "ANATOMY", 133, 139], ["cells", "ANATOMY", 220, 225], ["tissue", "TISSUE", 133, 139], ["cells", "CELL", 220, 225], ["spike protein", "PROTEIN", 242, 255], ["a long and cumbersome process", "TREATMENT", 49, 78], ["new vaccine production", "TREATMENT", 82, 104], ["Variation in tropisms", "PROBLEM", 105, 126], ["tissue affinities", "PROBLEM", 133, 150], ["the viral peplomer", "PROBLEM", 169, 187], ["virus to cells", "PROBLEM", 211, 225], ["the spike protein", "PROBLEM", 238, 255], ["altered tropism of the virus", "PROBLEM", 270, 298], ["affinities", "OBSERVATION_MODIFIER", 140, 150], ["viral peplomer", "OBSERVATION", 173, 187], ["virus", "OBSERVATION", 211, 216]]], ["Six of ten differences in amino acid sequences of Gray and JMK strains of IBV were found between residues 99 and 127; hence it was postulated that this region may play a role in differences in tissue tropism exhibited by these viruses (Kwon & Jackwood, 1995) .", [["tissue", "ANATOMY", 193, 199], ["amino acid", "CHEMICAL", 26, 36], ["amino acid", "CHEMICAL", 26, 36], ["amino acid", "AMINO_ACID", 26, 36], ["Gray", "GENE_OR_GENE_PRODUCT", 50, 54], ["JMK", "GENE_OR_GENE_PRODUCT", 59, 62], ["IBV", "ORGANISM", 74, 77], ["tissue", "TISSUE", 193, 199], ["amino acid sequences", "PROTEIN", 26, 46], ["IBV", "SPECIES", 74, 77], ["amino acid sequences", "TEST", 26, 46], ["IBV", "PROBLEM", 74, 77], ["tissue tropism", "PROBLEM", 193, 207]]], ["However, no correlation was found by Sapats et al. (1996) between SI amino acid sequences and nephropathogenicity of nine Australian strains of IBV.", [["amino acid", "CHEMICAL", 69, 79], ["amino acid", "CHEMICAL", 69, 79], ["amino acid", "AMINO_ACID", 69, 79], ["IBV", "ORGANISM", 144, 147], ["IBV", "SPECIES", 144, 147], ["SI amino acid sequences", "TEST", 66, 89], ["IBV", "PROBLEM", 144, 147]]], ["Nevertheless, it is not unreasonable to expect new variant strains of IBV to emerge with unusual tissue tropisms and such an example of this is strain 793/B. CONCLUSIONS IBV has been effectively controlled by the extensive use of vaccines but it still remains a major economic problem some 65 years after it was first reported.", [["tissue", "ANATOMY", 97, 103], ["IBV", "ORGANISM", 70, 73], ["tissue", "TISSUE", 97, 103], ["IBV", "ORGANISM", 170, 173], ["IBV", "SPECIES", 70, 73], ["IBV", "SPECIES", 170, 173], ["new variant strains of IBV", "PROBLEM", 47, 73], ["unusual tissue tropisms", "PROBLEM", 89, 112], ["IBV", "PROBLEM", 170, 173], ["vaccines", "TREATMENT", 230, 238], ["extensive", "OBSERVATION_MODIFIER", 213, 222]]], ["The constant emergence of variant strains has challenged vaccination strategies.", [["variant strains", "PROBLEM", 26, 41], ["challenged vaccination strategies", "TREATMENT", 46, 79]]], ["With the advent of molecular techniques much of the recent work on IBV has concentrated on improved diagnostic and strain differentiation methods.", [["IBV", "ORGANISM", 67, 70], ["IBV", "SPECIES", 67, 70], ["IBV", "TREATMENT", 67, 70]]], ["However, the appearance and spread of the economically-important variant strain 793/B has given us a reminder of the need for a more detailed understanding of the immunopathogenesis of the disease and to be prepared for emergence of variants with unusual tissue tropisms and disease manifestations. tionstraktes angesehen wird, k\u00f6nnen verschiedene IBV-St\u00e4mme unterschiedliche Gewebstropismen aufweisen und, mit ernsten Folgen, auch den Eileiter und die Nieren befallen.", [["tissue", "ANATOMY", 255, 261], ["793/B", "CHEMICAL", 80, 85], ["793/B", "CELL", 80, 85], ["tissue", "TISSUE", 255, 261], ["k\u00f6nnen verschiedene IBV-St\u00e4mme unterschiedliche Gewebstropismen aufweisen und, mit ernsten Folgen, auch den Eileiter und die Nieren befallen", "SPECIES", 328, 468], ["the disease", "PROBLEM", 185, 196], ["unusual tissue tropisms", "PROBLEM", 247, 270], ["disease manifestations", "PROBLEM", 275, 297], ["spread", "OBSERVATION_MODIFIER", 28, 34]]], ["Mehrere Faktoren k\u00f6nnen den Verlauf der Infektion mit IBV beeinflussen und umfassen das Alter, die Rasse und die F\u00fctterung des Huhnes, die Umgebung und die interkurrente Infektion mit anderen Infektionserregern.", [["Mehrere Faktoren k\u00f6nnen den Verlauf der Infektion mit IBV beeinflussen und umfassen das Alter, die Rasse und die F\u00fctterung des Huhnes, die Umgebung und die interkurrente Infektion mit anderen", "SPECIES", 0, 191], ["Mehrere", "TREATMENT", 0, 7]]], ["Die immunogenen Bestandteile des Virus sind die S (spike)-Proteine und das N-Nukleoprotein.", [["N-Nukleoprotein", "SIMPLE_CHEMICAL", 75, 90], ["Die", "PROBLEM", 0, 3], ["Nukleoprotein", "TREATMENT", 77, 90]]], ["Die humoralen, lokalen und zellul\u00e4ren Reaktionen des Huhnes gegen IBV sowie die genetische Resistenz des Huhnes werden besprochen.", [["humoralen", "TREATMENT", 4, 13], ["lokalen", "TREATMENT", 15, 22]]], ["Bei der langfristigen IBV-Persistenz sind die Blinddarmtonsillen oder die Nieren als Orte der Persistenz vermutet worden.", [["Bei der langfristigen IBV-Persistenz sind die Blinddarmtonsillen oder die Nieren als Orte der Persistenz vermutet worden", "SPECIES", 0, 120]]], ["Die Antigenvariation bei IBV-St\u00e4mmen h\u00e4ngt mit relativ kleinen Unterschieden der Aminos\u00e4uresequenzen im Spike-Protein S1 zusammen.", [["Die Antigenvariation bei IBV-St\u00e4mmen h\u00e4ngt mit relativ kleinen Unterschieden der Aminos\u00e4uresequenzen im Spike-Protein S1 zusammen", "SPECIES", 0, 129], ["IBV", "TEST", 25, 28]]], ["Antigenuntersuchungen alleine reichen jedoch nicht aus, um immunologische Beziehungen zwischen Virusst\u00e4mmen ausreichend zu definieren, und Kreuzimmunisierungsversuche sind benutzt worden, um IBV-Isolate in 'Protektotypen' zu klassifizieren.", [["Antigenuntersuchungen alleine reichen jedoch nicht aus, um immunologische Beziehungen zwischen Virusst\u00e4mmen ausreichend zu definieren, und Kreuzimmunisierungsversuche sind benutzt worden, um IBV-Isolate in 'Protektotypen' zu klassifizieren", "SPECIES", 0, 239], ["Antigenuntersuchungen alleine reichen jedoch", "TREATMENT", 0, 44]]], ["Es sind Vermutungen dar\u00fcber angestellt worden, da\u00df Ver\u00e4nderungen im Spike-Protein S1 eine Beziehung zu Unterschieden der Gewebstropismen, die verschiedene St\u00e4mme aufweisen, haben k\u00f6nnten.", [["Protein S1 eine Beziehung", "TREATMENT", 74, 99]]], ["Vielleicht k\u00f6nnten in der Zukunft neue IBV-St\u00e4mme auftauchen, die Organe oder Systeme befallen, welche normalerweise keinen Zusammenhang mit der IB haben.RESUMENVirus de la bronquitis infecciosa: Inmunopatogenia de la infeccion en la gallina Se revisa la inmunopatogenia de la infeccion por el virus de la bronquitis infecciosa en la gallina.", [["Se", "CHEMICAL", 242, 244], ["bronquitis infecciosa", "ORGANISM", 173, 194], ["bronquitis infecciosa", "SPECIES", 173, 194], ["bronquitis infecciosa", "SPECIES", 306, 327], ["Inmunopatogenia", "PROBLEM", 196, 211], ["Se revisa la inmunopatogenia de la infeccion", "PROBLEM", 242, 286], ["el virus", "PROBLEM", 291, 299]]], ["Mientras que la bronquitis infecciosa (IB) es considerada primariamente una enfermedad del aparato respiratorio, distintas cepas de IBV pueden mostrar tropismos diversos y afectar tambien al oviducto y el ri\u00f1\u00f3n con consecuencias serias.", [["Mientras", "TEST", 0, 8]]], ["Algunas cepas se replican en el intestino pero aparentemente sin producir lesiones.", [["Algunas cepas", "TREATMENT", 0, 13]]], ["Una reciente variante de IBV ha sido relacionada con la miopatia pectoral.", [["IBV", "ORGANISM", 25, 28], ["Una reciente variante", "TREATMENT", 0, 21], ["IBV ha sido relacionada con la miopatia pectoral", "TREATMENT", 25, 73], ["pectoral", "ANATOMY", 65, 73]]], ["Los componentes inmunog\u00e9nicos del virus incluyen las proteinas S y la nucleoprote\u00edna N. Se revisan las respuestas inmunes humorales y celulares de las gallinas frente a IBV asi como la resistencia gen\u00e9tica de la gallina.", [["Los componentes", "TEST", 0, 15], ["del virus", "TEST", 30, 39]]], ["No obstante, los estudios antigenicos por si solos no son capaces de definir adecuadamente las relaciones entre las cepas, y se han utilizado estudios de inmunizaci\u00f3n cruzada para clasificar los aislamientos de IBV en \"protectotipos\".", [["obstante", "PROBLEM", 3, 11], ["los estudios", "OBSERVATION", 13, 25]]], ["Se especula que los cambios en la prote\u00edna S1 puedan estar relacionados con las diferencias en el tropismo tisular que presentan ciertas cepas.", [["en la prote\u00edna S1", "TREATMENT", 28, 45]]]], "b918011e2c1eeccd0748fccdb7fb75eca74c4eca": [["IntroductionWe write this introduction in the middle of the COVID-19 pandemic, a pandemic which has challenged established expertise in medicine but has also resulted in an enormous need for radical changes in knowledge, regulations, and work practices for countries around the world.", [["radical changes", "TREATMENT", 191, 206], ["middle", "ANATOMY_MODIFIER", 46, 52]]], ["Rather, the situation requires a fundamental structuring of prior knowledge and practices (Ohlsson, 2011) and the generation of new strategies to deal with uncertain and ambiguous information (Merenluoto & Lehtinen, 2004) .IntroductionAlready before the pandemic, increasingly fast changes and turbulence in the workplace generated research focusing on the processes needed to cope with and manage change in the workforce.", [["increasingly fast changes", "PROBLEM", 264, 289], ["turbulence", "OBSERVATION_MODIFIER", 294, 304]]], ["However, change, especially in the case of aging workers, is not easy to come about; there are considerable resistances to change, and some research has attempted to uncover possible reasons (Dent & Goldberg, 1999; Kunze, Boehm, & Bruch, 2013; Oreg, 2006) .", [["considerable", "OBSERVATION_MODIFIER", 95, 107], ["resistances", "OBSERVATION", 108, 119]]], ["The purpose of the present Special Issue is to investigate whether and how conceptual change research can be extended from learning in schools to learning in professional life.IntroductionThere are various 'change drivers' that require new solutions, work processes and ways to organize individual and collective work (Palonen, Boshuizen, & Lehtinen, 2014) .", [["new solutions", "TREATMENT", 236, 249]]], ["Demographic and political changes, economic turbulence, changing norms and legislation, new scientific findings, new technologies and environmental challenges, such as climate change, lead to new knowledge and skills to be incorporated in work procedures; they also give birth to new jobs, or hybridize existing jobs .", [["political changes", "PROBLEM", 16, 33], ["economic turbulence", "PROBLEM", 35, 54], ["economic", "OBSERVATION_MODIFIER", 35, 43], ["turbulence", "OBSERVATION", 44, 54], ["new", "OBSERVATION_MODIFIER", 88, 91]]], ["Many studies address the strategies required to get employees involved in the change and to deal with resistance to change.", [["Many studies", "TEST", 0, 12]]], ["Remarkably, many of these studies fall back on classical social psychological theories, such as Kurt Levin's change model (Talib Hussain et al., 2018) or Leon Festinger's theory of cognitive dissonance (Hinojosa, Gardner, Walker, Cogliser, & Gullifor, 2017) .", [["cognitive dissonance", "DISEASE", 181, 201], ["these studies", "TEST", 20, 33]]], ["These theories may explain social phenomena, but they do not provide sufficient theoretical understanding of the individual level learning needed in becoming and being a professional, and particularly in coping with radical changes in the workplace.IntroductionConceptual change research investigates the changes in individual cognition that take place when learners need to revise their prior knowledge in order to learn new and counter-intuitive concepts.", [["social phenomena", "PROBLEM", 27, 43], ["radical changes", "TREATMENT", 216, 231], ["may explain", "UNCERTAINTY", 15, 26], ["social phenomena", "OBSERVATION", 27, 43]]], ["Researchers have applied conceptual change theories and methodologies to understand learning in many areas of knowledge, such as biology (Inagaki & Hatano, 2002; Sinatra, Brem, & Evans, 2008) , psychology (Wellman, 2002) , history (Leinhardt & Ravi, 2008; Lim\u00f3n, 2002) , political science (Voss & Wiley, 2006) , medicine (Badenhorst et al., 2016; Kaufman, Keselman, & Patel, 2008; S\u00f6dervik, Vilppu, \u00d6 sterholm, & Mikkil\u00e4-Erdmann, 2017) and mathematics (Lehtinen, Merenluoto, & Kasanen, 1997; Vosniadou & Verschaffel, 2004) .IntroductionOver the years a considerable body of research has emerged which has documented the processes of conceptual change, the learning mechanisms involved in the construction of new concepts, and the instructional methods and strategies that can promote conceptual changes.", [["conceptual change theories", "TREATMENT", 25, 51], ["conceptual change", "PROBLEM", 633, 650]]], ["This research has focused primarily on school learning and on the conceptual changes needed when students are exposed to scientific concepts that require major re-organisations of prior knowledge, acquired mainly through everyday experiences in the context of lay culture (Amin & Levrini, 2017; Vosniadou, 2013b) .IntroductionHowever, it is becoming increasingly apparent that conceptual changes not only have to take place when there is inconsistency between individuals' knowledge based on everyday experience and scientific concepts and theories; they are also required in working life, when there is a discrepancy between established science and new scientific concepts emerging from rapid changes in science and technology in today's culture.", [["lay culture", "TEST", 260, 271], ["today's culture", "TEST", 731, 746]]], ["Yet, the investigation of conceptual changes in working life involves going beyond traditional conceptual change research and understanding processes and mechanisms involved when expertise development interacts with workplace learning processes.", [["conceptual changes", "PROBLEM", 26, 44]]], ["For example, conceptual changes may be required when formal, school learning is applied in practice.", [["conceptual changes", "PROBLEM", 13, 31]]], ["Conceptual changes during school learning are usually accomplished through deliberate instruction, often guided by cognitive conflict, self-explanation, and reflection.", [["Conceptual changes", "PROBLEM", 0, 18]]], ["Such learning is no longer sanctioned by a formal curriculum but is self-directed or happens as part of work processes within a community.", [["no longer", "UNCERTAINTY", 17, 26]]], ["Such changes are, for example, the introduction of ICT and serious games in teaching, the regulations for the reduction of nitrogen emission in farming, the introduction of new imaging techniques in medicine, and the massive introduction of working from home.", [["nitrogen", "CHEMICAL", 123, 131], ["nitrogen", "CHEMICAL", 123, 131], ["the reduction of nitrogen emission", "TREATMENT", 106, 140], ["new imaging techniques", "TREATMENT", 173, 195], ["massive", "OBSERVATION_MODIFIER", 217, 224]]], ["One might wonder if these learning processes can be considered as requiring conceptual changes and how these take place.IntroductionThe studies brought together in this Special Issue share the focus of conceptual changes in professional knowledge and/or in professional life.", [["The studies", "TEST", 132, 143]]], ["The study focuses on medical students' conceptual understanding of the central cardiovascular system during the first two years of medical school.", [["cardiovascular", "ANATOMY", 79, 93], ["central cardiovascular system", "ANATOMICAL_SYSTEM", 71, 100], ["The study", "TEST", 0, 9], ["central", "ANATOMY_MODIFIER", 71, 78], ["cardiovascular system", "ANATOMY", 79, 100]]], ["The results showed that even the highly selective medical students in the sample had false beliefs as well as deeper misconceptions about the functioning of the cardiovascular system.", [["cardiovascular", "ANATOMY", 161, 175], ["cardiovascular", "ANATOMICAL_SYSTEM", 161, 175], ["system", "ANATOMICAL_SYSTEM", 176, 182], ["cardiovascular system", "ANATOMY", 161, 182]]], ["During the basic course false beliefs decreased, although the number of false beliefs fluctuated between measurement points.", [["decreased", "OBSERVATION_MODIFIER", 38, 47], ["false", "OBSERVATION", 72, 77], ["fluctuated", "OBSERVATION_MODIFIER", 86, 96]]], ["The researchers concluded that the instruction in the cardiovascular course supported knowledge enrichment and belief revision but did not result in mental model transformation.", [["cardiovascular", "ANATOMY", 54, 68], ["cardiovascular", "ANATOMICAL_SYSTEM", 54, 68], ["belief revision", "TREATMENT", 111, 126], ["mental model transformation", "PROBLEM", 149, 176], ["mental model transformation", "OBSERVATION", 149, 176]]], ["In addition, there was some evidence that the quality of biomedical knowledge was related to students' later success in a clinical application task.IntroductionThe work by Vosniadou et al., 2020 focuses on the examination of learning happening at the divide between school and practice learning in teaching.", [["the examination", "TEST", 206, 221]]], ["Their study extends conceptual change research from school learning to learning at the workplace.", [["Their study", "TEST", 0, 11]]], ["The studies show that the expertise needed in diagnosing various medical images consists of several layers of knowledge and skills including biomedical conceptual knowledge, illness scripts, knowledge of the affordances of various imaging technologies and disciplinary professional practices.", [["illness", "DISEASE", 174, 181], ["The studies", "TEST", 0, 11], ["diagnosing various medical images", "TEST", 46, 79], ["various imaging technologies", "TEST", 223, 251]]], ["Traditional theories of conceptual change only regarded the biomedical conceptual knowledge but due to rapid technological development, remarkable changes are needed at all levels of this complex system of knowledge and skills.IntroductionBoshuizen and Marambe's (this issue) review study focuses on the whole learning trajectory from (pre)school into professional life, and the associated structural changes in professional knowledge in medicine.", [["review study", "TEST", 276, 288]]], ["The results showed that the focus of the articles identified changed according to the level of learning, reflecting the goals of education: from beliefs about health and disease, to scientific biomedical knowledge, to knowledge about (groups of) patients and how to treat them.", [["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 246, 254], ["disease", "PROBLEM", 170, 177]]], ["Remarkably, no studies including further advanced stages of experience could be located.", [["studies", "TEST", 15, 22]]], ["It was concluded that several processes and domain features interact in the creation and sustainment, as well as the prevention and rectification of misconceptions and other knowledge weaknesses.", [["several processes and domain features", "PROBLEM", 22, 59], ["other knowledge weaknesses", "PROBLEM", 168, 194]]], ["Special attention is called to factors The dark rectangle at the bottom depicts scientific knowledge that has to be developed, improved and kept up-to-date.", [["dark rectangle", "OBSERVATION_MODIFIER", 43, 57]]], ["The light blue shaded triangle and rectangles represent application affected by task, role, context, etc. The vertical two-headed arrows represent the cognitive processes at the interface of the two; the curved arrows depict knowledge restructuring processes emerging from knowledge application in professional practice affected by task requirements and change processes.", [["The light blue shaded triangle and rectangles", "TREATMENT", 0, 45], ["The vertical two-headed arrows", "PROBLEM", 106, 136], ["change processes", "PROBLEM", 354, 370], ["blue shaded", "OBSERVATION", 10, 21], ["vertical", "OBSERVATION_MODIFIER", 110, 118], ["two", "OBSERVATION_MODIFIER", 119, 122], ["cognitive processes", "OBSERVATION", 151, 170]]], ["The numbers 1 -5 refer to the articles listed below. related to shared misconceptions and blind spots emanating from established research practices, to unintended but potentially harmful side-effects of professional practices, and to the importance of lifelong critical thinking and reflection.IntroductionKainulainen, Puurtinen and Chinn's study (this issue) presents a theoretical analysis of historians' conceptions of their topic 'history' (history as 'the past' vs history as 'human production') and associated different professional practices.", [["human", "ORGANISM", 482, 487], ["human", "SPECIES", 482, 487], ["human", "SPECIES", 482, 487], ["shared misconceptions", "PROBLEM", 64, 85], ["blind spots", "PROBLEM", 90, 101], ["professional practices", "TREATMENT", 203, 225], ["IntroductionKainulainen", "TREATMENT", 294, 317], ["Puurtinen", "TREATMENT", 319, 328], ["Chinn's study", "TEST", 333, 346]]], ["Traditional approaches of conceptual change research have focused on specific topics in various domains.", [["conceptual change research", "TREATMENT", 26, 52]]], ["In addition, the coexistence of multiple expert conceptions of history highlight the importance of metaconceptual awareness, which enables adaptive and flexible shifts between the different views of history.IntroductionThe contributions in this Special Issue show, among other things, that as we move to higher levels of expertise the phenomena investigated become more complex, regardless of whether they involve perceptual skills, professional practices, or technical skills and values.IntroductionFurthermore, meta-concepts and metaconceptual awareness seem to play an increasingly more important role.", [["metaconceptual awareness", "PROBLEM", 99, 123], ["multiple", "OBSERVATION_MODIFIER", 32, 40]]], ["The findings of the review study by Boshuizen and Marambe (this issue) regarding the absence of research to investigate conceptual changes at higher levels of expertise suggests that such changes are either less meaningful or harder to document at more advanced phases of people's professional careers.", [["people", "ORGANISM", 272, 278], ["people", "SPECIES", 272, 278], ["the review study", "TEST", 16, 32], ["conceptual changes", "PROBLEM", 120, 138]]], ["The analyses so far and the conclusions that can be drawn from the present research give some initial answers while at the same time raise new questions that need to be answered; questions such as what are some of the cognitive/conceptual preconditions for later professional learning and good practice, how does the quality of prior conceptual knowledge affect adaptations to changes in science and practices of a profession, or what is the role of conceptual change within the complex system of knowledge, skills, and practices needed in turbulent working life.", [["The analyses", "TEST", 0, 12]]]], "PMC7505267": [["Study population ::: MATERIALS AND METHODSThe Institutional Review Board of the Third Xiangya Hospital of Central South University approved our study and waived the need for informed consent because of the retrospective nature of this study.", [["our study", "TEST", 140, 149], ["this study", "TEST", 230, 240]]], ["All consecutive adult patients with confirmed COVID-19 who were treated at the Third Xiangya Hospital of Central South University, Changsha Public Health Treatment Center, First Hospital of Yueyang, Junshan People\u2019s Hospital of Yueyang, Central Hospital of Shaoyang, Central Hospital of Xiangtan, Second Hospital of Changde, Central Hospital of Loudi, and First Affiliated Hospital of University of South China between January 17, 2020 and February 28, 2020 were enrolled.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["Patients without available clinical or imaging data were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["imaging data", "TEST", 39, 51]]], ["The diagnosis of COVID-19 was established on the basis of the World Health Organization interim guidelines, and a confirmed case was defined as positive on the basis of the presence of SARS-CoV-2 RNA on high-throughput sequencing or real-time reverse transcription-polymerase chain reaction (RT-PCR) assay in nasal and pharyngeal swab specimens.Collection of clinical and imaging data ::: MATERIALS AND METHODSData on demographic, epidemiological history, chronic comorbidities, clinical symptoms, and laboratory findings were obtained at admission from electronic medical records.", [["nasal", "ANATOMY", 309, 314], ["pharyngeal swab specimens", "ANATOMY", 319, 344], ["SARS", "DISEASE", 185, 189], ["nasal", "ORGANISM_SUBDIVISION", 309, 314], ["pharyngeal swab specimens", "CANCER", 319, 344], ["SARS-CoV-2 RNA", "RNA", 185, 199], ["COVID", "TEST", 17, 22], ["SARS", "PROBLEM", 185, 189], ["CoV", "TEST", 190, 193], ["2 RNA", "PROBLEM", 194, 199], ["polymerase chain reaction", "PROBLEM", 265, 290], ["RT-PCR", "TEST", 292, 298], ["assay", "TEST", 300, 305], ["nasal and pharyngeal swab specimens", "TEST", 309, 344], ["clinical and imaging data", "TEST", 359, 384], ["chronic comorbidities", "PROBLEM", 456, 477], ["clinical symptoms", "PROBLEM", 479, 496], ["nasal", "ANATOMY", 309, 314], ["pharyngeal swab", "ANATOMY", 319, 334], ["chronic", "OBSERVATION_MODIFIER", 456, 463], ["comorbidities", "OBSERVATION", 464, 477]]], ["Medication history among individuals with hypertension was recorded, including treatment with ACEIs or ARBs, calcium antagonists, \u03b2-blockers, and diuretic agents.", [["hypertension", "DISEASE", 42, 54], ["ACEIs", "CHEMICAL", 94, 99], ["ARBs", "CHEMICAL", 103, 107], ["calcium", "CHEMICAL", 109, 116], ["calcium", "CHEMICAL", 109, 116], ["individuals", "ORGANISM", 25, 36], ["ACEIs", "SIMPLE_CHEMICAL", 94, 99], ["ARBs", "SIMPLE_CHEMICAL", 103, 107], ["calcium antagonists", "SIMPLE_CHEMICAL", 109, 128], ["\u03b2-blockers", "SIMPLE_CHEMICAL", 130, 140], ["diuretic agents", "SIMPLE_CHEMICAL", 146, 161], ["hypertension", "PROBLEM", 42, 54], ["ACEIs", "TREATMENT", 94, 99], ["ARBs", "TREATMENT", 103, 107], ["calcium antagonists", "TREATMENT", 109, 128], ["\u03b2-blockers", "TREATMENT", 130, 140], ["diuretic agents", "TREATMENT", 146, 161], ["hypertension", "OBSERVATION", 42, 54]]], ["Body mass index (BMI) was calculated as weight divided by height squared, and obesity was defined as BMI \u2265 28 kg/m2 according to the Chinese-specific cut-offs for general adiposity [17].", [["Body", "ANATOMY", 0, 4], ["obesity", "DISEASE", 78, 85], ["Body mass index", "PROBLEM", 0, 15], ["BMI", "TEST", 17, 20], ["weight", "TEST", 40, 46], ["obesity", "PROBLEM", 78, 85], ["BMI", "TEST", 101, 104], ["general adiposity", "PROBLEM", 163, 180], ["mass", "OBSERVATION", 5, 9]]], ["All laboratory tests were performed according to the clinical care need of the patient during hospitalization, including complete blood count, assessment of liver and renal function, coagulation testing, and measures of electrolyte, creatine kinase, lactate dehydrogenase (LDH), procalcitonin, and C-reactive protein levels.", [["blood", "ANATOMY", 130, 135], ["liver", "ANATOMY", 157, 162], ["renal", "ANATOMY", 167, 172], ["creatine", "CHEMICAL", 233, 241], ["lactate", "CHEMICAL", 250, 257], ["creatine", "CHEMICAL", 233, 241], ["lactate", "CHEMICAL", 250, 257], ["patient", "ORGANISM", 79, 86], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["liver", "ORGAN", 157, 162], ["renal", "ORGAN", 167, 172], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 233, 248], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 250, 271], ["LDH", "GENE_OR_GENE_PRODUCT", 273, 276], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 279, 292], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 298, 316], ["creatine kinase", "PROTEIN", 233, 248], ["lactate dehydrogenase", "PROTEIN", 250, 271], ["LDH", "PROTEIN", 273, 276], ["procalcitonin", "PROTEIN", 279, 292], ["C-reactive protein", "PROTEIN", 298, 316], ["patient", "SPECIES", 79, 86], ["All laboratory tests", "TEST", 0, 20], ["complete blood count", "TEST", 121, 141], ["assessment of liver", "TEST", 143, 162], ["coagulation testing", "TEST", 183, 202], ["electrolyte, creatine kinase", "TEST", 220, 248], ["lactate dehydrogenase", "TEST", 250, 271], ["LDH", "TEST", 273, 276], ["procalcitonin", "TEST", 279, 292], ["C-reactive protein levels", "TEST", 298, 323], ["liver", "ANATOMY", 157, 162], ["renal", "ANATOMY", 167, 172], ["reactive protein levels", "OBSERVATION", 300, 323]]], ["Respiratory tract specimens were collected daily from patients during the course of hospitalization and tested for SARS-CoV-2 RNA.", [["Respiratory tract specimens", "ANATOMY", 0, 27], ["Respiratory tract specimens", "CANCER", 0, 27], ["patients", "ORGANISM", 54, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["SARS-CoV-2 RNA", "RNA", 115, 129], ["patients", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 115, 123], ["Respiratory tract specimens", "TEST", 0, 27], ["SARS", "PROBLEM", 115, 119], ["CoV", "TEST", 120, 123]]], ["The treatment protocol for each patient during hospitalization was also recorded, and the exposure of lopinavir/ritonavir was defined as having received at least one dosage of lopinavir/ritonavir treatment.", [["lopinavir/ritonavir", "CHEMICAL", 102, 121], ["lopinavir/ritonavir", "CHEMICAL", 176, 195], ["lopinavir", "CHEMICAL", 102, 111], ["ritonavir", "CHEMICAL", 112, 121], ["lopinavir", "CHEMICAL", 176, 185], ["ritonavir", "CHEMICAL", 186, 195], ["patient", "ORGANISM", 32, 39], ["lopinavir", "SIMPLE_CHEMICAL", 102, 111], ["ritonavir", "SIMPLE_CHEMICAL", 112, 121], ["lopinavir", "SIMPLE_CHEMICAL", 176, 185], ["ritonavir", "SIMPLE_CHEMICAL", 186, 195], ["patient", "SPECIES", 32, 39], ["The treatment protocol", "TREATMENT", 0, 22], ["lopinavir", "TREATMENT", 102, 111], ["ritonavir", "TREATMENT", 112, 121], ["lopinavir", "TREATMENT", 176, 185], ["ritonavir treatment", "TREATMENT", 186, 205]]], ["CT images were acquired at admission and at intervals of 3-5 days during hospitalization and were reviewed independently by two experienced radiologists.", [["CT images", "TEST", 0, 9]]], ["Typical CT findings for COVID-19 were defined as peripherally distributed multifocal ground-glass opacities (GGOs) with patchy consolidations and a predilection for involvement of the posterior part or lower lobe of the lung [18].", [["GGOs", "ANATOMY", 109, 113], ["posterior part", "ANATOMY", 184, 198], ["lower lobe", "ANATOMY", 202, 212], ["lung", "ANATOMY", 220, 224], ["GGOs", "DISEASE", 109, 113], ["posterior part", "MULTI-TISSUE_STRUCTURE", 184, 198], ["lower lobe", "ORGAN", 202, 212], ["lung", "ORGAN", 220, 224], ["Typical CT findings", "TEST", 0, 19], ["COVID", "TEST", 24, 29], ["peripherally distributed multifocal ground-glass opacities", "PROBLEM", 49, 107], ["patchy consolidations", "PROBLEM", 120, 141], ["peripherally", "OBSERVATION_MODIFIER", 49, 61], ["distributed", "OBSERVATION_MODIFIER", 62, 73], ["multifocal", "OBSERVATION_MODIFIER", 74, 84], ["ground-glass opacities", "OBSERVATION", 85, 107], ["patchy", "OBSERVATION_MODIFIER", 120, 126], ["consolidations", "OBSERVATION", 127, 141], ["posterior", "ANATOMY_MODIFIER", 184, 193], ["lower lobe", "ANATOMY", 202, 212], ["lung", "ANATOMY", 220, 224]]], ["Each of the five lung lobes was reviewed for GGO and consolidation.", [["lung lobes", "ANATOMY", 17, 27], ["GGO", "DISEASE", 45, 48], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 17, 27], ["GGO", "PROBLEM", 45, 48], ["consolidation", "PROBLEM", 53, 66], ["lung", "ANATOMY", 17, 21], ["lobes", "ANATOMY_MODIFIER", 22, 27], ["consolidation", "OBSERVATION", 53, 66]]], ["The extent of the lesions within each lung lobe was semi-quantitatively evaluated by scoring from 0 to 5 based on the degree of involvement, as follows: score 0, no involvement; score 1, \u2264 5% involvement; score 2, 6%-25% involvement; score 3, 26%-50% involvement; score 4, 51%-75% involvement; and score 5, >75% involvement.", [["lesions", "ANATOMY", 18, 25], ["lung lobe", "ANATOMY", 38, 47], ["lesions", "CANCER", 18, 25], ["lung lobe", "CANCER", 38, 47], ["the lesions within each lung lobe", "PROBLEM", 14, 47], ["score", "TEST", 178, 183], ["\u2264", "TEST", 187, 188], ["score", "TEST", 205, 210], ["score", "TEST", 234, 239], ["score", "TEST", 264, 269], ["score", "TEST", 298, 303], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["lesions", "OBSERVATION", 18, 25], ["lung", "ANATOMY", 38, 42], ["lobe", "ANATOMY_MODIFIER", 43, 47], ["involvement", "OBSERVATION", 128, 139], ["no", "UNCERTAINTY", 162, 164]]], ["The total score was calculated by summing the scores of all five lobes to provide a lung CT score ranging from 0 to 25 [19].", [["lung", "ANATOMY", 84, 88], ["lung", "ORGAN", 84, 88], ["The total score", "TEST", 0, 15], ["a lung CT score", "TEST", 82, 97], ["lung", "ANATOMY", 84, 88]]], ["The mean values of lung CT scores evaluated by the two radiologists were used for analysis.Collection of clinical and imaging data ::: MATERIALS AND METHODSThe disease severity of COVID-19 was defined as follows: (1) mild type, with fever or respiratory tract symptoms but without radiological pneumonia; (2) moderate type, with fever, respiratory tract symptoms, and radiological evidence of pneumonia; (3) severe type, with one of the following: a) respiratory distress (respiratory rate \u2265 30 beats/min), b) hypoxia (oxygen saturation \u2264 93% in the resting state), or c) hypoxemia (arterial blood oxygen partial pressure/oxygen concentration \u2264 300mmHg); (4) critical type, with one of the following: a) respiratory failure requiring mechanical ventilation, b) shock, or c) intensive care unit (ICU) admission because of combined other organ failure.Collection of clinical and imaging data ::: MATERIALS AND METHODSDuration of viral shedding after illness onset was considered as the number of days from symptom onset to persistent negative results on respiratory tract viral RT-PCR testing.", [["lung", "ANATOMY", 19, 23], ["respiratory tract", "ANATOMY", 242, 259], ["respiratory tract", "ANATOMY", 336, 353], ["respiratory", "ANATOMY", 451, 462], ["respiratory", "ANATOMY", 473, 484], ["arterial", "ANATOMY", 583, 591], ["blood", "ANATOMY", 592, 597], ["respiratory", "ANATOMY", 704, 715], ["organ", "ANATOMY", 836, 841], ["fever", "DISEASE", 233, 238], ["respiratory tract symptoms", "DISEASE", 242, 268], ["pneumonia", "DISEASE", 294, 303], ["fever", "DISEASE", 329, 334], ["respiratory tract symptoms", "DISEASE", 336, 362], ["pneumonia", "DISEASE", 393, 402], ["respiratory distress", "DISEASE", 451, 471], ["hypoxia", "DISEASE", 510, 517], ["oxygen", "CHEMICAL", 519, 525], ["hypoxemia", "DISEASE", 572, 581], ["oxygen", "CHEMICAL", 598, 604], ["oxygen", "CHEMICAL", 622, 628], ["respiratory failure", "DISEASE", 704, 723], ["shock", "DISEASE", 761, 766], ["organ failure", "DISEASE", 836, 849], ["illness", "DISEASE", 948, 955], ["oxygen", "CHEMICAL", 519, 525], ["oxygen", "CHEMICAL", 598, 604], ["oxygen", "CHEMICAL", 622, 628], ["lung", "ORGAN", 19, 23], ["tract", "ORGANISM_SUBDIVISION", 254, 259], ["tract", "ORGANISM_SUBDIVISION", 348, 353], ["oxygen", "SIMPLE_CHEMICAL", 519, 525], ["blood", "ORGANISM_SUBSTANCE", 592, 597], ["oxygen", "SIMPLE_CHEMICAL", 598, 604], ["oxygen", "SIMPLE_CHEMICAL", 622, 628], ["organ", "ORGAN", 836, 841], ["lung CT scores", "TEST", 19, 33], ["analysis", "TEST", 82, 90], ["clinical and imaging data", "TEST", 105, 130], ["METHODSThe disease severity", "TEST", 149, 176], ["COVID", "TEST", 180, 185], ["mild type", "PROBLEM", 217, 226], ["fever", "PROBLEM", 233, 238], ["respiratory tract symptoms", "PROBLEM", 242, 268], ["radiological pneumonia", "PROBLEM", 281, 303], ["moderate type", "PROBLEM", 309, 322], ["fever", "PROBLEM", 329, 334], ["respiratory tract symptoms", "PROBLEM", 336, 362], ["pneumonia", "PROBLEM", 393, 402], ["a) respiratory distress", "PROBLEM", 448, 471], ["respiratory rate", "TEST", 473, 489], ["hypoxia", "PROBLEM", 510, 517], ["oxygen saturation", "TEST", 519, 536], ["hypoxemia", "PROBLEM", 572, 581], ["arterial blood oxygen partial pressure", "TEST", 583, 621], ["oxygen concentration", "TEST", 622, 642], ["a) respiratory failure", "PROBLEM", 701, 723], ["mechanical ventilation", "TREATMENT", 734, 756], ["shock", "PROBLEM", 761, 766], ["combined other organ failure", "PROBLEM", 821, 849], ["clinical and imaging data", "TEST", 864, 889], ["viral shedding", "PROBLEM", 927, 941], ["symptom", "PROBLEM", 1004, 1011], ["respiratory tract viral RT", "TEST", 1052, 1078], ["PCR testing", "TEST", 1079, 1090], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["lung", "ANATOMY", 19, 23], ["mild", "OBSERVATION_MODIFIER", 217, 221], ["respiratory tract", "ANATOMY", 242, 259], ["without", "UNCERTAINTY", 273, 280], ["pneumonia", "OBSERVATION", 294, 303], ["moderate", "OBSERVATION_MODIFIER", 309, 317], ["fever", "OBSERVATION", 329, 334], ["respiratory tract", "ANATOMY", 336, 353], ["pneumonia", "OBSERVATION", 393, 402], ["respiratory", "ANATOMY", 451, 462], ["distress", "OBSERVATION", 463, 471], ["hypoxia", "OBSERVATION", 510, 517], ["hypoxemia", "OBSERVATION", 572, 581], ["respiratory", "ANATOMY", 704, 715], ["failure", "OBSERVATION", 716, 723], ["organ", "ANATOMY", 836, 841], ["failure", "OBSERVATION", 842, 849], ["viral", "OBSERVATION_MODIFIER", 927, 932], ["respiratory tract", "ANATOMY", 1052, 1069]]], ["All samples from the same patient were tested until two consecutive samples showed negative results, with the first negative result defining the duration of shedding.Statistical Analysis ::: MATERIALS AND METHODSContinuous variables are presented as the median and interquartile range (IQR), and categorical variables are presented as frequency and percentage.", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 68, 75], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["All samples", "TEST", 0, 11], ["percentage", "OBSERVATION_MODIFIER", 349, 359]]], ["Differences between groups were analyzed using Student\u2019s t-test or the Mann-Whitney U test for quantitative variables according to the normal distribution and the Chi-square test or Fisher\u2019s exact test for categorical variables.", [["Student\u2019s t-test", "TEST", 47, 63], ["quantitative variables", "TEST", 95, 117], ["the Chi-square test", "TEST", 159, 178]]], ["Univariate and multivariate logistic regressions with backward stepwise selection on the basis of the likelihood ratio were used to identify the risk factors for the development of severe or critical pneumonia, and the corresponding odds ratios (ORs) and 95% confidence intervals (CIs) were determined.", [["pneumonia", "DISEASE", 200, 209], ["Univariate", "TREATMENT", 0, 10], ["multivariate logistic regressions", "TREATMENT", 15, 48], ["backward stepwise selection", "TREATMENT", 54, 81], ["severe or critical pneumonia", "PROBLEM", 181, 209], ["CIs", "TEST", 281, 284], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["critical", "OBSERVATION_MODIFIER", 191, 199], ["pneumonia", "OBSERVATION", 200, 209]]], ["The cumulative percentage of patients with positive SARS-CoV-2 RNA was calculated using Kaplan Meier curves, and comparisons between groups were performed using the log-rank test.", [["patients", "ORGANISM", 29, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["positive SARS-CoV-2 RNA", "RNA", 43, 66], ["patients", "SPECIES", 29, 37], ["positive SARS-CoV-2 RNA", "PROBLEM", 43, 66], ["Kaplan Meier curves", "TEST", 88, 107], ["the log-rank test", "TEST", 161, 178], ["cumulative", "OBSERVATION_MODIFIER", 4, 14], ["percentage", "OBSERVATION_MODIFIER", 15, 25]]], ["The Cox proportional hazard model was adopted for multivariate analyses of potential risk factors associated with the discontinuation of viral shedding, and the hazard ratio (HR) and 95% CI were calculated.", [["The Cox proportional hazard model", "TREATMENT", 0, 33], ["potential risk factors", "PROBLEM", 75, 97], ["viral shedding", "PROBLEM", 137, 151], ["the hazard ratio", "TEST", 157, 173], ["HR", "TEST", 175, 177], ["95% CI", "TEST", 183, 189]]], ["The analyses regarding different factors were based on non-missing data, and missing data were not imputed.", [["different factors", "PROBLEM", 23, 40], ["non-missing data", "TEST", 55, 71]]], ["All statistical analyses were performed using SPSS statistics software (version 22.0, IBM SPSS Inc., Chicago, IL, USA).", [["All statistical analyses", "TEST", 0, 24], ["SPSS statistics software", "TEST", 46, 70]]], ["A two-sided P value of less than 0.05 was considered statistically significant.Statistical Analysis ::: MATERIALS AND METHODS", [["A two-sided P value", "TEST", 0, 19], ["sided", "ANATOMY_MODIFIER", 6, 11]]]], "06d4c2299cf3f4604baaee1309a54daa5d4ec2a7": [["Definitions and Approaches'Blood' is a fluid tissue, composed from various cells with complex functions (erythrocytes, red cells -oxygen carriers; leucocytes and lymphocytes, white cells -immune response to disease; and thrombocytes -clotting factor), which are carried by plasma.", [["Blood", "ANATOMY", 27, 32], ["fluid tissue", "ANATOMY", 39, 51], ["cells", "ANATOMY", 75, 80], ["erythrocytes", "ANATOMY", 105, 117], ["red cells", "ANATOMY", 119, 128], ["leucocytes", "ANATOMY", 147, 157], ["lymphocytes", "ANATOMY", 162, 173], ["white cells", "ANATOMY", 175, 186], ["thrombocytes", "ANATOMY", 220, 232], ["plasma", "ANATOMY", 273, 279], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "CHEMICAL", 130, 136], ["Blood", "ORGANISM_SUBSTANCE", 27, 32], ["fluid tissue", "TISSUE", 39, 51], ["cells", "CELL", 75, 80], ["erythrocytes", "CELL", 105, 117], ["red cells", "CELL", 119, 128], ["oxygen", "SIMPLE_CHEMICAL", 130, 136], ["leucocytes", "CELL", 147, 157], ["lymphocytes", "CELL", 162, 173], ["white cells", "CELL", 175, 186], ["thrombocytes -clotting factor", "GENE_OR_GENE_PRODUCT", 220, 249], ["plasma", "ORGANISM_SUBSTANCE", 273, 279], ["erythrocytes", "CELL_TYPE", 105, 117], ["red cells", "CELL_TYPE", 119, 128], ["leucocytes", "CELL_TYPE", 147, 157], ["lymphocytes", "CELL_TYPE", 162, 173], ["white cells", "CELL_TYPE", 175, 186], ["thrombocytes", "CELL_TYPE", 220, 232], ["clotting factor", "PROTEIN", 234, 249], ["a fluid tissue", "PROBLEM", 37, 51], ["complex functions", "PROBLEM", 86, 103], ["erythrocytes", "TEST", 105, 117], ["red cells", "TEST", 119, 128], ["oxygen carriers", "TEST", 130, 145], ["leucocytes", "TEST", 147, 157], ["lymphocytes", "TEST", 162, 173], ["white cells", "TEST", 175, 186], ["disease", "PROBLEM", 207, 214], ["thrombocytes", "TEST", 220, 232], ["clotting factor", "PROBLEM", 234, 249], ["fluid tissue", "OBSERVATION", 39, 51], ["red cells", "OBSERVATION", 119, 128], ["leucocytes", "ANATOMY", 147, 157], ["lymphocytes", "ANATOMY", 162, 173]]], ["Blood is vital as carrying oxygen, nutrients, and other essential elements to the tissues and removing residues of cellular metabolism.", [["Blood", "ANATOMY", 0, 5], ["tissues", "ANATOMY", 82, 89], ["cellular", "ANATOMY", 115, 123], ["oxygen", "CHEMICAL", 27, 33], ["oxygen", "CHEMICAL", 27, 33], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["oxygen", "SIMPLE_CHEMICAL", 27, 33], ["tissues", "TISSUE", 82, 89], ["cellular", "CELL", 115, 123], ["Blood", "TEST", 0, 5], ["carrying oxygen", "TREATMENT", 18, 33], ["cellular metabolism", "PROBLEM", 115, 134], ["cellular metabolism", "OBSERVATION", 115, 134]]], ["It also carries various clotting factors which normally intervene when bleeding occurs.Definitions and ApproachesBlood donation is a benevolent gesture of offering blood for patients in need.", [["Blood", "ANATOMY", 113, 118], ["blood", "ANATOMY", 164, 169], ["bleeding", "DISEASE", 71, 79], ["Blood", "ORGANISM_SUBSTANCE", 113, 118], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["patients", "ORGANISM", 174, 182], ["clotting factors", "PROTEIN", 24, 40], ["patients", "SPECIES", 174, 182], ["various clotting factors", "PROBLEM", 16, 40], ["bleeding", "PROBLEM", 71, 79], ["various", "OBSERVATION_MODIFIER", 16, 23], ["clotting", "OBSERVATION", 24, 32]]], ["Every healthy individual 18 to 65 years of age can donate blood, about 7 ml per kg body weight, up to a maximum of 450 ml whole blood per donation.", [["blood", "ANATOMY", 58, 63], ["body", "ANATOMY", 83, 87], ["blood", "ANATOMY", 128, 133], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["body", "ORGANISM_SUBDIVISION", 83, 87], ["blood", "ORGANISM_SUBSTANCE", 128, 133]]], ["The interval between two whole blood donations has to be at least 72 days.", [["blood", "ANATOMY", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["two whole blood donations", "TREATMENT", 21, 46]]], ["Voluntary nonremunerated blood donation is considered a cornerstone of blood safety and it is advocated and supported by many international bodies, such as World Health Organization, the International Federation of Red Cross and Red Crescent Societies, and the International Federation of Blood Donor Organizations (see Relevant Websites).Definitions and ApproachesBlood transfusion is a medical treatment in which blood, blood components, or blood products are collected and prepared from a healthy person (a donor) and administered to the patient being treated.", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 71, 76], ["Blood", "ANATOMY", 289, 294], ["Blood", "ANATOMY", 365, 370], ["blood", "ANATOMY", 415, 420], ["blood", "ANATOMY", 422, 427], ["blood", "ANATOMY", 443, 448], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["Blood", "ORGANISM_SUBSTANCE", 365, 370], ["blood", "ORGANISM_SUBSTANCE", 415, 420], ["blood", "ORGANISM_SUBSTANCE", 422, 427], ["blood", "ORGANISM_SUBSTANCE", 443, 448], ["products", "ORGANISM_SUBSTANCE", 449, 457], ["patient", "ORGANISM", 541, 548], ["person", "SPECIES", 500, 506], ["patient", "SPECIES", 541, 548], ["Voluntary nonremunerated blood donation", "TREATMENT", 0, 39], ["Blood transfusion", "TREATMENT", 365, 382], ["a medical treatment", "TREATMENT", 386, 405], ["blood, blood components", "TEST", 415, 438], ["blood products", "TREATMENT", 443, 457], ["a donor)", "TREATMENT", 508, 516], ["Crescent", "OBSERVATION_MODIFIER", 233, 241]]], ["The most appropriate blood transfusion therapy should provide for the missing or reduced element.", [["blood", "ANATOMY", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["The most appropriate blood transfusion therapy", "TREATMENT", 0, 46], ["the missing or reduced element", "PROBLEM", 66, 96]]], ["Transfusion of whole blood can be life-saving in situations such as massive blood loss due to trauma or extensive surgery.", [["whole blood", "ANATOMY", 15, 26], ["blood", "ANATOMY", 76, 81], ["blood loss", "DISEASE", 76, 86], ["trauma", "DISEASE", 94, 100], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["Transfusion of whole blood", "TREATMENT", 0, 26], ["massive blood loss", "PROBLEM", 68, 86], ["trauma", "PROBLEM", 94, 100], ["extensive surgery", "TREATMENT", 104, 121], ["extensive", "OBSERVATION_MODIFIER", 104, 113], ["surgery", "OBSERVATION", 114, 121]]], ["Blood component therapy is used to treat conditions in which the specific element is missing; for example, severe anemia (a reduction in oxygen supply to vital organs) or an abnormal decrease in the number of platelets.", [["Blood", "ANATOMY", 0, 5], ["organs", "ANATOMY", 160, 166], ["platelets", "ANATOMY", 209, 218], ["anemia", "DISEASE", 114, 120], ["oxygen", "CHEMICAL", 137, 143], ["oxygen", "CHEMICAL", 137, 143], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["oxygen", "SIMPLE_CHEMICAL", 137, 143], ["organs", "ORGAN", 160, 166], ["platelets", "CELL", 209, 218], ["platelets", "CELL_TYPE", 209, 218], ["Blood component therapy", "TREATMENT", 0, 23], ["conditions", "PROBLEM", 41, 51], ["severe anemia", "PROBLEM", 107, 120], ["a reduction in oxygen supply", "TREATMENT", 122, 150], ["an abnormal decrease", "PROBLEM", 171, 191], ["platelets", "TEST", 209, 218], ["component", "OBSERVATION_MODIFIER", 6, 15], ["therapy", "OBSERVATION", 16, 23], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["anemia", "OBSERVATION", 114, 120], ["reduction", "OBSERVATION_MODIFIER", 124, 133], ["abnormal", "OBSERVATION_MODIFIER", 174, 182], ["decrease", "OBSERVATION_MODIFIER", 183, 191]]], ["People suffering from sickle-cell disease may require frequent transfusion of red cell concentrates.", [["sickle-cell", "ANATOMY", 22, 33], ["red cell", "ANATOMY", 78, 86], ["sickle-cell disease", "DISEASE", 22, 41], ["People", "ORGANISM", 0, 6], ["sickle-cell", "CELL", 22, 33], ["red cell", "CELL", 78, 86], ["People", "SPECIES", 0, 6], ["sickle-cell disease", "PROBLEM", 22, 41], ["frequent transfusion of red cell concentrates", "TREATMENT", 54, 99], ["sickle-cell disease", "OBSERVATION", 22, 41], ["red cell concentrates", "OBSERVATION", 78, 99]]], ["In the case of hemophilia, the administration of the missing clotting factor is required.", [["hemophilia", "DISEASE", 15, 25], ["clotting factor", "GENE_OR_GENE_PRODUCT", 61, 76], ["clotting factor", "PROTEIN", 61, 76], ["hemophilia", "PROBLEM", 15, 25], ["the missing clotting factor", "TREATMENT", 49, 76], ["hemophilia", "OBSERVATION", 15, 25]]], ["Blood transfusion treatment is usually performed in health-care settings.Definitions and ApproachesBlood transfusion service is an organization which deals with various aspects of the blood transfusion chain, from the potential donor (information and selection of donors, blood collection, blood testing, blood processing, blood storage, blood transportation) to the potential recipient (selection and distribution of appropriate components for transfusion), and should link to the clinical interface or administration of blood and patient follow-up.Definitions and ApproachesThis process is usually carried out by organizations or health departments operating at a local, regional, or national level.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ANATOMY", 99, 104], ["blood", "ANATOMY", 184, 189], ["blood", "ANATOMY", 272, 277], ["blood", "ANATOMY", 290, 295], ["blood", "ANATOMY", 305, 310], ["blood", "ANATOMY", 323, 328], ["blood", "ANATOMY", 338, 343], ["blood", "ANATOMY", 522, 527], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 99, 104], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["donors", "ORGANISM", 264, 270], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["blood", "ORGANISM_SUBSTANCE", 290, 295], ["blood", "ORGANISM_SUBSTANCE", 305, 310], ["blood", "ORGANISM_SUBSTANCE", 323, 328], ["blood", "ORGANISM_SUBSTANCE", 338, 343], ["blood", "ORGANISM_SUBSTANCE", 522, 527], ["patient", "ORGANISM", 532, 539], ["patient", "SPECIES", 532, 539], ["Blood transfusion treatment", "TREATMENT", 0, 27], ["Blood transfusion service", "TREATMENT", 99, 124], ["the blood transfusion chain", "TREATMENT", 180, 207], ["donors", "TREATMENT", 264, 270], ["blood collection", "TEST", 272, 288], ["blood testing", "TEST", 290, 303], ["blood processing", "TEST", 305, 321], ["blood storage", "TEST", 323, 336], ["blood transportation", "TEST", 338, 358], ["transfusion", "TREATMENT", 445, 456]]], ["In some countries blood services are hospital based.", [["blood", "ANATOMY", 18, 23], ["blood", "ORGANISM_SUBSTANCE", 18, 23]]], ["The range of responsibilities of the hospital blood banks varies, therefore, according to the organization of the national health-care system.", [["blood", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["range", "OBSERVATION_MODIFIER", 4, 9]]], ["Usually, the hospital transfusion department bears the responsibilities of storage, selection (compatibility testing), and distribution of blood components according to medical prescription.Definitions and ApproachesA blood component results from separation of collected whole blood through centrifugation at various speeds.", [["blood", "ANATOMY", 139, 144], ["blood", "ANATOMY", 218, 223], ["whole blood", "ANATOMY", 271, 282], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["blood", "ORGANISM_SUBSTANCE", 218, 223], ["blood", "ORGANISM_SUBSTANCE", 277, 282], ["selection (compatibility testing", "TEST", 84, 116], ["blood components", "PROBLEM", 139, 155], ["ApproachesA blood component", "TEST", 206, 233], ["collected whole blood through centrifugation", "TREATMENT", 261, 305]]], ["Components include red cells, white cells, thrombocytes, and plasma.", [["red cells", "ANATOMY", 19, 28], ["white cells", "ANATOMY", 30, 41], ["thrombocytes", "ANATOMY", 43, 55], ["plasma", "ANATOMY", 61, 67], ["red cells", "CELL", 19, 28], ["white cells", "CELL", 30, 41], ["thrombocytes", "CELL", 43, 55], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["red cells", "CELL_TYPE", 19, 28], ["white cells", "CELL_TYPE", 30, 41], ["thrombocytes", "CELL_TYPE", 43, 55], ["red cells", "TEST", 19, 28], ["white cells", "TEST", 30, 41], ["thrombocytes", "TEST", 43, 55], ["plasma", "TEST", 61, 67], ["red cells", "OBSERVATION", 19, 28], ["white cells", "OBSERVATION", 30, 41]]], ["Each component has specific characteristics, including a special storage temperature and shelf life (e.g., thrombocytes must be stored at \u00fe21 C; plasma must be frozen at -40 C).", [["thrombocytes", "ANATOMY", 107, 119], ["plasma", "ANATOMY", 145, 151], ["thrombocytes", "CELL", 107, 119], ["plasma", "ORGANISM_SUBSTANCE", 145, 151], ["thrombocytes", "CELL_TYPE", 107, 119], ["a special storage temperature", "PROBLEM", 55, 84], ["thrombocytes", "TEST", 107, 119], ["plasma", "TEST", 145, 151]]], ["Blood components can also be collected from the individual donor through apheresis procedures (separation of the required component from collected blood during the donation procedure, with the remaining being returned to the donor at the end of the separation process).", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 147, 152], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["Blood components", "PROBLEM", 0, 16], ["apheresis procedures", "TREATMENT", 73, 93], ["the donation procedure", "TREATMENT", 160, 182]]], ["The procedure can be fully or partially automated.Definitions and ApproachesIn separating blood derivatives or components, raw plasma is subject to industrial fractionation procedures.", [["blood", "ANATOMY", 90, 95], ["plasma", "ANATOMY", 127, 133], ["ApproachesIn", "SIMPLE_CHEMICAL", 66, 78], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["The procedure", "TREATMENT", 0, 13], ["ApproachesIn separating blood derivatives", "TREATMENT", 66, 107], ["industrial fractionation procedures", "TREATMENT", 148, 183]]], ["These procedures must follow the pharmaceutical current good manufacturing practices (cGMP) so that resulting products comply with required safety standards.", [["cGMP", "CHEMICAL", 86, 90], ["cGMP", "CHEMICAL", 86, 90], ["cGMP", "SIMPLE_CHEMICAL", 86, 90], ["These procedures", "TREATMENT", 0, 16], ["safety standards", "TREATMENT", 140, 156]]], ["The purified and concentrated coagulation factors (e.g., Factor VIII, Factor IX) and human albumin are usually prepared as 5% or 20% solutions, and immune globulins are the most frequently used blood derivatives.Definitions and ApproachesTechnological progress has been achieved in obtaining recombinant coagulation factors, as well as volume replacement solutions and plasma expanders, in the continuous search to identify responses to an insufficient blood supply which is increasingly exposed to safety threats.Safety Aspects of Blood TransfusionBeing a complex but undeniable life source, blood has been given historically mythical attributes.", [["blood", "ANATOMY", 194, 199], ["plasma", "ANATOMY", 369, 375], ["blood", "ANATOMY", 453, 458], ["Blood", "ANATOMY", 532, 537], ["blood", "ANATOMY", 593, 598], ["Factor VIII", "GENE_OR_GENE_PRODUCT", 57, 68], ["Factor IX", "GENE_OR_GENE_PRODUCT", 70, 79], ["human", "ORGANISM", 85, 90], ["albumin", "GENE_OR_GENE_PRODUCT", 91, 98], ["immune globulins", "GENE_OR_GENE_PRODUCT", 148, 164], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["plasma", "ORGANISM_SUBSTANCE", 369, 375], ["blood", "ORGANISM_SUBSTANCE", 453, 458], ["Blood", "ORGANISM_SUBSTANCE", 532, 537], ["blood", "ORGANISM_SUBSTANCE", 593, 598], ["coagulation factors", "PROTEIN", 30, 49], ["Factor VIII", "PROTEIN", 57, 68], ["Factor IX", "PROTEIN", 70, 79], ["human albumin", "PROTEIN", 85, 98], ["immune globulins", "PROTEIN", 148, 164], ["recombinant coagulation factors", "PROTEIN", 292, 323], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["concentrated coagulation factors", "PROBLEM", 17, 49], ["Factor VIII", "TEST", 57, 68], ["Factor IX", "TEST", 70, 79], ["human albumin", "TEST", 85, 98], ["immune globulins", "TEST", 148, 164], ["blood derivatives", "TREATMENT", 194, 211], ["recombinant coagulation factors", "TREATMENT", 292, 323], ["volume replacement solutions", "TREATMENT", 336, 364], ["plasma expanders", "TREATMENT", 369, 385], ["an insufficient blood supply", "PROBLEM", 437, 465], ["concentrated", "OBSERVATION_MODIFIER", 17, 29], ["coagulation", "OBSERVATION", 30, 41]]], ["After unsuccessful transfusions of blood from animals to humans, and sometimes from humans to humans as well, it was only after 1900, when Karl Landsteiner discovered the ABO major blood groups, that blood transfusion therapy became possible.", [["blood", "ANATOMY", 35, 40], ["blood", "ANATOMY", 181, 186], ["blood", "ANATOMY", 200, 205], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["humans", "ORGANISM", 57, 63], ["humans", "ORGANISM", 84, 90], ["humans", "ORGANISM", 94, 100], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["humans", "SPECIES", 57, 63], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 57, 63], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 94, 100], ["unsuccessful transfusions of blood", "TREATMENT", 6, 40], ["blood transfusion therapy", "TREATMENT", 200, 225]]], ["The history of blood transfusion has shown that once the blood group compatibility barrier had been overcome, there are infectious threats to which increased attention must be given.", [["blood", "ANATOMY", 15, 20], ["blood", "ANATOMY", 57, 62], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["blood transfusion", "TREATMENT", 15, 32], ["the blood group compatibility barrier", "TREATMENT", 53, 90], ["infectious", "OBSERVATION", 120, 130]]], ["Blood-borne pathogens can be transferred with the donor's blood to the recipient patient.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 58, 63], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["Blood-borne pathogens", "PROBLEM", 0, 21]]], ["Such pathogens may be viruses (e.g., HIV/ AIDS, hepatitis B and C), parasites (e.g., malaria, Chagas' disease), bacteria (e.g., syphilis, brucellosis), or prions (e.g., vCJD).Safety Aspects of Blood TransfusionIn the late 1980s the transmission of the HIV virus by blood, blood components, and by pharmaceutically manufactured blood derivatives raised important concerns.", [["Blood", "ANATOMY", 193, 198], ["blood", "ANATOMY", 265, 270], ["blood", "ANATOMY", 272, 277], ["blood", "ANATOMY", 327, 332], ["HIV/ AIDS, hepatitis B", "DISEASE", 37, 59], ["malaria", "DISEASE", 85, 92], ["Chagas' disease", "DISEASE", 94, 109], ["syphilis", "DISEASE", 128, 136], ["brucellosis", "DISEASE", 138, 149], ["vCJD", "DISEASE", 169, 173], ["hepatitis B", "ORGANISM", 48, 59], ["Blood", "ORGANISM_SUBSTANCE", 193, 198], ["HIV virus", "ORGANISM", 252, 261], ["blood", "ORGANISM_SUBSTANCE", 265, 270], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["blood", "ORGANISM_SUBSTANCE", 327, 332], ["HIV", "SPECIES", 37, 40], ["HIV virus", "SPECIES", 252, 261], ["HIV", "SPECIES", 37, 40], ["HIV virus", "SPECIES", 252, 261], ["Such pathogens", "PROBLEM", 0, 14], ["viruses", "PROBLEM", 22, 29], ["HIV/ AIDS", "PROBLEM", 37, 46], ["hepatitis B and C)", "PROBLEM", 48, 66], ["parasites", "PROBLEM", 68, 77], ["malaria", "PROBLEM", 85, 92], ["Chagas' disease)", "PROBLEM", 94, 110], ["bacteria", "PROBLEM", 112, 120], ["syphilis", "PROBLEM", 128, 136], ["brucellosis", "PROBLEM", 138, 149], ["prions (e.g., vCJD)", "PROBLEM", 155, 174], ["Blood TransfusionIn", "TEST", 193, 212], ["the HIV virus", "PROBLEM", 248, 261], ["blood components", "TEST", 272, 288], ["pharmaceutically manufactured blood derivatives", "TREATMENT", 297, 344], ["may be", "UNCERTAINTY", 15, 21], ["viruses", "OBSERVATION", 22, 29], ["brucellosis", "OBSERVATION", 138, 149]]], ["A large number of patients chronically depending on therapy with blood components or derivatives were proven to be infected with HIV and other blood-borne pathogens.", [["blood", "ANATOMY", 65, 70], ["blood", "ANATOMY", 143, 148], ["patients", "ORGANISM", 18, 26], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["HIV", "ORGANISM", 129, 132], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["patients", "SPECIES", 18, 26], ["HIV", "SPECIES", 129, 132], ["HIV", "SPECIES", 129, 132], ["therapy", "TREATMENT", 52, 59], ["blood components", "TREATMENT", 65, 81], ["derivatives", "TREATMENT", 85, 96], ["HIV", "PROBLEM", 129, 132], ["other blood-borne pathogens", "PROBLEM", 137, 164], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["These findings led to more firm regulations of the entire blood transfusion area, with patient protection being of central importance.", [["blood", "ANATOMY", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["the entire blood transfusion area", "TREATMENT", 47, 80], ["more", "OBSERVATION_MODIFIER", 22, 26], ["firm", "OBSERVATION_MODIFIER", 27, 31]]], ["Intensive work in the field of quality assurance of blood-banking operations, including viral inactivation of blood derivatives, was initiated.", [["blood", "ANATOMY", 52, 57], ["blood", "ANATOMY", 110, 115], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["blood-banking operations", "TREATMENT", 52, 76], ["viral inactivation of blood derivatives", "TREATMENT", 88, 127]]], ["For a more comprehensive overview of the history of blood transfusion, see Starr (1998) .Safety Aspects of Blood TransfusionOther crisis situations, such as the variant Creutzfeldt-Jakob disease (vCJD) infections (mad cow disease), severe acute respiratory syndrome (SARS), or avian flu epidemics, have strongly affected the availability of the blood supply at times.", [["blood", "ANATOMY", 52, 57], ["Blood", "ANATOMY", 107, 112], ["blood", "ANATOMY", 345, 350], ["Creutzfeldt-Jakob disease", "DISEASE", 169, 194], ["vCJD", "DISEASE", 196, 200], ["infections", "DISEASE", 202, 212], ["cow disease", "DISEASE", 218, 229], ["acute respiratory syndrome", "DISEASE", 239, 265], ["SARS", "DISEASE", 267, 271], ["flu epidemics", "DISEASE", 283, 296], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["Blood", "ORGANISM_SUBSTANCE", 107, 112], ["cow", "ORGANISM_SUBDIVISION", 218, 221], ["blood", "ORGANISM_SUBSTANCE", 345, 350], ["cow", "SPECIES", 218, 221], ["avian flu", "SPECIES", 277, 286], ["Creutzfeldt-Jakob disease (vCJD)", "SPECIES", 169, 201], ["cow", "SPECIES", 218, 221], ["blood transfusion", "TREATMENT", 52, 69], ["Blood TransfusionOther crisis situations", "PROBLEM", 107, 147], ["Jakob disease (vCJD) infections (mad cow disease)", "PROBLEM", 181, 230], ["severe acute respiratory syndrome", "PROBLEM", 232, 265], ["SARS", "PROBLEM", 267, 271], ["avian flu epidemics", "PROBLEM", 277, 296], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["respiratory syndrome", "OBSERVATION", 245, 265]]], ["A more complete list of infectious agents which can be transmitted by blood transfusion is presented in Table 1 .", [["blood", "ANATOMY", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["infectious agents", "TREATMENT", 24, 41], ["blood transfusion", "TEST", 70, 87], ["infectious", "OBSERVATION", 24, 34]]], ["It is important to note that these agents in their early stage of infection induce a healthy carrier state with few or no symptoms of disease.Present SituationThe safety and availability of and access to adequate blood supplies remain challenges in many parts of the world.", [["blood", "ANATOMY", 213, 218], ["infection", "DISEASE", 66, 75], ["blood", "ORGANISM_SUBSTANCE", 213, 218], ["these agents", "TREATMENT", 29, 41], ["infection", "PROBLEM", 66, 75], ["symptoms of disease", "PROBLEM", 122, 141], ["adequate blood supplies", "TREATMENT", 204, 227], ["infection", "OBSERVATION", 66, 75], ["disease", "OBSERVATION", 134, 141]]], ["According to the WHO global database for blood safety, 81 million units of whole blood and 20 million liters of plasma were donated annually in the period 2001-2002.", [["blood", "ANATOMY", 41, 46], ["whole blood", "ANATOMY", 75, 86], ["plasma", "ANATOMY", 112, 118], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["plasma", "ORGANISM_SUBSTANCE", 112, 118], ["blood safety", "TEST", 41, 53], ["whole blood", "TREATMENT", 75, 86], ["plasma", "TREATMENT", 112, 118]]], ["Analysis of blood donations in relation to the human development index (HDI -United Nations indicators) showed that 82% of the world's population, which lives in low and medium HDI countries, has access to only 39% of the total blood supply.", [["blood", "ANATOMY", 12, 17], ["blood", "ANATOMY", 228, 233], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["human", "ORGANISM", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 228, 233], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["blood donations", "TEST", 12, 27], ["the total blood supply", "TREATMENT", 218, 240]]], ["This limited access has a dramatic impact on the capacity to respond to various health needs of the population, and the strong links between blood availability and maternal mortality rates have been demonstrated.", [["blood", "ANATOMY", 141, 146], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["the capacity", "PROBLEM", 45, 57], ["blood availability", "TEST", 141, 159], ["maternal mortality rates", "PROBLEM", 164, 188], ["dramatic", "OBSERVATION_MODIFIER", 26, 34]]], ["The differences in blood donation rates reflect not only the degree of awareness of the population with respect to blood transfusion, but also the level of development of health care in which the blood service is embedded.", [["blood", "ANATOMY", 19, 24], ["blood", "ANATOMY", 115, 120], ["blood", "ANATOMY", 196, 201], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 196, 201], ["blood donation rates", "TEST", 19, 39], ["blood transfusion", "TREATMENT", 115, 132], ["health care", "TREATMENT", 171, 182]]], ["With mounting safety requirements and technological progress, blood transfusion services have become an increasingly expensive part of public health.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["mounting safety requirements", "PROBLEM", 5, 33], ["blood transfusion services", "TREATMENT", 62, 88]]], ["In countries with restricted resources, the safety of blood transfusion is of particular concern, especially because these countries often have high prevalence rates of HIV, hepatitis B and C, and other particular blood-borne diseases.", [["blood", "ANATOMY", 54, 59], ["blood", "ANATOMY", 214, 219], ["HIV, hepatitis B", "DISEASE", 169, 185], ["blood-borne diseases", "DISEASE", 214, 234], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["hepatitis B", "ORGANISM", 174, 185], ["blood", "ORGANISM_SUBSTANCE", 214, 219], ["HIV", "SPECIES", 169, 172], ["HIV", "SPECIES", 169, 172], ["blood transfusion", "TREATMENT", 54, 71], ["HIV", "PROBLEM", 169, 172], ["hepatitis B and C", "PROBLEM", 174, 191], ["other particular blood-borne diseases", "PROBLEM", 197, 234], ["borne diseases", "OBSERVATION", 220, 234]]], ["(See Relevant Websites for the WHO global database on blood safety.)", [["blood", "ANATOMY", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["blood safety", "TEST", 54, 66]]], ["An appropriate blood supply -defined as a situation in which no patient will die due to lack of appropriate treatment with blood or blood components -varies from one country to another.Essentials in Blood SafetyImportant components of blood safety are:Essentials in Blood Safety.", [["blood", "ANATOMY", 15, 20], ["blood", "ANATOMY", 123, 128], ["blood", "ANATOMY", 132, 137], ["Blood", "ANATOMY", 199, 204], ["blood", "ANATOMY", 235, 240], ["Blood", "ANATOMY", 266, 271], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["patient", "ORGANISM", 64, 71], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["blood", "ORGANISM_SUBSTANCE", 235, 240], ["Blood", "ORGANISM_SUBSTANCE", 266, 271], ["patient", "SPECIES", 64, 71], ["blood or blood components", "PROBLEM", 123, 148], ["Blood SafetyImportant", "OBSERVATION", 199, 220]]], ["Organization and regulatory framework for the blood transfusion services; .", [["blood", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["the blood transfusion services", "TREATMENT", 42, 72]]], ["Safe blood donors -education, recruitment, retention;Essentials in Blood Safety.", [["blood", "ANATOMY", 5, 10], ["Blood", "ANATOMY", 67, 72], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["Blood", "ORGANISM_SUBSTANCE", 67, 72], ["Safe blood donors -education", "TREATMENT", 0, 28]]], ["Testing of all blood units and further processing; Table 1 Transfusion-transmitted infectious diseasesAgentRemarks with respect to geographical distribution or generated disease .", [["blood", "ANATOMY", 15, 20], ["infectious diseases", "DISEASE", 83, 102], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["all blood units", "TREATMENT", 11, 26], ["further processing", "TEST", 31, 49], ["transmitted infectious diseases", "PROBLEM", 71, 102], ["AgentRemarks", "TREATMENT", 102, 114], ["generated disease", "PROBLEM", 160, 177], ["infectious", "OBSERVATION", 83, 93], ["geographical distribution", "OBSERVATION", 131, 156], ["generated disease", "OBSERVATION", 160, 177]]], ["Appropriate use of blood and blood components at the clinical site; .", [["blood", "ANATOMY", 19, 24], ["blood", "ANATOMY", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["blood and blood components", "TREATMENT", 19, 45], ["blood", "ANATOMY", 19, 24], ["blood", "ANATOMY", 29, 34]]], ["Hemovigilance, reporting and follow-up on safety issues and transfusion outcomes.AgentWHO-integrated strategy for blood safety recommends nationally coordinated blood services with quality systems functional in all areas and a blood supply based on voluntary nonremunerated blood donors from low-risk populations that is appropriately tested (100% for blood-borne pathogens, blood grouping, and compatibility testing), processed, stored, and distributed, as well as adequately used at the hospital site (alternatives to transfusion should be available), including posttransfusion follow-up.Organization and Supportive Frameworks for the Blood Transfusion ServicesThe blood transfusion service should be integrated with the health-care system of a country.", [["blood", "ANATOMY", 114, 119], ["blood", "ANATOMY", 161, 166], ["blood", "ANATOMY", 227, 232], ["blood", "ANATOMY", 274, 279], ["blood", "ANATOMY", 352, 357], ["blood", "ANATOMY", 375, 380], ["Blood", "ANATOMY", 637, 642], ["blood", "ANATOMY", 667, 672], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["blood", "ORGANISM_SUBSTANCE", 227, 232], ["blood", "ORGANISM_SUBSTANCE", 274, 279], ["donors", "ORGANISM_SUBSTANCE", 280, 286], ["blood", "ORGANISM_SUBSTANCE", 352, 357], ["blood", "ORGANISM_SUBSTANCE", 375, 380], ["Blood", "ORGANISM_SUBSTANCE", 637, 642], ["blood", "ORGANISM_SUBSTANCE", 667, 672], ["transfusion outcomes", "TREATMENT", 60, 80], ["a blood supply", "TREATMENT", 225, 239], ["voluntary nonremunerated blood donors", "PROBLEM", 249, 286], ["low-risk populations", "PROBLEM", 292, 312], ["blood-borne pathogens", "PROBLEM", 352, 373], ["blood grouping", "TEST", 375, 389], ["compatibility testing", "TEST", 395, 416], ["transfusion", "TREATMENT", 520, 531], ["the Blood Transfusion Services", "TREATMENT", 633, 663], ["The blood transfusion service", "TREATMENT", 663, 692]]], ["Its appropriateness depends on the strength of public health interventions, the level of health service delivery, and on the health status of the population and existing patterns of disease.Organization and Supportive Frameworks for the Blood Transfusion ServicesThe blood transfusion service usually functions under government responsibility.", [["Blood", "ANATOMY", 237, 242], ["blood", "ANATOMY", 267, 272], ["Blood", "ORGANISM_SUBSTANCE", 237, 242], ["blood", "ORGANISM_SUBSTANCE", 267, 272], ["public health interventions", "TREATMENT", 47, 74], ["health service delivery", "TREATMENT", 89, 112], ["disease", "PROBLEM", 182, 189], ["the Blood Transfusion Services", "TREATMENT", 233, 263], ["The blood transfusion service", "TREATMENT", 263, 292], ["disease", "OBSERVATION", 182, 189]]], ["A national blood policy and plan should define the vision and the steps required for strengthening quality, safety, availability, and access to adequate blood supplies.", [["blood", "ANATOMY", 11, 16], ["blood", "ANATOMY", 153, 158], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["A national blood policy", "TREATMENT", 0, 23]]], ["A national blood program for defined periods of time will allow addressing priorities and monitoring progress in the field.", [["blood", "ANATOMY", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["A national blood program", "TREATMENT", 0, 24], ["addressing priorities", "TREATMENT", 64, 85]]], ["Appropriate and sustainable resources, including funding mechanisms, are vital.Organization and Supportive Frameworks for the Blood Transfusion ServicesInvolvement of the various stakeholders in the process is essential, and a dedicated national commission can play an advisory function at a high decision-making level with respect to blood safety issues, as well as enhance dialogue among interested parties, such as blood transfusion specialists, clinicians, and patients.Organization and Supportive Frameworks for the Blood Transfusion ServicesExperience has shown that the organization of blood services on a nationally coordinated basis ensures harmonized quality standards along the blood chain and increases consistency in delivery of products, information, and statistics.", [["Blood", "ANATOMY", 126, 131], ["blood", "ANATOMY", 335, 340], ["blood", "ANATOMY", 418, 423], ["Blood", "ANATOMY", 521, 526], ["blood", "ANATOMY", 593, 598], ["blood", "ANATOMY", 689, 694], ["blood", "ORGANISM_SUBSTANCE", 335, 340], ["blood", "ORGANISM_SUBSTANCE", 418, 423], ["patients", "ORGANISM", 465, 473], ["blood", "ORGANISM_SUBSTANCE", 593, 598], ["blood", "ORGANISM_SUBSTANCE", 689, 694], ["patients", "SPECIES", 465, 473], ["the Blood Transfusion Services", "TREATMENT", 122, 152], ["the Blood Transfusion Services", "TREATMENT", 517, 547], ["the blood chain", "TEST", 685, 700], ["delivery of products", "TREATMENT", 730, 750]]], ["In addition, such organization has been proven to be more cost effective owing to economies of scale.Standards and Regular Inspections of Blood Transfusion ServicesFollowing the early period of the HIV/AIDS epidemic, the blood transfusion community began to realize that production of blood should take place in a more controlled environment.", [["Blood", "ANATOMY", 138, 143], ["blood", "ANATOMY", 221, 226], ["blood", "ANATOMY", 285, 290], ["HIV/AIDS", "DISEASE", 198, 206], ["Blood", "ORGANISM_SUBSTANCE", 138, 143], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["blood", "ORGANISM_SUBSTANCE", 285, 290], ["HIV", "SPECIES", 198, 201], ["economies of scale", "TREATMENT", 82, 100], ["Blood Transfusion Services", "TREATMENT", 138, 164], ["the HIV/AIDS epidemic", "PROBLEM", 194, 215], ["the blood transfusion community", "TREATMENT", 217, 248], ["production of blood", "PROBLEM", 271, 290]]], ["In order to accomplish this, two specific initiatives were taken: (1) quality standards for blood components were established, as well as for the raw plasma used in pharmaceutical processing, and (2) quality management systems were implemented to ensure that products meet the established standards.", [["blood", "ANATOMY", 92, 97], ["plasma", "ANATOMY", 150, 156], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["plasma", "ORGANISM_SUBSTANCE", 150, 156], ["blood components", "TEST", 92, 108], ["pharmaceutical processing", "TREATMENT", 165, 190]]], ["This has generated enhanced work of national and international organizations to support both the development and implementation of quality and safety standards for the blood services and deliverables (e.g., Council of Europe ''Guide to the Preparation, Use and Quality Assurance of Blood Components,'' AABB Standard for Blood Banks).", [["blood", "ANATOMY", 168, 173], ["Blood", "ANATOMY", 282, 287], ["Blood", "ANATOMY", 320, 325], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["Blood", "ORGANISM_SUBSTANCE", 282, 287], ["Blood", "ORGANISM_SUBSTANCE", 320, 325], ["the blood services", "TREATMENT", 164, 182]]], ["These standards are all grounded in more general standards, such as the ISO 9000series standards and the current good manufacturing practice (cGMP) guidelines for medicinal products for human and veterinary use (e.g., EU published by the European Commission).", [["cGMP", "CHEMICAL", 142, 146], ["cGMP", "SIMPLE_CHEMICAL", 142, 146], ["human", "ORGANISM", 186, 191], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["cGMP) guidelines", "TREATMENT", 142, 158], ["medicinal products", "TREATMENT", 163, 181]]], ["These specify basic requirements and principles for quality management, including personnel management and training, premises and equipment layout, production operations and requirements for standard operating procedures, design and methods for ensuring maintenance and documentation for all activities, how to perform quality controls, contract manufacture and analysis, and how to perform and document self-inspection.", [["quality management", "TREATMENT", 52, 70], ["personnel management", "TREATMENT", 82, 102], ["training", "TREATMENT", 107, 115], ["production operations", "TREATMENT", 148, 169], ["standard operating procedures", "TREATMENT", 191, 220]]], ["Monitoring the compliance to defined standards is part of a regular process of quality assessment and control.Standards and Regular Inspections of Blood Transfusion ServicesIn line with the above, WHO developed a comprehensive training program (including interactive toolkit and external quality assessment schemes) in quality management principles for the blood service.Safe Blood DonorsAccording to data available from various sources and studies, voluntary nonremunerated regular blood donors recruited from low-risk populations carry a much lower risk of infections.", [["Blood", "ANATOMY", 147, 152], ["blood", "ANATOMY", 357, 362], ["Blood", "ANATOMY", 376, 381], ["blood", "ANATOMY", 483, 488], ["infections", "DISEASE", 559, 569], ["Blood", "ORGANISM_SUBSTANCE", 147, 152], ["blood", "ORGANISM_SUBSTANCE", 357, 362], ["Blood", "ORGANISM_SUBSTANCE", 376, 381], ["blood", "ORGANISM_SUBSTANCE", 483, 488], ["donors", "ORGANISM", 489, 495], ["quality assessment", "TEST", 79, 97], ["Blood Transfusion ServicesIn line", "TREATMENT", 147, 180], ["a comprehensive training program", "TREATMENT", 211, 243], ["interactive toolkit", "TREATMENT", 255, 274], ["external quality assessment schemes", "TREATMENT", 279, 314], ["the blood service", "TREATMENT", 353, 370], ["studies", "TEST", 441, 448], ["regular blood donors", "TREATMENT", 475, 495], ["infections", "PROBLEM", 559, 569], ["infections", "OBSERVATION", 559, 569]]], ["The safe blood donors are the cornerstone of a safe blood supply and therefore an important and central point in WHO recommendations as well as those emerging from the IFRCRCS, the ISBT, and other international organizations concerned.Safe Blood DonorsEstablishing a pool of safe blood donors requires longterm commitments to education, information, and social involvement.", [["blood", "ANATOMY", 9, 14], ["blood", "ANATOMY", 52, 57], ["Blood", "ANATOMY", 240, 245], ["blood", "ANATOMY", 280, 285], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["Blood", "ORGANISM_SUBSTANCE", 240, 245], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["The safe blood donors", "TREATMENT", 0, 21], ["a safe blood supply", "TREATMENT", 45, 64], ["the IFRCRCS", "TEST", 164, 175], ["the ISBT", "TEST", 177, 185], ["safe blood donors", "TREATMENT", 275, 292]]], ["Co-sponsored by WHO, the International Federation of Red Cross and Red Crescent Societies (IFRCRCS), International Federation of Blood Donor Organizations (IFBDO/FIODS) and International Society of Blood Transfusion (ISBT), it aims to increase awareness toward blood donation and enhance the different steps in the process of education, recruitment, and retention of low-risk donors and establishment of youth donor programs.Safe Blood DonorsSafe donor selection criteria -the education to healthy lifestyles -proved to be highly effective in the prevention of sexually transmitted infections, including HIV/AIDS.", [["Blood", "ANATOMY", 198, 203], ["blood", "ANATOMY", 261, 266], ["Blood", "ANATOMY", 430, 435], ["sexually transmitted infections", "DISEASE", 561, 592], ["HIV/AIDS", "DISEASE", 604, 612], ["Blood", "ORGANISM_SUBSTANCE", 198, 203], ["blood", "ORGANISM_SUBSTANCE", 261, 266], ["donors", "ORGANISM", 376, 382], ["HIV", "SPECIES", 604, 607], ["HIV", "SPECIES", 604, 607], ["Red Cross", "TEST", 53, 62], ["Blood Transfusion", "TREATMENT", 198, 215], ["blood donation", "TREATMENT", 261, 275], ["low-risk donors", "TREATMENT", 367, 382], ["youth donor programs", "TREATMENT", 404, 424], ["sexually transmitted infections", "PROBLEM", 561, 592], ["HIV/AIDS", "PROBLEM", 604, 612], ["Crescent", "OBSERVATION_MODIFIER", 71, 79]]], ["The 'Club 25' initiative in Africa (youth initiative promoting lifestyles and regular blood donation, aiming for about 20 blood donations by the age of 25) led to a dramatic decrease in transfusion-transmitted infections and related risks, to the mutual benefit of donors and recipient patients.Testing and Processing of BloodCollected blood needs to be screened for blood-borne pathogens prior to transfusion.", [["blood", "ANATOMY", 86, 91], ["blood", "ANATOMY", 122, 127], ["blood", "ANATOMY", 336, 341], ["blood", "ANATOMY", 367, 372], ["transfusion-transmitted infections", "DISEASE", 186, 220], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["donors", "ORGANISM", 265, 271], ["patients", "ORGANISM", 286, 294], ["blood", "ORGANISM_SUBSTANCE", 336, 341], ["blood", "ORGANISM_SUBSTANCE", 367, 372], ["patients", "SPECIES", 286, 294], ["regular blood donation", "TREATMENT", 78, 100], ["a dramatic decrease in transfusion", "TREATMENT", 163, 197], ["transmitted infections", "PROBLEM", 198, 220], ["donors and recipient patients", "TREATMENT", 265, 294], ["Testing", "TEST", 295, 302], ["BloodCollected blood", "TEST", 321, 341], ["blood-borne pathogens", "PROBLEM", 367, 388], ["transfusion", "TREATMENT", 398, 409], ["dramatic", "OBSERVATION_MODIFIER", 165, 173], ["decrease", "OBSERVATION_MODIFIER", 174, 182]]], ["Basic screening includes tests for HIV, hepatitis B, hepatitis C, and syphilis.", [["HIV, hepatitis B, hepatitis C", "DISEASE", 35, 64], ["syphilis", "DISEASE", 70, 78], ["HIV", "ORGANISM", 35, 38], ["hepatitis B", "ORGANISM", 40, 51], ["hepatitis C", "ORGANISM", 53, 64], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 35, 38], ["hepatitis B", "SPECIES", 40, 51], ["hepatitis C", "SPECIES", 53, 64], ["Basic screening", "TEST", 0, 15], ["tests", "TEST", 25, 30], ["HIV", "PROBLEM", 35, 38], ["hepatitis B", "PROBLEM", 40, 51], ["hepatitis C", "PROBLEM", 53, 64], ["syphilis", "PROBLEM", 70, 78], ["hepatitis", "OBSERVATION", 40, 49]]], ["In some parts of the world, additional tests are necessary for local epidemiological threats.", [["additional tests", "TEST", 28, 44]]], ["It is the responsibility of health authorities to outline a national strategy for screening of all donated blood and specify the most appropriate testing and diagnostic algorithms to be used.", [["blood", "ANATOMY", 107, 112], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["all donated blood", "PROBLEM", 95, 112], ["diagnostic algorithms", "TEST", 158, 179]]], ["In addition, testing for ABO and RhD blood groups, as well as screening for irregular antibodies, are performed to avoid an incompatible (hemolytic) transfusion reaction.Testing and Processing of BloodReliable testing of blood units requires the following:Testing and Processing of Blood1.", [["blood", "ANATOMY", 37, 42], ["blood", "ANATOMY", 221, 226], ["hemolytic", "DISEASE", 138, 147], ["ABO", "GENE_OR_GENE_PRODUCT", 25, 28], ["RhD", "GENE_OR_GENE_PRODUCT", 33, 36], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["ABO", "PROTEIN", 25, 28], ["irregular antibodies", "PROTEIN", 76, 96], ["Blood1", "PROTEIN", 282, 288], ["testing", "TEST", 13, 20], ["ABO", "TEST", 25, 28], ["RhD blood groups", "TEST", 33, 49], ["screening", "TEST", 62, 71], ["irregular antibodies", "PROBLEM", 76, 96], ["an incompatible (hemolytic) transfusion reaction", "PROBLEM", 121, 169], ["Testing", "TEST", 170, 177], ["BloodReliable testing", "TEST", 196, 217], ["Testing", "TEST", 256, 263], ["Blood1", "TEST", 282, 288]]], ["Uninterrupted supply of high-quality test systems; this includes procurement, supply, central storage, and distribution of reagents and materials to ensure continuity of testing; 2..", [["central storage", "TREATMENT", 86, 101], ["continuity of testing", "TEST", 156, 177], ["high-quality", "OBSERVATION_MODIFIER", 24, 36]]], ["Maintenance of a quality assurance system and good laboratory practice, including the use of standard operating procedures (SOPs) for all aspects of blood screening and processing; 3.", [["blood", "ANATOMY", 149, 154], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["standard operating procedures", "TREATMENT", 93, 122], ["blood screening", "TEST", 149, 164]]], ["Continuous training of staff members in all aspects of blood screening and processing of blood units, including storage and transportation of blood products.Testing and Processing of BloodCollected whole blood can be stored for a time depending on the mixture of anticoagulant preservation solution used.", [["blood", "ANATOMY", 55, 60], ["blood", "ANATOMY", 89, 94], ["blood", "ANATOMY", 142, 147], ["whole blood", "ANATOMY", 198, 209], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["blood screening", "TEST", 55, 70], ["blood units", "TREATMENT", 89, 100], ["storage", "TREATMENT", 112, 119], ["blood products", "TREATMENT", 142, 156], ["Testing", "TEST", 157, 164], ["BloodCollected whole blood", "TREATMENT", 183, 209], ["anticoagulant preservation solution", "TREATMENT", 263, 298]]], ["The whole blood unit may be separated into major blood components -red cell concentrates, fresh frozen plasma, and platelet concentrate -to increase efficiency of use.", [["blood", "ANATOMY", 10, 15], ["blood", "ANATOMY", 49, 54], ["red cell", "ANATOMY", 67, 75], ["plasma", "ANATOMY", 103, 109], ["platelet", "ANATOMY", 115, 123], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["red cell", "CELL", 67, 75], ["plasma", "ORGANISM_SUBSTANCE", 103, 109], ["platelet", "CELL", 115, 123], ["The whole blood unit", "TREATMENT", 0, 20], ["red cell concentrates", "TREATMENT", 67, 88], ["fresh frozen plasma", "TEST", 90, 109], ["platelet concentrate", "TREATMENT", 115, 135], ["red cell concentrates", "OBSERVATION", 67, 88]]], ["Processing of donated blood into its different components reduces the occurrence of adverse transfusion reactions and tailors therapeutic response to the particular needs of the patient.", [["blood", "ANATOMY", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["donated blood into its different components", "PROBLEM", 14, 57], ["adverse transfusion reactions", "PROBLEM", 84, 113], ["tailors", "TREATMENT", 118, 125], ["different", "OBSERVATION_MODIFIER", 37, 46], ["components", "OBSERVATION_MODIFIER", 47, 57], ["adverse", "OBSERVATION_MODIFIER", 84, 91], ["transfusion reactions", "OBSERVATION", 92, 113]]], ["Since each blood component can be stored according to its specific requirements, effectiveness is increased and shelf-life adjusted.", [["blood", "ANATOMY", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["increased", "OBSERVATION_MODIFIER", 98, 107]]], ["For example, fresh frozen plasma can be stored at -40 C for 24 months, platelet suspended in plasma or suspension media (T-SOL) can be stored at \u00fe20-24 C for 3-5 days, and red cells suspended in an additive solution (SAG-MAN or ADSOL) can be used up to 45 days if stored at \u00fe4 C.Appropriate Clinical Use of BloodBlood is a scarce resource and should always be used with care.", [["plasma", "ANATOMY", 26, 32], ["platelet", "ANATOMY", 71, 79], ["plasma", "ANATOMY", 93, 99], ["red cells", "ANATOMY", 172, 181], ["SAG-MAN", "CHEMICAL", 217, 224], ["ADSOL", "CHEMICAL", 228, 233], ["MAN", "CHEMICAL", 221, 224], ["plasma", "ORGANISM_SUBSTANCE", 26, 32], ["platelet", "CELL", 71, 79], ["plasma", "ORGANISM_SUBSTANCE", 93, 99], ["red cells", "CELL", 172, 181], ["SAG-MAN", "SIMPLE_CHEMICAL", 217, 224], ["ADSOL", "SIMPLE_CHEMICAL", 228, 233], ["platelet", "CELL_TYPE", 71, 79], ["red cells", "CELL_TYPE", 172, 181], ["fresh frozen plasma", "TEST", 13, 32], ["platelet", "TEST", 71, 79], ["plasma or suspension media", "TREATMENT", 93, 119], ["red cells", "TREATMENT", 172, 181], ["an additive solution (SAG-MAN or ADSOL)", "TREATMENT", 195, 234]]], ["As with any medical procedure, it carries also a measurable risk to the recipient patient.", [["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["any medical procedure", "TREATMENT", 8, 29]]], ["In evaluating the indication for blood transfusion therapy, the benefits for the patient should outweigh the risks.", [["blood", "ANATOMY", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["blood transfusion therapy", "TREATMENT", 33, 58]]], ["Several international recommendations and guidelines have been developed in this respect, but these are not always available and in many circumstances the process continues to rest on historically based practices and the clinical experience of the attending physicians.Appropriate Clinical Use of BloodThe training of clinical users in the adequate use of blood is an important endeavor which requires constant updates not only regarding scientific progress and technologies but also the availability of and access to alternatives to blood (e.g., volume replacement solutions).", [["Blood", "ANATOMY", 297, 302], ["blood", "ANATOMY", 356, 361], ["blood", "ANATOMY", 534, 539], ["Blood", "ORGANISM_SUBSTANCE", 297, 302], ["blood", "ORGANISM_SUBSTANCE", 356, 361], ["blood", "ORGANISM_SUBSTANCE", 534, 539], ["Blood", "TEST", 297, 302], ["blood (e.g., volume replacement solutions", "TREATMENT", 534, 575]]], ["Strengthening the cooperation with other sectors of health care (i.e., primary health care) may help reduce blood usage through (1) early diagnosis and treatment of diseases or conditions which may lead to the need for blood transfusion (obstetric antenatal care, iron substitution); (2) pre-operative blood collection for auto-transfusion; (3) intra-operative normo-volemic hemodilution;Appropriate Clinical Use of Blood(4) per-operative and post-operative blood salvage.Appropriate Clinical Use of BloodBlood usage in Western Europe and North America shows a moderate decrease in number of units used, mostly due to modern surgical techniques, such as endoscopic interventions with minimal tissue injury.", [["blood", "ANATOMY", 108, 113], ["blood", "ANATOMY", 219, 224], ["blood", "ANATOMY", 302, 307], ["Blood", "ANATOMY", 416, 421], ["blood", "ANATOMY", 458, 463], ["tissue", "ANATOMY", 692, 698], ["iron", "CHEMICAL", 264, 268], ["hemodilution", "DISEASE", 375, 387], ["iron", "CHEMICAL", 264, 268], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["iron", "SIMPLE_CHEMICAL", 264, 268], ["blood", "ORGANISM_SUBSTANCE", 302, 307], ["Blood", "ORGANISM_SUBSTANCE", 416, 421], ["blood", "ORGANISM_SUBSTANCE", 458, 463], ["tissue", "TISSUE", 692, 698], ["diseases", "PROBLEM", 165, 173], ["blood transfusion", "TREATMENT", 219, 236], ["obstetric antenatal care", "TREATMENT", 238, 262], ["iron substitution", "TREATMENT", 264, 281], ["pre-operative blood collection", "TEST", 288, 318], ["auto-transfusion", "TREATMENT", 323, 339], ["intra-operative normo-volemic hemodilution", "TREATMENT", 345, 387], ["post-operative blood salvage", "TREATMENT", 443, 471], ["a moderate decrease", "PROBLEM", 559, 578], ["modern surgical techniques", "TREATMENT", 618, 644], ["endoscopic interventions", "TREATMENT", 654, 678], ["minimal tissue injury", "PROBLEM", 684, 705], ["moderate", "OBSERVATION_MODIFIER", 561, 569], ["decrease", "OBSERVATION_MODIFIER", 570, 578], ["minimal tissue", "OBSERVATION_MODIFIER", 684, 698], ["injury", "OBSERVATION", 699, 705]]], ["To further respond to blood availability challenges, increasing attention is given to the development of blood substitutes and oxygen carriers.", [["blood", "ANATOMY", 22, 27], ["blood", "ANATOMY", 105, 110], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "CHEMICAL", 127, 133], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["blood availability challenges", "TREATMENT", 22, 51], ["blood substitutes", "TREATMENT", 105, 122], ["oxygen carriers", "TREATMENT", 127, 142]]], ["The Network for Advancement of Transfusion Alternatives also aims to reduce unnecessary blood transfusion and provides additional information.HemovigilanceThe word 'hemovigilance' is derived from the word 'pharmacovigilance,' which encompasses activities and systems to collect information useful in supervising medicinal products, with particular reference to adverse drug reactions in human beings, and to evaluate such information scientifically.", [["blood", "ANATOMY", 88, 93], ["adverse drug reactions", "DISEASE", 361, 383], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["human", "ORGANISM", 387, 392], ["human", "SPECIES", 387, 392], ["human", "SPECIES", 387, 392], ["Advancement of Transfusion Alternatives", "TREATMENT", 16, 55], ["unnecessary blood transfusion", "TREATMENT", 76, 105]]], ["It comprises a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow-up of the transfused patient).HemovigilanceThe aim of hemovigilance is to detect, collect, and analyze all information of unexpected or undesirable effects resulting from the therapeutic use of blood and blood components in order to correct their cause, prevent recurrence, and improve the safety of blood transfusion.", [["blood", "ANATOMY", 107, 112], ["blood", "ANATOMY", 340, 345], ["blood", "ANATOMY", 350, 355], ["blood", "ANATOMY", 446, 451], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["patient", "ORGANISM", 167, 174], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["blood", "ORGANISM_SUBSTANCE", 446, 451], ["patient", "SPECIES", 167, 174], ["surveillance procedures", "TREATMENT", 22, 45], ["the whole transfusion chain", "TREATMENT", 55, 82], ["blood and blood components", "TREATMENT", 340, 366], ["recurrence", "PROBLEM", 408, 418], ["blood transfusion", "TREATMENT", 446, 463], ["chain", "OBSERVATION_MODIFIER", 77, 82], ["recurrence", "OBSERVATION", 408, 418]]], ["Adverse reactions are defined as reactions which are harmful and unintended and which occur at doses normally used for prophylaxis, diagnosis, or treatment of various conditions.HemovigilanceHemovigilance concerns blood components (e.g., whole blood, erythrocyte concentrates, platelet concentrates, and fresh frozen plasma).", [["blood", "ANATOMY", 214, 219], ["whole blood", "ANATOMY", 238, 249], ["erythrocyte", "ANATOMY", 251, 262], ["platelet", "ANATOMY", 277, 285], ["plasma", "ANATOMY", 317, 323], ["blood", "ORGANISM_SUBSTANCE", 214, 219], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["erythrocyte", "CELL", 251, 262], ["platelet", "CELL", 277, 285], ["plasma", "ORGANISM_SUBSTANCE", 317, 323], ["Adverse reactions", "PROBLEM", 0, 17], ["prophylaxis", "TREATMENT", 119, 130], ["various conditions", "PROBLEM", 159, 177], ["blood components", "TEST", 214, 230], ["whole blood", "TEST", 238, 249], ["erythrocyte concentrates", "TEST", 251, 275], ["platelet concentrates", "TEST", 277, 298], ["fresh frozen plasma", "TEST", 304, 323]]], ["Pharmacovigilance in transfusion medicine concerns plasma derivatives (e.g., clotting factor concentrates, immunoglobulins, albumin, and other fractionated products).HemovigilanceReporting of serious adverse events related to transfusion therapy appears to be one of the oldest reporting systems in place.", [["plasma", "ANATOMY", 51, 57], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["derivatives", "SIMPLE_CHEMICAL", 58, 69], ["clotting factor concentrates", "GENE_OR_GENE_PRODUCT", 77, 105], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 107, 122], ["albumin", "GENE_OR_GENE_PRODUCT", 124, 131], ["clotting factor concentrates", "PROTEIN", 77, 105], ["immunoglobulins", "PROTEIN", 107, 122], ["albumin", "PROTEIN", 124, 131], ["Pharmacovigilance in transfusion medicine", "TREATMENT", 0, 41], ["plasma derivatives", "TREATMENT", 51, 69], ["clotting factor concentrates", "TREATMENT", 77, 105], ["immunoglobulins", "TREATMENT", 107, 122], ["albumin", "TREATMENT", 124, 131], ["other fractionated products", "TREATMENT", 137, 164], ["serious adverse events", "PROBLEM", 192, 214], ["transfusion therapy", "TREATMENT", 226, 245], ["serious", "OBSERVATION_MODIFIER", 192, 199], ["transfusion therapy", "OBSERVATION", 226, 245]]], ["However, the development of national hemovigilance systems poses increasing challenges due to the various taxonomies in use, the limited resources for supportive informative technologies, and, mainly, the need for enhanced communication between blood services and hospital services.", [["blood", "ANATOMY", 245, 250], ["blood", "ORGANISM_SUBSTANCE", 245, 250], ["national hemovigilance systems", "TREATMENT", 28, 58], ["increasing challenges", "TREATMENT", 65, 86]]], ["The increasing role of the patient in this process is expected to strengthen hemovigilance at its operational level.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["increasing", "OBSERVATION_MODIFIER", 4, 14]]], ["Several websites provide data on hemovigilance (national and regional), such as those from the United Kingdom, the European Haemovigilance Network, and the Danish Haemovigilance Network.IntroductionBotulism is a rare, severe, neuroparalytic disease caused by accidental or intentional exposure to seven distinct botulinum toxins (BoNTs, A-G types) that affect humans and a variety of domestic and wild lower animals.", [["IntroductionBotulism", "DISEASE", 186, 206], ["botulinum toxins", "SIMPLE_CHEMICAL", 312, 328], ["BoNTs", "SIMPLE_CHEMICAL", 330, 335], ["A-G", "GENE_OR_GENE_PRODUCT", 337, 340], ["humans", "ORGANISM", 360, 366], ["humans", "SPECIES", 360, 366], ["humans", "SPECIES", 360, 366], ["a rare, severe, neuroparalytic disease", "PROBLEM", 210, 248], ["seven distinct botulinum toxins", "PROBLEM", 297, 328], ["severe", "OBSERVATION_MODIFIER", 218, 224]]], ["The disease is characterized by symmetrical cranial nerve palsies that may be followed by descending, symmetric flaccid paralysis of voluntary muscles, which may lead to death because of respiratory or heart failure.IntroductionBotulinum toxins are neurotoxins of extreme potency and lethality (they can be lethal at doses as low as 1 mg/kg orally) released by vegetative cell death and lysis.", [["cranial nerve", "ANATOMY", 44, 57], ["flaccid", "ANATOMY", 112, 119], ["muscles", "ANATOMY", 143, 150], ["respiratory", "ANATOMY", 187, 198], ["heart", "ANATOMY", 202, 207], ["cell", "ANATOMY", 372, 376], ["cranial nerve palsies", "DISEASE", 44, 65], ["paralysis", "DISEASE", 120, 129], ["death", "DISEASE", 170, 175], ["respiratory or heart failure", "DISEASE", 187, 215], ["death", "DISEASE", 377, 382], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 44, 57], ["muscles", "ORGAN", 143, 150], ["heart", "ORGAN", 202, 207], ["Botulinum toxins", "ORGANISM", 228, 244], ["cell", "CELL", 372, 376], ["The disease", "PROBLEM", 0, 11], ["symmetrical cranial nerve palsies", "PROBLEM", 32, 65], ["symmetric flaccid paralysis of voluntary muscles", "PROBLEM", 102, 150], ["death", "PROBLEM", 170, 175], ["respiratory or heart failure", "PROBLEM", 187, 215], ["IntroductionBotulinum toxins", "TREATMENT", 216, 244], ["lethality", "PROBLEM", 284, 293], ["lysis", "TREATMENT", 387, 392], ["disease", "OBSERVATION", 4, 11], ["symmetrical", "OBSERVATION_MODIFIER", 32, 43], ["cranial nerve", "ANATOMY", 44, 57], ["palsies", "OBSERVATION", 58, 65], ["descending", "ANATOMY_MODIFIER", 90, 100], ["symmetric", "OBSERVATION_MODIFIER", 102, 111], ["flaccid", "OBSERVATION_MODIFIER", 112, 119], ["paralysis", "OBSERVATION", 120, 129], ["voluntary muscles", "ANATOMY", 133, 150], ["heart", "ANATOMY", 202, 207], ["failure", "OBSERVATION", 208, 215], ["vegetative cell death", "OBSERVATION", 361, 382]]], ["Four toxigenic anaerobic Gram-positive spore-forming bacteria of the genus Clostridium produce the botulinum toxins: the classic C. botulinum that produces type A, B, C, D, E, and F toxins (BoNT/A-F), C. argentinense that produces type G toxin (BoNT/G), and two rare strains of C. butyricum and C. baratii that produce types E and F botulinum-like toxins, respectively.", [["Gram-", "CHEMICAL", 25, 30], ["C. botulinum", "ORGANISM", 129, 141], ["B", "GENE_OR_GENE_PRODUCT", 164, 165], ["C", "GENE_OR_GENE_PRODUCT", 167, 168], ["D, E", "SIMPLE_CHEMICAL", 170, 174], ["F toxins", "SIMPLE_CHEMICAL", 180, 188], ["BoNT/A-F", "SIMPLE_CHEMICAL", 190, 198], ["C. argentinense", "ORGANISM", 201, 216], ["type G toxin", "GENE_OR_GENE_PRODUCT", 231, 243], ["BoNT/G", "GENE_OR_GENE_PRODUCT", 245, 251], ["C. butyricum", "ORGANISM", 278, 290], ["C. baratii", "ORGANISM", 295, 305], ["F botulinum-like toxins", "SIMPLE_CHEMICAL", 331, 354], ["type G toxin", "PROTEIN", 231, 243], ["C. botulinum", "SPECIES", 129, 141], ["C. argentinense", "SPECIES", 201, 216], ["C. butyricum", "SPECIES", 278, 290], ["C. baratii", "SPECIES", 295, 305], ["F botulinum", "SPECIES", 331, 342], ["C. botulinum", "SPECIES", 129, 141], ["C. argentinense", "SPECIES", 201, 216], ["C. butyricum", "SPECIES", 278, 290], ["C. baratii", "SPECIES", 295, 305], ["Four toxigenic anaerobic Gram-positive spore", "PROBLEM", 0, 44], ["the genus Clostridium", "PROBLEM", 65, 86], ["the botulinum toxins", "TEST", 95, 115], ["the classic C. botulinum", "PROBLEM", 117, 141], ["type A, B, C, D, E", "PROBLEM", 156, 174], ["F toxins", "TEST", 180, 188], ["BoNT", "TEST", 190, 194], ["type G toxin", "PROBLEM", 231, 243], ["BoNT/G", "TEST", 245, 251], ["C. butyricum", "PROBLEM", 278, 290], ["C. baratii", "PROBLEM", 295, 305], ["positive spore", "OBSERVATION", 30, 44], ["bacteria", "OBSERVATION_MODIFIER", 53, 61], ["genus Clostridium", "OBSERVATION", 69, 86]]]], "PMC2791231": [["IntroductionA new virus, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), was responsible for an outbreak of acute respiratory illness in 2003, which affected about 30 countries with over 8000 cumulative infections and more than 900 deaths [1].", [["respiratory", "ANATOMY", 128, 139], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 36, 74], ["SARS-CoV)", "DISEASE", 76, 85], ["acute respiratory illness", "DISEASE", 122, 147], ["infections", "DISEASE", 217, 227], ["deaths", "DISEASE", 246, 252], ["SARS-CoV", "ORGANISM", 76, 84], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 29, 84], ["IntroductionA new virus", "PROBLEM", 0, 23], ["the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "PROBLEM", 25, 84], ["acute respiratory illness", "PROBLEM", 122, 147], ["virus", "OBSERVATION", 18, 23], ["Severe", "OBSERVATION_MODIFIER", 29, 35], ["Acute", "OBSERVATION_MODIFIER", 36, 41], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 42, 74], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["respiratory illness", "OBSERVATION", 128, 147]]], ["The SARS-CoV is a positive-stranded RNA virus with an \u223c30 kb genome [2], [3].", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV", "DNA", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["a positive-stranded RNA virus", "PROBLEM", 16, 45]]], ["Compared to other human and animal coronaviruses, the SARS-CoV genome consists of 9 unique open reading frames (orfs) [4].", [["SARS", "DISEASE", 54, 58], ["human", "ORGANISM", 18, 23], ["animal coronaviruses", "ORGANISM", 28, 48], ["SARS-CoV", "ORGANISM", 54, 62], ["SARS-CoV genome", "DNA", 54, 69], ["open reading frames", "DNA", 91, 110], ["orfs", "DNA", 112, 116], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["SARS-CoV", "SPECIES", 54, 62], ["animal coronaviruses", "PROBLEM", 28, 48], ["the SARS-CoV genome", "PROBLEM", 50, 69]]], ["Of these, orf3a is the largest and encodes a protein of 274 amino acids.", [["amino acids", "CHEMICAL", 60, 71], ["amino acids", "CHEMICAL", 60, 71], ["orf3a", "GENE_OR_GENE_PRODUCT", 10, 15], ["amino acids", "AMINO_ACID", 60, 71], ["orf3a", "DNA", 10, 15], ["a protein", "TEST", 43, 52], ["amino acids", "TEST", 60, 71], ["largest", "OBSERVATION_MODIFIER", 23, 30]]], ["The 3a protein is part of the virus particle, is expressed abundantly in infected as well as transfected cells, localizes to intracellular and plasma membranes [5], and induces apoptosis in transfected and infected cells [6], [7].IntroductionThe endoplasmic reticulum (ER) regulates cellular metabolism and protein synthesis in response to perturbations in protein synthesis and folding.", [["cells", "ANATOMY", 105, 110], ["intracellular", "ANATOMY", 125, 138], ["plasma membranes", "ANATOMY", 143, 159], ["cells", "ANATOMY", 215, 220], ["endoplasmic reticulum", "ANATOMY", 246, 267], ["ER", "ANATOMY", 269, 271], ["cellular", "ANATOMY", 283, 291], ["3a", "GENE_OR_GENE_PRODUCT", 4, 6], ["cells", "CELL", 105, 110], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["plasma membranes", "CELLULAR_COMPONENT", 143, 159], ["cells", "CELL", 215, 220], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 246, 267], ["ER", "GENE_OR_GENE_PRODUCT", 269, 271], ["cellular", "CELL", 283, 291], ["3a protein", "PROTEIN", 4, 14], ["transfected cells", "CELL_LINE", 93, 110], ["ER", "PROTEIN", 269, 271], ["the virus particle", "PROBLEM", 26, 44], ["intracellular and plasma membranes", "TEST", 125, 159], ["apoptosis in transfected and infected cells", "PROBLEM", 177, 220], ["cellular metabolism", "TEST", 283, 302], ["protein synthesis", "PROBLEM", 307, 324], ["perturbations in protein synthesis", "PROBLEM", 340, 374], ["virus particle", "OBSERVATION", 30, 44], ["infected", "OBSERVATION", 73, 81], ["transfected cells", "OBSERVATION", 93, 110], ["apoptosis", "OBSERVATION_MODIFIER", 177, 186], ["infected cells", "OBSERVATION", 206, 220], ["endoplasmic reticulum", "OBSERVATION", 246, 267], ["cellular metabolism", "OBSERVATION", 283, 302], ["protein synthesis", "OBSERVATION", 307, 324], ["protein synthesis", "OBSERVATION", 357, 374]]], ["Since the ER is the site for translation and processing of proteins destined for secretion or membrane insertion, many viruses, including the SARS-CoV exploit this organelle.", [["membrane", "ANATOMY", 94, 102], ["organelle", "ANATOMY", 164, 173], ["ER", "GENE_OR_GENE_PRODUCT", 10, 12], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["SARS-CoV", "ORGANISM", 142, 150], ["organelle", "CELLULAR_COMPONENT", 164, 173], ["ER", "PROTEIN", 10, 12], ["SARS-CoV", "SPECIES", 142, 150], ["processing of proteins", "TREATMENT", 45, 67], ["secretion", "PROBLEM", 81, 90], ["membrane insertion", "TREATMENT", 94, 112], ["many viruses", "PROBLEM", 114, 126], ["viruses", "OBSERVATION", 119, 126]]], ["During viral replication there is high biosynthetic burden on the cell for producing viral proteins.", [["cell", "ANATOMY", 66, 70], ["cell", "CELL", 66, 70], ["viral proteins", "PROTEIN", 85, 99], ["viral replication", "TREATMENT", 7, 24], ["high biosynthetic burden on the cell", "PROBLEM", 34, 70], ["viral proteins", "PROBLEM", 85, 99], ["viral replication", "OBSERVATION", 7, 24], ["high", "OBSERVATION_MODIFIER", 34, 38], ["biosynthetic", "OBSERVATION_MODIFIER", 39, 51], ["burden", "OBSERVATION_MODIFIER", 52, 58], ["viral proteins", "OBSERVATION", 85, 99]]], ["The accumulation of nascent and unfolded viral secretory and transmembrane proteins in the ER lumen can lead to ER stress and the downstream activation of multiple signaling pathways [8].", [["transmembrane", "ANATOMY", 61, 74], ["ER lumen", "ANATOMY", 91, 99], ["transmembrane", "CELLULAR_COMPONENT", 61, 74], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["ER", "GENE_OR_GENE_PRODUCT", 112, 114], ["unfolded viral secretory and transmembrane proteins", "PROTEIN", 32, 83], ["ER", "PROTEIN", 112, 114], ["The accumulation of nascent and unfolded viral secretory", "PROBLEM", 0, 56], ["transmembrane proteins in the ER lumen", "TREATMENT", 61, 99], ["ER stress", "PROBLEM", 112, 121], ["multiple signaling pathways", "PROBLEM", 155, 182], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["nascent", "OBSERVATION_MODIFIER", 20, 27], ["unfolded", "OBSERVATION_MODIFIER", 32, 40], ["viral secretory", "OBSERVATION", 41, 56], ["transmembrane proteins", "OBSERVATION", 61, 83], ["lumen", "ANATOMY_MODIFIER", 94, 99]]], ["To adjust the biosynthetic burden and capacity of the ER for maintaining cellular homeostasis, the Unfolded Protein Response (UPR) is activated.", [["ER", "ANATOMY", 54, 56], ["cellular", "ANATOMY", 73, 81], ["ER", "GENE_OR_GENE_PRODUCT", 54, 56], ["cellular", "CELL", 73, 81], ["Unfolded Protein", "GENE_OR_GENE_PRODUCT", 99, 115], ["ER", "PROTEIN", 54, 56], ["UPR", "PROTEIN", 126, 129], ["the biosynthetic burden", "TREATMENT", 10, 33], ["cellular homeostasis", "OBSERVATION", 73, 93]]], ["The UPR is a complex pathway that is mediated by three distinct signaling tracks initiated by the sensors inositol-requiring enzyme 1 (IRE-1), activating transcription factor 6 (ATF6) and PKR-like ER kinase (PERK) [9].", [["inositol", "CHEMICAL", 106, 114], ["inositol", "CHEMICAL", 106, 114], ["inositol-requiring enzyme 1", "GENE_OR_GENE_PRODUCT", 106, 133], ["IRE-1", "GENE_OR_GENE_PRODUCT", 135, 140], ["activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 143, 176], ["ATF6", "GENE_OR_GENE_PRODUCT", 178, 182], ["PKR-like ER kinase", "GENE_OR_GENE_PRODUCT", 188, 206], ["PERK", "GENE_OR_GENE_PRODUCT", 208, 212], ["UPR", "PROTEIN", 4, 7], ["inositol-requiring enzyme 1", "PROTEIN", 106, 133], ["IRE-1", "PROTEIN", 135, 140], ["activating transcription factor 6", "PROTEIN", 143, 176], ["ATF6", "PROTEIN", 178, 182], ["PKR", "PROTEIN", 188, 191], ["ER kinase", "PROTEIN", 197, 206], ["PERK", "PROTEIN", 208, 212], ["the sensors inositol", "TEST", 94, 114], ["enzyme", "TEST", 125, 131], ["activating transcription factor", "TEST", 143, 174], ["ATF6", "TEST", 178, 182], ["PKR", "TEST", 188, 191]]], ["These proteins transduce adaptive signals to the cytosol and nucleus, leading to global effects on ER function [10] and recovery from ER stress.", [["cytosol", "ANATOMY", 49, 56], ["nucleus", "ANATOMY", 61, 68], ["ER", "ANATOMY", 99, 101], ["cytosol", "CELLULAR_COMPONENT", 49, 56], ["nucleus", "CELLULAR_COMPONENT", 61, 68], ["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["ER", "GENE_OR_GENE_PRODUCT", 134, 136], ["ER", "PROTEIN", 99, 101], ["ER", "PROTEIN", 134, 136], ["ER function", "TEST", 99, 110], ["ER stress", "PROBLEM", 134, 143], ["nucleus", "ANATOMY", 61, 68]]], ["But, prolonged ER stress can also trigger apoptosis.IntroductionViruses have developed various strategies to modulate the UPR [11]\u2013[14].", [["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["ER", "PROTEIN", 15, 17], ["prolonged ER stress", "PROBLEM", 5, 24], ["apoptosis", "PROBLEM", 42, 51], ["IntroductionViruses", "TREATMENT", 52, 71]]], ["The hepatitis C virus (HCV) causes increased transcription from the glucose regulated protein 78 (GRP78) and GRP94 promoters through the activation of PERK and ATF6 pathways [15], [16], [17], with simultaneous suppression of the IRE1-X box binding protein (XBP1) pathway [18].", [["hepatitis C", "DISEASE", 4, 15], ["glucose", "CHEMICAL", 68, 75], ["glucose", "CHEMICAL", 68, 75], ["hepatitis C virus", "ORGANISM", 4, 21], ["HCV", "ORGANISM", 23, 26], ["glucose regulated protein 78", "GENE_OR_GENE_PRODUCT", 68, 96], ["GRP78", "GENE_OR_GENE_PRODUCT", 98, 103], ["GRP94", "GENE_OR_GENE_PRODUCT", 109, 114], ["PERK", "GENE_OR_GENE_PRODUCT", 151, 155], ["ATF6", "GENE_OR_GENE_PRODUCT", 160, 164], ["[17]", "SIMPLE_CHEMICAL", 186, 190], ["IRE1-X box binding protein", "GENE_OR_GENE_PRODUCT", 229, 255], ["XBP1", "GENE_OR_GENE_PRODUCT", 257, 261], ["glucose regulated protein 78 (GRP78) and GRP94 promoters", "DNA", 68, 124], ["PERK", "PROTEIN", 151, 155], ["ATF6", "PROTEIN", 160, 164], ["IRE1", "PROTEIN", 229, 233], ["X box binding protein", "PROTEIN", 234, 255], ["XBP1", "PROTEIN", 257, 261], ["hepatitis C virus", "SPECIES", 4, 21], ["hepatitis C virus", "SPECIES", 4, 21], ["HCV", "SPECIES", 23, 26], ["The hepatitis C virus (HCV)", "PROBLEM", 0, 27], ["increased transcription", "PROBLEM", 35, 58], ["the glucose regulated protein", "TEST", 64, 93], ["GRP94 promoters", "TREATMENT", 109, 124], ["PERK and ATF6 pathways", "TEST", 151, 173], ["the IRE1", "TEST", 225, 233], ["hepatitis", "OBSERVATION", 4, 13]]], ["The human cytomegalovirus (CMV) affects UPR through activation of the PERK and IRE-1 branches but spares the ATF6 pathway [19], [20].", [["human", "ORGANISM", 4, 9], ["cytomegalovirus", "ORGANISM", 10, 25], ["CMV", "ORGANISM", 27, 30], ["UPR", "GENE_OR_GENE_PRODUCT", 40, 43], ["PERK", "GENE_OR_GENE_PRODUCT", 70, 74], ["IRE-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["ATF6", "GENE_OR_GENE_PRODUCT", 109, 113], ["PERK", "PROTEIN", 70, 74], ["IRE", "PROTEIN", 79, 82], ["ATF6", "PROTEIN", 109, 113], ["human", "SPECIES", 4, 9], ["human cytomegalovirus", "SPECIES", 4, 25], ["CMV", "SPECIES", 27, 30], ["The human cytomegalovirus", "TEST", 0, 25], ["cytomegalovirus", "OBSERVATION", 10, 25], ["branches", "ANATOMY_MODIFIER", 85, 93]]], ["A cytopathic strain of bovine viral diarrhea virus (BVDV) induces apoptosis through UPR by activating the PERK pathway [21].", [["bovine viral diarrhea", "DISEASE", 23, 44], ["bovine viral diarrhea virus", "ORGANISM", 23, 50], ["BVDV", "ORGANISM", 52, 56], ["UPR", "GENE_OR_GENE_PRODUCT", 84, 87], ["PERK", "GENE_OR_GENE_PRODUCT", 106, 110], ["UPR", "PROTEIN", 84, 87], ["PERK", "PROTEIN", 106, 110], ["bovine viral diarrhea virus", "SPECIES", 23, 50], ["bovine viral diarrhea virus", "SPECIES", 23, 50], ["BVDV", "SPECIES", 52, 56], ["A cytopathic strain of bovine viral diarrhea virus", "PROBLEM", 0, 50], ["apoptosis", "PROBLEM", 66, 75], ["cytopathic", "OBSERVATION_MODIFIER", 2, 12], ["bovine", "OBSERVATION_MODIFIER", 23, 29], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["diarrhea virus", "OBSERVATION", 36, 50]]], ["The S protein of SARS-CoV modulates UPR by the transcriptional activation of GRP78/94 and upregulation of the PERK pathway, but has little or no effect on the other two arms of UPR [4].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["UPR", "GENE_OR_GENE_PRODUCT", 36, 39], ["GRP78/94", "GENE_OR_GENE_PRODUCT", 77, 85], ["PERK", "GENE_OR_GENE_PRODUCT", 110, 114], ["S protein", "PROTEIN", 4, 13], ["UPR", "PROTEIN", 36, 39], ["GRP78/94", "PROTEIN", 77, 85], ["PERK", "PROTEIN", 110, 114], ["SARS-CoV", "SPECIES", 17, 25], ["The S protein", "TEST", 0, 13], ["SARS", "PROBLEM", 17, 21], ["the PERK pathway", "TEST", 106, 122]]], ["Since the 3a protein of SARS-CoV is also a transmembrane protein that localizes to the ER-Golgi region and plasma membranes of cells and induces apoptosis, we studied its effects on ER stress and UPR.IntroductionType1 interferon (IFN) signaling exerts anti-proliferative and anti-viral effects through a cell surface cognate receptor consisting of two subunits, the interferon alpha receptor subunit 1 (IFNAR1) and IFNAR2 [22].", [["transmembrane", "ANATOMY", 43, 56], ["ER-Golgi region", "ANATOMY", 87, 102], ["plasma membranes", "ANATOMY", 107, 123], ["cells", "ANATOMY", 127, 132], ["cell surface", "ANATOMY", 304, 316], ["SARS", "DISEASE", 24, 28], ["SARS-CoV", "ORGANISM", 24, 32], ["transmembrane", "CELLULAR_COMPONENT", 43, 56], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["Golgi region", "CELLULAR_COMPONENT", 90, 102], ["plasma membranes", "CELLULAR_COMPONENT", 107, 123], ["cells", "CELL", 127, 132], ["ER", "GENE_OR_GENE_PRODUCT", 182, 184], ["UPR", "GENE_OR_GENE_PRODUCT", 196, 199], ["IntroductionType1 interferon", "GENE_OR_GENE_PRODUCT", 200, 228], ["IFN", "GENE_OR_GENE_PRODUCT", 230, 233], ["cell", "CELL", 304, 308], ["interferon alpha receptor subunit 1", "GENE_OR_GENE_PRODUCT", 366, 401], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 403, 409], ["IFNAR2", "GENE_OR_GENE_PRODUCT", 415, 421], ["SARS-CoV", "PROTEIN", 24, 32], ["transmembrane protein", "PROTEIN", 43, 64], ["ER", "PROTEIN", 87, 89], ["ER", "PROTEIN", 182, 184], ["UPR", "PROTEIN", 196, 199], ["interferon", "PROTEIN", 218, 228], ["IFN", "PROTEIN", 230, 233], ["cell surface cognate receptor", "PROTEIN", 304, 333], ["interferon alpha receptor subunit 1", "PROTEIN", 366, 401], ["IFNAR1", "PROTEIN", 403, 409], ["IFNAR2", "PROTEIN", 415, 421], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["a transmembrane protein", "PROBLEM", 41, 64], ["plasma membranes of cells", "PROBLEM", 107, 132], ["apoptosis", "PROBLEM", 145, 154], ["ER stress", "TEST", 182, 191], ["IntroductionType1 interferon (IFN)", "TREATMENT", 200, 234], ["anti-proliferative", "TREATMENT", 252, 270], ["anti-viral effects", "TREATMENT", 275, 293], ["a cell surface cognate receptor", "TREATMENT", 302, 333], ["two subunits", "TREATMENT", 348, 360], ["the interferon alpha receptor subunit", "TREATMENT", 362, 399], ["SARS", "OBSERVATION", 24, 28], ["plasma membranes", "OBSERVATION", 107, 123], ["apoptosis", "OBSERVATION_MODIFIER", 145, 154]]], ["Dimerization of these receptor subunits in response to the binding of type I interferons (IFN\u03b1 or IFN\u03b2) causes the activation of Janus kinase (Jak) family members, Jak1 and Tyk2, which eventually activate the signal transducers and activators of transcription (Stat1 and Stat2) proteins [23].", [["type I interferons", "GENE_OR_GENE_PRODUCT", 70, 88], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 90, 94], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 98, 102], ["Janus kinase", "GENE_OR_GENE_PRODUCT", 129, 141], ["Jak", "GENE_OR_GENE_PRODUCT", 143, 146], ["Jak1", "GENE_OR_GENE_PRODUCT", 164, 168], ["Tyk2", "GENE_OR_GENE_PRODUCT", 173, 177], ["signal transducers and activators of transcription", "GENE_OR_GENE_PRODUCT", 209, 259], ["Stat1", "GENE_OR_GENE_PRODUCT", 261, 266], ["Stat2", "GENE_OR_GENE_PRODUCT", 271, 276], ["receptor subunits", "PROTEIN", 22, 39], ["type I interferons", "PROTEIN", 70, 88], ["IFN\u03b1", "PROTEIN", 90, 94], ["IFN\u03b2", "PROTEIN", 98, 102], ["Janus kinase (Jak) family members", "PROTEIN", 129, 162], ["Jak1", "PROTEIN", 164, 168], ["Tyk2", "PROTEIN", 173, 177], ["signal transducers and activators of transcription (Stat1 and Stat2) proteins", "PROTEIN", 209, 286], ["these receptor subunits", "TREATMENT", 16, 39], ["type I interferons (IFN\u03b1", "TREATMENT", 70, 94], ["the activation of Janus kinase", "PROBLEM", 111, 141]]], ["The Stat proteins cause transcriptional activation of IFN-regulated genes.", [["Stat", "GENE_OR_GENE_PRODUCT", 4, 8], ["IFN", "GENE_OR_GENE_PRODUCT", 54, 57], ["Stat proteins", "PROTEIN", 4, 17], ["IFN-regulated genes", "DNA", 54, 73], ["The Stat proteins", "TEST", 0, 17], ["transcriptional activation of IFN", "PROBLEM", 24, 57], ["transcriptional activation", "OBSERVATION", 24, 50]]], ["The cell surface downmodulation and ensuing degradation of the IFN receptor in response to IFN\u03b1 treatment is a crucial event in limiting the extent of interferon-mediated cellular responses [24], [25].", [["cell surface", "ANATOMY", 4, 16], ["cellular", "ANATOMY", 171, 179], ["IFN\u03b1", "CHEMICAL", 91, 95], ["cell", "CELL", 4, 8], ["IFN receptor", "GENE_OR_GENE_PRODUCT", 63, 75], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 91, 95], ["interferon", "GENE_OR_GENE_PRODUCT", 151, 161], ["cellular", "CELL", 171, 179], ["IFN receptor", "PROTEIN", 63, 75], ["IFN\u03b1", "PROTEIN", 91, 95], ["interferon", "PROTEIN", 151, 161], ["The cell surface downmodulation", "TREATMENT", 0, 31], ["the IFN receptor", "TREATMENT", 59, 75], ["IFN\u03b1 treatment", "TREATMENT", 91, 105], ["a crucial event", "PROBLEM", 109, 124], ["cell", "OBSERVATION_MODIFIER", 4, 8], ["surface", "OBSERVATION_MODIFIER", 9, 16], ["downmodulation", "OBSERVATION_MODIFIER", 17, 31]]], ["The mechanism involves ligand-induced Tyk2 activity-dependent [26], [27], [28], [29] or ligand-and Jak-independent [30] phosphorylation of the Ser535 residue in the degradation motif (degron) of IFNAR1, which is followed by its ubiquitination and lysosomal degradation [26].IntroductionActivation of the PERK arm of UPR affects innate immunity of a cell by accelerating degradation of the IFNAR1 subunit; during infections by vesicular stomatitis virus (VSV) and the hepatitis C virus (HCV) this reduces the sensitivity of the infected cell to IFN [31].", [["lysosomal", "ANATOMY", 247, 256], ["cell", "ANATOMY", 349, 353], ["cell", "ANATOMY", 536, 540], ["infections", "DISEASE", 412, 422], ["vesicular stomatitis virus", "DISEASE", 426, 452], ["hepatitis C", "DISEASE", 467, 478], ["Ser535", "CHEMICAL", 143, 149], ["Tyk2", "GENE_OR_GENE_PRODUCT", 38, 42], ["[26]", "SIMPLE_CHEMICAL", 62, 66], ["[27], [28], [29]", "SIMPLE_CHEMICAL", 68, 84], ["Ser535", "AMINO_ACID", 143, 149], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 195, 201], ["lysosomal", "CELLULAR_COMPONENT", 247, 256], ["PERK", "GENE_OR_GENE_PRODUCT", 304, 308], ["UPR", "GENE_OR_GENE_PRODUCT", 316, 319], ["cell", "CELL", 349, 353], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 389, 395], ["vesicular stomatitis virus", "ORGANISM", 426, 452], ["VSV", "ORGANISM", 454, 457], ["hepatitis C virus", "ORGANISM", 467, 484], ["HCV", "ORGANISM", 486, 489], ["cell", "CELL", 536, 540], ["Tyk2", "PROTEIN", 38, 42], ["Ser535 residue", "PROTEIN", 143, 157], ["degradation motif", "PROTEIN", 165, 182], ["IFNAR1", "PROTEIN", 195, 201], ["PERK", "PROTEIN", 304, 308], ["UPR", "PROTEIN", 316, 319], ["IFNAR1 subunit", "PROTEIN", 389, 403], ["IFN", "PROTEIN", 544, 547], ["vesicular stomatitis virus", "SPECIES", 426, 452], ["hepatitis C virus", "SPECIES", 467, 484], ["vesicular stomatitis virus", "SPECIES", 426, 452], ["VSV", "SPECIES", 454, 457], ["hepatitis C virus", "SPECIES", 467, 484], ["HCV", "SPECIES", 486, 489], ["ligand", "TEST", 88, 94], ["IFNAR1", "PROBLEM", 195, 201], ["a cell", "PROBLEM", 347, 353], ["the IFNAR1 subunit", "TREATMENT", 385, 403], ["infections", "PROBLEM", 412, 422], ["vesicular stomatitis virus (VSV", "PROBLEM", 426, 457], ["the hepatitis C virus", "PROBLEM", 463, 484], ["HCV", "PROBLEM", 486, 489], ["vesicular stomatitis", "OBSERVATION", 426, 446], ["infected cell", "OBSERVATION", 527, 540]]], ["The degradation signal is phosphorylation of a serine residue within the IFNAR1 degron, which leads to increased ubiquitination and receptor degradation through the lysosomal pathway in virus infected cells [31].", [["lysosomal", "ANATOMY", 165, 174], ["cells", "ANATOMY", 201, 206], ["serine", "CHEMICAL", 47, 53], ["serine", "AMINO_ACID", 47, 53], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 73, 79], ["lysosomal", "CELLULAR_COMPONENT", 165, 174], ["cells", "CELL", 201, 206], ["IFNAR1 degron", "PROTEIN", 73, 86], ["virus infected cells", "CELL_TYPE", 186, 206], ["The degradation signal", "PROBLEM", 0, 22], ["a serine residue within the IFNAR1 degron", "PROBLEM", 45, 86], ["increased ubiquitination", "PROBLEM", 103, 127], ["receptor degradation", "PROBLEM", 132, 152], ["virus infected cells", "PROBLEM", 186, 206], ["IFNAR1 degron", "OBSERVATION", 73, 86], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["ubiquitination", "OBSERVATION_MODIFIER", 113, 127], ["receptor degradation", "OBSERVATION", 132, 152]]], ["In the current study we present evidence that the 3a protein of SARS-CoV elicits UPR by modulating the PERK pathway, and this leads to phosphorylation, ubiquitination and lysosomal degradation of IFNAR1.The SARS-CoV 3a Protein Induces ER Stress ::: ResultsThe SARS-CoV utilizes the ER for processing its structural and nonstructural proteins [32].", [["lysosomal", "ANATOMY", 171, 180], ["SARS", "DISEASE", 64, 68], ["SARS", "DISEASE", 207, 211], ["SARS", "DISEASE", 260, 264], ["SARS-CoV", "ORGANISM", 64, 72], ["UPR", "GENE_OR_GENE_PRODUCT", 81, 84], ["PERK", "GENE_OR_GENE_PRODUCT", 103, 107], ["lysosomal", "CELLULAR_COMPONENT", 171, 180], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 196, 202], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 207, 217], ["ER", "GENE_OR_GENE_PRODUCT", 235, 237], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 260, 268], ["ER", "GENE_OR_GENE_PRODUCT", 282, 284], ["UPR", "PROTEIN", 81, 84], ["PERK", "PROTEIN", 103, 107], ["IFNAR1", "PROTEIN", 196, 202], ["ER", "PROTEIN", 235, 237], ["ER", "PROTEIN", 282, 284], ["nonstructural proteins", "PROTEIN", 319, 341], ["SARS-CoV", "SPECIES", 64, 72], ["SARS-CoV", "SPECIES", 207, 215], ["SARS-CoV", "SPECIES", 260, 268], ["the current study", "TEST", 3, 20], ["SARS", "PROBLEM", 64, 68], ["phosphorylation", "TREATMENT", 135, 150], ["ubiquitination", "PROBLEM", 152, 166], ["lysosomal degradation of IFNAR1", "PROBLEM", 171, 202], ["The SARS", "TEST", 203, 211], ["lysosomal degradation", "OBSERVATION", 171, 192]]], ["During viral replication, substantial amounts of viral transmembrane glycoproteins such as the spike (S) and matrix (M) proteins are produced [32], of which the S protein induces ER stress [4].", [["transmembrane", "ANATOMY", 55, 68], ["spike (S)", "GENE_OR_GENE_PRODUCT", 95, 104], ["matrix (M)", "GENE_OR_GENE_PRODUCT", 109, 119], ["ER", "GENE_OR_GENE_PRODUCT", 179, 181], ["viral transmembrane glycoproteins", "PROTEIN", 49, 82], ["spike (S) and matrix (M) proteins", "PROTEIN", 95, 128], ["S protein", "PROTEIN", 161, 170], ["ER", "PROTEIN", 179, 181], ["viral replication", "TREATMENT", 7, 24], ["viral transmembrane glycoproteins", "PROBLEM", 49, 82], ["the spike (S) and matrix (M) proteins", "TEST", 91, 128], ["viral replication", "OBSERVATION", 7, 24], ["substantial", "OBSERVATION_MODIFIER", 26, 37], ["amounts", "OBSERVATION_MODIFIER", 38, 45], ["viral transmembrane glycoproteins", "OBSERVATION", 49, 82]]], ["Since the 3a protein is also a transmembrane glycoprotein that localizes to the ER-Golgi compartments, we studied its potential to induce ER stress.The SARS-CoV 3a Protein Induces ER Stress ::: ResultsTo investigate this, we looked at the transcriptional activation of grp78 and grp94 genes, which encode crucial ER chaperones that are markers of ER stress, in cells expressing the 3a protein.", [["transmembrane", "ANATOMY", 31, 44], ["ER-Golgi compartments", "ANATOMY", 80, 101], ["cells", "ANATOMY", 361, 366], ["SARS", "DISEASE", 152, 156], ["transmembrane", "CELLULAR_COMPONENT", 31, 44], ["ER", "GENE_OR_GENE_PRODUCT", 80, 82], ["Golgi compartments", "CELLULAR_COMPONENT", 83, 101], ["ER", "GENE_OR_GENE_PRODUCT", 138, 140], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 152, 162], ["ER", "GENE_OR_GENE_PRODUCT", 180, 182], ["grp78", "GENE_OR_GENE_PRODUCT", 269, 274], ["grp94", "GENE_OR_GENE_PRODUCT", 279, 284], ["ER", "GENE_OR_GENE_PRODUCT", 313, 315], ["ER", "GENE_OR_GENE_PRODUCT", 347, 349], ["cells", "CELL", 361, 366], ["3a", "GENE_OR_GENE_PRODUCT", 382, 384], ["3a protein", "PROTEIN", 10, 20], ["transmembrane glycoprotein", "PROTEIN", 31, 57], ["ER", "PROTEIN", 80, 82], ["ER", "PROTEIN", 138, 140], ["ER", "PROTEIN", 180, 182], ["grp78 and grp94 genes", "DNA", 269, 290], ["ER chaperones", "PROTEIN", 313, 326], ["ER", "PROTEIN", 347, 349], ["3a protein", "PROTEIN", 382, 392], ["SARS-CoV", "SPECIES", 152, 160], ["a transmembrane glycoprotein", "PROBLEM", 29, 57], ["ER stress", "PROBLEM", 138, 147], ["The SARS", "TEST", 148, 156], ["ER stress", "PROBLEM", 347, 356], ["grp94 genes", "OBSERVATION", 279, 290]]], ["To rule out induction of ER stress merely due to over-expression of a viral protein, we also studied the effects of the HIV proteins Nef and Vpu, and the hepatitis E virus (HEV) Orf3 protein, on grp78 and grp94 activation.", [["hepatitis E", "DISEASE", 154, 165], ["ER", "GENE_OR_GENE_PRODUCT", 25, 27], ["Nef", "GENE_OR_GENE_PRODUCT", 133, 136], ["Vpu", "GENE_OR_GENE_PRODUCT", 141, 144], ["hepatitis E virus", "ORGANISM", 154, 171], ["HEV", "ORGANISM", 173, 176], ["Orf3", "GENE_OR_GENE_PRODUCT", 178, 182], ["grp78", "GENE_OR_GENE_PRODUCT", 195, 200], ["grp94", "GENE_OR_GENE_PRODUCT", 205, 210], ["ER", "PROTEIN", 25, 27], ["viral protein", "PROTEIN", 70, 83], ["HIV proteins", "PROTEIN", 120, 132], ["Nef", "PROTEIN", 133, 136], ["Vpu", "PROTEIN", 141, 144], ["hepatitis E virus (HEV) Orf3 protein", "PROTEIN", 154, 190], ["grp78", "PROTEIN", 195, 200], ["grp94", "PROTEIN", 205, 210], ["hepatitis E virus", "SPECIES", 154, 171], ["HIV", "SPECIES", 120, 123], ["hepatitis E virus", "SPECIES", 154, 171], ["HEV", "SPECIES", 173, 176], ["ER stress", "PROBLEM", 25, 34], ["a viral protein", "PROBLEM", 68, 83], ["the HIV proteins Nef", "PROBLEM", 116, 136], ["Vpu", "TEST", 141, 144], ["the hepatitis E virus", "PROBLEM", 150, 171], ["Orf3 protein", "TEST", 178, 190], ["grp94 activation", "TEST", 205, 221]]], ["A luciferase reporter construct driven by the grp78 promoter and either plasmid pSGI, pEGFP, pEYFP (vector controls) or pSGI-3a-HA, pEGFP-Vpu, pEGFP-Orf3 or pEYFP-Nef were transiently transfected into Huh7 cells.", [["plasmid", "ANATOMY", 72, 79], ["Huh7 cells", "ANATOMY", 201, 211], ["luciferase", "GENE_OR_GENE_PRODUCT", 2, 12], ["grp78", "GENE_OR_GENE_PRODUCT", 46, 51], ["pSGI", "GENE_OR_GENE_PRODUCT", 80, 84], ["pEGFP", "GENE_OR_GENE_PRODUCT", 86, 91], ["pEYFP", "GENE_OR_GENE_PRODUCT", 93, 98], ["pSGI-3a-HA", "GENE_OR_GENE_PRODUCT", 120, 130], ["pEGFP-Vpu", "GENE_OR_GENE_PRODUCT", 132, 141], ["pEGFP-Orf3", "GENE_OR_GENE_PRODUCT", 143, 153], ["pEYFP-Nef", "GENE_OR_GENE_PRODUCT", 157, 166], ["Huh7 cells", "CELL", 201, 211], ["luciferase reporter construct", "DNA", 2, 31], ["grp78 promoter", "DNA", 46, 60], ["pSGI", "DNA", 80, 84], ["pEGFP", "DNA", 86, 91], ["pEYFP", "DNA", 93, 98], ["pSGI", "DNA", 120, 124], ["HA", "DNA", 128, 130], ["pEGFP", "DNA", 132, 137], ["Vpu", "DNA", 138, 141], ["pEGFP", "DNA", 143, 148], ["Orf3", "DNA", 149, 153], ["pEYFP", "DNA", 157, 162], ["Nef", "PROTEIN", 163, 166], ["Huh7 cells", "CELL_LINE", 201, 211], ["A luciferase reporter construct", "TREATMENT", 0, 31], ["plasmid pSGI", "TREATMENT", 72, 84], ["pEGFP", "TEST", 86, 91], ["pSGI", "TEST", 120, 124], ["HA", "PROBLEM", 128, 130], ["pEGFP", "TEST", 132, 137], ["Vpu", "PROBLEM", 138, 141], ["pEGFP", "TEST", 143, 148], ["Orf3", "PROBLEM", 149, 153], ["pEYFP", "TEST", 157, 162], ["Nef", "PROBLEM", 163, 166], ["Huh7 cells", "OBSERVATION", 201, 211]]], ["The cells were harvested 48 hr post-transfection for measurement of luciferase activity.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 68, 78], ["luciferase", "PROTEIN", 68, 78], ["luciferase activity", "PROBLEM", 68, 87], ["luciferase activity", "OBSERVATION", 68, 87]]], ["We observed about 3 to 4 fold increase in luciferase activity in 3a expressing cells as compared to the vector control cells.", [["cells", "ANATOMY", 79, 84], ["cells", "ANATOMY", 119, 124], ["luciferase", "GENE_OR_GENE_PRODUCT", 42, 52], ["cells", "CELL", 79, 84], ["cells", "CELL", 119, 124], ["luciferase", "PROTEIN", 42, 52], ["3a expressing cells", "CELL_TYPE", 65, 84], ["vector control cells", "CELL_LINE", 104, 124], ["4 fold increase in luciferase activity in 3a expressing cells", "PROBLEM", 23, 84], ["about 3 to 4 fold", "OBSERVATION_MODIFIER", 12, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["luciferase activity", "OBSERVATION", 42, 61]]], ["The transient expression of HIV Vpu also gave a similar increase in grp78 promoter activity, HIV Nef did not show any effect, and HEV Orf 3 showed about 2.5 fold reduction in grp78 promoter activity (Fig. 1A).", [["HIV", "ORGANISM", 28, 31], ["Vpu", "GENE_OR_GENE_PRODUCT", 32, 35], ["grp78", "GENE_OR_GENE_PRODUCT", 68, 73], ["Nef", "GENE_OR_GENE_PRODUCT", 97, 100], ["HEV Orf 3", "GENE_OR_GENE_PRODUCT", 130, 139], ["grp78", "GENE_OR_GENE_PRODUCT", 175, 180], ["HIV Vpu", "PROTEIN", 28, 35], ["grp78 promoter", "DNA", 68, 82], ["HIV Nef", "PROTEIN", 93, 100], ["grp78 promoter", "DNA", 175, 189], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 93, 96], ["HEV", "SPECIES", 130, 133], ["HIV Vpu", "PROBLEM", 28, 35], ["grp78 promoter activity", "TREATMENT", 68, 91], ["HIV Nef", "PROBLEM", 93, 100], ["HEV Orf", "TEST", 130, 137], ["promoter activity", "OBSERVATION", 181, 198]]], ["We also tested the effects of the SARS-CoV 3a protein on grp78 promoter in two other cell lines, COS and Vero cells, and observed similar effects as in Huh7 cells (Fig. 1A).", [["cell lines", "ANATOMY", 85, 95], ["COS", "ANATOMY", 97, 100], ["Vero cells", "ANATOMY", 105, 115], ["Huh7 cells", "ANATOMY", 152, 162], ["SARS", "DISEASE", 34, 38], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 34, 44], ["grp78", "GENE_OR_GENE_PRODUCT", 57, 62], ["cell lines", "CELL", 85, 95], ["COS", "CELL", 97, 100], ["Vero cells", "CELL", 105, 115], ["Huh7 cells", "CELL", 152, 162], ["Fig. 1A", "CELL", 164, 171], ["grp78 promoter", "DNA", 57, 71], ["cell lines", "CELL_LINE", 85, 95], ["COS", "CELL_LINE", 97, 100], ["Vero cells", "CELL_LINE", 105, 115], ["Huh7 cells", "CELL_LINE", 152, 162], ["SARS-CoV", "SPECIES", 34, 42], ["the SARS", "TEST", 30, 38], ["grp78 promoter", "TREATMENT", 57, 71], ["cell lines", "OBSERVATION", 85, 95], ["Vero cells", "OBSERVATION", 105, 115], ["Huh7 cells", "OBSERVATION", 152, 162]]], ["Activation of the grp94 promoter by the SARS-CoV 3a protein was also tested in Huh7 and COS cells.", [["Huh7", "ANATOMY", 79, 83], ["COS cells", "ANATOMY", 88, 97], ["grp94", "GENE_OR_GENE_PRODUCT", 18, 23], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 40, 50], ["Huh7", "CELL", 79, 83], ["COS cells", "CELL", 88, 97], ["grp94 promoter", "DNA", 18, 32], ["SARS-CoV 3", "PROTEIN", 40, 50], ["Huh7", "CELL_LINE", 79, 83], ["COS cells", "CELL_LINE", 88, 97], ["SARS-CoV", "SPECIES", 40, 48], ["the grp94 promoter", "TREATMENT", 14, 32], ["a protein", "TEST", 50, 59], ["Huh7 and COS cells", "TREATMENT", 79, 97]]], ["This promoter was also activated about 3 to 4 folds by expression of the 3a protein (Fig. 1B).", [["Fig. 1B", "GENE_OR_GENE_PRODUCT", 85, 92], ["3a protein", "PROTEIN", 73, 83], ["Fig. 1B", "PROTEIN", 85, 92]]], ["These results using two different ER sensor reporters, multiple cell lines and other viral proteins as controls, suggest that the 3a protein causes ER stress.The 3a Protein Differentially Activates the PERK but Not the IRE-1 and ATF6 Branches of UPR ::: ResultsSince ER stress leads to activation of UPR, which comprises of three different branches, we tested for the effects of 3a expression on each of these.", [["cell lines", "ANATOMY", 64, 74], ["ER", "GENE_OR_GENE_PRODUCT", 34, 36], ["cell lines", "CELL", 64, 74], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["PERK", "GENE_OR_GENE_PRODUCT", 202, 206], ["IRE-1", "GENE_OR_GENE_PRODUCT", 219, 224], ["ATF6", "GENE_OR_GENE_PRODUCT", 229, 233], ["ER", "GENE_OR_GENE_PRODUCT", 267, 269], ["UPR", "GENE_OR_GENE_PRODUCT", 300, 303], ["ER sensor reporters", "DNA", 34, 53], ["multiple cell lines", "CELL_LINE", 55, 74], ["viral proteins", "PROTEIN", 85, 99], ["3a protein", "PROTEIN", 130, 140], ["ER", "PROTEIN", 148, 150], ["PERK", "PROTEIN", 202, 206], ["IRE", "DNA", 219, 222], ["ATF6", "PROTEIN", 229, 233], ["UPR", "PROTEIN", 246, 249], ["ER", "PROTEIN", 267, 269], ["UPR", "PROTEIN", 300, 303], ["multiple cell lines", "TREATMENT", 55, 74], ["other viral proteins", "TEST", 79, 99], ["ER stress", "PROBLEM", 148, 157], ["UPR", "TEST", 300, 303], ["cell lines", "OBSERVATION", 64, 74], ["Branches", "ANATOMY_MODIFIER", 234, 242], ["stress leads", "OBSERVATION", 270, 282], ["branches", "OBSERVATION_MODIFIER", 340, 348]]], ["The IRE-1 and ATF6 pathways lead to reprogramming of the cell and induction of ER associated degradation [33], [34], [35].", [["cell", "ANATOMY", 57, 61], ["IRE-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["ATF6", "GENE_OR_GENE_PRODUCT", 14, 18], ["cell", "CELL", 57, 61], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["IRE-1", "DNA", 4, 9], ["ATF6", "PROTEIN", 14, 18], ["ER", "PROTEIN", 79, 81], ["ATF6 pathways", "TREATMENT", 14, 27]]], ["Following the activation of IRE-1 by ER stress, its endoribonuclease activity causes unconventional splicing of the mRNA for the X box-binding protein 1 (XBP-1).", [["IRE-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["ER", "GENE_OR_GENE_PRODUCT", 37, 39], ["X box-binding protein 1", "GENE_OR_GENE_PRODUCT", 129, 152], ["XBP-1", "GENE_OR_GENE_PRODUCT", 154, 159], ["IRE-1", "DNA", 28, 33], ["ER", "PROTEIN", 37, 39], ["endoribonuclease", "PROTEIN", 52, 68], ["mRNA", "RNA", 116, 120], ["X box-binding protein 1", "PROTEIN", 129, 152], ["XBP-1", "PROTEIN", 154, 159], ["its endoribonuclease activity", "PROBLEM", 48, 77], ["the X box", "TEST", 125, 134], ["binding protein", "TEST", 135, 150], ["XBP", "TEST", 154, 157]]], ["To determine the effect of 3a expression on the IRE-1 pathway, we carried out reverse transcription-polymerase chain reaction (RT-PCR) for the spliced XBP-1 mRNA as described elsewhere [36].", [["IRE-1", "GENE_OR_GENE_PRODUCT", 48, 53], ["XBP-1", "GENE_OR_GENE_PRODUCT", 151, 156], ["IRE", "DNA", 48, 51], ["XBP-1 mRNA", "RNA", 151, 161], ["polymerase chain reaction", "PROBLEM", 100, 125], ["RT-PCR", "TREATMENT", 127, 133], ["the spliced XBP", "PROBLEM", 139, 154]]], ["The spliced XBP-1 RNA was not observed in vector control or 3a-expressing cells, but was present in cells treated with thapsigargin, a chemical inducer of ER stress (Fig. 2A).", [["cells", "ANATOMY", 74, 79], ["cells", "ANATOMY", 100, 105], ["thapsigargin", "CHEMICAL", 119, 131], ["thapsigargin", "CHEMICAL", 119, 131], ["XBP-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["3a", "GENE_OR_GENE_PRODUCT", 60, 62], ["cells", "CELL", 74, 79], ["cells", "CELL", 100, 105], ["thapsigargin", "SIMPLE_CHEMICAL", 119, 131], ["ER", "GENE_OR_GENE_PRODUCT", 155, 157], ["XBP-1 RNA", "RNA", 12, 21], ["3a-expressing cells", "CELL_LINE", 60, 79], ["ER", "PROTEIN", 155, 157], ["The spliced XBP", "TEST", 0, 15], ["thapsigargin", "TREATMENT", 119, 131]]], ["During ER stress, ATF6 is translocated to the Golgi where its cytoplasmic domain (ATF6f) is liberated by regulated proteolysis [37], [38].", [["Golgi", "ANATOMY", 46, 51], ["cytoplasmic", "ANATOMY", 62, 73], ["ER", "GENE_OR_GENE_PRODUCT", 7, 9], ["ATF6", "GENE_OR_GENE_PRODUCT", 18, 22], ["Golgi", "CELLULAR_COMPONENT", 46, 51], ["cytoplasmic", "ORGANISM_SUBSTANCE", 62, 73], ["ATF6f", "GENE_OR_GENE_PRODUCT", 82, 87], ["ER", "PROTEIN", 7, 9], ["ATF6", "PROTEIN", 18, 22], ["cytoplasmic domain", "PROTEIN", 62, 80], ["ATF6f", "PROTEIN", 82, 87]]], ["To study the effect of 3a expression on the ATF6 pathway, we looked at the levels of ATF6f following cotransfection of a FLAG-tagged ATF6 expression plasmid that mimicked ATF6 processing upon induction of ER stress, and either the empty pSGI vector or the pSGI-3a-HA expression vector.", [["3a", "GENE_OR_GENE_PRODUCT", 23, 25], ["ATF6", "GENE_OR_GENE_PRODUCT", 44, 48], ["ATF6f", "GENE_OR_GENE_PRODUCT", 85, 90], ["FLAG", "GENE_OR_GENE_PRODUCT", 121, 125], ["ATF6", "GENE_OR_GENE_PRODUCT", 133, 137], ["ATF6", "GENE_OR_GENE_PRODUCT", 171, 175], ["ER", "GENE_OR_GENE_PRODUCT", 205, 207], ["pSGI", "GENE_OR_GENE_PRODUCT", 237, 241], ["pSGI-3a", "GENE_OR_GENE_PRODUCT", 256, 263], ["ATF6", "PROTEIN", 44, 48], ["ATF6f", "PROTEIN", 85, 90], ["FLAG", "PROTEIN", 121, 125], ["ATF6 expression plasmid", "DNA", 133, 156], ["ATF6", "PROTEIN", 171, 175], ["ER", "PROTEIN", 205, 207], ["pSGI vector", "DNA", 237, 248], ["pSGI-3a-HA expression vector", "DNA", 256, 284], ["a FLAG-tagged ATF6 expression plasmid", "TREATMENT", 119, 156], ["the pSGI", "TEST", 252, 260]]], ["We did not observe any significant increase in the cleaved ATF6f (p50) product arising from transfected FLAG-tagged ATF6 (p90) in 3a expressing cells as compared to control cells; however, treatment with thapsigargin led to increased levels of the p50 form (not shown).The 3a Protein Differentially Activates the PERK but Not the IRE-1 and ATF6 Branches of UPR ::: ResultsUnder conditions of ER stress the kinase activity of PERK is activated, phosphorylating its downstream target, the eukaryotic translation initiation factor 2 subunit \u03b1 (eIF2\u03b1).", [["cells", "ANATOMY", 144, 149], ["cells", "ANATOMY", 173, 178], ["thapsigargin", "CHEMICAL", 204, 216], ["thapsigargin", "CHEMICAL", 204, 216], ["ATF6f", "GENE_OR_GENE_PRODUCT", 59, 64], ["p50", "GENE_OR_GENE_PRODUCT", 66, 69], ["FLAG", "GENE_OR_GENE_PRODUCT", 104, 108], ["ATF6 (p90", "GENE_OR_GENE_PRODUCT", 116, 125], ["cells", "CELL", 144, 149], ["cells", "CELL", 173, 178], ["thapsigargin", "SIMPLE_CHEMICAL", 204, 216], ["p50", "GENE_OR_GENE_PRODUCT", 248, 251], ["PERK", "GENE_OR_GENE_PRODUCT", 313, 317], ["IRE-1", "GENE_OR_GENE_PRODUCT", 330, 335], ["ATF6", "GENE_OR_GENE_PRODUCT", 340, 344], ["ER", "GENE_OR_GENE_PRODUCT", 392, 394], ["PERK", "GENE_OR_GENE_PRODUCT", 425, 429], ["eukaryotic translation initiation factor 2 subunit \u03b1", "GENE_OR_GENE_PRODUCT", 487, 539], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 541, 546], ["ATF6f (p50) product", "PROTEIN", 59, 78], ["FLAG", "PROTEIN", 104, 108], ["ATF6", "PROTEIN", 116, 120], ["3a expressing cells", "CELL_TYPE", 130, 149], ["control cells", "CELL_TYPE", 165, 178], ["p50 form", "PROTEIN", 248, 256], ["PERK", "PROTEIN", 313, 317], ["IRE", "DNA", 330, 333], ["ATF6", "PROTEIN", 340, 344], ["UPR", "PROTEIN", 357, 360], ["ER", "PROTEIN", 392, 394], ["PERK", "PROTEIN", 425, 429], ["eukaryotic translation initiation factor 2 subunit \u03b1", "PROTEIN", 487, 539], ["eIF2\u03b1", "PROTEIN", 541, 546], ["any significant increase", "PROBLEM", 19, 43], ["transfected FLAG", "TEST", 92, 108], ["thapsigargin", "TREATMENT", 204, 216], ["ER stress", "PROBLEM", 392, 401], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["Branches", "ANATOMY_MODIFIER", 345, 353]]], ["To test if 3a protein-mediated ER stress was through the PERK pathway, we first looked at the phosphorylation status of eIF2\u03b1 by western blotting of transfected cell lysates.", [["cell lysates", "ANATOMY", 161, 173], ["3a", "GENE_OR_GENE_PRODUCT", 11, 13], ["ER", "GENE_OR_GENE_PRODUCT", 31, 33], ["PERK", "GENE_OR_GENE_PRODUCT", 57, 61], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 120, 125], ["cell lysates", "CELL", 161, 173], ["ER", "PROTEIN", 31, 33], ["PERK", "PROTEIN", 57, 61], ["eIF2\u03b1", "PROTEIN", 120, 125], ["3a protein", "TEST", 11, 21], ["ER stress", "PROBLEM", 31, 40], ["transfected cell lysates", "PROBLEM", 149, 173], ["transfected cell lysates", "OBSERVATION", 149, 173]]], ["Compared to control cells, the 3a-expressing cells showed increased levels of phospho-eIF2\u03b1 (peIF2\u03b1) without a concomitant increase in total eIF2\u03b1 levels (Fig. 2B).", [["cells", "ANATOMY", 20, 25], ["cells", "ANATOMY", 45, 50], ["phospho", "CHEMICAL", 78, 85], ["cells", "CELL", 20, 25], ["cells", "CELL", 45, 50], ["phospho-eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 78, 91], ["peIF2\u03b1", "GENE_OR_GENE_PRODUCT", 93, 99], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 141, 146], ["3a-expressing cells", "CELL_LINE", 31, 50], ["phospho-eIF2\u03b1", "PROTEIN", 78, 91], ["peIF2\u03b1", "PROTEIN", 93, 99], ["eIF2\u03b1", "PROTEIN", 141, 146], ["control cells", "TEST", 12, 25], ["increased levels", "PROBLEM", 58, 74], ["phospho-eIF2", "TEST", 78, 90], ["a concomitant increase", "PROBLEM", 109, 131], ["total eIF2\u03b1 levels", "TEST", 135, 153], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["concomitant", "OBSERVATION_MODIFIER", 111, 122], ["increase", "OBSERVATION_MODIFIER", 123, 131]]], ["We then cotransfected cells with expression plasmids for wild type eIF2\u03b1 or its dominant-negative (DN) or dominant active (DA) mutants, pGRP78-Luc and either pSGI or pSG-3a-HA.", [["cells", "ANATOMY", 22, 27], ["plasmids", "ANATOMY", 44, 52], ["DA", "CHEMICAL", 123, 125], ["cells", "CELL", 22, 27], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 67, 72], ["pGRP78-Luc", "GENE_OR_GENE_PRODUCT", 136, 146], ["pSG-3a-HA", "GENE_OR_GENE_PRODUCT", 166, 175], ["expression plasmids", "DNA", 33, 52], ["wild type eIF2\u03b1", "PROTEIN", 57, 72], ["dominant-negative (DN) or dominant active (DA) mutants", "PROTEIN", 80, 134], ["pGRP78", "PROTEIN", 136, 142], ["Luc", "PROTEIN", 143, 146], ["pSGI", "PROTEIN", 158, 162], ["pSG", "PROTEIN", 166, 169], ["3a-HA", "PROTEIN", 170, 175], ["expression plasmids", "TREATMENT", 33, 52], ["pSGI", "TEST", 158, 162], ["pSG", "TEST", 166, 169], ["HA", "PROBLEM", 173, 175], ["active", "OBSERVATION_MODIFIER", 115, 121]]], ["Since the DN form of eIF2\u03b1 constitutively inhibits phosphorylation of eIF2\u03b1, the promoter activity of GRP78/94 would be compromised.", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 70, 75], ["GRP78/94", "GENE_OR_GENE_PRODUCT", 102, 110], ["eIF2\u03b1", "PROTEIN", 21, 26], ["eIF2\u03b1", "PROTEIN", 70, 75], ["GRP78/94", "PROTEIN", 102, 110], ["phosphorylation of eIF2\u03b1", "TREATMENT", 51, 75]]], ["We observed that the induction of ER stress in 3a expressing cells, measured with the grp78-luc reporter, was compromised in the presence of eIF2\u03b1 DN (Fig. 2C), confirming the role of 3a protein in activating the PERK-eIF2\u03b1 pathway.The 3a Protein Differentially Activates the PERK but Not the IRE-1 and ATF6 Branches of UPR ::: ResultsWhile PERK-mediated phosphorylation of eIF2\u03b1 leads to a decrease in its activity, it also causes a paradoxical increase in translation of ATF4 mRNA [39], [40], [41].", [["cells", "ANATOMY", 61, 66], ["ER", "GENE_OR_GENE_PRODUCT", 34, 36], ["cells", "CELL", 61, 66], ["grp78", "GENE_OR_GENE_PRODUCT", 86, 91], ["luc", "GENE_OR_GENE_PRODUCT", 92, 95], ["eIF2", "GENE_OR_GENE_PRODUCT", 141, 145], ["3a", "GENE_OR_GENE_PRODUCT", 184, 186], ["PERK", "GENE_OR_GENE_PRODUCT", 213, 217], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 218, 223], ["PERK", "GENE_OR_GENE_PRODUCT", 276, 280], ["IRE-1", "GENE_OR_GENE_PRODUCT", 293, 298], ["ATF6", "GENE_OR_GENE_PRODUCT", 303, 307], ["UPR", "GENE_OR_GENE_PRODUCT", 320, 323], ["PERK", "GENE_OR_GENE_PRODUCT", 341, 345], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 374, 379], ["ATF4", "GENE_OR_GENE_PRODUCT", 473, 477], ["ER", "PROTEIN", 34, 36], ["3a expressing cells", "CELL_TYPE", 47, 66], ["grp78", "PROTEIN", 86, 91], ["luc reporter", "DNA", 92, 104], ["eIF2", "PROTEIN", 141, 145], ["3a protein", "PROTEIN", 184, 194], ["PERK", "PROTEIN", 213, 217], ["eIF2\u03b1", "PROTEIN", 218, 223], ["PERK", "PROTEIN", 276, 280], ["IRE", "DNA", 293, 296], ["ATF6", "PROTEIN", 303, 307], ["UPR", "PROTEIN", 320, 323], ["PERK", "PROTEIN", 341, 345], ["eIF2\u03b1", "PROTEIN", 374, 379], ["ATF4 mRNA", "RNA", 473, 482], ["PERK", "TEST", 341, 345], ["a decrease in its activity", "PROBLEM", 389, 415], ["a paradoxical increase", "PROBLEM", 432, 454], ["ATF4 mRNA", "TEST", 473, 482], ["Branches", "ANATOMY_MODIFIER", 308, 316], ["decrease", "OBSERVATION_MODIFIER", 391, 399], ["paradoxical", "OBSERVATION_MODIFIER", 434, 445], ["increase", "OBSERVATION_MODIFIER", 446, 454]]], ["The ATF4 protein is a transcription factor that binds to and activates the promoter of C/EBP homologous protein (CHOP, also called as GADD153) gene [39], [40], [41].", [["ATF4", "GENE_OR_GENE_PRODUCT", 4, 8], ["C/EBP homologous protein", "GENE_OR_GENE_PRODUCT", 87, 111], ["CHOP", "GENE_OR_GENE_PRODUCT", 113, 117], ["GADD153", "GENE_OR_GENE_PRODUCT", 134, 141], ["ATF4 protein", "PROTEIN", 4, 16], ["transcription factor", "PROTEIN", 22, 42], ["promoter", "DNA", 75, 83], ["C/EBP homologous protein", "PROTEIN", 87, 111], ["CHOP", "PROTEIN", 113, 117], ["GADD153", "PROTEIN", 134, 141], ["C/EBP homologous protein (CHOP", "TREATMENT", 87, 117]]], ["To investigate the effect of 3a and other viral proteins on downstream effectors of the PERK pathway, we employed the construct TK.mATF4.UTR.Luc.pGL3, which contains the 5\u2032-untranslated region of ATF4 fused to the coding region of firefly luciferase, for studying ATF4 translation in transiently transfected cells.", [["cells", "ANATOMY", 308, 313], ["3a", "GENE_OR_GENE_PRODUCT", 29, 31], ["PERK", "GENE_OR_GENE_PRODUCT", 88, 92], ["UTR.Luc.pGL3", "GENE_OR_GENE_PRODUCT", 137, 149], ["ATF4", "GENE_OR_GENE_PRODUCT", 196, 200], ["luciferase", "GENE_OR_GENE_PRODUCT", 239, 249], ["ATF4", "GENE_OR_GENE_PRODUCT", 264, 268], ["cells", "CELL", 308, 313], ["viral proteins", "PROTEIN", 42, 56], ["PERK", "PROTEIN", 88, 92], ["UTR.Luc.pGL3", "DNA", 137, 149], ["5\u2032-untranslated region", "DNA", 170, 192], ["ATF4", "PROTEIN", 196, 200], ["firefly luciferase", "DNA", 231, 249], ["ATF4", "PROTEIN", 264, 268], ["transiently transfected cells", "CELL_LINE", 284, 313], ["other viral proteins", "TREATMENT", 36, 56], ["ATF4 translation", "TREATMENT", 264, 280], ["transiently transfected cells", "PROBLEM", 284, 313], ["ATF4 fused", "OBSERVATION", 196, 206], ["firefly luciferase", "OBSERVATION", 231, 249], ["transfected cells", "OBSERVATION", 296, 313]]], ["There was about 17-fold increase in ATF4 expression in 3a-expressing cells compared to control cells; the other viral proteins did not show any significant effect on ATF4 translation (Fig. 3A).", [["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 95, 100], ["ATF4", "GENE_OR_GENE_PRODUCT", 36, 40], ["3a", "GENE_OR_GENE_PRODUCT", 55, 57], ["cells", "CELL", 69, 74], ["cells", "CELL", 95, 100], ["ATF4", "GENE_OR_GENE_PRODUCT", 166, 170], ["ATF4", "PROTEIN", 36, 40], ["3a-expressing cells", "CELL_LINE", 55, 74], ["control cells", "CELL_TYPE", 87, 100], ["viral proteins", "PROTEIN", 112, 126], ["ATF4", "PROTEIN", 166, 170], ["17-fold increase in ATF4 expression", "PROBLEM", 16, 51], ["3a-expressing cells", "TREATMENT", 55, 74], ["the other viral proteins", "TEST", 102, 126], ["ATF4 translation", "TREATMENT", 166, 182], ["17-fold", "OBSERVATION_MODIFIER", 16, 23], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["ATF4 expression", "OBSERVATION", 36, 51]]], ["The activity of the CHOP promoter was also assayed in cells cotransfected with the pSGI-3a-HA expression construct (or pSGI) and a luciferase reporter construct driven by CHOP promoter.", [["cells", "ANATOMY", 54, 59], ["CHOP", "GENE_OR_GENE_PRODUCT", 20, 24], ["cells", "CELL", 54, 59], ["pSGI-3a", "GENE_OR_GENE_PRODUCT", 83, 90], ["luciferase", "GENE_OR_GENE_PRODUCT", 131, 141], ["CHOP", "GENE_OR_GENE_PRODUCT", 171, 175], ["CHOP promoter", "DNA", 20, 33], ["pSGI-3a-HA expression construct", "DNA", 83, 114], ["pSGI", "DNA", 119, 123], ["luciferase reporter construct", "DNA", 131, 160], ["CHOP promoter", "DNA", 171, 184], ["the CHOP promoter", "TREATMENT", 16, 33], ["the pSGI", "TEST", 79, 87], ["a luciferase reporter construct", "TREATMENT", 129, 160]]], ["There was an \u223c4-fold increase in CHOP promoter activity in 3a-expressing cells (Fig. 3B); the other viral proteins showed variable results.", [["cells", "ANATOMY", 73, 78], ["CHOP", "GENE_OR_GENE_PRODUCT", 33, 37], ["cells", "CELL", 73, 78], ["Fig. 3B", "CELL", 80, 87], ["CHOP promoter", "DNA", 33, 46], ["expressing cells", "CELL_TYPE", 62, 78], ["viral proteins", "PROTEIN", 100, 114], ["an \u223c4-fold increase", "PROBLEM", 10, 29], ["CHOP promoter activity", "TREATMENT", 33, 55], ["the other viral proteins", "TEST", 90, 114], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["CHOP promoter activity", "OBSERVATION", 33, 55]]], ["The HEV Orf3 protein showed a decrease in CHOP promoter activity, whereas the HIV Nef and Vpu proteins and the HBV X protein showed marginal increases in the CHOP promoter activity (Fig. 3B).The 3a Protein Differentially Activates the PERK but Not the IRE-1 and ATF6 Branches of UPR ::: ResultsSince activation of the CHOP promoter can also be mediated by the p38 MAPK pathway and our earlier results show that the 3a protein can also activate this pathway, we employed SB203580, a chemical inhibitor of the p38 MAPK to dissect the effects of the 3a protein on CHOP activation.", [["SB203580", "CHEMICAL", 470, 478], ["SB203580", "CHEMICAL", 470, 478], ["HEV", "ORGANISM", 4, 7], ["Orf3", "GENE_OR_GENE_PRODUCT", 8, 12], ["CHOP", "GENE_OR_GENE_PRODUCT", 42, 46], ["Nef", "GENE_OR_GENE_PRODUCT", 82, 85], ["Vpu", "GENE_OR_GENE_PRODUCT", 90, 93], ["HBV X", "GENE_OR_GENE_PRODUCT", 111, 116], ["CHOP", "GENE_OR_GENE_PRODUCT", 158, 162], ["PERK", "GENE_OR_GENE_PRODUCT", 235, 239], ["IRE-1", "GENE_OR_GENE_PRODUCT", 252, 257], ["ATF6", "GENE_OR_GENE_PRODUCT", 262, 266], ["CHOP", "GENE_OR_GENE_PRODUCT", 318, 322], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 360, 368], ["3a", "GENE_OR_GENE_PRODUCT", 415, 417], ["SB203580", "SIMPLE_CHEMICAL", 470, 478], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 508, 516], ["CHOP", "GENE_OR_GENE_PRODUCT", 561, 565], ["HEV Orf3 protein", "PROTEIN", 4, 20], ["CHOP promoter", "DNA", 42, 55], ["HIV Nef", "PROTEIN", 78, 85], ["Vpu proteins", "PROTEIN", 90, 102], ["HBV X protein", "PROTEIN", 111, 124], ["CHOP promoter", "DNA", 158, 171], ["PERK", "PROTEIN", 235, 239], ["IRE", "DNA", 252, 255], ["ATF6", "PROTEIN", 262, 266], ["UPR", "PROTEIN", 279, 282], ["CHOP promoter", "DNA", 318, 331], ["p38 MAPK", "PROTEIN", 360, 368], ["p38 MAPK", "PROTEIN", 508, 516], ["3a protein", "PROTEIN", 547, 557], ["CHOP", "PROTEIN", 561, 565], ["HEV", "SPECIES", 4, 7], ["HIV", "SPECIES", 78, 81], ["HBV", "SPECIES", 111, 114], ["The HEV Orf3 protein", "TEST", 0, 20], ["CHOP promoter activity", "TREATMENT", 42, 64], ["the HIV Nef", "TEST", 74, 85], ["Vpu proteins", "TEST", 90, 102], ["the HBV X protein", "TEST", 107, 124], ["marginal increases", "PROBLEM", 132, 150], ["the CHOP promoter activity", "TREATMENT", 154, 180], ["the CHOP promoter", "TREATMENT", 314, 331], ["the p38 MAPK pathway", "TEST", 356, 376], ["a chemical inhibitor", "TREATMENT", 480, 500], ["the p38 MAPK", "TREATMENT", 504, 516], ["CHOP activation", "TREATMENT", 561, 576], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["CHOP promoter activity", "OBSERVATION", 42, 64], ["marginal", "OBSERVATION_MODIFIER", 132, 140], ["increases", "OBSERVATION_MODIFIER", 141, 150], ["Branches", "ANATOMY_MODIFIER", 267, 275]]], ["The CHOP promoter-reporter construct was cotransfected into cells with either the 3a expression plasmid (or the vector control plasmid).", [["cells", "ANATOMY", 60, 65], ["plasmid", "ANATOMY", 127, 134], ["CHOP", "GENE_OR_GENE_PRODUCT", 4, 8], ["cells", "CELL", 60, 65], ["CHOP promoter-reporter construct", "DNA", 4, 36], ["3a expression plasmid", "DNA", 82, 103], ["vector control plasmid", "DNA", 112, 134], ["The CHOP promoter", "TREATMENT", 0, 17], ["the 3a expression plasmid", "TREATMENT", 78, 103], ["the vector control plasmid", "TREATMENT", 108, 134]]], ["One set of transfected cultures was treated with SB203580, while the other was treated with the vehicle (DMSO).", [["cultures", "ANATOMY", 23, 31], ["SB203580", "CHEMICAL", 49, 57], ["DMSO", "CHEMICAL", 105, 109], ["SB203580", "CHEMICAL", 49, 57], ["DMSO", "CHEMICAL", 105, 109], ["cultures", "CELL", 23, 31], ["SB203580", "SIMPLE_CHEMICAL", 49, 57], ["DMSO", "SIMPLE_CHEMICAL", 105, 109], ["transfected cultures", "CELL_LINE", 11, 31], ["transfected cultures", "TEST", 11, 31], ["SB203580", "TREATMENT", 49, 57]]], ["Luciferase assays carried out on cell lysates did not reveal any significant effect of SB203580 on the activity of the CHOP promoter in 3a expressing cells at concentrations that inhibit p38 activity (Fig. 3C).", [["cell lysates", "ANATOMY", 33, 45], ["cells", "ANATOMY", 150, 155], ["SB203580", "CHEMICAL", 87, 95], ["SB203580", "CHEMICAL", 87, 95], ["cell lysates", "CELL", 33, 45], ["SB203580", "SIMPLE_CHEMICAL", 87, 95], ["CHOP", "GENE_OR_GENE_PRODUCT", 119, 123], ["cells", "CELL", 150, 155], ["p38", "GENE_OR_GENE_PRODUCT", 187, 190], ["CHOP promoter", "DNA", 119, 132], ["3a expressing cells", "CELL_TYPE", 136, 155], ["p38", "PROTEIN", 187, 190], ["Luciferase assays", "TEST", 0, 17], ["cell lysates", "TEST", 33, 45], ["the CHOP promoter", "TREATMENT", 115, 132]]], ["This shows that transcriptional activation of CHOP expression by the 3a protein was independent of its activation of the p38 MAPK pathway.The 3a Protein Promotes Phosphorylation, Ubiquitination and Lysosomal Degradation of the Interferon-Alpha Receptor Subunit 1 (IFNAR1) ::: ResultsThe activation of PERK causes phosphorylation of IFNAR1 within its degron region; this is important for its ubiquitination and downregulation at the cell surface [31].", [["cell surface", "ANATOMY", 432, 444], ["CHOP", "GENE_OR_GENE_PRODUCT", 46, 50], ["3a", "GENE_OR_GENE_PRODUCT", 69, 71], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 121, 129], ["Interferon-Alpha Receptor Subunit 1", "GENE_OR_GENE_PRODUCT", 227, 262], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 264, 270], ["PERK", "GENE_OR_GENE_PRODUCT", 301, 305], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 332, 338], ["cell surface", "CELLULAR_COMPONENT", 432, 444], ["CHOP", "PROTEIN", 46, 50], ["3a protein", "PROTEIN", 69, 79], ["p38 MAPK", "PROTEIN", 121, 129], ["Interferon-Alpha Receptor Subunit 1", "PROTEIN", 227, 262], ["IFNAR1", "PROTEIN", 264, 270], ["PERK", "PROTEIN", 301, 305], ["IFNAR1", "PROTEIN", 332, 338], ["degron region", "PROTEIN", 350, 363], ["CHOP expression", "TREATMENT", 46, 61], ["the p38 MAPK pathway", "TREATMENT", 117, 137], ["The 3a Protein Promotes Phosphorylation", "TREATMENT", 138, 177], ["Lysosomal Degradation", "TREATMENT", 198, 219], ["the Interferon-Alpha Receptor Subunit", "TREATMENT", 223, 260], ["phosphorylation of IFNAR1 within its degron region", "PROBLEM", 313, 363], ["transcriptional activation", "OBSERVATION", 16, 42]]], ["To investigate the fate of IFNAR1 in 3a expressing cells, we first looked at its phosphorylation levels.", [["cells", "ANATOMY", 51, 56], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 27, 33], ["cells", "CELL", 51, 56], ["IFNAR1", "PROTEIN", 27, 33], ["3a expressing cells", "CELL_TYPE", 37, 56]]], ["Increased IFNAR1 phosphorylation was observed in 3a expressing cells, compared to control cells (Fig. 4A).", [["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 90, 95], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 10, 16], ["cells", "CELL", 63, 68], ["cells", "CELL", 90, 95], ["Fig. 4A", "CELL", 97, 104], ["IFNAR1", "PROTEIN", 10, 16], ["3a expressing cells", "CELL_TYPE", 49, 68], ["control cells", "CELL_TYPE", 82, 95], ["Increased IFNAR1 phosphorylation", "PROBLEM", 0, 32], ["IFNAR1 phosphorylation", "OBSERVATION", 10, 32]]], ["As a positive control, tunicamycin, a chemical inducer of ER stress also showed increased IFNAR1 phosphorylation.", [["tunicamycin", "CHEMICAL", 23, 34], ["tunicamycin", "CHEMICAL", 23, 34], ["tunicamycin", "SIMPLE_CHEMICAL", 23, 34], ["ER", "GENE_OR_GENE_PRODUCT", 58, 60], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 90, 96], ["ER", "PROTEIN", 58, 60], ["IFNAR1", "PROTEIN", 90, 96], ["a positive control", "TREATMENT", 3, 21], ["tunicamycin", "TREATMENT", 23, 34], ["ER stress", "TEST", 58, 67], ["increased IFNAR1 phosphorylation", "PROBLEM", 80, 112], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["IFNAR1 phosphorylation", "OBSERVATION", 90, 112]]], ["There was also a slight decrease in the steady state levels of the IFNAR1 protein in cells that were either treated with tunicamycin or expressed the 3a protein (Fig. 4A).", [["cells", "ANATOMY", 85, 90], ["tunicamycin", "CHEMICAL", 121, 132], ["tunicamycin", "CHEMICAL", 121, 132], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 67, 73], ["cells", "CELL", 85, 90], ["tunicamycin", "SIMPLE_CHEMICAL", 121, 132], ["IFNAR1 protein", "PROTEIN", 67, 81], ["3a protein", "PROTEIN", 150, 160], ["Fig. 4A", "PROTEIN", 162, 169], ["a slight decrease", "PROBLEM", 15, 32], ["the IFNAR1 protein in cells", "PROBLEM", 63, 90], ["tunicamycin", "TREATMENT", 121, 132], ["slight", "OBSERVATION_MODIFIER", 17, 23], ["decrease", "OBSERVATION_MODIFIER", 24, 32], ["steady", "OBSERVATION_MODIFIER", 40, 46], ["IFNAR1 protein", "OBSERVATION", 67, 81]]], ["This would indicate either decreased synthesis or increased degradation of the IFNAR1 protein under these conditions.", [["IFNAR1", "GENE_OR_GENE_PRODUCT", 79, 85], ["IFNAR1 protein", "PROTEIN", 79, 93], ["decreased synthesis", "PROBLEM", 27, 46], ["increased degradation of the IFNAR1 protein", "PROBLEM", 50, 93], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["synthesis", "OBSERVATION", 37, 46], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["degradation", "OBSERVATION_MODIFIER", 60, 71]]], ["Since IFNAR1 phosphorylation is established as a signal for its ubiquitination, we tested for that by immunoprecipitating lysates from transiently transfected cells with anti-IFNAR1 antibodies and then western blotting the precipitates with an anti-ubiquitin antibody.", [["lysates", "ANATOMY", 122, 129], ["cells", "ANATOMY", 159, 164], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 6, 12], ["lysates", "ORGANISM_SUBSTANCE", 122, 129], ["cells", "CELL", 159, 164], ["anti-IFNAR1 antibodies", "GENE_OR_GENE_PRODUCT", 170, 192], ["IFNAR1", "PROTEIN", 6, 12], ["transiently transfected cells", "CELL_LINE", 135, 164], ["anti-IFNAR1 antibodies", "PROTEIN", 170, 192], ["anti-ubiquitin antibody", "PROTEIN", 244, 267], ["IFNAR1 phosphorylation", "PROBLEM", 6, 28], ["immunoprecipitating lysates", "PROBLEM", 102, 129], ["transiently transfected cells", "PROBLEM", 135, 164], ["anti-IFNAR1 antibodies", "TREATMENT", 170, 192], ["an anti-ubiquitin antibody", "TREATMENT", 241, 267], ["transfected cells", "OBSERVATION", 147, 164]]], ["Compared to control cells, the 3a expressing cells showed increased ubiquitination of the IFNAR1 protein (Fig. 4B).The 3a Protein Promotes Phosphorylation, Ubiquitination and Lysosomal Degradation of the Interferon-Alpha Receptor Subunit 1 (IFNAR1) ::: ResultsUbiquitinated IFNAR1 is destined to undergo degradation through a lysosomal pathway [26], [42], [43].", [["cells", "ANATOMY", 20, 25], ["cells", "ANATOMY", 45, 50], ["lysosomal", "ANATOMY", 326, 335], ["cells", "CELL", 20, 25], ["cells", "CELL", 45, 50], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 90, 96], ["Fig. 4B", "GENE_OR_GENE_PRODUCT", 106, 113], ["Lysosomal", "CELLULAR_COMPONENT", 175, 184], ["Interferon-Alpha Receptor Subunit 1", "GENE_OR_GENE_PRODUCT", 204, 239], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 241, 247], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 274, 280], ["lysosomal", "CELLULAR_COMPONENT", 326, 335], ["3a expressing cells", "CELL_TYPE", 31, 50], ["IFNAR1 protein", "PROTEIN", 90, 104], ["Fig. 4B", "PROTEIN", 106, 113], ["Interferon-Alpha Receptor Subunit 1 (IFNAR1) ::: ResultsUbiquitinated IFNAR1", "PROTEIN", 204, 280], ["increased ubiquitination of the IFNAR1 protein", "PROBLEM", 58, 104], ["The 3a Protein Promotes Phosphorylation", "TREATMENT", 115, 154], ["Ubiquitination", "TREATMENT", 156, 170], ["Lysosomal Degradation", "TREATMENT", 175, 196], ["the Interferon-Alpha Receptor Subunit 1 (IFNAR1)", "TREATMENT", 200, 248], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["ubiquitination", "OBSERVATION_MODIFIER", 68, 82]]], ["To test for this, we took cells transiently expressing either the enhanced cyan fluorescent protein (ECFP) as a control or the 3a-ECFP-fusion protein, and co-stained these cells with an antibody to IFNAR1 and Lysotracker.", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 172, 177], ["cells", "CELL", 26, 31], ["cyan fluorescent protein", "GENE_OR_GENE_PRODUCT", 75, 99], ["ECFP", "GENE_OR_GENE_PRODUCT", 101, 105], ["ECFP", "GENE_OR_GENE_PRODUCT", 130, 134], ["cells", "CELL", 172, 177], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 198, 204], ["cyan fluorescent protein", "PROTEIN", 75, 99], ["ECFP", "PROTEIN", 101, 105], ["3a-ECFP", "PROTEIN", 127, 134], ["fusion protein", "PROTEIN", 135, 149], ["IFNAR1", "PROTEIN", 198, 204], ["Lysotracker", "PROTEIN", 209, 220], ["the 3a-ECFP-fusion protein", "TREATMENT", 123, 149], ["an antibody", "TREATMENT", 183, 194], ["Lysotracker", "TREATMENT", 209, 220]]], ["Multiple cells were imaged by confocal microscopy and colocalization of the IFNAR1 and Lysotracker signals was quantitated.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 76, 82], ["Lysotracker", "GENE_OR_GENE_PRODUCT", 87, 98], ["IFNAR1", "PROTEIN", 76, 82], ["Multiple cells", "PROBLEM", 0, 14], ["confocal microscopy", "TEST", 30, 49], ["the IFNAR1 and Lysotracker signals", "TEST", 72, 106]]], ["There was increased localization of IFNAR1 in the lysosomal compartment in 3a expressing cells compared to control cells (Fig. 5).The 3a Protein Promotes Phosphorylation, Ubiquitination and Lysosomal Degradation of the Interferon-Alpha Receptor Subunit 1 (IFNAR1) ::: ResultsIncreased ubiquitination and lysosomal translocation of IFNAR1 in 3a expressing cells is likely to result in reduced IFNAR1 levels in these cells.", [["lysosomal compartment", "ANATOMY", 50, 71], ["cells", "ANATOMY", 89, 94], ["cells", "ANATOMY", 115, 120], ["lysosomal", "ANATOMY", 304, 313], ["cells", "ANATOMY", 355, 360], ["cells", "ANATOMY", 415, 420], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 36, 42], ["lysosomal compartment", "CELLULAR_COMPONENT", 50, 71], ["cells", "CELL", 89, 94], ["cells", "CELL", 115, 120], ["Interferon-Alpha Receptor Subunit 1", "GENE_OR_GENE_PRODUCT", 219, 254], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 256, 262], ["lysosomal", "CELLULAR_COMPONENT", 304, 313], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 331, 337], ["cells", "CELL", 355, 360], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 392, 398], ["cells", "CELL", 415, 420], ["IFNAR1", "PROTEIN", 36, 42], ["3a expressing cells", "CELL_TYPE", 75, 94], ["control cells", "CELL_TYPE", 107, 120], ["Interferon-Alpha Receptor Subunit 1", "PROTEIN", 219, 254], ["IFNAR1", "PROTEIN", 256, 262], ["IFNAR1", "PROTEIN", 331, 337], ["3a expressing cells", "CELL_TYPE", 341, 360], ["IFNAR1", "PROTEIN", 392, 398], ["increased localization of IFNAR1 in the lysosomal compartment", "PROBLEM", 10, 71], ["The 3a Protein Promotes Phosphorylation", "TREATMENT", 130, 169], ["Lysosomal Degradation", "TREATMENT", 190, 211], ["the Interferon-Alpha Receptor Subunit", "TREATMENT", 215, 252], ["Increased ubiquitination", "PROBLEM", 275, 299], ["lysosomal translocation of IFNAR1 in 3a expressing cells", "PROBLEM", 304, 360], ["reduced IFNAR1 levels in these cells", "PROBLEM", 384, 420], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["localization", "OBSERVATION_MODIFIER", 20, 32], ["IFNAR1", "OBSERVATION_MODIFIER", 36, 42], ["lysosomal compartment", "ANATOMY", 50, 71], ["Increased", "OBSERVATION_MODIFIER", 275, 284], ["ubiquitination", "OBSERVATION_MODIFIER", 285, 299], ["lysosomal translocation", "OBSERVATION", 304, 327], ["likely to", "UNCERTAINTY", 364, 373], ["reduced", "OBSERVATION_MODIFIER", 384, 391], ["IFNAR1 levels", "OBSERVATION", 392, 405]]], ["We tested this by staining for IFNAR1 in a flow cytometric assay using cells transiently expressing either the control ECFP or the 3a-ECFP-fusion protein.", [["cells", "ANATOMY", 71, 76], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 31, 37], ["cells", "CELL", 71, 76], ["ECFP", "GENE_OR_GENE_PRODUCT", 119, 123], ["3a-", "GENE_OR_GENE_PRODUCT", 131, 134], ["ECFP", "GENE_OR_GENE_PRODUCT", 134, 138], ["IFNAR1", "PROTEIN", 31, 37], ["ECFP", "PROTEIN", 119, 123], ["3a-ECFP-fusion protein", "PROTEIN", 131, 153], ["IFNAR1", "PROBLEM", 31, 37], ["a flow cytometric assay", "TEST", 41, 64], ["the 3a-ECFP-fusion protein", "TREATMENT", 127, 153]]], ["As shown in Fig. 6, there was a significant decrease in the equilibrium levels of IFNAR1 in 3a-ECFP expressing cells compared to control cells.", [["cells", "ANATOMY", 111, 116], ["cells", "ANATOMY", 137, 142], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 82, 88], ["ECFP", "GENE_OR_GENE_PRODUCT", 95, 99], ["cells", "CELL", 111, 116], ["cells", "CELL", 137, 142], ["IFNAR1", "PROTEIN", 82, 88], ["3a-ECFP expressing cells", "CELL_LINE", 92, 116], ["control cells", "CELL_TYPE", 129, 142], ["a significant decrease in the equilibrium levels of IFNAR1", "PROBLEM", 30, 88], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["decrease", "OBSERVATION_MODIFIER", 44, 52]]], ["To verify involvement of the lysosomal pathway in reduced IFNAR1 levels, we also treated 3a-ECFP expressing cells with the lysosomal inhibitor, 3-methyl adenine (3-MA), which led to an increase in the cellular IFNAR1 signal (Fig. 6), thus confirming a role for the lysosomal pathway in its reduction in 3a expressing cells.DiscussionThe 3a protein of SARS-CoV has multiple functions.", [["lysosomal", "ANATOMY", 29, 38], ["cells", "ANATOMY", 108, 113], ["lysosomal", "ANATOMY", 123, 132], ["cellular", "ANATOMY", 201, 209], ["lysosomal", "ANATOMY", 265, 274], ["cells", "ANATOMY", 317, 322], ["3-methyl adenine", "CHEMICAL", 144, 160], ["3-MA", "CHEMICAL", 162, 166], ["3-methyl adenine", "CHEMICAL", 144, 160], ["3-MA", "CHEMICAL", 162, 166], ["lysosomal", "CELLULAR_COMPONENT", 29, 38], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 58, 64], ["ECFP", "GENE_OR_GENE_PRODUCT", 92, 96], ["cells", "CELL", 108, 113], ["3-methyl adenine", "SIMPLE_CHEMICAL", 144, 160], ["3-MA", "SIMPLE_CHEMICAL", 162, 166], ["cellular", "CELL", 201, 209], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 210, 216], ["lysosomal", "CELLULAR_COMPONENT", 265, 274], ["cells", "CELL", 317, 322], ["SARS-CoV", "ORGANISM", 351, 359], ["IFNAR1", "PROTEIN", 58, 64], ["3a-ECFP expressing cells", "CELL_LINE", 89, 113], ["IFNAR1", "PROTEIN", 210, 216], ["3a expressing cells", "CELL_TYPE", 303, 322], ["SARS-CoV", "SPECIES", 351, 359], ["the lysosomal pathway", "TEST", 25, 46], ["reduced IFNAR1 levels", "PROBLEM", 50, 71], ["the lysosomal inhibitor", "TREATMENT", 119, 142], ["3-methyl adenine", "TREATMENT", 144, 160], ["an increase in the cellular IFNAR1 signal", "PROBLEM", 182, 223], ["the lysosomal pathway", "TREATMENT", 261, 282], ["SARS", "PROBLEM", 351, 355], ["increase", "OBSERVATION_MODIFIER", 185, 193], ["cellular IFNAR1", "OBSERVATION", 201, 216], ["reduction", "OBSERVATION_MODIFIER", 290, 299]]], ["It has an ion channel activity [44], modulates trafficking properties of SARS-CoV spike (S) protein [5], upregulates the expression of fibrinogen in A549 lung epithelial cells [45] and induces apoptosis in various cell types in vitro and in vivo[6], [46].DiscussionAll viruses encode proteins that are synthesized by the host cell and are processed through the cellular protein translocation machinery.", [["A549 lung epithelial cells", "ANATOMY", 149, 175], ["cell", "ANATOMY", 214, 218], ["cell", "ANATOMY", 326, 330], ["cellular", "ANATOMY", 361, 369], ["SARS-CoV spike (S)", "GENE_OR_GENE_PRODUCT", 73, 91], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 135, 145], ["A549 lung epithelial cells [45", "CELL", 149, 179], ["cell", "CELL", 214, 218], ["host cell", "CELL", 321, 330], ["cellular", "CELL", 361, 369], ["SARS-CoV spike (S) protein", "PROTEIN", 73, 99], ["fibrinogen", "PROTEIN", 135, 145], ["A549 lung epithelial cells", "CELL_LINE", 149, 175], ["SARS", "PROBLEM", 73, 77], ["CoV spike", "TEST", 78, 87], ["protein", "TEST", 92, 99], ["fibrinogen", "TEST", 135, 145], ["A549 lung epithelial cells", "TEST", 149, 175], ["apoptosis", "PROBLEM", 193, 202], ["the cellular protein translocation machinery", "TREATMENT", 357, 401], ["ion channel", "OBSERVATION_MODIFIER", 10, 21], ["activity", "OBSERVATION_MODIFIER", 22, 30], ["lung", "ANATOMY", 154, 158], ["epithelial cells", "OBSERVATION", 159, 175], ["various cell types", "OBSERVATION", 206, 224], ["host cell", "OBSERVATION", 321, 330]]], ["This puts an added burden on the ER, resulting in ER stress.", [["ER", "GENE_OR_GENE_PRODUCT", 33, 35], ["ER", "GENE_OR_GENE_PRODUCT", 50, 52], ["ER", "PROTEIN", 33, 35], ["ER", "PROTEIN", 50, 52], ["ER stress", "PROBLEM", 50, 59]]], ["To overcome the effects of ER stress, many viruses, including coronaviruses, modulate the UPR [47].", [["ER", "GENE_OR_GENE_PRODUCT", 27, 29], ["ER", "PROTEIN", 27, 29], ["ER stress", "PROBLEM", 27, 36], ["many viruses", "PROBLEM", 38, 50], ["coronaviruses", "PROBLEM", 62, 75], ["viruses", "OBSERVATION", 43, 50]]], ["The S protein of SARS-CoV that forms its surface coat, is produced in large amounts in infected cells and is trafficked through the ER, modulates UPR [4].", [["surface", "ANATOMY", 41, 48], ["cells", "ANATOMY", 96, 101], ["ER", "ANATOMY", 132, 134], ["SARS-CoV", "ORGANISM", 17, 25], ["cells", "CELL", 96, 101], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["S protein", "PROTEIN", 4, 13], ["SARS-CoV", "PROTEIN", 17, 25], ["infected cells", "CELL_TYPE", 87, 101], ["ER", "PROTEIN", 132, 134], ["SARS-CoV", "SPECIES", 17, 25], ["The S protein", "TEST", 0, 13], ["SARS", "PROBLEM", 17, 21], ["CoV", "PROBLEM", 22, 25], ["large amounts in infected cells", "PROBLEM", 70, 101], ["large", "OBSERVATION_MODIFIER", 70, 75], ["amounts", "OBSERVATION_MODIFIER", 76, 83], ["infected cells", "OBSERVATION", 87, 101]]], ["The 3a protein is another viral transmembrane glycoprotein expressed in SARS-CoV infected cells, which has previously been shown to localize to the ER-Golgi network and plasma membrane in cells [5], and to viral particles.", [["transmembrane", "ANATOMY", 32, 45], ["cells", "ANATOMY", 90, 95], ["ER-Golgi network", "ANATOMY", 148, 164], ["plasma membrane", "ANATOMY", 169, 184], ["cells", "ANATOMY", 188, 193], ["3a", "GENE_OR_GENE_PRODUCT", 4, 6], ["SARS-CoV", "ORGANISM", 72, 80], ["cells", "CELL", 90, 95], ["ER", "GENE_OR_GENE_PRODUCT", 148, 150], ["Golgi network", "CELLULAR_COMPONENT", 151, 164], ["plasma membrane", "CELLULAR_COMPONENT", 169, 184], ["cells", "CELL", 188, 193], ["3a protein", "PROTEIN", 4, 14], ["viral transmembrane glycoprotein", "PROTEIN", 26, 58], ["SARS-CoV infected cells", "CELL_TYPE", 72, 95], ["ER", "PROTEIN", 148, 150], ["SARS-CoV", "SPECIES", 72, 80], ["another viral transmembrane glycoprotein", "PROBLEM", 18, 58], ["SARS", "PROBLEM", 72, 76], ["CoV infected cells", "PROBLEM", 77, 95], ["plasma membrane in cells", "PROBLEM", 169, 193], ["viral particles", "PROBLEM", 206, 221], ["infected cells", "OBSERVATION", 81, 95], ["viral particles", "OBSERVATION", 206, 221]]], ["We show here that the 3a protein also induces UPR.DiscussionIn the cell, UPR progresses through three different pathways that are mediated by IRE-1, ATF6 and PERK.", [["cell", "ANATOMY", 67, 71], ["UPR", "GENE_OR_GENE_PRODUCT", 46, 49], ["cell", "CELL", 67, 71], ["IRE-1", "GENE_OR_GENE_PRODUCT", 142, 147], ["ATF6", "GENE_OR_GENE_PRODUCT", 149, 153], ["PERK", "GENE_OR_GENE_PRODUCT", 158, 162], ["UPR", "PROTEIN", 46, 49], ["IRE-1", "PROTEIN", 142, 147], ["ATF6", "PROTEIN", 149, 153], ["PERK", "PROTEIN", 158, 162]]], ["The IRE-1 and ATF6 pathways lead to reprogramming of the cell and induction of ER associated degradation, which reduces burden on the ER [33], [34], [35].", [["cell", "ANATOMY", 57, 61], ["IRE-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["ATF6", "GENE_OR_GENE_PRODUCT", 14, 18], ["cell", "CELL", 57, 61], ["ER", "GENE_OR_GENE_PRODUCT", 79, 81], ["ER", "GENE_OR_GENE_PRODUCT", 134, 136], ["IRE-1", "DNA", 4, 9], ["ATF6", "PROTEIN", 14, 18], ["ER", "PROTEIN", 79, 81], ["ATF6 pathways", "TREATMENT", 14, 27], ["ER associated degradation", "PROBLEM", 79, 104]]], ["IRE-1 is a type I transmembrane protein kinase endoribonuclease [48], [49] containing three ER stress-regulated domains, which include a lumenal dimerization domain, a cytosolic kinase and an endoribonuclease [50].", [["lumenal", "ANATOMY", 137, 144], ["cytosolic", "ANATOMY", 168, 177], ["IRE-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 92, 94], ["IRE-1", "DNA", 0, 5], ["type I transmembrane protein kinase endoribonuclease", "PROTEIN", 11, 63], ["ER stress-regulated domains", "PROTEIN", 92, 119], ["lumenal dimerization domain", "PROTEIN", 137, 164], ["cytosolic kinase", "PROTEIN", 168, 184], ["endoribonuclease", "PROTEIN", 192, 208], ["a type I transmembrane protein kinase endoribonuclease", "PROBLEM", 9, 63], ["a lumenal dimerization domain", "TEST", 135, 164], ["a cytosolic kinase", "TEST", 166, 184], ["lumenal", "ANATOMY_MODIFIER", 137, 144]]], ["Following ER stress, IRE-1 dimerizes and undergoes autophosphorylation and activation of its endoribonuclease activity.", [["ER", "GENE_OR_GENE_PRODUCT", 10, 12], ["IRE-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["ER", "PROTEIN", 10, 12], ["IRE-1", "PROTEIN", 21, 26], ["endoribonuclease", "PROTEIN", 93, 109], ["autophosphorylation", "TREATMENT", 51, 70]]], ["This causes unconventional splicing of the IRE-1 effector X box-binding protein 1 (XBP-1) mRNA that encodes XBP-1, a basic leucine zipper (bZIP) transcription factor and belongs to ATF/CREB family [51], [52], [53].", [["leucine", "CHEMICAL", 123, 130], ["IRE-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["X box-binding protein 1", "GENE_OR_GENE_PRODUCT", 58, 81], ["XBP-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["XBP-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["basic leucine zipper", "GENE_OR_GENE_PRODUCT", 117, 137], ["bZIP", "GENE_OR_GENE_PRODUCT", 139, 143], ["ATF", "GENE_OR_GENE_PRODUCT", 181, 184], ["CREB", "GENE_OR_GENE_PRODUCT", 185, 189], ["IRE-1 effector X box", "DNA", 43, 63], ["binding protein 1 (XBP-1) mRNA", "RNA", 64, 94], ["XBP-1", "PROTEIN", 108, 113], ["basic leucine zipper (bZIP) transcription factor", "PROTEIN", 117, 165], ["ATF", "PROTEIN", 181, 184], ["CREB family", "PROTEIN", 185, 196], ["the IRE", "TREATMENT", 39, 46], ["binding protein", "TEST", 64, 79], ["XBP", "TEST", 83, 86], ["XBP", "TEST", 108, 111], ["a basic leucine zipper", "TREATMENT", 115, 137], ["splicing", "OBSERVATION", 27, 35]]], ["The ATF6 is a type II transmembrane protein whose cytosolic domain is a bZIP transcription factor [37].", [["cytosolic", "ANATOMY", 50, 59], ["ATF6", "GENE_OR_GENE_PRODUCT", 4, 8], ["ATF6", "PROTEIN", 4, 8], ["type II transmembrane protein", "PROTEIN", 14, 43], ["cytosolic domain", "PROTEIN", 50, 66], ["bZIP transcription factor", "PROTEIN", 72, 97], ["a type II transmembrane protein whose cytosolic domain", "PROBLEM", 12, 66]]], ["During ER stress it is translocated to the Golgi [54], where its cytoplasmic domain (ATF6f) is liberated by regulated proteolysis and translocates into the nucleus to activate transcription [37], [38].", [["Golgi", "ANATOMY", 43, 48], ["cytoplasmic", "ANATOMY", 65, 76], ["nucleus", "ANATOMY", 156, 163], ["ER", "GENE_OR_GENE_PRODUCT", 7, 9], ["Golgi", "CELLULAR_COMPONENT", 43, 48], ["cytoplasmic", "ORGANISM_SUBSTANCE", 65, 76], ["ATF6f", "GENE_OR_GENE_PRODUCT", 85, 90], ["nucleus", "CELLULAR_COMPONENT", 156, 163], ["ER", "PROTEIN", 7, 9], ["cytoplasmic domain", "PROTEIN", 65, 83], ["ATF6f", "PROTEIN", 85, 90], ["regulated proteolysis", "PROBLEM", 108, 129], ["proteolysis", "OBSERVATION", 118, 129]]], ["Our results show neither XBP-1 mRNA splicing nor ATF6 proteolysis in 3a expressing cells, suggesting that the IRE-1 and ATF6 pathways are not activated in these cells.DiscussionWe did however find activation of the PERK pathway of UPR by the 3a protein.", [["cells", "ANATOMY", 83, 88], ["cells", "ANATOMY", 161, 166], ["XBP-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["ATF6", "GENE_OR_GENE_PRODUCT", 49, 53], ["cells", "CELL", 83, 88], ["IRE-1", "GENE_OR_GENE_PRODUCT", 110, 115], ["ATF6", "GENE_OR_GENE_PRODUCT", 120, 124], ["cells", "CELL", 161, 166], ["PERK", "GENE_OR_GENE_PRODUCT", 215, 219], ["UPR", "GENE_OR_GENE_PRODUCT", 231, 234], ["XBP-1 mRNA", "RNA", 25, 35], ["ATF6", "PROTEIN", 49, 53], ["3a expressing cells", "CELL_TYPE", 69, 88], ["IRE", "DNA", 110, 113], ["ATF6", "PROTEIN", 120, 124], ["PERK", "PROTEIN", 215, 219], ["UPR", "PROTEIN", 231, 234], ["3a protein", "PROTEIN", 242, 252], ["XBP", "TEST", 25, 28], ["ATF6 proteolysis", "PROBLEM", 49, 65], ["the IRE", "TEST", 106, 113], ["ATF6 pathways", "TEST", 120, 133], ["nor", "UNCERTAINTY", 45, 48], ["ATF6 proteolysis", "OBSERVATION", 49, 65]]], ["On activation, the PERK kinase causes phosphorylation of eIF2\u03b1, which leads to reduced translation of cellular proteins, but stimulates expression of ER molecular chaperones such as GRP78 and GRP94 [55].", [["cellular", "ANATOMY", 102, 110], ["PERK", "GENE_OR_GENE_PRODUCT", 19, 23], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 57, 62], ["cellular", "CELL", 102, 110], ["ER", "GENE_OR_GENE_PRODUCT", 150, 152], ["GRP78", "GENE_OR_GENE_PRODUCT", 182, 187], ["GRP94 [55]", "GENE_OR_GENE_PRODUCT", 192, 202], ["PERK kinase", "PROTEIN", 19, 30], ["eIF2\u03b1", "PROTEIN", 57, 62], ["cellular proteins", "PROTEIN", 102, 119], ["ER molecular chaperones", "PROTEIN", 150, 173], ["GRP78", "PROTEIN", 182, 187], ["GRP94", "PROTEIN", 192, 197], ["the PERK kinase", "TEST", 15, 30], ["phosphorylation of eIF2\u03b1", "PROBLEM", 38, 62], ["reduced translation of cellular proteins", "PROBLEM", 79, 119], ["GRP78", "TEST", 182, 187], ["GRP94", "TEST", 192, 197], ["cellular proteins", "OBSERVATION", 102, 119]]], ["Modulation of UPR by the 3a protein represents another function aimed at regulating the cellular response.", [["cellular", "ANATOMY", 88, 96], ["UPR", "GENE_OR_GENE_PRODUCT", 14, 17], ["cellular", "CELL", 88, 96], ["UPR", "PROTEIN", 14, 17], ["3a protein", "PROTEIN", 25, 35], ["UPR", "ANATOMY_MODIFIER", 14, 17], ["cellular response", "OBSERVATION", 88, 105]]], ["Increased transcriptional activation and biosynthesis of ER chaperones would enhance folding of the 3a and other viral proteins in the ER lumen.", [["ER lumen", "ANATOMY", 135, 143], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["3a", "GENE_OR_GENE_PRODUCT", 100, 102], ["ER", "GENE_OR_GENE_PRODUCT", 135, 137], ["lumen", "CELLULAR_COMPONENT", 138, 143], ["ER chaperones", "PROTEIN", 57, 70], ["viral proteins", "PROTEIN", 113, 127], ["Increased transcriptional activation", "PROBLEM", 0, 36], ["biosynthesis of ER chaperones", "TREATMENT", 41, 70], ["transcriptional activation", "OBSERVATION", 10, 36], ["viral proteins", "OBSERVATION", 113, 127], ["lumen", "ANATOMY_MODIFIER", 138, 143]]], ["The induction of Endoplasmic Reticulum Associated Degredation (ERAD) to reduce the protein-folding load on the ER requires activation of the IRE1/XBP1 and ATF6 pathways.", [["ER", "ANATOMY", 111, 113], ["Endoplasmic Reticulum Associated Degredation", "GENE_OR_GENE_PRODUCT", 17, 61], ["ERAD", "GENE_OR_GENE_PRODUCT", 63, 67], ["ER", "GENE_OR_GENE_PRODUCT", 111, 113], ["IRE1", "GENE_OR_GENE_PRODUCT", 141, 145], ["XBP1", "GENE_OR_GENE_PRODUCT", 146, 150], ["ATF6", "GENE_OR_GENE_PRODUCT", 155, 159], ["Endoplasmic Reticulum Associated Degredation", "PROTEIN", 17, 61], ["ERAD", "PROTEIN", 63, 67], ["ER", "PROTEIN", 111, 113], ["IRE1", "PROTEIN", 141, 145], ["XBP1", "PROTEIN", 146, 150], ["ATF6", "PROTEIN", 155, 159], ["Endoplasmic Reticulum Associated Degredation (ERAD", "TREATMENT", 17, 67], ["the protein-folding load", "PROBLEM", 79, 103], ["the IRE1/XBP1", "TREATMENT", 137, 150], ["Endoplasmic Reticulum", "OBSERVATION", 17, 38]]], ["This includes ER degradation-enhancing \u03b1-mannosidase-like protein (EDEM), which is directly involved in recognition and targeting of unfolded proteins for degradation during UPR [33].", [["ER", "ANATOMY", 14, 16], ["ER", "GENE_OR_GENE_PRODUCT", 14, 16], ["\u03b1-mannosidase-like protein", "GENE_OR_GENE_PRODUCT", 39, 65], ["EDEM", "GENE_OR_GENE_PRODUCT", 67, 71], ["ER", "PROTEIN", 14, 16], ["\u03b1-mannosidase", "PROTEIN", 39, 52], ["like protein", "PROTEIN", 53, 65], ["EDEM", "PROTEIN", 67, 71], ["unfolded proteins", "PROTEIN", 133, 150], ["ER degradation", "TEST", 14, 28], ["unfolded proteins", "PROBLEM", 133, 150], ["enhancing", "OBSERVATION_MODIFIER", 29, 38]]], ["By activating only the PERK, but not the IRE-1 and ATF6 pathways during UPR, the 3a protein potentially protects itself and other viral proteins from ERAD, while promoting the expression of ER chaperones and folding of proteins that have accumulated in the ER.DiscussionWe showed earlier that the 3a protein activates p38 MAPK and is proapoptotic [7].", [["ER", "ANATOMY", 257, 259], ["PERK", "GENE_OR_GENE_PRODUCT", 23, 27], ["IRE-1", "GENE_OR_GENE_PRODUCT", 41, 46], ["ATF6", "GENE_OR_GENE_PRODUCT", 51, 55], ["UPR", "GENE_OR_GENE_PRODUCT", 72, 75], ["ERAD", "GENE_OR_GENE_PRODUCT", 150, 154], ["ER", "GENE_OR_GENE_PRODUCT", 190, 192], ["ER", "GENE_OR_GENE_PRODUCT", 257, 259], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 318, 326], ["PERK", "PROTEIN", 23, 27], ["IRE", "PROTEIN", 41, 44], ["ATF6", "PROTEIN", 51, 55], ["UPR", "PROTEIN", 72, 75], ["viral proteins", "PROTEIN", 130, 144], ["ERAD", "PROTEIN", 150, 154], ["ER chaperones", "PROTEIN", 190, 203], ["ER", "PROTEIN", 257, 259], ["p38 MAPK", "PROTEIN", 318, 326], ["other viral proteins from ERAD", "PROBLEM", 124, 154], ["ER chaperones", "TREATMENT", 190, 203], ["folding of proteins", "PROBLEM", 208, 227]]], ["The expression of C/EBP homologous protein (CHOP), which is known to have a pro-apoptotic effect, is activated by p38 MAPK as well as through the PERK signaling pathway [56], [57].", [["C/EBP homologous protein", "GENE_OR_GENE_PRODUCT", 18, 42], ["CHOP", "GENE_OR_GENE_PRODUCT", 44, 48], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 114, 122], ["PERK", "GENE_OR_GENE_PRODUCT", 146, 150], ["C/EBP homologous protein", "PROTEIN", 18, 42], ["CHOP", "PROTEIN", 44, 48], ["p38 MAPK", "PROTEIN", 114, 122], ["PERK", "PROTEIN", 146, 150], ["C/EBP homologous protein (CHOP", "TREATMENT", 18, 48], ["p38 MAPK", "TEST", 114, 122], ["the PERK signaling pathway", "TEST", 142, 168], ["pro-apoptotic effect", "OBSERVATION", 76, 96]]], ["The over-expression of CHOP leads to translocation of Bax from the cytosol to the mitochondria [58].", [["cytosol", "ANATOMY", 67, 74], ["mitochondria", "ANATOMY", 82, 94], ["CHOP", "GENE_OR_GENE_PRODUCT", 23, 27], ["Bax", "GENE_OR_GENE_PRODUCT", 54, 57], ["cytosol", "CELLULAR_COMPONENT", 67, 74], ["mitochondria", "CELLULAR_COMPONENT", 82, 94], ["CHOP", "PROTEIN", 23, 27], ["Bax", "PROTEIN", 54, 57], ["CHOP", "TREATMENT", 23, 27], ["Bax", "TREATMENT", 54, 57]]], ["The CHOP-mediated death signal is finally transmitted to the mitochondria, which functions as an integrator and amplifier of the death pathway but the other mechanistic details of CHOP action are still unclear [57].", [["mitochondria", "ANATOMY", 61, 73], ["death", "DISEASE", 18, 23], ["death", "DISEASE", 129, 134], ["CHOP", "GENE_OR_GENE_PRODUCT", 4, 8], ["mitochondria", "CELLULAR_COMPONENT", 61, 73], ["CHOP", "GENE_OR_GENE_PRODUCT", 180, 184], ["CHOP", "PROTEIN", 4, 8], ["CHOP", "PROTEIN", 180, 184], ["CHOP action", "TREATMENT", 180, 191]]], ["We show the 3a protein to cause increased phosphorylation of eIF2\u03b1, which is indicative of activation of the PERK arm of UPR [55], [59].", [["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 61, 66], ["PERK", "GENE_OR_GENE_PRODUCT", 109, 113], ["eIF2\u03b1", "PROTEIN", 61, 66], ["PERK arm", "PROTEIN", 109, 117], ["increased phosphorylation of eIF2\u03b1", "PROBLEM", 32, 66], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["phosphorylation", "OBSERVATION", 42, 57], ["indicative of", "UNCERTAINTY", 77, 90], ["PERK arm", "ANATOMY", 109, 117]]], ["The activation of downstream effectors such as ATF4 and CHOP indicates yet another mechanism through which the 3a protein can be pro-apoptotic.", [["ATF4", "GENE_OR_GENE_PRODUCT", 47, 51], ["CHOP", "GENE_OR_GENE_PRODUCT", 56, 60], ["3a", "GENE_OR_GENE_PRODUCT", 111, 113], ["downstream effectors", "PROTEIN", 18, 38], ["ATF4", "PROTEIN", 47, 51], ["CHOP", "PROTEIN", 56, 60], ["downstream effectors", "TREATMENT", 18, 38], ["ATF4 and CHOP", "TREATMENT", 47, 60], ["downstream effectors", "OBSERVATION", 18, 38]]], ["Since the p38 MAPK inhibitor SB203580 showed no significant effect on transcriptional activation of the CHOP promoter in 3a expressing cells, the p38 MAPK pathway is not likely to mediate these effects of the 3a protein.", [["cells", "ANATOMY", 135, 140], ["SB203580", "CHEMICAL", 29, 37], ["SB203580", "CHEMICAL", 29, 37], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 10, 18], ["SB203580", "SIMPLE_CHEMICAL", 29, 37], ["CHOP", "GENE_OR_GENE_PRODUCT", 104, 108], ["cells", "CELL", 135, 140], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 146, 154], ["p38 MAPK", "PROTEIN", 10, 18], ["CHOP promoter", "DNA", 104, 117], ["3a expressing cells", "CELL_TYPE", 121, 140], ["p38", "PROTEIN", 146, 149], ["MAPK", "PROTEIN", 150, 154], ["3a protein", "PROTEIN", 209, 219], ["the p38 MAPK inhibitor SB203580", "TEST", 6, 37], ["significant effect", "PROBLEM", 48, 66], ["the CHOP promoter", "TREATMENT", 100, 117], ["the p38 MAPK pathway", "TEST", 142, 162], ["no", "UNCERTAINTY", 45, 47], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["not likely", "UNCERTAINTY", 166, 176]]], ["Overall, our results show that 3a-expressing cells respond to ER stress by activation of the PERK pathway, which enhances protein folding in the ER instead of activating ERAD, the latter being detrimental to virion biosynthesis.", [["cells", "ANATOMY", 45, 50], ["ER", "ANATOMY", 145, 147], ["cells", "CELL", 45, 50], ["ER", "GENE_OR_GENE_PRODUCT", 62, 64], ["PERK", "GENE_OR_GENE_PRODUCT", 93, 97], ["ER", "GENE_OR_GENE_PRODUCT", 145, 147], ["ERAD", "GENE_OR_GENE_PRODUCT", 170, 174], ["3a-expressing cells", "CELL_LINE", 31, 50], ["ER", "PROTEIN", 62, 64], ["PERK", "PROTEIN", 93, 97], ["ER", "PROTEIN", 145, 147], ["ERAD", "PROTEIN", 170, 174], ["3a-expressing cells", "PROBLEM", 31, 50], ["the PERK pathway", "TEST", 89, 105], ["protein folding", "PROBLEM", 122, 137], ["activating ERAD", "PROBLEM", 159, 174], ["virion biosynthesis", "TREATMENT", 208, 227], ["protein folding", "OBSERVATION", 122, 137], ["virion biosynthesis", "OBSERVATION", 208, 227]]], ["However, prolonged PERK activation would lead to apoptosis.DiscussionSince our approach was based on transient transfection, it was important to rule out ER stress effects simply due to over-expression of the SARS-CoV 3a protein.", [["PERK", "GENE_OR_GENE_PRODUCT", 19, 23], ["ER", "GENE_OR_GENE_PRODUCT", 154, 156], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 209, 219], ["PERK", "PROTEIN", 19, 23], ["ER", "PROTEIN", 154, 156], ["SARS-CoV 3a protein", "PROTEIN", 209, 228], ["SARS-CoV", "SPECIES", 209, 217], ["prolonged PERK activation", "PROBLEM", 9, 34], ["apoptosis", "PROBLEM", 49, 58], ["ER stress effects", "PROBLEM", 154, 171], ["the SARS", "PROBLEM", 205, 213]]], ["Therefore other viral proteins were also tested for upstream (grp78 promoter activation) and downstream (ATF4, CHOP) markers of ER stress.", [["grp78", "GENE_OR_GENE_PRODUCT", 62, 67], ["ATF4", "GENE_OR_GENE_PRODUCT", 105, 109], ["CHOP", "GENE_OR_GENE_PRODUCT", 111, 115], ["ER", "GENE_OR_GENE_PRODUCT", 128, 130], ["viral proteins", "PROTEIN", 16, 30], ["grp78 promoter", "DNA", 62, 76], ["ATF4", "PROTEIN", 105, 109], ["CHOP", "PROTEIN", 111, 115], ["ER", "PROTEIN", 128, 130], ["other viral proteins", "TEST", 10, 30], ["downstream (ATF4, CHOP", "TREATMENT", 93, 115], ["ER stress", "PROBLEM", 128, 137]]], ["The HIV-1 Vpu protein being a type I transmembrane protein [59] caused grp78 promoter activation but it did not significantly affect downstream effectors of the PERK pathway.", [["HIV-1", "ORGANISM", 4, 9], ["Vpu", "GENE_OR_GENE_PRODUCT", 10, 13], ["type I transmembrane protein [59]", "GENE_OR_GENE_PRODUCT", 30, 63], ["grp78", "GENE_OR_GENE_PRODUCT", 71, 76], ["PERK", "GENE_OR_GENE_PRODUCT", 161, 165], ["HIV-1 Vpu protein", "PROTEIN", 4, 21], ["type I transmembrane protein", "PROTEIN", 30, 58], ["grp78 promoter", "DNA", 71, 85], ["PERK", "PROTEIN", 161, 165], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["The HIV", "TEST", 0, 7], ["Vpu protein", "TEST", 10, 21], ["transmembrane protein", "TEST", 37, 58], ["grp78 promoter activation", "PROBLEM", 71, 96]]], ["The HIV-1 Nef protein, a membrane-anchored protein also did not show any significant effects on ER stress.", [["membrane", "ANATOMY", 25, 33], ["HIV-1", "ORGANISM", 4, 9], ["Nef", "GENE_OR_GENE_PRODUCT", 10, 13], ["membrane", "CELLULAR_COMPONENT", 25, 33], ["ER", "GENE_OR_GENE_PRODUCT", 96, 98], ["HIV-1 Nef protein", "PROTEIN", 4, 21], ["membrane-anchored protein", "PROTEIN", 25, 50], ["ER", "PROTEIN", 96, 98], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["The HIV", "TEST", 0, 7], ["Nef protein", "TEST", 10, 21], ["a membrane-anchored protein", "TEST", 23, 50], ["ER stress", "PROBLEM", 96, 105]]], ["The HBV X protein has been shown to cause ER stress [60]; in our studies it caused mild activation of ATF4 and CHOP.", [["HBV X", "GENE_OR_GENE_PRODUCT", 4, 9], ["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["ATF4", "GENE_OR_GENE_PRODUCT", 102, 106], ["CHOP", "GENE_OR_GENE_PRODUCT", 111, 115], ["HBV X protein", "PROTEIN", 4, 17], ["ER", "PROTEIN", 42, 44], ["ATF4", "PROTEIN", 102, 106], ["CHOP", "PROTEIN", 111, 115], ["HBV", "SPECIES", 4, 7], ["The HBV X protein", "TEST", 0, 17], ["our studies", "TEST", 61, 72], ["mild activation of ATF4", "PROBLEM", 83, 106], ["CHOP", "TREATMENT", 111, 115], ["mild", "OBSERVATION_MODIFIER", 83, 87]]], ["Finally, the HEV Orf3 protein, which associates with cytoskeletal and mebrane fractions [61], showed a reduction in ER stress measured through the transcriptional activation of grp78 and to a lesser extent that of CHOP.", [["cytoskeletal", "ANATOMY", 53, 65], ["HEV", "ORGANISM", 13, 16], ["Orf3", "GENE_OR_GENE_PRODUCT", 17, 21], ["cytoskeletal", "CELLULAR_COMPONENT", 53, 65], ["ER", "GENE_OR_GENE_PRODUCT", 116, 118], ["grp78", "GENE_OR_GENE_PRODUCT", 177, 182], ["CHOP", "GENE_OR_GENE_PRODUCT", 214, 218], ["HEV Orf3 protein", "PROTEIN", 13, 29], ["ER", "PROTEIN", 116, 118], ["grp78", "PROTEIN", 177, 182], ["CHOP", "PROTEIN", 214, 218], ["HEV", "SPECIES", 13, 16], ["the HEV Orf3 protein", "TEST", 9, 29], ["cytoskeletal and mebrane fractions", "PROBLEM", 53, 87], ["a reduction in ER stress", "PROBLEM", 101, 125], ["reduction", "OBSERVATION_MODIFIER", 103, 112], ["lesser extent", "OBSERVATION_MODIFIER", 192, 205]]], ["Interestingly, another protein of this virus, the Orf2 protein, was earlier shown to cause ER stress [62].", [["Orf2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["Orf2 protein", "PROTEIN", 50, 62], ["ER", "PROTEIN", 91, 93], ["this virus", "PROBLEM", 34, 44], ["the Orf2 protein", "TEST", 46, 62]]], ["Thus, our results clearly show specific activation of ER stress and the PERK signaling pathway by the SARS-CoV 3a protein.DiscussionThe co-evolution of viruses with their hosts has also led to viral evasion strategies, including those that limit the effects of innate and adaptive immunity [63].", [["ER", "GENE_OR_GENE_PRODUCT", 54, 56], ["PERK", "GENE_OR_GENE_PRODUCT", 72, 76], ["SARS-CoV 3a", "GENE_OR_GENE_PRODUCT", 102, 113], ["ER", "PROTEIN", 54, 56], ["PERK", "PROTEIN", 72, 76], ["SARS-CoV 3a protein", "PROTEIN", 102, 121], ["SARS-CoV", "SPECIES", 102, 110], ["ER stress", "PROBLEM", 54, 63], ["the SARS", "TEST", 98, 106], ["viruses", "PROBLEM", 152, 159], ["viral evasion strategies", "TREATMENT", 193, 217], ["viruses", "OBSERVATION", 152, 159]]], ["An important innate response following viral infection is the synthesis and action of interferons [64].", [["viral infection", "DISEASE", 39, 54], ["interferons", "PROTEIN", 86, 97], ["viral infection", "PROBLEM", 39, 54], ["viral", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 45, 54]]], ["Interferons (IFN) are synthesized and secreted by infected cells, and act on neighboring cells to elicit a variety of protective responses that limit the further spread of viral infection [64].", [["cells", "ANATOMY", 59, 64], ["cells", "ANATOMY", 89, 94], ["viral infection", "DISEASE", 172, 187], ["Interferons", "GENE_OR_GENE_PRODUCT", 0, 11], ["IFN", "GENE_OR_GENE_PRODUCT", 13, 16], ["cells", "CELL", 59, 64], ["cells", "CELL", 89, 94], ["Interferons", "PROTEIN", 0, 11], ["IFN", "PROTEIN", 13, 16], ["infected cells", "CELL_TYPE", 50, 64], ["neighboring cells", "CELL_TYPE", 77, 94], ["Interferons (IFN)", "TREATMENT", 0, 17], ["infected cells", "PROBLEM", 50, 64], ["viral infection", "PROBLEM", 172, 187], ["infected cells", "OBSERVATION", 50, 64], ["viral", "OBSERVATION_MODIFIER", 172, 177], ["infection", "OBSERVATION", 178, 187]]], ["For interferons to act on cells, they must first bind their cognate receptors on the cell surface [65], [66].", [["cells", "ANATOMY", 26, 31], ["cell surface", "ANATOMY", 85, 97], ["cells", "CELL", 26, 31], ["cell", "CELL", 85, 89], ["interferons", "PROTEIN", 4, 15], ["cognate receptors", "PROTEIN", 60, 77], ["interferons to act on cells", "TREATMENT", 4, 31]]], ["Not surprisingly, therefore, one viral evasion mechanism is down regulation of the IFN receptor.", [["IFN receptor", "GENE_OR_GENE_PRODUCT", 83, 95], ["IFN receptor", "PROTEIN", 83, 95], ["one viral evasion mechanism", "PROBLEM", 29, 56], ["the IFN receptor", "TREATMENT", 79, 95]]], ["Recently, ligand-independent downregulation of type I IFN signaling was observed in virus-infected cells [31].", [["cells", "ANATOMY", 99, 104], ["type I IFN", "GENE_OR_GENE_PRODUCT", 47, 57], ["cells", "CELL", 99, 104], ["type I IFN", "PROTEIN", 47, 57], ["type I IFN signaling", "PROBLEM", 47, 67], ["infected cells", "PROBLEM", 90, 104], ["infected cells", "OBSERVATION", 90, 104]]], ["This involved PERK activation during UPR causing the phosphorylation-dependent ubiquitination and degradation of IFNAR1.", [["PERK", "GENE_OR_GENE_PRODUCT", 14, 18], ["UPR", "GENE_OR_GENE_PRODUCT", 37, 40], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 113, 119], ["PERK", "PROTEIN", 14, 18], ["UPR", "PROTEIN", 37, 40], ["IFNAR1", "PROTEIN", 113, 119], ["PERK activation", "PROBLEM", 14, 29], ["the phosphorylation", "PROBLEM", 49, 68], ["dependent ubiquitination", "PROBLEM", 69, 93], ["IFNAR1", "PROBLEM", 113, 119], ["PERK activation", "OBSERVATION", 14, 29]]], ["Since the 3a protein also activated PERK and its downstream effectors, we tested the effects of this viral protein on IFNAR1.", [["PERK", "GENE_OR_GENE_PRODUCT", 36, 40], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 118, 124], ["PERK", "PROTEIN", 36, 40], ["viral protein", "PROTEIN", 101, 114], ["IFNAR1", "PROTEIN", 118, 124], ["this viral protein on IFNAR1", "TREATMENT", 96, 124]]], ["Our results showed ligand (IFN)-independent phosphorylation and ubiquitination of IFNAR1 in 3a expressing cells, increased translocation of IFNAR1 to the lysosomal compartment for degradation and reduced levels in these cells.DiscussionThe hepatitis C virus (HCV) expresses viral proteins that cause ER stress [67], and HCV-induced UPR promotes IFNAR1 phosphorylation, ubiquitination and downregulation [31].", [["cells", "ANATOMY", 106, 111], ["lysosomal compartment", "ANATOMY", 154, 175], ["cells", "ANATOMY", 220, 225], ["hepatitis C", "DISEASE", 240, 251], ["IFN", "GENE_OR_GENE_PRODUCT", 27, 30], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 82, 88], ["cells", "CELL", 106, 111], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 140, 146], ["lysosomal compartment", "CELLULAR_COMPONENT", 154, 175], ["cells", "CELL", 220, 225], ["hepatitis C virus", "ORGANISM", 240, 257], ["HCV", "ORGANISM", 259, 262], ["ER", "GENE_OR_GENE_PRODUCT", 300, 302], ["HCV", "ORGANISM", 320, 323], ["UPR", "GENE_OR_GENE_PRODUCT", 332, 335], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 345, 351], ["IFN", "PROTEIN", 27, 30], ["IFNAR1", "PROTEIN", 82, 88], ["3a expressing cells", "CELL_TYPE", 92, 111], ["IFNAR1", "PROTEIN", 140, 146], ["viral proteins", "PROTEIN", 274, 288], ["ER", "PROTEIN", 300, 302], ["UPR", "PROTEIN", 332, 335], ["IFNAR1", "PROTEIN", 345, 351], ["hepatitis C virus", "SPECIES", 240, 257], ["hepatitis C virus", "SPECIES", 240, 257], ["HCV", "SPECIES", 259, 262], ["HCV", "SPECIES", 320, 323], ["ligand (IFN)", "PROBLEM", 19, 31], ["IFNAR1", "PROBLEM", 82, 88], ["increased translocation of IFNAR1", "PROBLEM", 113, 146], ["reduced levels in these cells", "PROBLEM", 196, 225], ["The hepatitis C virus", "PROBLEM", 236, 257], ["viral proteins", "PROBLEM", 274, 288], ["ER stress", "PROBLEM", 300, 309], ["HCV", "PROBLEM", 320, 323], ["downregulation", "TEST", 388, 402], ["increased", "OBSERVATION_MODIFIER", 113, 122]]], ["The vesicular stomatitis virus (VSV) also evokes a similar response [31].", [["vesicular stomatitis", "DISEASE", 4, 24], ["vesicular stomatitis virus", "ORGANISM", 4, 30], ["VSV", "ORGANISM", 32, 35], ["vesicular stomatitis virus", "SPECIES", 4, 30], ["stomatitis virus", "SPECIES", 14, 30], ["VSV", "SPECIES", 32, 35], ["The vesicular stomatitis virus", "PROBLEM", 0, 30], ["vesicular stomatitis virus", "OBSERVATION", 4, 30]]], ["Our results suggest that the SARS-CoV 3a protein might specifically inhibit type I IFN signaling and antiviral defenses thereby making 3a expressing or virus-infected cells less sensitive to IFN\u03b1.", [["cells", "ANATOMY", 167, 172], ["SARS", "DISEASE", 29, 33], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 29, 39], ["type I IFN", "GENE_OR_GENE_PRODUCT", 76, 86], ["cells", "CELL", 167, 172], ["IFN", "PROTEIN", 83, 86], ["virus-infected cells", "CELL_TYPE", 152, 172], ["IFN", "PROTEIN", 191, 194], ["SARS-CoV", "SPECIES", 29, 37], ["the SARS-CoV", "PROBLEM", 25, 37], ["type I IFN signaling", "PROBLEM", 76, 96], ["antiviral defenses", "PROBLEM", 101, 119], ["virus", "PROBLEM", 152, 157], ["infected cells", "PROBLEM", 158, 172]]], ["Interestingly, the treatment of SARS patients with only IFN\u03b1 is also reported to have shown low efficacy during the 2003 outbreak [68].DiscussionWe propose here that the 3a protein of SARS-CoV induces degradation of IFNAR1 and elicits apoptotic conditions by transcriptional upregulation of CHOP through differential activation of the PERK arm of UPR.", [["SARS", "DISEASE", 32, 36], ["SARS", "DISEASE", 184, 188], ["patients", "ORGANISM", 37, 45], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 56, 60], ["SARS-CoV", "ORGANISM", 184, 192], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 216, 222], ["CHOP", "GENE_OR_GENE_PRODUCT", 291, 295], ["PERK", "GENE_OR_GENE_PRODUCT", 335, 339], ["UPR", "GENE_OR_GENE_PRODUCT", 347, 350], ["IFN\u03b1", "PROTEIN", 56, 60], ["IFNAR1", "PROTEIN", 216, 222], ["CHOP", "PROTEIN", 291, 295], ["PERK", "PROTEIN", 335, 339], ["UPR", "PROTEIN", 347, 350], ["patients", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 184, 192], ["SARS", "PROBLEM", 32, 36], ["low efficacy", "PROBLEM", 92, 104], ["SARS", "PROBLEM", 184, 188], ["IFNAR1", "PROBLEM", 216, 222], ["apoptotic conditions", "TREATMENT", 235, 255], ["transcriptional upregulation of CHOP", "TREATMENT", 259, 295], ["low efficacy", "OBSERVATION_MODIFIER", 92, 104]]], ["Further studies are needed, especially in an animal model of disease, to confirm the extent of these effects in SARS-CoV pathogenesis.Materials, Plasmids and Primers ::: Materials and MethodsAll common reagents were from Sigma Chemical Co. (St. Louis, MO, USA) unless stated otherwise.", [["SARS", "DISEASE", 112, 116], ["SARS-CoV", "ORGANISM", 112, 120], ["St. Louis", "ORGANISM", 241, 250], ["SARS-CoV", "SPECIES", 112, 120], ["Further studies", "TEST", 0, 15], ["disease", "PROBLEM", 61, 68], ["SARS", "PROBLEM", 112, 116], ["CoV pathogenesis", "PROBLEM", 117, 133], ["disease", "OBSERVATION", 61, 68], ["SARS", "OBSERVATION", 112, 116]]], ["COS-1 and Vero cells were obtained from American Type Culture Collection (Manassas, Va, USA), and Huh7 cells were from Dr. J. Sato, Okayama University, Japan.", [["COS-1", "ANATOMY", 0, 5], ["Vero cells", "ANATOMY", 10, 20], ["Huh7 cells", "ANATOMY", 98, 108], ["COS-1", "CELL", 0, 5], ["Vero cells", "CELL", 10, 20], ["Huh7 cells", "CELL", 98, 108], ["COS-1 and Vero cells", "CELL_LINE", 0, 20], ["Huh7 cells", "CELL_LINE", 98, 108], ["COS", "TEST", 0, 3], ["Vero cells", "PROBLEM", 10, 20], ["American Type Culture Collection", "TEST", 40, 72], ["Huh7 cells", "PROBLEM", 98, 108], ["Huh7 cells", "OBSERVATION", 98, 108]]], ["All cell lines were cultured at 37\u00b0C in 10% CO2 in complete Dulbecco modified Eagle medium (DMEM containing 1 g/lit glucose, 2 mM L-glutamine, 1.5 g/lit sodium bicarbonate, 0.1 mM non-essential amino acids, 0.1 mg/ml streptomycin, 100 U penicillin) and 5% fetal bovine serum (FBS).", [["cell lines", "ANATOMY", 4, 14], ["fetal bovine serum", "ANATOMY", 256, 274], ["FBS", "ANATOMY", 276, 279], ["CO2", "CHEMICAL", 44, 47], ["glucose", "CHEMICAL", 116, 123], ["L-glutamine", "CHEMICAL", 130, 141], ["sodium bicarbonate", "CHEMICAL", 153, 171], ["amino acids", "CHEMICAL", 194, 205], ["streptomycin", "CHEMICAL", 217, 229], ["penicillin", "CHEMICAL", 237, 247], ["CO2", "CHEMICAL", 44, 47], ["glucose", "CHEMICAL", 116, 123], ["L-glutamine", "CHEMICAL", 130, 141], ["sodium bicarbonate", "CHEMICAL", 153, 171], ["amino acids", "CHEMICAL", 194, 205], ["streptomycin", "CHEMICAL", 217, 229], ["penicillin", "CHEMICAL", 237, 247], ["cell lines", "CELL", 4, 14], ["CO2", "SIMPLE_CHEMICAL", 44, 47], ["glucose", "SIMPLE_CHEMICAL", 116, 123], ["L-glutamine", "SIMPLE_CHEMICAL", 130, 141], ["sodium", "SIMPLE_CHEMICAL", 153, 159], ["bicarbonate", "SIMPLE_CHEMICAL", 160, 171], ["amino acids", "AMINO_ACID", 194, 205], ["streptomycin", "SIMPLE_CHEMICAL", 217, 229], ["penicillin", "SIMPLE_CHEMICAL", 237, 247], ["bovine", "ORGANISM", 262, 268], ["serum", "ORGANISM_SUBSTANCE", 269, 274], ["FBS", "ORGANISM_SUBSTANCE", 276, 279], ["cell lines", "CELL_LINE", 4, 14], ["bovine", "SPECIES", 262, 268], ["bovine", "SPECIES", 262, 268], ["All cell lines", "TREATMENT", 0, 14], ["glucose", "TEST", 116, 123], ["2 mM L-glutamine", "TREATMENT", 125, 141], ["sodium bicarbonate", "TREATMENT", 153, 171], ["mM non-essential amino acids", "TREATMENT", 177, 205], ["streptomycin", "TREATMENT", 217, 229], ["100 U penicillin", "TREATMENT", 231, 247], ["5% fetal bovine serum (FBS", "TREATMENT", 253, 279], ["cell lines", "OBSERVATION", 4, 14]]], ["Antibodies generated against a recombinant 3a protein have been described previously [69].", [["recombinant 3a protein", "PROTEIN", 31, 53], ["Antibodies", "TEST", 0, 10], ["a recombinant 3a protein", "TREATMENT", 29, 53]]], ["The ATF6 and IRE-1\u03b1 reagents were kindly provided by Ron Prywes, Columbia University, New York [70], the ATF4 and eIF2\u03b1 reagents were from David Ron, NYU Medical Center, New York, the pCHOP-Luc reporter plasmid containing human C/EBP homologous protein (CHOP) promoter was from Nai Sum Wong, Faculty of Medicine, University of Hong Kong [71], and the pGRP78-Luc and pGRP94-Luc reporter constructs were from Kazutoshi Mori, Kyoto University, Japan [72].", [["ATF6", "GENE_OR_GENE_PRODUCT", 4, 8], ["IRE-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["ATF4", "GENE_OR_GENE_PRODUCT", 105, 109], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 114, 119], ["human", "ORGANISM", 222, 227], ["C/EBP homologous protein", "GENE_OR_GENE_PRODUCT", 228, 252], ["CHOP", "GENE_OR_GENE_PRODUCT", 254, 258], ["pGRP78", "GENE_OR_GENE_PRODUCT", 351, 357], ["Luc", "GENE_OR_GENE_PRODUCT", 358, 361], ["pGRP94", "GENE_OR_GENE_PRODUCT", 366, 372], ["ATF6", "PROTEIN", 4, 8], ["IRE", "PROTEIN", 13, 16], ["ATF4", "PROTEIN", 105, 109], ["eIF2\u03b1", "PROTEIN", 114, 119], ["pCHOP-Luc reporter plasmid", "DNA", 184, 210], ["human C/EBP homologous protein (CHOP) promoter", "DNA", 222, 268], ["pGRP78-Luc and pGRP94-Luc reporter constructs", "DNA", 351, 396], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 222, 227], ["The ATF6", "TEST", 0, 8], ["IRE", "TEST", 13, 16], ["the pCHOP", "TREATMENT", 180, 189], ["Luc reporter plasmid", "TREATMENT", 190, 210], ["human C/EBP homologous protein (CHOP) promoter", "TREATMENT", 222, 268]]], ["Antibodies to phospho-eIF2\u03b1 and eIF2\u03b1 were from Cell Signaling Technology and the IFNAR1 and anti-Ubiquitin antibodies were from Santa Cruz Biotechnology.", [["Cell", "ANATOMY", 48, 52], ["phospho-eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 14, 27], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 32, 37], ["Cell", "CELL", 48, 52], ["IFNAR1", "GENE_OR_GENE_PRODUCT", 82, 88], ["anti-Ubiquitin antibodies", "GENE_OR_GENE_PRODUCT", 93, 118], ["phospho-eIF2\u03b1", "PROTEIN", 14, 27], ["eIF2\u03b1", "PROTEIN", 32, 37], ["IFNAR1", "PROTEIN", 82, 88], ["anti-Ubiquitin antibodies", "PROTEIN", 93, 118], ["Santa Cruz Biotechnology", "PROTEIN", 129, 153], ["Antibodies", "TEST", 0, 10], ["phospho-eIF2", "TEST", 14, 26], ["the IFNAR1", "TEST", 78, 88]]], ["The cloning of orf3a and construction of the pSGI-3a-HA and p3a-ECFP expression vectors has been described previously [69].", [["orf3a", "GENE_OR_GENE_PRODUCT", 15, 20], ["pSGI-3a-HA", "GENE_OR_GENE_PRODUCT", 45, 55], ["p3a-ECFP", "GENE_OR_GENE_PRODUCT", 60, 68], ["orf3a", "DNA", 15, 20], ["pSGI-3a-HA and p3a-ECFP expression vectors", "DNA", 45, 87], ["the pSGI", "TEST", 41, 49], ["HA and p3a-ECFP expression vectors", "TREATMENT", 53, 87]]], ["The cloning of other viral proteins like Nef [73], Vpu [74], HEV Orf 3 [75] and HBV X [76] has been described elsewhere.", [["Nef [73]", "GENE_OR_GENE_PRODUCT", 41, 49], ["Vpu", "GENE_OR_GENE_PRODUCT", 51, 54], ["HEV Orf 3", "GENE_OR_GENE_PRODUCT", 61, 70], ["viral proteins", "PROTEIN", 21, 35], ["Nef", "PROTEIN", 41, 44], ["Vpu", "PROTEIN", 51, 54], ["other viral proteins", "TEST", 15, 35], ["Nef", "TEST", 41, 44], ["Vpu", "TEST", 51, 54], ["HEV Orf", "TEST", 61, 68], ["HBV X", "TEST", 80, 85]]], ["The primers for amplifying unspliced (u) and spliced (s) forms of XBP-1 transcripts were: 5\u2032-TTACGAG AGAAAACTCATGGC-3\u2032 and 5\u2032-GGGTCCAAGTTGTCCAGAATGC-3\u2032, and amplification was according to the protocol described elsewhere [77].", [["XBP-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["XBP", "PROTEIN", 66, 69], ["The primers", "TREATMENT", 0, 11], ["XBP", "TEST", 66, 69], ["AGAAAACTCATGGC", "TEST", 101, 115], ["GGGTCCAAGTTGTCCAGAATGC", "TEST", 126, 148]]], ["Histone transcripts were amplified with the primers 5\u2032-TGAGAGACAACATTCAGGGCATCAC -3\u2032 and 5\u2032-CGCTTGAGCGCGTACACCACATCCAT-3\u2032.Transfection and Immunoblotting ::: Materials and MethodsTranfections were done with the Fugene 6 reagent (Roche, Mannheim, Germany) according to the manufacturer's instructions.", [["Histone", "GENE_OR_GENE_PRODUCT", 0, 7], ["Histone transcripts", "PROBLEM", 0, 19], ["the primers", "TREATMENT", 40, 51], ["TGAGAGACAACATTCAGGGCATCAC", "TEST", 55, 80], ["CGCTTGAGCGCGTACACCACATCCAT", "TEST", 92, 118], ["MethodsTranfections", "TEST", 172, 191]]], ["At the indicated times post-transfection, cells were scraped, lysed and processed as described previously [7].", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47]]], ["The protein concentration of the lysate was estimated using Bradford regeant (Bio-Rad), and immunoblotting was carried out as described previously [69].Luciferase Reporter Assays ::: Materials and MethodsTransfected cells were harvested after 48 hrs and lysed in the cell lysis buffer (Luciferase Assay Kit; Promega, Madison, WI, USA).", [["lysate", "ANATOMY", 33, 39], ["cells", "ANATOMY", 216, 221], ["cell", "ANATOMY", 267, 271], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 78, 85], ["cells", "CELL", 216, 221], ["cell", "CELL", 267, 271], ["The protein concentration", "TREATMENT", 0, 25], ["the lysate", "TREATMENT", 29, 39], ["immunoblotting", "TEST", 92, 106], ["MethodsTransfected cells", "TREATMENT", 197, 221], ["the cell lysis buffer", "TREATMENT", 263, 284]]], ["Normalized cell lysates were analyzed for luciferase activity according to the supplier's protocol and readings were taken on a luminometer (Sirius, Berthold, Germany).Immunoprecipitation ::: Materials and MethodsTransfected cells were lysed in a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM NaF, 1 mM sodium orthovandate and a protease inhibitor cocktail (Roche, Mannheim, Germany).", [["cell lysates", "ANATOMY", 11, 23], ["cells", "ANATOMY", 225, 230], ["Tris-HCl", "CHEMICAL", 271, 279], ["NaCl", "CHEMICAL", 296, 300], ["EGTA", "CHEMICAL", 318, 322], ["Triton X-100", "CHEMICAL", 327, 339], ["NaF", "CHEMICAL", 346, 349], ["sodium orthovandate", "CHEMICAL", 356, 375], ["Tris", "CHEMICAL", 271, 275], ["HCl", "CHEMICAL", 276, 279], ["NaCl", "CHEMICAL", 296, 300], ["EDTA", "CHEMICAL", 307, 311], ["EGTA", "CHEMICAL", 318, 322], ["Triton X-100", "CHEMICAL", 327, 339], ["NaF", "CHEMICAL", 346, 349], ["sodium orthovandate", "CHEMICAL", 356, 375], ["cell lysates", "CELL", 11, 23], ["luciferase", "GENE_OR_GENE_PRODUCT", 42, 52], ["cells", "CELL", 225, 230], ["Tris-HCl", "SIMPLE_CHEMICAL", 271, 279], ["EDTA", "SIMPLE_CHEMICAL", 307, 311], ["EGTA", "SIMPLE_CHEMICAL", 318, 322], ["Triton X-100", "SIMPLE_CHEMICAL", 327, 339], ["NaF", "SIMPLE_CHEMICAL", 346, 349], ["sodium orthovandate", "SIMPLE_CHEMICAL", 356, 375], ["luciferase", "PROTEIN", 42, 52], ["Normalized cell lysates", "TREATMENT", 0, 23], ["luciferase activity", "TEST", 42, 61], ["the supplier's protocol", "TEST", 75, 98], ["MethodsTransfected cells", "TREATMENT", 206, 230], ["Tris", "TEST", 271, 275], ["pH", "TEST", 281, 283], ["NaCl", "TEST", 296, 300], ["EDTA", "TEST", 307, 311], ["EGTA", "TEST", 318, 322], ["1 mM sodium orthovandate", "TREATMENT", 351, 375], ["a protease inhibitor cocktail", "TREATMENT", 380, 409], ["cell lysates", "OBSERVATION", 11, 23]]], ["The lysates were clarified by centrifugation at 16,000\u00d7g for 20 min at 4\u00b0C. Protein quantitation was done by Bradford assay (Bio-Rad Laboratories).", [["lysates", "ANATOMY", 4, 11], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["The lysates", "TREATMENT", 0, 11], ["Protein quantitation", "TEST", 76, 96]]], ["For immunoprecipitation of phosphoprotein, 0.7 to 1 mg of total protein in 400\u2013500 \u00b5l lysis buffer was first incubated with 20 \u00b5l of Protein G-agarose beads (GE Healthcare, Uppsala, Sweden) for 1 hr at 4\u00b0C. The pre-cleared lysate was then incubated with 2 \u00b5g of the antibody overnight at 4\u00b0C, followed by 20 \u00b5l of equilibrated Protein G-agarose beads for 3 hr at 4\u00b0C. After washing five times in lysis buffer, the beads were boiled in Laemmli buffer, the proteins were separated by SDS-PAGE, followed by immunoblotting as described previously [69].Imunofluorescence and Subcellular Localization ::: Materials and MethodsFor transient transfection, cells were grown on coverslips to 40\u201350% confluence and transfected with Fugene 6 (Roche, Mannheim, Germany).", [["lysate", "ANATOMY", 223, 229], ["Subcellular", "ANATOMY", 570, 581], ["cells", "ANATOMY", 648, 653], ["cells", "CELL", 648, 653], ["phosphoprotein", "PROTEIN", 27, 41], ["immunoprecipitation of phosphoprotein", "PROBLEM", 4, 41], ["total protein", "TREATMENT", 58, 71], ["\u00b5l lysis buffer", "TREATMENT", 83, 98], ["Protein G-agarose beads", "TREATMENT", 133, 156], ["The pre-cleared lysate", "TREATMENT", 207, 229], ["the antibody", "TREATMENT", 262, 274], ["equilibrated Protein G-agarose beads", "TREATMENT", 314, 350], ["lysis buffer", "TREATMENT", 396, 408], ["the beads", "TREATMENT", 410, 419], ["Laemmli buffer", "TREATMENT", 435, 449], ["transient transfection, cells", "PROBLEM", 624, 653], ["coverslips", "TEST", 668, 678]]], ["Around 48 hr post-transfection, the cells were incubated with 100 nM Lysotracker (Molecular Probes, USA) in growth medium for 3 hr in dark, at 37\u00b0C in a 10% CO2 incubator.", [["cells", "ANATOMY", 36, 41], ["CO2", "CHEMICAL", 157, 160], ["Lysotracker", "CHEMICAL", 69, 80], ["CO2", "CHEMICAL", 157, 160], ["cells", "CELL", 36, 41], ["Lysotracker", "SIMPLE_CHEMICAL", 69, 80], ["CO2", "SIMPLE_CHEMICAL", 157, 160], ["a 10% CO2 incubator", "TREATMENT", 151, 170]]], ["The cells were then washed with PBS and fixed with 2% paraformaldehyde for 15 min at room temperature.", [["cells", "ANATOMY", 4, 9], ["paraformaldehyde", "CHEMICAL", 54, 70], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 54, 70], ["PBS", "TREATMENT", 32, 35], ["2% paraformaldehyde", "TREATMENT", 51, 70]]], ["For antibody staining, cells were permeabilized with 0.4% saponin for 15 min at room temperature, blocked with PBS containing 5% bovine serum albumin (BSA) for 30 min and then incubated with a 1\u223650 dilution of the primary antibody in PBS containing 5% BSA for 1 hr at room temperature.", [["cells", "ANATOMY", 23, 28], ["serum", "ANATOMY", 136, 141], ["saponin", "CHEMICAL", 58, 65], ["BSA", "CHEMICAL", 252, 255], ["saponin", "CHEMICAL", 58, 65], ["cells", "CELL", 23, 28], ["saponin", "SIMPLE_CHEMICAL", 58, 65], ["bovine", "ORGANISM", 129, 135], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["albumin", "SIMPLE_CHEMICAL", 142, 149], ["BSA", "SIMPLE_CHEMICAL", 151, 154], ["BSA", "SIMPLE_CHEMICAL", 252, 255], ["primary antibody", "PROTEIN", 214, 230], ["bovine", "SPECIES", 129, 135], ["antibody staining", "TEST", 4, 21], ["cells", "TEST", 23, 28], ["0.4% saponin", "TREATMENT", 53, 65], ["PBS", "TREATMENT", 111, 114], ["5% bovine serum albumin", "TREATMENT", 126, 149], ["BSA", "TEST", 151, 154], ["a 1\u223650 dilution", "TREATMENT", 191, 206], ["the primary antibody in PBS", "TREATMENT", 210, 237], ["5% BSA", "TREATMENT", 249, 255]]], ["The cells were washed thrice for 5 min each with PBS and then incubated with a 1\u2236500 dilution of the relevant Alexa 647 conjugated secondary antibody (Molecular Probes, USA) in PBS containing 5% BSA for 1 hr.", [["cells", "ANATOMY", 4, 9], ["BSA", "CHEMICAL", 195, 198], ["Alexa 647", "CHEMICAL", 110, 119], ["cells", "CELL", 4, 9], ["Alexa 647", "SIMPLE_CHEMICAL", 110, 119], ["BSA", "SIMPLE_CHEMICAL", 195, 198], ["Alexa 647 conjugated secondary antibody", "PROTEIN", 110, 149], ["PBS", "TREATMENT", 49, 52], ["a 1\u2236500 dilution", "TREATMENT", 77, 93], ["the relevant Alexa", "TREATMENT", 97, 115]]], ["The coverslips were mounted on slides with Antifade reagent (Bio-Rad, Hercules, USA) and sealed with a synthetic rubber-based adhesive (Fevicol; Pidilite Industries, India).", [["Fevicol", "CHEMICAL", 136, 143], ["The coverslips", "TREATMENT", 0, 14], ["Antifade reagent", "TREATMENT", 43, 59], ["a synthetic rubber-based adhesive (Fevicol", "TREATMENT", 101, 143]]], ["Imaging and analysis was done on a Nikon A1R confocal microscope.", [["Imaging", "TEST", 0, 7], ["analysis", "TEST", 12, 20]]], ["The Pearson coefficient for colocalization was calculated using the Nikon Elements Software.Flow Cytometry ::: Materials and MethodsHuh7 cells were transfected as above and 48 hr later the cells were washed twice with PBS.", [["MethodsHuh7 cells", "ANATOMY", 125, 142], ["cells", "ANATOMY", 189, 194], ["MethodsHuh7 cells", "CELL", 125, 142], ["cells", "CELL", 189, 194], ["Nikon Elements", "DNA", 68, 82], ["MethodsHuh7 cells", "CELL_LINE", 125, 142], ["MethodsHuh7 cells", "TREATMENT", 125, 142], ["PBS", "TREATMENT", 218, 221]]], ["Subsequently, 1.5 to1.8\u00d7106 cells were harvested in 1 mM EDTA in PBS for 1 min following by two washings with PBS.", [["to1.8\u00d7106 cells", "ANATOMY", 18, 33], ["EDTA", "CHEMICAL", 57, 61], ["EDTA", "CHEMICAL", 57, 61], ["cells", "CELL", 28, 33], ["EDTA", "SIMPLE_CHEMICAL", 57, 61], ["1 mM EDTA in PBS", "TREATMENT", 52, 68], ["PBS", "TREATMENT", 110, 113]]], ["The cells were fixed with 2% paraformaldehyde (PFA) for 20 min at 4\u00b0C, washed twice with PBS, then resuspended in permeabilization buffer (PB; 0.1% Saponin and 1% fetal calf serum in PBS) for 10 min at 4\u00b0C followed by two washings with PB.", [["cells", "ANATOMY", 4, 9], ["fetal calf serum", "ANATOMY", 163, 179], ["Saponin", "CHEMICAL", 148, 155], ["paraformaldehyde", "CHEMICAL", 29, 45], ["PFA", "CHEMICAL", 47, 50], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 29, 45], ["PFA", "SIMPLE_CHEMICAL", 47, 50], ["Saponin", "SIMPLE_CHEMICAL", 148, 155], ["calf", "ORGANISM", 169, 173], ["serum", "ORGANISM_SUBSTANCE", 174, 179], ["calf", "SPECIES", 169, 173], ["The cells", "TREATMENT", 0, 9], ["2% paraformaldehyde (PFA)", "TREATMENT", 26, 51], ["PBS", "TREATMENT", 89, 92], ["Saponin", "TREATMENT", 148, 155], ["1% fetal calf serum in PBS", "TREATMENT", 160, 186], ["PB", "TREATMENT", 236, 238]]], ["The cells were then incubated in PB containing 1\u223650 diluted rabbit anti-IFNAR1 for 30 min at 4\u00b0C. After washing twice with PB, the cells were incubated with 1\u2236100 diluted Alexa-488 conjugated anti-rabbit IgG (Molecular Probes, USA) for 30 min in dark at 4\u00b0C. Lastly, the cells were washed thrice with PB and kept in staining buffer (0.1% PFA, 1% FCS in PBS).", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 131, 136], ["cells", "ANATOMY", 271, 276], ["Alexa-488", "CHEMICAL", 171, 180], ["PFA", "CHEMICAL", 338, 341], ["cells", "CELL", 4, 9], ["rabbit", "ORGANISM", 60, 66], ["anti-IFNAR1", "SIMPLE_CHEMICAL", 67, 78], ["cells", "CELL", 131, 136], ["Alexa-488", "SIMPLE_CHEMICAL", 171, 180], ["cells", "CELL", 271, 276], ["PFA", "SIMPLE_CHEMICAL", 338, 341], ["anti-IFNAR1", "PROTEIN", 67, 78], ["Alexa-488 conjugated anti-rabbit IgG", "PROTEIN", 171, 207], ["rabbit", "SPECIES", 60, 66], ["anti-rabbit", "SPECIES", 192, 203], ["rabbit", "SPECIES", 60, 66], ["anti-rabbit", "SPECIES", 192, 203], ["diluted rabbit anti-IFNAR1", "TREATMENT", 52, 78], ["PB", "TREATMENT", 123, 125], ["diluted Alexa", "TREATMENT", 163, 176], ["conjugated anti-rabbit IgG", "TREATMENT", 181, 207], ["PB", "TREATMENT", 301, 303], ["1% FCS in PBS", "TREATMENT", 343, 356]]], ["For each sample, 25,000 events were acquired using a CyAn-ADP flow cytometer (Dako) and the data analyzed with Summit software (version 4.3).", [["ADP", "CHEMICAL", 58, 61], ["ADP", "CHEMICAL", 58, 61], ["ADP", "SIMPLE_CHEMICAL", 58, 61], ["a CyAn-ADP flow cytometer", "TEST", 51, 76], ["the data", "TEST", 88, 96], ["Summit software", "TEST", 111, 126]]], ["The cells were gated for ECFP or 3a-ECFP expression and Alexa-488 staining levels were determined in these cells.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 107, 112], ["Alexa-488", "CHEMICAL", 56, 65], ["cells", "CELL", 4, 9], ["ECFP", "GENE_OR_GENE_PRODUCT", 25, 29], ["3a-ECFP", "GENE_OR_GENE_PRODUCT", 33, 40], ["Alexa-488", "SIMPLE_CHEMICAL", 56, 65], ["cells", "CELL", 107, 112], ["ECFP", "PROTEIN", 36, 40], ["ECFP", "TEST", 25, 29], ["Alexa", "TEST", 56, 61], ["staining levels", "TEST", 66, 81]]], ["Expression levels (\u00b1SD) of IFNAR1 were calculated and the results were expressed as mean fluorescence intensity (MFI) values.", [["IFNAR1", "GENE_OR_GENE_PRODUCT", 27, 33], ["IFNAR1", "PROTEIN", 27, 33], ["Expression levels", "TEST", 0, 17], ["IFNAR1", "PROBLEM", 27, 33], ["mean fluorescence intensity", "TEST", 84, 111]]], ["The p values were calculated using Student's t-test with 95% confidence intervals.", [["The p values", "TEST", 0, 12], ["Student's t-test", "TEST", 35, 51]]]], "677b2ac7e842db35e264795e54c3e514f7f32ec1": [["However, each user's interest is differently distributed across multiple dimensions, and the consistency in one dimension does not mean consistency in other dimensions.", [["multiple dimensions", "OBSERVATION_MODIFIER", 64, 83]]], ["Therefore, a global scalar indicator used in existing methods cannot express the multifaceted interest correlations between friends.", [["a global scalar indicator", "PROBLEM", 11, 36]]], ["Unfortunately, there exists no explicit evidence to refine social networks into the elaborate correlation, and simply distinguishing items' categories would make the problem of data sparsity even more serious, which is not conducive to the learning of model parameters.IntroductionIn this paper, we propose a new embedding-based social recommendation method (Fig. 2) .", [["a new embedding", "TREATMENT", 307, 322], ["no explicit evidence to", "UNCERTAINTY", 28, 51]]], ["We propose to use a correlation vector, instead of a scalar value, to characterize the interest correlation between each pair of friends, and design a dimension-wise attention mechanism with the social network as input to learn it.", [["social network", "MULTI-TISSUE_STRUCTURE", 195, 209], ["a correlation vector", "TREATMENT", 18, 38], ["a scalar value", "TEST", 51, 65]]], ["The correlation vector has the same dimension with user's embedding, thus can sufficiently capture the high variation in users' interest correlations on each fine-grained dimension.", [["user's embedding", "TREATMENT", 51, 67], ["high variation", "OBSERVATION", 103, 117]]], ["The combination of the dimension-wise attention mechanism and the smoothing operation can impose strong and delicate unstructured correlations on users' embeddings while making interactions between users and items.", [["the smoothing operation", "TREATMENT", 62, 85]]], ["Although Yang et al. [28] integrate items' category information to train a matrix factorization model for each category of items, they make data too sparse to learn parameters, and they cannot utilize correlations among different categories.Related WorkAttention Mechanism has recently been used in recommendation tasks [15, 16, 24] .", [["a matrix factorization model", "TREATMENT", 73, 101]]], ["However, they still express users' interest correlation by a scalar value, which cannot sufficiently capture the high variation of users' interest correlation.Problem FormulationFor ease of description, we first formalize variables used and the problem dealt with in this paper.", [["a scalar value", "TEST", 59, 73]]], ["S u represents user u's friend set and S uv = 1(0) indicates whether there exists social relation between user u and user v. In our model, we learn a preference vector t u for each user u and a preference vector z i for each item I.Problem FormulationItem Recommendation: Given a set of users U with social relations S, a set of items I and U 's feedback over items I, item recommendation recommends for each target user u \u2208 U a list of items {i|i \u2208 I} consiting of items that the target user is potentially interested in and has not interacted with them up to the recommendation.Problem FormulationNext, we present the proposed Dimension-wise Attention model for Social Recommendation, i.e., DASR in Fig. 2 .Model ArchitectureUsers' interest is often differently distributed across multiple dimensions.", [["Model ArchitectureUsers'", "PROBLEM", 709, 733], ["ArchitectureUsers", "OBSERVATION", 715, 732], ["multiple", "OBSERVATION_MODIFIER", 783, 791], ["dimensions", "OBSERVATION_MODIFIER", 792, 802]]], ["Fortunately, attention mechanism seems to provide a feasible solution, since it can automatically models and selects pertinent piece of information with the attentive weights from a set of inputs, where higher (lower) weights indicate the corresponding inputs more informative to generate the outputs.", [["a feasible solution", "TREATMENT", 50, 69]]], ["Figure 2 shows the architecture of DASR, which includes an attention layer, a smoothing layer and a recommendation layer.", [["DASR", "OBSERVATION", 35, 39], ["layer", "OBSERVATION_MODIFIER", 69, 74]]], ["Instead of directly performing inner product between t u and z i in the recommendation layer, we first use embeddings of user u's friends to smooth user u's own embedding in the smoothing layer, and the smoothing weights are the correlation vector learned in the attention layer.", [["the smoothing weights", "TREATMENT", 199, 220]]], ["With these designs, we can learn strong and delicate unstructured correlations of users' embeddings in a fully data-driven manner and provide better item recommendation.Attention LayerWe input the embeddings of the target user u and users in his friend set S u to the attention layer, and compute the interest correlation vector between user u and each friend v.Attention LayerWe first use a weight matrix W a to perform self-attention on user u and friend v as follows:Attention Layerwhere t u and t v are embeddings of user u and friend v. T represents transposition and || denotes the concatenation operation.", [["the concatenation operation", "TREATMENT", 584, 611], ["operation", "OBSERVATION", 602, 611]]], ["LeakyReLU (x) = max(0, x) + \u03b2min(0, x) acts as non-linear activation function with \u03b2 as the negative slope. e uv is the attention coefficient that indicates the importance of friend v's features to user u.", [["LeakyReLU (x) = max(0, x) + \u03b2min", "CHEMICAL", 0, 32], ["\u03b2", "PROTEIN", 83, 84], ["LeakyReLU", "TEST", 0, 9], ["non-linear activation function", "TEST", 47, 77]]], ["To ensure that e uv can express the correlation of each dimension in user's embeddings, we design W a as a weight matrix with dimension 2d * d.Attention LayerFor user u, we get an interest correlation matrix C u , and each column of C u represents the correlation vector between user u and one of his friends.", [["a weight matrix with dimension", "TREATMENT", 105, 135]]], ["In this way, we can learn different patterns of each user's interest correlation, e.g., some users barely refer to their friends, while some users often refer to a few friends' suggestions, etc.Recommendation LayerIn the recommendation layer, we use user's smoothing embedding, i.e., h u , to make recommendation.Recommendation LayerDenote p ui as user u's preference to item i, and we compute p ui as follows:Recommendation Layerwhere z i denotes item i's embedding.", [["user's smoothing embedding", "TREATMENT", 250, 276]]], ["We define two types of objective functions according to the feedback type, including implicit feedback, e.g., users' check-in counts at POIs, and explicit feedback, e.g., users' rating scores to items.", [["objective functions", "PROBLEM", 23, 42], ["two types", "OBSERVATION_MODIFIER", 10, 19]]], ["For each positive feedback (u, i), we randomly select c negative samples from item set I with item i excluded and denote the set of negative samples as NEG(i).", [["samples", "ANATOMY", 141, 148]]], ["4, and take top n items as the recommendation list.DatasetsWe use two real-world datasets collected from Gowalla [20] and Epinions [12] respectively for evaluation.DatasetsGowalla is a Location-Based Social Network (LBSN), and we utilize users' check-in at Point-of-Interests (POIs) and the social network to make POI recommendation [19] .", [["evaluation", "TEST", 153, 163]]], ["The total number of users' friendship records is 86,985.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The total number of reviews is 664, 824.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The total number of issued trust statements is 487, 181.DatasetsFor each user u, we partition his feedback set into three parts, i.e., 70% as training data, 15% as validation data, and 15% as testing data.Evaluation MetricsTo evaluate the recommendation performance, we use two widely-used metrics on both datasets, namely, precision@n and recall@n, where n is the number of items in the recommendation list.", [["training data", "TEST", 142, 155], ["validation data", "TEST", 164, 179], ["testing data", "TEST", 192, 204], ["Evaluation", "TEST", 205, 215], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["They are computed as follows:Evaluation Metricswhere P n u is the set of top n items in user u's recommendation list, and T u is user u's ground truth set of items. |x| denotes the cardinality of set x.", [["Evaluation", "TEST", 29, 39]]], ["For each metric, we consider 4 values (i.e., 1, 5, 10, 20) of n in our experiments.Evaluation MetricsFor Epinions, we also evaluate the prediction on users' explicit rating scores with MAE, and it is computed as follows:Evaluation Metricswhere y ui is the true ratings given by user u for item i, and abs(\u00b7) is the absolute value function.BaselinesMany existing methods are available for POI recommendation, and it is impossible to list all of them as baselines.", [["Evaluation", "TEST", 83, 93], ["Evaluation", "TEST", 220, 230], ["POI recommendation", "TEST", 388, 406]]], ["The baselines include:Baselines-SoCF [3] : SoCF is a social-based collaborative filtering method, which recommend friends' visited items to users. -SoReg [11] : SoReg defines individual-based regularization with Pearson Correlation Coefficient (PCC) in traditional matrix factorization model.", [["Coefficient (PCC) in traditional matrix factorization model", "TREATMENT", 232, 291]]], ["The PCC-version regularization achieves the best performance, compared with other variants, as reported in [11] . -LOCABAL [17] : LOCABAL takes advantage of both local friends and users with high reputations for social recommendation. -PTPMF [22] : PTPMF is a probabilistic matrix factorization model that incorporates the distinction of strong and weak ties. -ASMF/ARMF [8] : ASMF and ARMF argument user-item matrix using friends' visited items as potential items.", [["PCC", "DNA", 4, 7], ["ASMF", "DNA", 361, 365], ["The PCC-version regularization", "TREATMENT", 0, 30], ["a probabilistic matrix factorization model", "PROBLEM", 258, 300], ["ASMF", "PROBLEM", 361, 365], ["ARMF", "PROBLEM", 366, 370], ["ASMF", "PROBLEM", 377, 381]]], ["ASMF optimizes a square-loss based matrix factorization model with potential items being assigned a score lower than a user's own visited items.", [["a square-loss based matrix factorization model", "TREATMENT", 15, 61], ["square", "OBSERVATION_MODIFIER", 17, 23]]], ["ARMF optimizes a ranking-based matrix factorization model which assumes that users' preference to different items are: visited items > friends' visited (potential) items > unvisited items.Experimental SettingsIn the experiments, we add a L 2 regularization term to the users' and items' embeddings when performing optimization, and the regularization coefficient is set as 0.001.", [["ARMF", "PROTEIN", 0, 4], ["a L 2 regularization term", "TREATMENT", 236, 261]]], ["We set the negative slope \u03b2 of the LeakyReLU function as 0.2.", [["the LeakyReLU function", "TEST", 31, 53], ["negative slope", "OBSERVATION_MODIFIER", 11, 25]]], ["For all latent vectors, we set their dimension as n = 128.", [["all latent vectors", "TREATMENT", 4, 22]]], ["We set the negative count c as 10.", [["negative count", "OBSERVATION_MODIFIER", 11, 25]]], ["The learning rate decreases from an initial value of 1.0 with the increase of iterations, and the decay factor is set as 0.5.", [["decreases", "OBSERVATION_MODIFIER", 18, 27]]], ["Fig. 4 present the precision@n and recall@n of all methods in comparison on the Gowalla dataset and the Epinions dataset respectively.", [["the Gowalla dataset", "TREATMENT", 76, 95]]], ["It can be observed that the proposed DASR method achieves the best performance under different settings of n on both datasets and both metrics, which demonstrates the superiority of our method to these state-of-the-art methods.", [["the proposed DASR method", "TREATMENT", 24, 48]]], ["SoReg integrates social relations as regularization term in matrix factorization model with feedback-based similarities as regularization coefficients, leading to that friends share similar embeddings.", [["Reg", "GENE_OR_GENE_PRODUCT", 2, 5], ["Reg", "PROTEIN", 2, 5]]], ["This makes LOCABAL outperform SoReg.", [["SoReg", "GENE_OR_GENE_PRODUCT", 30, 35], ["LOCABAL", "PROTEIN", 11, 18], ["SoReg", "PROTEIN", 30, 35], ["LOCABAL outperform SoReg", "TREATMENT", 11, 35]]], ["PTPMF splits social relations as strong ties and weak ties, and distinguish the different influence of the two types of social ties.", [["PTPMF", "PROTEIN", 0, 5]]], ["Since ARMF's performance is better than ASMF, we present ARMF only for comparison.", [["ARMF", "PROTEIN", 6, 10], ["ARMF's performance", "TEST", 6, 24]]], ["It is observed ARMF is the best baseline method.", [["ARMF", "OBSERVATION", 15, 19]]], ["Different from Fig. 3 , we can observe that LOCABAL is better than PTPMF on the Epinions dataset in Fig. 4 .", [["LOCABAL", "PROTEIN", 44, 51]]], ["This indicates that weak ties in Epinions dataset do not provide valuable suggestions for users.Rating PredictionFeedback in the Epinions dataset is users' rating scores for items.", [["weak ties in Epinions dataset", "PROBLEM", 20, 49], ["weak", "OBSERVATION_MODIFIER", 20, 24]]], ["We also present rating prediction results of different methods in comparison, as shown in Fig. 5 .Rating PredictionNote that, we use ASMF, rather than ARMF, since ASMF is a square loss-based method and ARMF focuses on item ranking.Rating PredictionIt is observed that the proposed DASR achieves the best MAE metric on the Epinions dataset.", [["DASR", "DNA", 281, 285], ["a square loss", "PROBLEM", 171, 184]]], ["The difference lies in that ARMF occupies the second best position in the comparison of recommendation results, while it is slightly better than SoCF only in the comparison of rating prediction.", [["ARMF", "SIMPLE_CHEMICAL", 28, 32], ["ARMF", "DNA", 28, 32], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["ARMF", "OBSERVATION", 28, 32], ["slightly", "OBSERVATION_MODIFIER", 124, 132], ["better", "OBSERVATION_MODIFIER", 133, 139]]], ["For ease of exhibition, we set the dimension of users' embeddings as 32 and train a new DASR model to get the attention weights between each user and his friends.", [["a new DASR model", "TREATMENT", 82, 98]]], ["Figure 6 shows u 1 's (left) and u 2 's (right) attention weights.", [["Figure", "TEST", 0, 6], ["u", "TEST", 33, 34], ["attention weights", "TEST", 48, 65], ["right", "ANATOMY_MODIFIER", 41, 46]]], ["For each user, we compute the norms of his correlation vectors with friends, and rearrange friend id in the descending order of the norm.Case Study: Correlation VectorsWe have the following observations: (1) Most dimensions of the attention vector between u 1 and friend 0 are large values, which indicate that they are very similar and we can recommend friend 0's visited items to u 1 .", [["descending", "ANATOMY", 108, 118]]], ["(3) By comparing u 1 and u 2 , we can find that each user's interest correlations with his friends have a specific patterns. u 1 may mainly refer to suggestions of several friends with very strong interest correlation, while u 2 may refer to suggestions of each friend dispersedly.Case Study: Correlation VectorsThese observations demonstrate that the proposed method outperforms baselines, and modeling users' multi-dimensional interest correlation can significantly improve recommendation performance.ConclusionsIn this paper, we propose a new embedding-based social recommendation method.", [["a new embedding", "TREATMENT", 540, 555]]], ["We use a correlation vector to characterize the high variation of users' interest correlations on all dimensions, and design a dimension-wise attention mechanism to learn the correlation vector.", [["a correlation vector", "TREATMENT", 7, 27], ["all dimensions", "OBSERVATION_MODIFIER", 98, 112]]], ["Experimental results on two realworld datasets collected from Gowalla and Epinions respectively demonstrate the superiority of our method to state-of-the-art methods.", [["two realworld datasets", "TEST", 24, 46]]]], "PMC7102341": [["IntroductionH1N1 influenza A was first described in humans in April 2009 [1].", [["influenza A", "DISEASE", 17, 28], ["H1N1 influenza A", "ORGANISM", 12, 28], ["humans", "ORGANISM", 52, 58], ["H1N1 influenza", "SPECIES", 12, 26], ["humans", "SPECIES", 52, 58], ["humans", "SPECIES", 52, 58], ["IntroductionH1N1 influenza A", "PROBLEM", 0, 28]]], ["This disease which was known to affect pigs was noted to have become established in human patients in Mexico and subsequently seen to spread to Southern California and thus worldwide.", [["pigs", "ORGANISM", 39, 43], ["human", "ORGANISM", 84, 89], ["patients", "ORGANISM", 90, 98], ["pigs", "SPECIES", 39, 43], ["human", "SPECIES", 84, 89], ["patients", "SPECIES", 90, 98], ["pigs", "SPECIES", 39, 43], ["human", "SPECIES", 84, 89], ["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12]]], ["The Centres for Disease Control and Prevention in the US subsequently confirmed that this new H1N1 strain (S-OIV) contained a number of unique segments that had not been previously identified in either humans or animals [2].IntroductionThe WHO has reported 506,770 confirmed cases of H1N1 and 15,174 deaths at the end of January 2010 [3].", [["H1N1", "DISEASE", 284, 288], ["deaths", "DISEASE", 300, 306], ["S-OIV", "ORGANISM", 107, 112], ["humans", "ORGANISM", 202, 208], ["humans", "SPECIES", 202, 208], ["humans", "SPECIES", 202, 208], ["Disease Control", "TREATMENT", 16, 31], ["the US", "TEST", 50, 56], ["this new H1N1 strain (S-OIV)", "PROBLEM", 85, 113], ["H1N1", "PROBLEM", 284, 288], ["new", "OBSERVATION_MODIFIER", 90, 93], ["H1N1", "OBSERVATION", 94, 98]]], ["This illness has become a global pandemic and by November 2009 the critical illness burden of H1N1 was known, with 30 patients per million of population admitted to intensive care units (ICU) [4].IntroductionIreland has been significantly affected by this global pandemic with 4,586 cases confirmed since April/May 2009, with 26 deaths [5].", [["H1N1", "DISEASE", 94, 98], ["deaths", "DISEASE", 329, 335], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["H1N1", "PROBLEM", 94, 98], ["H1N1", "OBSERVATION", 94, 98]]], ["The main burden of the illness is reported in the urban centres of Health Service Executive (HSE) South, HSE West and HSE East.", [["illness", "DISEASE", 23, 30], ["main", "OBSERVATION_MODIFIER", 4, 8], ["burden", "OBSERVATION_MODIFIER", 9, 15], ["illness", "OBSERVATION", 23, 30]]], ["80% of cases in Ireland have been reported in those under 35 years.IntroductionThe characteristic clinical features of this illness are still emerging due to the relative short time period since first discovery of the virus.", [["this illness", "PROBLEM", 119, 131], ["the virus", "PROBLEM", 214, 223], ["virus", "OBSERVATION", 218, 223]]], ["Symptoms of seasonal influenza such as cough, malaise, fever and gastrointestinal upset remain common hallmarks of H1N1 infection, however, confusion, dehydration and persistent pyrexia has also been reported.", [["gastrointestinal", "ANATOMY", 65, 81], ["influenza", "DISEASE", 21, 30], ["cough", "DISEASE", 39, 44], ["fever", "DISEASE", 55, 60], ["gastrointestinal upset", "DISEASE", 65, 87], ["H1N1 infection", "DISEASE", 115, 129], ["confusion", "DISEASE", 140, 149], ["dehydration", "DISEASE", 151, 162], ["pyrexia", "DISEASE", 178, 185], ["gastrointestinal", "ORGAN", 65, 81], ["Symptoms", "PROBLEM", 0, 8], ["seasonal influenza", "PROBLEM", 12, 30], ["cough", "PROBLEM", 39, 44], ["malaise", "PROBLEM", 46, 53], ["fever", "PROBLEM", 55, 60], ["gastrointestinal upset", "PROBLEM", 65, 87], ["H1N1 infection", "PROBLEM", 115, 129], ["confusion", "PROBLEM", 140, 149], ["dehydration", "PROBLEM", 151, 162], ["persistent pyrexia", "PROBLEM", 167, 185], ["seasonal", "OBSERVATION_MODIFIER", 12, 20], ["influenza", "OBSERVATION", 21, 30], ["gastrointestinal", "ANATOMY", 65, 81], ["H1N1", "OBSERVATION_MODIFIER", 115, 119], ["infection", "OBSERVATION", 120, 129], ["persistent", "OBSERVATION_MODIFIER", 167, 177], ["pyrexia", "OBSERVATION", 178, 185]]], ["Patients with underlying chronic illnesses and those under 2 years and over 65 have been noted as high-risk groups and the majority of hospitalisations occur in these subgroups [6].", [["chronic illnesses", "DISEASE", 25, 42], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["underlying chronic illnesses", "PROBLEM", 14, 42], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["illnesses", "OBSERVATION", 33, 42]]], ["Pregnant women and those with asthma were also noted to be high risk.IntroductionComplications of H1N1 that often lead to death include rapidly progressive pneumonia, acute respiratory distress syndrome (ARDS) and multi-organ failure [7, 8].", [["respiratory", "ANATOMY", 173, 184], ["multi-organ", "ANATOMY", 214, 225], ["asthma", "DISEASE", 30, 36], ["H1N1", "DISEASE", 98, 102], ["death", "DISEASE", 122, 127], ["pneumonia", "DISEASE", 156, 165], ["acute respiratory distress syndrome", "DISEASE", 167, 202], ["ARDS", "DISEASE", 204, 208], ["multi-organ failure", "DISEASE", 214, 233], ["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["asthma", "PROBLEM", 30, 36], ["H1N1", "PROBLEM", 98, 102], ["death", "PROBLEM", 122, 127], ["rapidly progressive pneumonia", "PROBLEM", 136, 165], ["acute respiratory distress syndrome", "PROBLEM", 167, 202], ["ARDS", "PROBLEM", 204, 208], ["multi-organ failure", "PROBLEM", 214, 233], ["H1N1", "OBSERVATION", 98, 102], ["rapidly", "OBSERVATION_MODIFIER", 136, 143], ["progressive", "OBSERVATION_MODIFIER", 144, 155], ["pneumonia", "OBSERVATION", 156, 165], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["respiratory distress syndrome", "OBSERVATION", 173, 202], ["ARDS", "OBSERVATION", 204, 208], ["multi-organ", "ANATOMY", 214, 225], ["failure", "OBSERVATION", 226, 233]]], ["Similar to seasonal influenza, bacterial superinfection can lead to a significantly increased mortality rate [9].IntroductionOver the past year, much has been published on the epidemiology and complications of this illness, with mortality rates reported of 7\u201314%, and ICU admission rates of 25% [10].", [["influenza", "DISEASE", 20, 29], ["bacterial superinfection", "DISEASE", 31, 55], ["seasonal influenza", "PROBLEM", 11, 29], ["bacterial superinfection", "PROBLEM", 31, 55], ["a significantly increased mortality rate", "PROBLEM", 68, 108], ["this illness", "PROBLEM", 210, 222], ["mortality rates", "TEST", 229, 244], ["seasonal", "OBSERVATION_MODIFIER", 11, 19], ["influenza", "OBSERVATION", 20, 29], ["bacterial superinfection", "OBSERVATION", 31, 55]]], ["The incidence of renal insufficiency and renal failure is not well described.", [["renal", "ANATOMY", 17, 22], ["renal", "ANATOMY", 41, 46], ["renal insufficiency", "DISEASE", 17, 36], ["renal failure", "DISEASE", 41, 54], ["renal", "ORGAN", 17, 22], ["renal", "ORGAN", 41, 46], ["renal insufficiency", "PROBLEM", 17, 36], ["renal failure", "PROBLEM", 41, 54], ["renal", "ANATOMY", 17, 22], ["insufficiency", "OBSERVATION", 23, 36], ["renal", "ANATOMY", 41, 46], ["failure", "OBSERVATION", 47, 54]]], ["The most significant biochemical abnormalities associated with this illness have been transiently raised liver enzymes, and sporadic cases of rhabdomyolysis [11].IntroductionThis study aims to highlight the common renal manifestations of H1N1 as seen in the Irish national tertiary referral centre for renal disease.MethodsThis was a retrospective cohort study of all patients who were admitted to our institution with clinical and/or virological evidence of H1N1 infection from July to November 2009.MethodsPatients were tested for H1N1 using standardised nasal/throat swabs which were subsequently analysed using Centers for Disease Control (CDC)/Health Protection Surveillance Centre based primers [12].", [["liver", "ANATOMY", 105, 110], ["renal", "ANATOMY", 214, 219], ["renal", "ANATOMY", 302, 307], ["nasal", "ANATOMY", 557, 562], ["rhabdomyolysis", "DISEASE", 142, 156], ["H1N1", "DISEASE", 238, 242], ["renal disease", "DISEASE", 302, 315], ["H1N1 infection", "DISEASE", 459, 473], ["liver", "ORGAN", 105, 110], ["renal", "ORGAN", 214, 219], ["renal", "ORGAN", 302, 307], ["patients", "ORGANISM", 368, 376], ["Patients", "ORGANISM", 508, 516], ["nasal", "ORGANISM_SUBDIVISION", 557, 562], ["liver enzymes", "PROTEIN", 105, 118], ["patients", "SPECIES", 368, 376], ["Patients", "SPECIES", 508, 516], ["The most significant biochemical abnormalities", "PROBLEM", 0, 46], ["this illness", "PROBLEM", 63, 75], ["liver enzymes", "TEST", 105, 118], ["rhabdomyolysis", "PROBLEM", 142, 156], ["This study", "TEST", 174, 184], ["the common renal manifestations", "PROBLEM", 203, 234], ["H1N1", "PROBLEM", 238, 242], ["renal disease", "PROBLEM", 302, 315], ["a retrospective cohort study", "TEST", 332, 360], ["H1N1 infection", "PROBLEM", 459, 473], ["H1N1", "PROBLEM", 533, 537], ["standardised nasal/throat swabs", "TREATMENT", 544, 575], ["Disease Control", "TREATMENT", 627, 642], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["biochemical", "OBSERVATION_MODIFIER", 21, 32], ["abnormalities", "OBSERVATION", 33, 46], ["rhabdomyolysis", "OBSERVATION", 142, 156], ["common renal", "ANATOMY", 207, 219], ["manifestations", "OBSERVATION", 220, 234], ["H1N1", "OBSERVATION", 238, 242], ["renal", "ANATOMY", 302, 307], ["disease", "OBSERVATION", 308, 315], ["H1N1", "OBSERVATION", 459, 463], ["throat", "ANATOMY", 563, 569]]], ["This is performed using real-time reverse transcriptase PCR, the most sensitive and specific method of diagnosis [13].", [["reverse transcriptase", "PROTEIN", 34, 55], ["transcriptase PCR", "TEST", 42, 59]]], ["All testing was performed at the National Virus Reference Laboratory, at University College Dublin.MethodsAll patients who were thought to have H1N1 infection were highlighted by the attending clinical nurse manager or physician to the hospital pandemic/infection control team.", [["H1N1 infection", "DISEASE", 144, 158], ["infection", "DISEASE", 254, 263], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["All testing", "TEST", 0, 11], ["H1N1 infection", "PROBLEM", 144, 158], ["infection", "OBSERVATION", 149, 158], ["infection", "OBSERVATION", 254, 263]]], ["Subsequent swab results, gender, and age were noted.", [["swab", "ANATOMY", 11, 15], ["Subsequent swab results", "TEST", 0, 23]]], ["The admission pathway of these patients was also logged, including admission length, location of care, and discharge dates.MethodsA patient was deemed to have H1N1 influenza when they exhibited symptoms, and a positive or weakly positive viral swab result, as defined by the European Union (EU) Commission document of 30th April 2009 [14].MethodsA subsequent standardised data collection protocol was created recording age, sex and biochemical values (sodium, potassium, urea and creatinine) at admission, discharge and peak values.", [["influenza", "DISEASE", 164, 173], ["sodium", "CHEMICAL", 452, 458], ["potassium", "CHEMICAL", 460, 469], ["urea", "CHEMICAL", 471, 475], ["creatinine", "CHEMICAL", 480, 490], ["sodium", "CHEMICAL", 452, 458], ["potassium", "CHEMICAL", 460, 469], ["urea", "CHEMICAL", 471, 475], ["creatinine", "CHEMICAL", 480, 490], ["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 132, 139], ["sodium", "SIMPLE_CHEMICAL", 452, 458], ["potassium", "SIMPLE_CHEMICAL", 460, 469], ["urea", "SIMPLE_CHEMICAL", 471, 475], ["creatinine", "SIMPLE_CHEMICAL", 480, 490], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 132, 139], ["H1N1 influenza", "PROBLEM", 159, 173], ["symptoms", "PROBLEM", 194, 202], ["a positive or weakly positive viral swab result", "PROBLEM", 208, 255], ["sodium", "TEST", 452, 458], ["potassium", "TEST", 460, 469], ["urea", "TEST", 471, 475], ["creatinine", "TEST", 480, 490], ["peak values", "TEST", 520, 531]]], ["Urinalysis was also recorded when available.MethodsMedical records of all H1N1-positive patients were then obtained to ascertain outcomes and interventions, including management of acute kidney injury, intensive care stay and need for renal replacement therapy.ResultsFrom 1st July to 31st November 2009, 378 patients were tested for H1N1 using nasal/throat swabs, of which 32 were positive.", [["kidney", "ANATOMY", 187, 193], ["renal", "ANATOMY", 235, 240], ["nasal", "ANATOMY", 345, 350], ["acute kidney injury", "DISEASE", 181, 200], ["H1N1", "DISEASE", 334, 338], ["H1N1", "ORGANISM", 74, 78], ["patients", "ORGANISM", 88, 96], ["kidney", "ORGAN", 187, 193], ["renal", "ORGAN", 235, 240], ["patients", "ORGANISM", 309, 317], ["nasal", "ORGANISM_SUBDIVISION", 345, 350], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 309, 317], ["Urinalysis", "TEST", 0, 10], ["interventions", "TREATMENT", 142, 155], ["management", "TREATMENT", 167, 177], ["acute kidney injury", "PROBLEM", 181, 200], ["renal replacement therapy", "TREATMENT", 235, 260], ["H1N1", "PROBLEM", 334, 338], ["nasal/throat swabs", "TEST", 345, 363], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["kidney", "ANATOMY", 187, 193], ["injury", "OBSERVATION", 194, 200], ["renal", "ANATOMY", 235, 240], ["replacement", "OBSERVATION", 241, 252], ["throat", "ANATOMY", 351, 357]]], ["Two more patients were subsequently diagnosed as having H1N1 despite negative PCR.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["H1N1", "PROBLEM", 56, 60]]], ["This represents 1.1% of all patients who tested positive during this time period in the Republic of Ireland.ResultsThe median age of patients with H1N1 admitted to Beaumont hospital was 28.5, with a range of 9\u201362 years.", [["H1N1", "DISEASE", 147, 151], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 133, 141], ["H1N1", "PROBLEM", 147, 151]]], ["The majority of patients were Caucasian, of Irish ethnicity (89%) with the remainder being Eastern European and Asian (Table 1).", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["majority", "OBSERVATION_MODIFIER", 4, 12]]]], "8352a3f13888fc4958f6b96a7dc06aed2724f52e": [["IntroductionDiabetic nephropathy (DN), a leading cause of endstage renal disease (ESRD), accounts for \u223c50% of all ESRD cases [1, 2] .", [["renal", "ANATOMY", 67, 72], ["IntroductionDiabetic nephropathy", "DISEASE", 0, 32], ["DN", "DISEASE", 34, 36], ["endstage renal disease", "DISEASE", 58, 80], ["ESRD", "DISEASE", 82, 86], ["ESRD", "DISEASE", 114, 118], ["renal", "ORGAN", 67, 72], ["IntroductionDiabetic nephropathy", "PROBLEM", 0, 32], ["endstage renal disease", "PROBLEM", 58, 80], ["ESRD", "PROBLEM", 82, 86], ["all ESRD cases", "PROBLEM", 110, 124], ["nephropathy", "OBSERVATION", 21, 32], ["endstage", "OBSERVATION_MODIFIER", 58, 66], ["renal", "ANATOMY", 67, 72], ["disease", "OBSERVATION", 73, 80]]], ["While glomerulopathy is a hallmark of early renal injury in DN [3] , tubulointerstitial fibrosis and tubular atrophy are major features of late-stage DN and are closely associated with loss of renal function [4] [5] [6] [7] .", [["renal", "ANATOMY", 44, 49], ["tubulointerstitial", "ANATOMY", 69, 87], ["tubular", "ANATOMY", 101, 108], ["renal", "ANATOMY", 193, 198], ["glomerulopathy", "DISEASE", 6, 20], ["renal injury", "DISEASE", 44, 56], ["fibrosis", "DISEASE", 88, 96], ["tubular atrophy", "DISEASE", 101, 116], ["DN", "DISEASE", 150, 152], ["renal", "ORGAN", 44, 49], ["tubulointerstitial", "MULTI-TISSUE_STRUCTURE", 69, 87], ["tubular", "MULTI-TISSUE_STRUCTURE", 101, 108], ["renal", "ORGAN", 193, 198], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 208, 223], ["glomerulopathy", "PROBLEM", 6, 20], ["early renal injury in DN", "PROBLEM", 38, 62], ["tubulointerstitial fibrosis", "PROBLEM", 69, 96], ["tubular atrophy", "PROBLEM", 101, 116], ["late-stage DN", "PROBLEM", 139, 152], ["loss of renal function", "PROBLEM", 185, 207], ["glomerulopathy", "OBSERVATION", 6, 20], ["hallmark", "OBSERVATION_MODIFIER", 26, 34], ["early", "OBSERVATION_MODIFIER", 38, 43], ["renal", "ANATOMY", 44, 49], ["injury", "OBSERVATION", 50, 56], ["tubulointerstitial", "OBSERVATION_MODIFIER", 69, 87], ["fibrosis", "OBSERVATION", 88, 96], ["tubular", "ANATOMY_MODIFIER", 101, 108], ["atrophy", "OBSERVATION", 109, 116], ["late", "OBSERVATION_MODIFIER", 139, 143], ["-stage", "OBSERVATION_MODIFIER", 143, 149], ["DN", "OBSERVATION", 150, 152], ["renal", "ANATOMY", 193, 198]]], ["The mechanisms underlying tubulointerstitial fibrosis, however, are incompletely understood.", [["tubulointerstitial", "ANATOMY", 26, 44], ["fibrosis", "DISEASE", 45, 53], ["tubulointerstitial", "MULTI-TISSUE_STRUCTURE", 26, 44], ["tubulointerstitial fibrosis", "PROBLEM", 26, 53], ["tubulointerstitial", "OBSERVATION_MODIFIER", 26, 44], ["fibrosis", "OBSERVATION", 45, 53]]], ["TGF-\u03b21 is considered to be the most potent inducer of fibrogenesis [8] .", [["fibrogenesis", "DISEASE", 54, 66], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 0, 6], ["TGF-\u03b21", "PROTEIN", 0, 6], ["TGF", "TEST", 0, 3], ["fibrogenesis", "PROBLEM", 54, 66], ["most potent", "OBSERVATION_MODIFIER", 31, 42], ["fibrogenesis", "OBSERVATION", 54, 66]]], ["Indeed, patients and animal models with type 1 or 2 diabetes have significantly elevated serum and urinary TGF-\u03b21 levels [9] [10] [11] as well as heightened TGF-\u03b21 mRNA and protein expression in glomeruli and the tubulointerstitium [12] [13] [14] [15] [16] .IntroductionWe previously reported that high glucose milieu enhances expression of angiotensinogen (AGT, the sole precursor of all angiotensins) through generation of reactive oxygen species (ROS) in cultured rat renal proximal tubular cells (RPTCs) [17, 18] .", [["serum", "ANATOMY", 89, 94], ["urinary", "ANATOMY", 99, 106], ["glomeruli", "ANATOMY", 195, 204], ["renal proximal tubular cells", "ANATOMY", 471, 499], ["RPTCs", "ANATOMY", 501, 506], ["diabetes", "DISEASE", 52, 60], ["glucose", "CHEMICAL", 303, 310], ["oxygen", "CHEMICAL", 434, 440], ["ROS", "CHEMICAL", 450, 453], ["tubulointerstitium", "CHEMICAL", 213, 231], ["glucose", "CHEMICAL", 303, 310], ["oxygen", "CHEMICAL", 434, 440], ["patients", "ORGANISM", 8, 16], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["urinary", "ORGANISM_SUBSTANCE", 99, 106], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 107, 113], ["[9] [10] [11]", "SIMPLE_CHEMICAL", 121, 134], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 157, 163], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 195, 204], ["tubulointerstitium [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 213, 256], ["glucose", "SIMPLE_CHEMICAL", 303, 310], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 341, 356], ["AGT", "GENE_OR_GENE_PRODUCT", 358, 361], ["angiotensins", "GENE_OR_GENE_PRODUCT", 389, 401], ["reactive oxygen species", "SIMPLE_CHEMICAL", 425, 448], ["ROS", "SIMPLE_CHEMICAL", 450, 453], ["rat", "ORGANISM", 467, 470], ["renal proximal tubular cells", "CELL", 471, 499], ["RPTCs", "CELL", 501, 506], ["TGF-\u03b21 mRNA", "RNA", 157, 168], ["angiotensinogen", "PROTEIN", 341, 356], ["AGT", "PROTEIN", 358, 361], ["angiotensins", "PROTEIN", 389, 401], ["cultured rat renal proximal tubular cells", "CELL_LINE", 458, 499], ["RPTCs", "CELL_TYPE", 501, 506], ["patients", "SPECIES", 8, 16], ["rat", "SPECIES", 467, 470], ["rat", "SPECIES", 467, 470], ["type 1 or 2 diabetes", "PROBLEM", 40, 60], ["significantly elevated serum", "PROBLEM", 66, 94], ["urinary TGF", "TEST", 99, 110], ["levels", "TEST", 114, 120], ["heightened TGF", "TEST", 146, 160], ["mRNA", "TEST", 164, 168], ["protein expression", "TEST", 173, 191], ["glomeruli", "TEST", 195, 204], ["the tubulointerstitium", "TEST", 209, 231], ["high glucose milieu", "PROBLEM", 298, 317], ["angiotensinogen (AGT", "TREATMENT", 341, 361], ["all angiotensins", "TREATMENT", 385, 401], ["reactive oxygen species", "PROBLEM", 425, 448], ["RPTCs", "TEST", 501, 506], ["urinary", "ANATOMY", 99, 106], ["glomeruli", "ANATOMY", 195, 204], ["tubulointerstitium", "ANATOMY", 213, 231], ["reactive", "OBSERVATION_MODIFIER", 425, 433], ["oxygen species", "OBSERVATION", 434, 448], ["renal", "ANATOMY", 471, 476], ["proximal", "ANATOMY_MODIFIER", 477, 485], ["tubular cells", "OBSERVATION", 486, 499]]], ["Rat AGT overexpression in RPTCs leads to hypertension, albuminuria and RPTC hypertrophy, and enhances TGF-\u03b21 expression in diabetic AGT-transgenic (Tg) mice [19, 20] .", [["RPTCs", "ANATOMY", 26, 31], ["hypertension", "DISEASE", 41, 53], ["albuminuria", "DISEASE", 55, 66], ["hypertrophy", "DISEASE", 76, 87], ["AGT", "GENE_OR_GENE_PRODUCT", 4, 7], ["RPTCs", "CELL", 26, 31], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 102, 108], ["AGT", "GENE_OR_GENE_PRODUCT", 132, 135], ["-transgenic (Tg) mice", "ORGANISM", 135, 156], ["AGT", "PROTEIN", 4, 7], ["RPTCs", "CELL_TYPE", 26, 31], ["TGF-\u03b21", "PROTEIN", 102, 108], ["AGT", "PROTEIN", 132, 135], ["mice", "SPECIES", 152, 156], ["Rat AGT overexpression in RPTCs", "PROBLEM", 0, 31], ["hypertension", "PROBLEM", 41, 53], ["albuminuria", "PROBLEM", 55, 66], ["RPTC hypertrophy", "PROBLEM", 71, 87], ["TGF", "TEST", 102, 105], ["diabetic AGT", "TEST", 123, 135], ["overexpression", "OBSERVATION_MODIFIER", 8, 22], ["hypertension", "OBSERVATION", 41, 53], ["albuminuria", "OBSERVATION", 55, 66], ["RPTC", "OBSERVATION_MODIFIER", 71, 75], ["hypertrophy", "OBSERVATION", 76, 87]]], ["Conversely, RPTC-selective overexpression of catalase or pharmacological blockade of the renin-angiotensin system (RAS) attenuates hypertension, ROS generation, kidney injury and normalised RPTC ACE-2 expression in mouse models of diabetes [21] [22] [23] [24] .", [["kidney", "ANATOMY", 161, 167], ["angiotensin", "CHEMICAL", 95, 106], ["hypertension", "DISEASE", 131, 143], ["ROS", "CHEMICAL", 145, 148], ["kidney injury", "DISEASE", 161, 174], ["diabetes", "DISEASE", 231, 239], ["RPTC", "SIMPLE_CHEMICAL", 12, 16], ["catalase", "GENE_OR_GENE_PRODUCT", 45, 53], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 89, 106], ["RAS", "GENE_OR_GENE_PRODUCT", 115, 118], ["ROS", "SIMPLE_CHEMICAL", 145, 148], ["kidney", "ORGAN", 161, 167], ["RPTC", "GENE_OR_GENE_PRODUCT", 190, 194], ["ACE-2", "GENE_OR_GENE_PRODUCT", 195, 200], ["mouse", "ORGANISM", 215, 220], ["[21] [22] [23] [24]", "SIMPLE_CHEMICAL", 240, 259], ["RPTC", "PROTEIN", 12, 16], ["catalase", "PROTEIN", 45, 53], ["renin", "PROTEIN", 89, 94], ["RPTC", "PROTEIN", 190, 194], ["ACE", "PROTEIN", 195, 198], ["mouse", "SPECIES", 215, 220], ["mouse", "SPECIES", 215, 220], ["RPTC", "TEST", 12, 16], ["catalase", "PROBLEM", 45, 53], ["pharmacological blockade", "TREATMENT", 57, 81], ["the renin-angiotensin system", "TREATMENT", 85, 113], ["hypertension", "PROBLEM", 131, 143], ["ROS generation", "PROBLEM", 145, 159], ["kidney injury", "PROBLEM", 161, 174], ["ACE", "TEST", 195, 198], ["diabetes", "PROBLEM", 231, 239], ["hypertension", "OBSERVATION", 131, 143], ["kidney", "ANATOMY", 161, 167], ["injury", "OBSERVATION", 168, 174]]], ["Taken together, these observations indicate that oxidative stress-induced upregulation of AGT expression and downregulation of ACE-2 expression in RPTCs, resulting in higher angiotensin (Ang)II/Ang 1-7 ratio, may be key determinants of development of hypertension and nephropathy in diabetes.IntroductionWe reported that insulin inhibits high glucose stimulation of rat renal Agt gene expression via two nuclear proteins-heterogeneous nuclear ribonucleoproteins F and K (hnRNP F, hnRNP K)-that interact with the insulin-responsive element (IRE) in the Agt gene promoter [25] [26] [27] [28] , and that hnRNP F overexpression in RPTCs inhibits Agt gene expression and kidney hypertrophy in Akita Hnrnpf-Tg mice [29] .", [["RPTCs", "ANATOMY", 147, 152], ["renal", "ANATOMY", 370, 375], ["nuclear", "ANATOMY", 404, 411], ["RPTCs", "ANATOMY", 627, 632], ["kidney", "ANATOMY", 666, 672], ["angiotensin", "CHEMICAL", 174, 185], ["Ang", "CHEMICAL", 187, 190], ["Ang", "CHEMICAL", 194, 197], ["hypertension", "DISEASE", 251, 263], ["nephropathy", "DISEASE", 268, 279], ["diabetes", "DISEASE", 283, 291], ["insulin", "CHEMICAL", 321, 328], ["glucose", "CHEMICAL", 343, 350], ["kidney hypertrophy", "DISEASE", 666, 684], ["glucose", "CHEMICAL", 343, 350], ["AGT", "GENE_OR_GENE_PRODUCT", 90, 93], ["ACE-2", "GENE_OR_GENE_PRODUCT", 127, 132], ["RPTCs", "GENE_OR_GENE_PRODUCT", 147, 152], ["angiotensin (Ang)II", "GENE_OR_GENE_PRODUCT", 174, 193], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 194, 201], ["insulin", "GENE_OR_GENE_PRODUCT", 321, 328], ["glucose", "SIMPLE_CHEMICAL", 343, 350], ["rat", "ORGANISM", 366, 369], ["renal", "ORGAN", 370, 375], ["Agt", "GENE_OR_GENE_PRODUCT", 376, 379], ["heterogeneous nuclear ribonucleoproteins F", "GENE_OR_GENE_PRODUCT", 421, 463], ["K", "GENE_OR_GENE_PRODUCT", 468, 469], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 471, 478], ["hnRNP K", "GENE_OR_GENE_PRODUCT", 480, 487], ["insulin", "GENE_OR_GENE_PRODUCT", 512, 519], ["IRE", "GENE_OR_GENE_PRODUCT", 540, 543], ["Agt", "GENE_OR_GENE_PRODUCT", 552, 555], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 601, 608], ["RPTCs", "CANCER", 627, 632], ["Agt", "GENE_OR_GENE_PRODUCT", 642, 645], ["kidney", "ORGAN", 666, 672], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 694, 700], ["AGT", "PROTEIN", 90, 93], ["ACE", "PROTEIN", 127, 130], ["RPTCs", "CELL_TYPE", 147, 152], ["rat renal Agt gene", "DNA", 366, 384], ["nuclear proteins", "PROTEIN", 404, 420], ["heterogeneous nuclear ribonucleoproteins F and K", "PROTEIN", 421, 469], ["hnRNP F", "PROTEIN", 471, 478], ["hnRNP K", "PROTEIN", 480, 487], ["insulin-responsive element", "DNA", 512, 538], ["IRE", "DNA", 540, 543], ["Agt gene promoter", "DNA", 552, 569], ["hnRNP F", "PROTEIN", 601, 608], ["RPTCs", "CELL_TYPE", 627, 632], ["Agt gene", "DNA", 642, 650], ["rat", "SPECIES", 366, 369], ["mice", "SPECIES", 704, 708], ["rat", "SPECIES", 366, 369], ["oxidative stress", "PROBLEM", 49, 65], ["AGT expression", "PROBLEM", 90, 104], ["downregulation of ACE", "TREATMENT", 109, 130], ["RPTCs", "TEST", 147, 152], ["higher angiotensin (Ang)II/Ang 1", "PROBLEM", 167, 199], ["hypertension", "PROBLEM", 251, 263], ["nephropathy", "PROBLEM", 268, 279], ["diabetes", "PROBLEM", 283, 291], ["insulin", "TREATMENT", 321, 328], ["high glucose stimulation", "TREATMENT", 338, 362], ["two nuclear proteins", "TEST", 400, 420], ["hnRNP K)", "TEST", 480, 488], ["the insulin-responsive element (IRE) in the Agt gene promoter", "TREATMENT", 508, 569], ["Agt gene expression", "PROBLEM", 642, 661], ["kidney hypertrophy", "PROBLEM", 666, 684], ["higher angiotensin", "OBSERVATION", 167, 185], ["hypertension", "OBSERVATION", 251, 263], ["nephropathy", "OBSERVATION", 268, 279], ["diabetes", "OBSERVATION", 283, 291], ["kidney", "ANATOMY", 666, 672], ["hypertrophy", "OBSERVATION", 673, 684]]], ["Here, we report that overexpression of hnRNP F stimulates Ace-2 gene transcription and suppresses profibrotic gene (Tgf-\u03b21, Tgf-\u03b2rII) expression in RPTCs of Akita Hnrnpf-Tg mice.", [["RPTCs", "ANATOMY", 148, 153], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 39, 46], ["Ace-2", "GENE_OR_GENE_PRODUCT", 58, 63], ["Tgf-\u03b21", "GENE_OR_GENE_PRODUCT", 116, 122], ["Tgf-\u03b2rII", "GENE_OR_GENE_PRODUCT", 124, 132], ["RPTCs", "PATHOLOGICAL_FORMATION", 148, 153], ["Akita Hnrnpf-Tg mice", "ORGANISM", 157, 177], ["hnRNP F", "PROTEIN", 39, 46], ["Ace-2 gene", "DNA", 58, 68], ["profibrotic gene", "DNA", 98, 114], ["Tgf", "DNA", 124, 127], ["\u03b2rII", "DNA", 128, 132], ["RPTCs", "CELL_TYPE", 148, 153], ["mice", "SPECIES", 173, 177], ["hnRNP F stimulates", "TREATMENT", 39, 57], ["Ace-2 gene transcription", "TREATMENT", 58, 82], ["profibrotic gene", "TEST", 98, 114], ["Tgf", "TEST", 116, 119], ["Tgf", "TEST", 124, 127]]], ["We have confirmed these changes by in vitro studies in rat RPTCs.", [["RPTCs", "ANATOMY", 59, 64], ["rat", "ORGANISM", 55, 58], ["RPTCs", "CELL", 59, 64], ["rat RPTCs", "CELL_TYPE", 55, 64], ["rat", "SPECIES", 55, 58], ["rat", "SPECIES", 55, 58], ["vitro studies", "TEST", 38, 51]]], ["We also show that hnRNP F overexpression prevents TGF-\u03b21 signalling and inhibition of Ace-2 gene expression in RPTCs.", [["RPTCs", "ANATOMY", 111, 116], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 18, 25], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 50, 56], ["Ace-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["RPTCs", "PATHOLOGICAL_FORMATION", 111, 116], ["hnRNP F", "PROTEIN", 18, 25], ["TGF-\u03b21", "PROTEIN", 50, 56], ["Ace-2 gene", "DNA", 86, 96], ["RPTCs", "CELL_TYPE", 111, 116], ["TGF", "TEST", 50, 53], ["Ace", "TEST", 86, 89]]], ["Finally, we identified the putative DNA response elements (REs) in the Ace-2 gene promoter that are responsive to hnRNP F and TGF-\u03b21.MethodsChemicals and constructs Active human recombinant TGF-\u03b21 was obtained from R&D Systems (Minneapolis, MN, USA).", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["Ace-2", "GENE_OR_GENE_PRODUCT", 71, 76], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 114, 121], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 126, 132], ["human", "ORGANISM", 172, 177], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 190, 196], ["DNA response elements", "DNA", 36, 57], ["REs", "DNA", 59, 62], ["Ace-2 gene promoter", "DNA", 71, 90], ["hnRNP F", "PROTEIN", 114, 121], ["TGF-\u03b21", "PROTEIN", 126, 132], ["human recombinant TGF-\u03b21", "PROTEIN", 172, 196], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["the Ace-2 gene promoter", "TREATMENT", 67, 90], ["TGF", "TEST", 126, 129], ["MethodsChemicals", "TEST", 133, 149], ["Active human recombinant TGF", "TEST", 165, 193]]], ["SB431542 (a TGF-\u03b2 receptor I [RI] inhibitor) and other chemicals were purchased from Sigma-Aldrich (Oakville, ON, Canada).", [["SB431542", "CHEMICAL", 0, 8], ["SB431542", "CHEMICAL", 0, 8], ["SB431542", "SIMPLE_CHEMICAL", 0, 8], ["TGF-\u03b2 receptor I", "GENE_OR_GENE_PRODUCT", 12, 28], ["RI", "GENE_OR_GENE_PRODUCT", 30, 32], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 85, 98], ["SB431542", "TEST", 0, 8], ["a TGF", "TEST", 10, 15], ["-\u03b2 receptor I [RI] inhibitor", "TREATMENT", 15, 43]]], ["The antibodies used in the present study are listed in electronic supplementary material (ESM) Table 1.", [["antibodies", "PROTEIN", 4, 14], ["The antibodies", "TREATMENT", 0, 14], ["the present study", "TEST", 23, 40]]], ["The pKAP2 plasmid containing the kidney-specific androgen-regulated protein (KAP) promoter was a gift from C. D. Sigmund (University of Iowa, Iowa City, IA, USA) [30] .", [["kidney", "ANATOMY", 33, 39], ["androgen", "CHEMICAL", 49, 57], ["pKAP2", "GENE_OR_GENE_PRODUCT", 4, 9], ["kidney", "ORGAN", 33, 39], ["androgen-regulated protein", "GENE_OR_GENE_PRODUCT", 49, 75], ["KAP", "GENE_OR_GENE_PRODUCT", 77, 80], ["pKAP2 plasmid", "DNA", 4, 17], ["kidney-specific androgen-regulated protein (KAP) promoter", "DNA", 33, 90], ["The pKAP2 plasmid", "TREATMENT", 0, 17], ["kidney", "ANATOMY", 33, 39]]], ["Full-length rat Hnrnpf cDNA fused with HA tag (encoding amino acid residues 98-106 [YPYDVPDYA] of human influenza virus hemagglutinin) was inserted into pKAP2 plasmid at the NotI site at both 5\u2032 and 3\u2032 termini [25, 29] . pGL4.20 vector containing Luciferase reporter was obtained from Promega (Sunnyvale, CA, USA).", [["amino acid", "CHEMICAL", 56, 66], ["amino acid", "CHEMICAL", 56, 66], ["rat", "ORGANISM", 12, 15], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 16, 22], ["HA tag", "GENE_OR_GENE_PRODUCT", 39, 45], ["amino acid", "AMINO_ACID", 56, 66], ["human influenza virus hemagglutinin", "ORGANISM", 98, 133], ["pKAP2", "GENE_OR_GENE_PRODUCT", 153, 158], ["NotI", "GENE_OR_GENE_PRODUCT", 174, 178], ["pGL4", "GENE_OR_GENE_PRODUCT", 221, 225], ["Luciferase", "GENE_OR_GENE_PRODUCT", 247, 257], ["Promega", "ORGANISM", 285, 292], ["Hnrnpf cDNA", "DNA", 16, 27], ["HA tag", "DNA", 39, 45], ["YPYDVPDYA", "PROTEIN", 84, 93], ["pKAP2 plasmid", "DNA", 153, 166], ["NotI site", "DNA", 174, 183], ["pGL4", "PROTEIN", 221, 225], ["Luciferase reporter", "DNA", 247, 266], ["rat", "SPECIES", 12, 15], ["human", "SPECIES", 98, 103], ["influenza virus hemagglutinin", "SPECIES", 104, 133], ["human influenza virus", "SPECIES", 98, 119], ["HA tag", "TREATMENT", 39, 45], ["amino acid residues", "TEST", 56, 75], ["human influenza virus hemagglutinin)", "TREATMENT", 98, 134], ["Luciferase reporter", "TEST", 247, 266]]], ["Rat Ace-2 gene promoter (N-1,091/+83) was cloned from rat genomic DNA with specific primers (ESM Table 2 ), as described by Milsted et al [31] and then inserted into pGL4.20 plasmid at HindIII and KpnI restriction sites.", [["plasmid", "ANATOMY", 174, 181], ["Ace-2", "GENE_OR_GENE_PRODUCT", 4, 9], ["rat", "ORGANISM", 54, 57], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["pGL4", "GENE_OR_GENE_PRODUCT", 166, 170], ["HindIII", "GENE_OR_GENE_PRODUCT", 185, 192], ["KpnI", "GENE_OR_GENE_PRODUCT", 197, 201], ["Rat Ace-2 gene promoter", "DNA", 0, 23], ["N-1,091/+83", "DNA", 25, 36], ["rat genomic DNA", "DNA", 54, 69], ["pGL4", "DNA", 166, 170], ["20 plasmid", "DNA", 171, 181], ["HindIII and KpnI restriction sites", "DNA", 185, 219], ["Rat", "SPECIES", 0, 3], ["rat", "SPECIES", 54, 57], ["rat", "SPECIES", 54, 57], ["Rat Ace-2 gene promoter", "TREATMENT", 0, 23], ["plasmid at HindIII and KpnI restriction sites", "TREATMENT", 174, 219], ["KpnI restriction", "OBSERVATION", 197, 213], ["sites", "OBSERVATION_MODIFIER", 214, 219]]], ["Scrambled Silencer Negative Control no. 1 small interfering RNA (siRNA) and Hnrnpf siRNA were bought from Ambion (Austin, TX, USA).", [["Ambion", "ORGANISM", 106, 112], ["Scrambled Silencer Negative Control no. 1 small interfering RNA", "RNA", 0, 63], ["small interfering RNA (siRNA)", "PROBLEM", 42, 71], ["Hnrnpf siRNA", "TREATMENT", 76, 88], ["small", "OBSERVATION_MODIFIER", 42, 47], ["interfering RNA", "OBSERVATION", 48, 63]]], ["QuickChange II Site-Directed Mutagenesis Kit and LightShift Chemiluminescent electrophoretic mobility shift assay (EMSA) Kit were procured from Agilent Technologies (Santa Clara, CA, USA) and Thermo Scientific (Life Technologies, Burlington, ON, Canada), respectively.", [["Directed Mutagenesis Kit", "TREATMENT", 20, 44], ["LightShift Chemiluminescent electrophoretic mobility", "TEST", 49, 101]]], ["The primer biotinlabelling kit was purchased from Integrated DNATechnologies (Coralville, IA, USA).MethodsPhysiological studies Adult male heterozygous Akita mice (Mus musculus) with a mutated Ins2 gene (C57BL6-Ins2 Akita /J) were purchased from Jackson Laboratories (Bar Harbor, ME, USA: http://jaxmice.jax.org).", [["Akita mice", "ORGANISM", 152, 162], ["Mus musculus", "ORGANISM", 164, 176], ["Ins2", "GENE_OR_GENE_PRODUCT", 193, 197], ["mutated Ins2 gene", "DNA", 185, 202], ["mice", "SPECIES", 158, 162], ["Mus musculus", "SPECIES", 164, 176], ["mice", "SPECIES", 158, 162], ["Mus musculus", "SPECIES", 164, 176], ["The primer biotinlabelling kit", "TEST", 0, 30], ["MethodsPhysiological studies", "TEST", 99, 127], ["a mutated Ins2 gene", "PROBLEM", 183, 202]]], ["Akita Tg mice (C57Bl/6 background) overexpressing rat hnRNP F-HA in RPTCs (line 937) were created in our laboratory (by J. S. D. Chan) [29] .", [["RPTCs", "ANATOMY", 68, 73], ["Akita Tg mice", "ORGANISM", 0, 13], ["C57Bl/6 background", "ORGANISM", 15, 33], ["rat", "ORGANISM", 50, 53], ["hnRNP F-HA", "GENE_OR_GENE_PRODUCT", 54, 64], ["rat hnRNP F", "PROTEIN", 50, 61], ["RPTCs", "CELL_LINE", 68, 73], ["line 937", "CELL_LINE", 75, 83], ["mice", "SPECIES", 9, 13], ["rat", "SPECIES", 50, 53], ["mice", "SPECIES", 9, 13], ["overexpressing rat hnRNP F", "PROBLEM", 35, 61], ["HA", "PROBLEM", 62, 64]]], ["Male adult non-Tg and non-Akita littermates served as wild-type (WT) controls, and were tested along with Hnrnpf-Tg, Akita and Akita Hnrnpf-Tg mice.", [["Male adult non-Tg", "ORGANISM", 0, 17], ["non-Akita littermates", "ORGANISM", 22, 43], ["wild-type (WT) controls", "ORGANISM", 54, 77], ["Hnrnpf-Tg", "GENE_OR_GENE_PRODUCT", 106, 115], ["Akita", "GENE_OR_GENE_PRODUCT", 117, 122], ["Akita Hnrnpf-Tg mice", "ORGANISM", 127, 147], ["Hnrnpf", "PROTEIN", 106, 112], ["Hnrnpf", "PROTEIN", 133, 139], ["mice", "SPECIES", 143, 147], ["Hnrnpf", "TREATMENT", 106, 112]]], ["All animals were fed standard mouse chow and water ad libitum.", [["mouse", "ORGANISM", 30, 35], ["chow", "ORGANISM_SUBDIVISION", 36, 40], ["mouse", "SPECIES", 30, 35], ["mouse", "SPECIES", 30, 35]]], ["Animal care and procedures were approved by the CRCHUM Animal Care Committee and followed the Principles of Laboratory Animal Care (NIH publication no. 85-23, revised 1985: http:// grants1.nih.gov/grants/olaw/references/phspol.htm).MethodsBlood glucose levels, following 4-5 h fasting, were determined with an Accu-Chek Performa System (Roche Diagnostics, Laval, QC, Canada).", [["Blood", "ANATOMY", 239, 244], ["glucose", "CHEMICAL", 245, 252], ["glucose", "CHEMICAL", 245, 252], ["Blood", "ORGANISM_SUBSTANCE", 239, 244], ["glucose", "SIMPLE_CHEMICAL", 245, 252], ["Animal care", "TREATMENT", 0, 11], ["procedures", "TREATMENT", 16, 26], ["MethodsBlood glucose levels", "TEST", 232, 259]]], ["Body weight (BW) was recorded.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["Body weight", "TEST", 0, 11]]], ["Urine was collected and assayed for albumin/creatinine ratio (ACR) by enzyme-linked immunosorbent assays (Albuwell and Creatinine Companion, Exocell, Philadelphia, PA, USA).", [["Urine", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 44, 54], ["creatinine", "CHEMICAL", 44, 54], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["albumin", "GENE_OR_GENE_PRODUCT", 36, 43], ["creatinine", "SIMPLE_CHEMICAL", 44, 54], ["albumin", "PROTEIN", 36, 43], ["Urine", "TEST", 0, 5], ["albumin", "TEST", 36, 43], ["creatinine ratio", "TEST", 44, 60], ["ACR", "TEST", 62, 65], ["enzyme", "TEST", 70, 76], ["immunosorbent assays", "TEST", 84, 104], ["Albuwell", "TEST", 106, 114], ["Creatinine", "TEST", 119, 129]]], ["GFR was measured as described by Qi et al [32] as recommended by the Animal Models of Diabetic Complications Consortium (www.diacomp.org) with fluorescein isothiocyanate inulin [23, 28, 33] .MethodsKidneys were removed immediately after GFR measurement, decapsulated and weighed.", [["Diabetic", "DISEASE", 86, 94], ["fluorescein isothiocyanate inulin", "CHEMICAL", 143, 176], ["fluorescein isothiocyanate", "CHEMICAL", 143, 169], ["fluorescein isothiocyanate inulin", "SIMPLE_CHEMICAL", 143, 176], ["GFR", "TEST", 0, 3], ["Diabetic Complications", "PROBLEM", 86, 108], ["fluorescein isothiocyanate inulin", "TREATMENT", 143, 176], ["MethodsKidneys", "TREATMENT", 191, 205], ["GFR measurement", "TEST", 237, 252]]], ["The left kidneys were processed for histology and immunostaining, and right renal cortices were harvested for renal proximal tubules (RPTs) isolation by Percoll gradient centrifugation [23, 24, 28, 29] .", [["left kidneys", "ANATOMY", 4, 16], ["right renal cortices", "ANATOMY", 70, 90], ["renal proximal tubules", "ANATOMY", 110, 132], ["RPTs", "ANATOMY", 134, 138], ["kidneys", "ORGAN", 9, 16], ["renal cortices", "MULTI-TISSUE_STRUCTURE", 76, 90], ["renal proximal tubules", "MULTI-TISSUE_STRUCTURE", 110, 132], ["histology", "TEST", 36, 45], ["immunostaining", "TEST", 50, 64], ["renal proximal tubules (RPTs) isolation", "TREATMENT", 110, 149], ["Percoll gradient centrifugation", "TREATMENT", 153, 184], ["left", "ANATOMY_MODIFIER", 4, 8], ["kidneys", "ANATOMY", 9, 16], ["right", "ANATOMY_MODIFIER", 70, 75], ["renal", "ANATOMY", 76, 81], ["cortices", "ANATOMY_MODIFIER", 82, 90], ["harvested", "OBSERVATION", 96, 105], ["renal", "ANATOMY", 110, 115], ["proximal", "ANATOMY_MODIFIER", 116, 124], ["tubules", "ANATOMY_MODIFIER", 125, 132]]], ["Aliquots of freshly isolated RPTs from individual mice were immediately processed for total RNA and protein isolation.MethodsImmunohistochemical staining Immunohistochemical staining was performed by the standard avidin-biotin-peroxidase complex method in four to five sections (4 \u03bcm thick) per kidney and three mouse kidneys per group (ABC Staining System; Santa Cruz Biotechnology [Santa Cruz, CA, USA]) [23, 24, 28, 29] .", [["Aliquots", "ANATOMY", 0, 8], ["RPTs", "ANATOMY", 29, 33], ["sections", "ANATOMY", 269, 277], ["kidney", "ANATOMY", 295, 301], ["kidneys", "ANATOMY", 318, 325], ["biotin", "CHEMICAL", 220, 226], ["biotin", "CHEMICAL", 220, 226], ["RPTs", "CELL", 29, 33], ["mice", "ORGANISM", 50, 54], ["avidin", "GENE_OR_GENE_PRODUCT", 213, 219], ["biotin", "SIMPLE_CHEMICAL", 220, 226], ["peroxidase", "GENE_OR_GENE_PRODUCT", 227, 237], ["kidney", "ORGAN", 295, 301], ["mouse", "ORGANISM", 312, 317], ["kidneys", "ORGAN", 318, 325], ["avidin-biotin-peroxidase complex", "PROTEIN", 213, 245], ["mice", "SPECIES", 50, 54], ["mouse", "SPECIES", 312, 317], ["mice", "SPECIES", 50, 54], ["mouse", "SPECIES", 312, 317], ["freshly isolated RPTs", "TREATMENT", 12, 33], ["total RNA", "TREATMENT", 86, 95], ["protein isolation", "TREATMENT", 100, 117], ["Methods", "TEST", 118, 125], ["Immunohistochemical staining", "TEST", 125, 153], ["Immunohistochemical staining", "TEST", 154, 182], ["the standard avidin-biotin-peroxidase complex method", "TREATMENT", 200, 252], ["kidney", "ANATOMY", 295, 301], ["kidneys", "ANATOMY", 318, 325]]], ["The collected images were assessed by National Institutes of Health Image J software (http://rsb.info.nih.gov/ij/) [23, 24, 28, 29] .MethodsUrinary AGT, Ang II and Ang 1-7 measurement Mouse urinary AGT, Ang II and Ang 1-7 levels were analysed by ELISA (Immuno-Biological Laboratories, IBL America, Minneapolis, MN, USA) and normalised by urinary creatinine levels as described [23, 24, 28, 29, 34] .MethodsCell culture Immortalised rat RPTCs (passages 12-18) [35] were cultured in 5 mmol/l D-glucose DMEM containing 5% FBS until they reached 60-70% confluence.", [["urinary", "ANATOMY", 190, 197], ["urinary", "ANATOMY", 338, 345], ["Cell", "ANATOMY", 406, 410], ["RPTCs", "ANATOMY", 436, 441], ["FBS", "ANATOMY", 519, 522], ["Ang II", "CHEMICAL", 153, 159], ["Ang", "CHEMICAL", 164, 167], ["Ang II", "CHEMICAL", 203, 209], ["Ang", "CHEMICAL", 214, 217], ["creatinine", "CHEMICAL", 346, 356], ["D-glucose", "CHEMICAL", 490, 499], ["creatinine", "CHEMICAL", 346, 356], ["D-glucose", "CHEMICAL", 490, 499], ["AGT", "GENE_OR_GENE_PRODUCT", 148, 151], ["Ang II", "GENE_OR_GENE_PRODUCT", 153, 159], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 164, 171], ["Mouse", "ORGANISM", 184, 189], ["urinary", "ORGANISM_SUBDIVISION", 190, 197], ["AGT", "GENE_OR_GENE_PRODUCT", 198, 201], ["Ang II", "GENE_OR_GENE_PRODUCT", 203, 209], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 214, 221], ["urinary", "ORGANISM_SUBSTANCE", 338, 345], ["creatinine", "SIMPLE_CHEMICAL", 346, 356], ["Cell", "CELL", 406, 410], ["rat", "ORGANISM", 432, 435], ["RPTCs", "CELL", 436, 441], ["D-glucose", "SIMPLE_CHEMICAL", 490, 499], ["FBS", "ORGANISM_SUBSTANCE", 519, 522], ["AGT", "PROTEIN", 148, 151], ["Immortalised rat RPTCs", "CELL_LINE", 419, 441], ["Mouse", "SPECIES", 184, 189], ["rat", "SPECIES", 432, 435], ["rat", "SPECIES", 432, 435], ["The collected images", "TEST", 0, 20], ["MethodsUrinary AGT", "TREATMENT", 133, 151], ["Ang", "TEST", 164, 167], ["Mouse urinary AGT", "TEST", 184, 201], ["Ang II", "TEST", 203, 209], ["Ang", "TEST", 214, 217], ["urinary creatinine levels", "TEST", 338, 363], ["MethodsCell culture", "TEST", 399, 418], ["RPTCs", "TEST", 436, 441], ["passages", "TEST", 443, 451], ["glucose DMEM", "TREATMENT", 492, 504], ["5% FBS", "TREATMENT", 516, 522], ["urinary AGT", "ANATOMY", 190, 201], ["urinary", "ANATOMY", 338, 345]]], ["The media were then changed to serum-free DMEM, ensuring that endogenously secreted TGF-\u03b21 would not interfere in the assay.", [["serum", "ANATOMY", 31, 36], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 84, 90], ["TGF", "PROTEIN", 84, 87], ["\u03b21", "PROTEIN", 88, 90], ["The media", "TREATMENT", 0, 9], ["serum-free DMEM", "TREATMENT", 31, 46]]], ["After 45 min preincubation, active human recombinant TGF-\u03b21 [36] (0 to 10 ng/ml) was added (considered as time 0 h) and incubated for various time periods up to 24 h.", [["human", "ORGANISM", 35, 40], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 53, 59], ["TGF", "PROTEIN", 53, 56], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["active human recombinant TGF", "TREATMENT", 28, 56]]], ["In separate experiments, RPTCs were incubated for 24 h in serum-free medium in the presence or absence of TGF-\u03b21\u00b1 various concentrations of SB431542.MethodsReal-time quantitative PCR Hnrnpf, Ace, Ace-2, MasR, Tgf-\u03b21, Tgf-\u03b2rI, Tgf-\u03b2rII, collagen type IV, collagen type I, fibronectin 1 and \u03b2-actin mRNA expression levels in RPTs were quantified by real-time quantitative PCR (RT-qPCR) with forward and reverse primers (ESM Table 2 ) [23, 24, 28, 29] .MethodsWestern blotting Western blotting (WB) was performed as described previously [23, 24, 28, 29] .", [["RPTCs", "ANATOMY", 25, 30], ["serum", "ANATOMY", 58, 63], ["RPTs", "ANATOMY", 323, 327], ["SB431542", "CHEMICAL", 140, 148], ["SB431542", "CHEMICAL", 140, 148], ["RPTCs", "CELL", 25, 30], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 106, 112], ["SB431542", "SIMPLE_CHEMICAL", 140, 148], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 183, 189], ["Ace", "GENE_OR_GENE_PRODUCT", 191, 194], ["Ace-2", "GENE_OR_GENE_PRODUCT", 196, 201], ["MasR", "GENE_OR_GENE_PRODUCT", 203, 207], ["Tgf-\u03b21", "GENE_OR_GENE_PRODUCT", 209, 215], ["Tgf-\u03b2rI", "GENE_OR_GENE_PRODUCT", 217, 224], ["Tgf-\u03b2rII", "GENE_OR_GENE_PRODUCT", 226, 234], ["collagen type IV", "GENE_OR_GENE_PRODUCT", 236, 252], ["collagen type I", "GENE_OR_GENE_PRODUCT", 254, 269], ["fibronectin 1", "GENE_OR_GENE_PRODUCT", 271, 284], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 289, 296], ["RPTs", "CANCER", 323, 327], ["RPTCs", "CELL_TYPE", 25, 30], ["TGF", "PROTEIN", 106, 109], ["Hnrnpf, Ace, Ace-2", "DNA", 183, 201], ["MasR", "DNA", 203, 207], ["Tgf", "DNA", 209, 212], ["\u03b21", "DNA", 213, 215], ["Tgf", "DNA", 217, 220], ["\u03b2rI", "DNA", 221, 224], ["Tgf", "DNA", 226, 229], ["\u03b2rII", "DNA", 230, 234], ["collagen type IV", "DNA", 236, 252], ["collagen type I", "DNA", 254, 269], ["fibronectin 1", "DNA", 271, 284], ["\u03b2-actin", "DNA", 289, 296], ["RPTCs", "TEST", 25, 30], ["serum", "TEST", 58, 63], ["TGF", "TEST", 106, 109], ["Methods", "TEST", 149, 156], ["Hnrnpf", "TEST", 183, 189], ["Ace", "TEST", 191, 194], ["Ace", "TEST", 196, 199], ["MasR", "TEST", 203, 207], ["Tgf", "TEST", 209, 212], ["Tgf", "TEST", 217, 220], ["\u03b2rI", "TEST", 221, 224], ["Tgf", "TEST", 226, 229], ["collagen type IV", "TREATMENT", 236, 252], ["fibronectin", "TEST", 271, 282], ["\u03b2-actin mRNA expression levels", "TEST", 289, 319], ["RPTs", "TEST", 323, 327], ["quantitative PCR", "TEST", 357, 373], ["RT-qPCR", "TEST", 375, 382]]], ["The relative densities of hnRNP F, ACE, ACE-2, Ang 1-7 receptor (MasR), TGF-\u03b21, TGF-\u03b2 RI, TGF-\u03b2 RII, fibronectin 1, p-Smad2/3, Smad2/3 Akita compared with WT mice and Hnrnpf-Tg mice.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 26, 33], ["ACE", "GENE_OR_GENE_PRODUCT", 35, 38], ["ACE-2", "GENE_OR_GENE_PRODUCT", 40, 45], ["Ang 1-7 receptor", "GENE_OR_GENE_PRODUCT", 47, 63], ["MasR", "GENE_OR_GENE_PRODUCT", 65, 69], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 72, 78], ["TGF-\u03b2 RI", "GENE_OR_GENE_PRODUCT", 80, 88], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 90, 99], ["fibronectin 1", "GENE_OR_GENE_PRODUCT", 101, 114], ["p-Smad2/3", "GENE_OR_GENE_PRODUCT", 116, 125], ["Smad2", "GENE_OR_GENE_PRODUCT", 127, 132], ["3", "GENE_OR_GENE_PRODUCT", 133, 134], ["Akita", "GENE_OR_GENE_PRODUCT", 135, 140], ["WT mice", "ORGANISM", 155, 162], ["Hnrnpf-Tg mice", "ORGANISM", 167, 181], ["hnRNP F", "PROTEIN", 26, 33], ["ACE", "PROTEIN", 35, 38], ["ACE", "PROTEIN", 40, 43], ["Ang 1-7 receptor", "PROTEIN", 47, 63], ["MasR", "PROTEIN", 65, 69], ["TGF-\u03b21", "PROTEIN", 72, 78], ["TGF-\u03b2 RI", "PROTEIN", 80, 88], ["TGF-\u03b2 RII", "PROTEIN", 90, 99], ["fibronectin 1", "PROTEIN", 101, 114], ["p-Smad2", "PROTEIN", 116, 123], ["Smad2/3 Akita", "PROTEIN", 127, 140], ["Hnrnpf", "PROTEIN", 167, 173], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 158, 162], ["hnRNP F", "TREATMENT", 26, 33], ["ACE", "TEST", 35, 38], ["ACE", "TEST", 40, 43], ["Ang", "TEST", 47, 50], ["MasR", "TEST", 65, 69], ["TGF", "TEST", 72, 75], ["TGF", "TEST", 80, 83], ["RI", "TEST", 86, 88], ["TGF", "TEST", 90, 93], ["RII", "TEST", 96, 99], ["fibronectin", "TEST", 101, 112], ["p-Smad2", "TEST", 116, 123], ["densities", "OBSERVATION", 13, 22]]], ["Overexpression of hnRNP F had no effect on blood glucose levels in Akita Hnrnpf-Tg mice.", [["blood", "ANATOMY", 43, 48], ["glucose", "CHEMICAL", 49, 56], ["glucose", "CHEMICAL", 49, 56], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 18, 25], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["glucose", "SIMPLE_CHEMICAL", 49, 56], ["Akita Hnrnpf-Tg mice", "ORGANISM", 67, 87], ["hnRNP F", "PROTEIN", 18, 25], ["Hnrnpf", "PROTEIN", 73, 79], ["mice", "SPECIES", 83, 87], ["blood glucose levels", "TEST", 43, 63]]], ["Systolic BP (SBP), kidney weight (KW)/BW and KW/tibial length (TL) ratios, GFR and ACR were all elevated in Akita mice, compared with both WT controls and Hnrnpf-Tg mice.", [["kidney", "ANATOMY", 19, 25], ["tibial", "ANATOMY", 48, 54], ["kidney", "ORGAN", 19, 25], ["tibial", "MULTI-TISSUE_STRUCTURE", 48, 54], ["Akita mice", "ORGANISM", 108, 118], ["Hnrnpf-Tg mice", "ORGANISM", 155, 169], ["Hnrnpf", "PROTEIN", 155, 161], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 165, 169], ["mice", "SPECIES", 114, 118], ["Systolic BP", "TEST", 0, 11], ["SBP", "TEST", 13, 16], ["kidney weight", "TEST", 19, 32], ["KW", "TEST", 34, 36], ["BW", "TEST", 38, 40], ["KW", "TEST", 45, 47], ["tibial length", "TEST", 48, 61], ["TL) ratios", "TEST", 63, 73], ["GFR", "TEST", 75, 78], ["ACR", "TEST", 83, 86], ["kidney", "ANATOMY", 19, 25], ["tibial", "ANATOMY", 48, 54], ["elevated", "OBSERVATION_MODIFIER", 96, 104]]], ["HnRNP F overexpression in RPTCs markedly attenuated these changes in diabetic Akita Hnrnpf-Tg mice.", [["RPTCs", "ANATOMY", 26, 31], ["diabetic", "DISEASE", 69, 77], ["HnRNP F", "GENE_OR_GENE_PRODUCT", 0, 7], ["RPTCs", "SIMPLE_CHEMICAL", 26, 31], ["Akita", "ORGANISM", 78, 83], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 84, 90], ["HnRNP F", "PROTEIN", 0, 7], ["mice", "SPECIES", 94, 98], ["markedly", "OBSERVATION_MODIFIER", 32, 40], ["attenuated", "OBSERVATION", 41, 51], ["diabetic Akita", "OBSERVATION", 69, 83]]], ["Furthermore, Akita mice exhibited elevated urinary AGT and Ang II levels, parallel with decreased Ang 1-7 levels, compared with WT mice.", [["urinary", "ANATOMY", 43, 50], ["Ang II", "CHEMICAL", 59, 65], ["Ang", "CHEMICAL", 98, 101], ["Akita mice", "ORGANISM", 13, 23], ["urinary", "ORGANISM_SUBSTANCE", 43, 50], ["AGT", "GENE_OR_GENE_PRODUCT", 51, 54], ["Ang II", "GENE_OR_GENE_PRODUCT", 59, 65], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 98, 105], ["WT mice", "ORGANISM", 128, 135], ["urinary AGT", "PROTEIN", 43, 54], ["Ang II", "PROTEIN", 59, 65], ["Ang 1-7", "PROTEIN", 98, 105], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 131, 135], ["elevated urinary AGT", "PROBLEM", 34, 54], ["Ang II levels", "TEST", 59, 72], ["elevated", "OBSERVATION", 34, 42], ["urinary AGT", "ANATOMY", 43, 54], ["decreased", "OBSERVATION_MODIFIER", 88, 97]]], ["HnRNP F overexpression partially reduced urinary AGT and Ang II levels, whereas it completely normalised urinary Ang 1-7 levels-a novel finding.MethodsEffect of hnRNP F overexpression on AGT, ACE, ACE-2 and MasR expression in Akita Hnrnpf-Tg mouse kidneys Immunostaining revealed that HnRNP F (Fig. 1a) was overexpressed in RPTCs of Hnrnpf-Tg and Akita Hnrnpf-Tg mice compared with WT and Akita mice, respectively.", [["urinary", "ANATOMY", 41, 48], ["urinary", "ANATOMY", 105, 112], ["kidneys", "ANATOMY", 248, 255], ["RPTCs", "ANATOMY", 324, 329], ["Ang II", "CHEMICAL", 57, 63], ["Ang", "CHEMICAL", 113, 116], ["HnRNP F", "GENE_OR_GENE_PRODUCT", 0, 7], ["urinary", "ORGANISM_SUBSTANCE", 41, 48], ["AGT", "GENE_OR_GENE_PRODUCT", 49, 52], ["Ang II", "GENE_OR_GENE_PRODUCT", 57, 63], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 113, 120], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 161, 168], ["AGT", "GENE_OR_GENE_PRODUCT", 187, 190], ["ACE", "GENE_OR_GENE_PRODUCT", 192, 195], ["ACE-2", "GENE_OR_GENE_PRODUCT", 197, 202], ["MasR", "GENE_OR_GENE_PRODUCT", 207, 211], ["Akita", "ORGANISM", 226, 231], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 232, 238], ["mouse", "ORGANISM", 242, 247], ["kidneys", "ORGAN", 248, 255], ["HnRNP F", "GENE_OR_GENE_PRODUCT", 285, 292], ["Fig. 1a", "GENE_OR_GENE_PRODUCT", 294, 301], ["RPTCs", "CANCER", 324, 329], ["Hnrnpf-Tg", "GENE_OR_GENE_PRODUCT", 333, 342], ["Akita", "ORGANISM", 347, 352], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 353, 359], ["Akita mice", "ORGANISM", 389, 399], ["HnRNP F", "PROTEIN", 0, 7], ["urinary AGT", "PROTEIN", 41, 52], ["Ang II", "PROTEIN", 57, 63], ["hnRNP F", "PROTEIN", 161, 168], ["MasR", "PROTEIN", 207, 211], ["Hnrnpf", "PROTEIN", 232, 238], ["HnRNP F", "PROTEIN", 285, 292], ["RPTCs", "CELL_TYPE", 324, 329], ["Hnrnpf", "PROTEIN", 353, 359], ["mouse", "SPECIES", 242, 247], ["mice", "SPECIES", 363, 367], ["mice", "SPECIES", 395, 399], ["mouse", "SPECIES", 242, 247], ["mice", "SPECIES", 363, 367], ["mice", "SPECIES", 395, 399], ["partially reduced urinary AGT", "PROBLEM", 23, 52], ["Ang II levels", "TEST", 57, 70], ["urinary Ang", "TEST", 105, 116], ["AGT", "TEST", 187, 190], ["ACE", "TREATMENT", 192, 195], ["ACE", "TEST", 197, 200], ["MasR expression", "TREATMENT", 207, 222], ["Hnrnpf", "TREATMENT", 333, 339], ["partially", "OBSERVATION_MODIFIER", 23, 32], ["reduced", "OBSERVATION_MODIFIER", 33, 40], ["urinary AGT", "OBSERVATION", 41, 52], ["Ang II", "OBSERVATION_MODIFIER", 57, 63], ["urinary", "ANATOMY", 105, 112], ["kidneys", "ANATOMY", 248, 255]]], ["ACE-2 ( Fig. 1b) and MasR (Fig. 1c ) expression was decreased in Akita mice compared with WT controls and normalised in Akita Hnrnpf-Tg mice.", [["ACE-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Fig. 1b", "GENE_OR_GENE_PRODUCT", 8, 15], ["MasR (Fig. 1c", "GENE_OR_GENE_PRODUCT", 21, 34], ["Akita mice", "ORGANISM", 65, 75], ["Akita Hnrnpf-Tg mice", "ORGANISM", 120, 140], ["ACE", "PROTEIN", 0, 3], ["MasR", "PROTEIN", 21, 25], ["Hnrnpf", "PROTEIN", 126, 132], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 71, 75], ["ACE", "TEST", 0, 3], ["MasR (Fig. 1c ) expression", "TREATMENT", 21, 47], ["decreased", "OBSERVATION_MODIFIER", 52, 61]]], ["RPTC ACE (Fig. 1d ) expression did not differ between WT and Hnrnpf-Tg mice, whereas ACE expression was significantly higher in Akita mice than in WT controls and was not normalised in Akita Hnrnpf-Tg mice.", [["RPTC ACE", "GENE_OR_GENE_PRODUCT", 0, 8], ["Fig. 1d", "GENE_OR_GENE_PRODUCT", 10, 17], ["Hnrnpf-Tg mice", "ORGANISM", 61, 75], ["ACE", "GENE_OR_GENE_PRODUCT", 85, 88], ["Akita mice", "ORGANISM", 128, 138], ["WT controls", "ORGANISM", 147, 158], ["Akita Hnrnpf-Tg mice", "ORGANISM", 185, 205], ["RPTC ACE", "PROTEIN", 0, 8], ["Hnrnpf", "PROTEIN", 61, 67], ["ACE", "PROTEIN", 85, 88], ["Hnrnpf", "PROTEIN", 191, 197], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 134, 138], ["WT", "TEST", 54, 56], ["ACE expression", "TEST", 85, 99]]], ["WB and RT-qPCR for hnRNP F, ACE-2, MasR and ACE protein and their mRNA levels ( Fig. 1e -l, respectively) confirmed these observations.MethodsEffect of hnRNP F overexpression on TGF-\u03b21, TGF-\u03b2 RII and TGF-\u03b2 RI expression in Akita Hnrnpf-Tg mouse kidneys Immunostaining of TGF-\u03b21 (Fig. 2a) and TGF-\u03b2 RII (Fig. 2b) , WB of TGF-\u03b21 (Fig. 2d) and TGF-\u03b2 RII expression Values are means+SEM corrected to \u03b2-actin, n=6. *p<0.05; **p<0.01 (Fig. 2e) , and RT-qPCR of Tgf-\u03b21 (Fig. 2g) and Tgf-\u03b2rII (Fig. 2h ) mRNA expression showed significantly higher TGF-\u03b21 and TGF-\u03b2 RII expression in RPTCs of Akita mice than in WT controls and Hnrnpf-Tg mice, and they were attenuated in Akita Hnrnpf-Tg mice.", [["WB", "ANATOMY", 0, 2], ["kidneys", "ANATOMY", 245, 252], ["RPTCs", "ANATOMY", 575, 580], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 19, 26], ["ACE-2", "GENE_OR_GENE_PRODUCT", 28, 33], ["MasR", "GENE_OR_GENE_PRODUCT", 35, 39], ["ACE", "GENE_OR_GENE_PRODUCT", 44, 47], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 152, 159], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 178, 184], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 186, 195], ["TGF-\u03b2 RI", "GENE_OR_GENE_PRODUCT", 200, 208], ["Akita", "ORGANISM", 223, 228], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 229, 235], ["mouse", "ORGANISM", 239, 244], ["kidneys", "ORGAN", 245, 252], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 271, 277], ["Fig. 2a", "GENE_OR_GENE_PRODUCT", 279, 286], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 292, 301], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 320, 326], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 341, 350], ["Tgf-\u03b21", "GENE_OR_GENE_PRODUCT", 455, 461], ["Fig. 2g", "GENE_OR_GENE_PRODUCT", 463, 470], ["Tgf-\u03b2rII", "GENE_OR_GENE_PRODUCT", 476, 484], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 540, 546], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 551, 560], ["RPTCs", "PATHOLOGICAL_FORMATION", 575, 580], ["Akita mice", "ORGANISM", 584, 594], ["WT controls", "ORGANISM", 603, 614], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 619, 625], ["-Tg mice", "ORGANISM", 625, 633], ["Akita Hnrnpf-Tg mice", "ORGANISM", 663, 683], ["hnRNP F", "PROTEIN", 19, 26], ["ACE", "PROTEIN", 28, 31], ["MasR", "PROTEIN", 35, 39], ["ACE protein", "PROTEIN", 44, 55], ["hnRNP F", "PROTEIN", 152, 159], ["TGF-\u03b21", "PROTEIN", 271, 277], ["TGF", "PROTEIN", 292, 295], ["\u03b2 RII", "PROTEIN", 296, 301], ["TGF", "PROTEIN", 320, 323], ["\u03b21", "PROTEIN", 324, 326], ["TGF", "PROTEIN", 341, 344], ["\u03b2-actin", "PROTEIN", 396, 403], ["Tgf", "PROTEIN", 455, 458], ["Tgf-\u03b2rII (Fig. 2h ) mRNA", "RNA", 476, 500], ["TGF-\u03b21", "PROTEIN", 540, 546], ["TGF", "PROTEIN", 551, 554], ["RPTCs", "CELL_TYPE", 575, 580], ["Hnrnpf", "PROTEIN", 669, 675], ["mouse", "SPECIES", 239, 244], ["mice", "SPECIES", 590, 594], ["mice", "SPECIES", 629, 633], ["mice", "SPECIES", 679, 683], ["mouse", "SPECIES", 239, 244], ["mice", "SPECIES", 590, 594], ["mice", "SPECIES", 629, 633], ["WB", "TEST", 0, 2], ["RT", "TEST", 7, 9], ["hnRNP F", "TEST", 19, 26], ["ACE", "TEST", 28, 31], ["MasR", "TREATMENT", 35, 39], ["ACE protein", "TREATMENT", 44, 55], ["their mRNA levels", "TEST", 60, 77], ["overexpression", "TEST", 160, 174], ["TGF", "TEST", 178, 181], ["TGF", "TEST", 186, 189], ["RII", "TEST", 192, 195], ["TGF", "TEST", 200, 203], ["RI expression", "TEST", 206, 219], ["Akita", "TEST", 223, 228], ["Hnrnpf", "TEST", 229, 235], ["Immunostaining", "TEST", 253, 267], ["TGF", "TEST", 271, 274], ["TGF", "TEST", 292, 295], ["RII", "TEST", 298, 301], ["WB", "TEST", 314, 316], ["TGF", "TEST", 320, 323], ["TGF", "TEST", 341, 344], ["SEM", "TEST", 379, 382], ["\u03b2-actin", "TEST", 396, 403], ["RT", "TEST", 444, 446], ["Tgf", "TEST", 455, 458], ["Tgf", "TEST", 476, 479], ["mRNA expression", "TEST", 496, 511], ["TGF", "TEST", 540, 543], ["TGF", "TEST", 551, 554], ["kidneys", "ANATOMY", 245, 252]]], ["In contrast, TGF-\u03b2 RI expression was similar in all groups studied (Fig. 2c,f,i) .MethodsHnRNP F overexpression suppresses renal fibrosis in Akita Hnrnpf-Tg mice Akita mice developed renal structural damage compared with WT and Hnrnpf-Tg mice (ESM Fig. 1a , PAS staining), including tubular luminal dilatation with accumulation of cell debris, increased extracellular matrix proteins in glomeruli and tubules, and proximal tubule cell atrophy.", [["renal", "ANATOMY", 123, 128], ["renal", "ANATOMY", 183, 188], ["tubular luminal", "ANATOMY", 283, 298], ["cell", "ANATOMY", 331, 335], ["extracellular matrix", "ANATOMY", 354, 374], ["glomeruli", "ANATOMY", 387, 396], ["tubules", "ANATOMY", 401, 408], ["tubule cell", "ANATOMY", 423, 434], ["fibrosis", "DISEASE", 129, 137], ["renal structural damage", "DISEASE", 183, 206], ["luminal", "CHEMICAL", 291, 298], ["TGF-\u03b2 RI", "GENE_OR_GENE_PRODUCT", 13, 21], ["MethodsHnRNP F", "GENE_OR_GENE_PRODUCT", 82, 96], ["renal", "ORGAN", 123, 128], ["Akita Hnrnpf-Tg mice Akita mice", "ORGANISM", 141, 172], ["renal", "ORGAN", 183, 188], ["Hnrnpf-Tg mice", "ORGANISM", 228, 242], ["tubular luminal", "MULTI-TISSUE_STRUCTURE", 283, 298], ["cell", "CELL", 331, 335], ["extracellular matrix", "CELLULAR_COMPONENT", 354, 374], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 387, 396], ["tubules", "TISSUE", 401, 408], ["tubule cell", "CELL", 423, 434], ["TGF-\u03b2 RI", "PROTEIN", 13, 21], ["MethodsHnRNP F", "PROTEIN", 82, 96], ["Hnrnpf", "PROTEIN", 228, 234], ["extracellular matrix proteins", "PROTEIN", 354, 383], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 238, 242], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 168, 172], ["mice", "SPECIES", 238, 242], ["TGF", "TEST", 13, 16], ["renal fibrosis", "PROBLEM", 123, 137], ["renal structural damage", "PROBLEM", 183, 206], ["WT", "TEST", 221, 223], ["Hnrnpf", "TEST", 228, 234], ["ESM Fig.", "TEST", 244, 252], ["PAS staining", "TEST", 258, 270], ["tubular luminal dilatation", "PROBLEM", 283, 309], ["cell debris", "PROBLEM", 331, 342], ["increased extracellular matrix proteins in glomeruli and tubules", "PROBLEM", 344, 408], ["proximal tubule cell atrophy", "PROBLEM", 414, 442], ["renal", "ANATOMY", 123, 128], ["fibrosis", "OBSERVATION", 129, 137], ["renal", "ANATOMY", 183, 188], ["damage", "OBSERVATION", 200, 206], ["tubular", "ANATOMY_MODIFIER", 283, 290], ["luminal", "ANATOMY_MODIFIER", 291, 298], ["dilatation", "OBSERVATION", 299, 309], ["accumulation of cell debris", "OBSERVATION", 315, 342], ["increased", "OBSERVATION_MODIFIER", 344, 353], ["extracellular matrix proteins", "OBSERVATION", 354, 383], ["glomeruli", "ANATOMY", 387, 396], ["tubules", "ANATOMY_MODIFIER", 401, 408], ["proximal", "ANATOMY_MODIFIER", 414, 422], ["tubule cell atrophy", "OBSERVATION", 423, 442]]], ["HnRNP F overexpression markedly reversed but never completely resolved these abnormalities in Akita mice.", [["HnRNP F", "GENE_OR_GENE_PRODUCT", 0, 7], ["Akita mice", "ORGANISM", 94, 104], ["HnRNP F", "PROTEIN", 0, 7], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104], ["these abnormalities", "PROBLEM", 71, 90], ["markedly", "OBSERVATION_MODIFIER", 23, 31], ["reversed", "OBSERVATION", 32, 40]]], ["We detected significant increases in Masson's trichrome staining (Fig. 3a) and immunostaining for collagen type IV (Fig. 3b) , fibronectin 1 expression (Fig. 3c ) and collagen type I (Fig. 3d) in glomerulotubular areas in Akita mice compared with WT controls and Hnrnpf-Tg mice.", [["glomerulotubular areas", "ANATOMY", 196, 218], ["collagen type IV", "GENE_OR_GENE_PRODUCT", 98, 114], ["Fig. 3b", "GENE_OR_GENE_PRODUCT", 116, 123], ["fibronectin 1", "GENE_OR_GENE_PRODUCT", 127, 140], ["Fig. 3c", "GENE_OR_GENE_PRODUCT", 153, 160], ["collagen type I", "GENE_OR_GENE_PRODUCT", 167, 182], ["glomerulotubular areas", "MULTI-TISSUE_STRUCTURE", 196, 218], ["Akita mice", "ORGANISM", 222, 232], ["WT controls", "ORGANISM", 247, 258], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 263, 269], ["-Tg mice", "ORGANISM", 269, 277], ["collagen type IV", "PROTEIN", 98, 114], ["Fig. 3b", "PROTEIN", 116, 123], ["fibronectin 1", "PROTEIN", 127, 140], ["collagen type I", "PROTEIN", 167, 182], ["Fig. 3d", "PROTEIN", 184, 191], ["Hnrnpf", "PROTEIN", 263, 269], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 273, 277], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 273, 277], ["significant increases", "PROBLEM", 12, 33], ["Masson's trichrome staining", "PROBLEM", 37, 64], ["immunostaining", "TEST", 79, 93], ["collagen type IV (Fig. 3b)", "TREATMENT", 98, 124], ["fibronectin 1 expression (Fig.", "TREATMENT", 127, 157], ["collagen type I (Fig. 3d) in glomerulotubular areas", "TREATMENT", 167, 218], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["Masson's", "OBSERVATION", 37, 45], ["trichrome staining", "OBSERVATION", 46, 64]]], ["These changes were reduced in Akita Hnrnpf-Tg mice.", [["Akita", "ORGANISM", 30, 35], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 36, 42], ["Hnrnpf", "PROTEIN", 36, 42], ["mice", "SPECIES", 46, 50], ["reduced", "OBSERVATION_MODIFIER", 19, 26]]], ["Quantification of Masson's trichrome-stained (ESM Fig. 1b) , immunostaining of collagen IV (Fig. 3e) , fibronectin 1 (Fig. 3f) and collagen I (Fig. 3g) , and RT-qPCR quantification of mRNA levels (Fig. 3h-j) confirmed their expression.MethodsHnRNP F overexpression enhances Ace-2 and suppresses Agt, Tgf-\u03b21 and Tgf-\u03b2rII gene expression and protein levels in rat RPTCs in vitro RPTCs stably transfected with pcDNA 3.1/Hnrnpf (RPTC-pcDNA 3.1/Hnrnpf) exhibited considerably higher levels of hnRNP F (Fig. 4a,b) , lower amounts of AGT (Fig. 4a,c) and a higher amount of ACE-2 (Fig. 4a,d) than non-transfected RPTCs or RPTCs stably transfected with pcDNA 3.1 (RPTC-pcDNA 3.1).MethodsIn contrast, TGF-\u03b21 and TGF-\u03b2 RII protein levels were significantly decreased in RPTC-pcDNA 3.1/Hnrnpf compared with non-transfected RPTCs or RPTC-pcDNA 3.1 (p<0.01) (Fig. 4e,f,g, respectively) .", [["RPTCs", "ANATOMY", 362, 367], ["RPTCs", "ANATOMY", 377, 382], ["RPTCs", "ANATOMY", 605, 610], ["RPTCs", "ANATOMY", 614, 619], ["RPTCs", "ANATOMY", 811, 816], ["collagen IV", "GENE_OR_GENE_PRODUCT", 79, 90], ["Fig. 3e", "GENE_OR_GENE_PRODUCT", 92, 99], ["fibronectin 1", "GENE_OR_GENE_PRODUCT", 103, 116], ["Fig. 3f", "GENE_OR_GENE_PRODUCT", 118, 125], ["collagen I", "GENE_OR_GENE_PRODUCT", 131, 141], ["MethodsHnRNP F", "GENE_OR_GENE_PRODUCT", 235, 249], ["Ace-2", "GENE_OR_GENE_PRODUCT", 274, 279], ["Agt", "GENE_OR_GENE_PRODUCT", 295, 298], ["Tgf-\u03b21", "GENE_OR_GENE_PRODUCT", 300, 306], ["Tgf-\u03b2rII", "GENE_OR_GENE_PRODUCT", 311, 319], ["rat", "ORGANISM", 358, 361], ["RPTCs", "CELL", 362, 367], ["pcDNA 3.1", "ORGANISM", 407, 416], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 417, 423], ["RPTC-pcDNA 3.1", "GENE_OR_GENE_PRODUCT", 425, 439], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 440, 446], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 488, 495], ["Fig. 4a", "GENE_OR_GENE_PRODUCT", 497, 504], ["b", "GENE_OR_GENE_PRODUCT", 505, 506], ["AGT", "GENE_OR_GENE_PRODUCT", 527, 530], ["c", "GENE_OR_GENE_PRODUCT", 540, 541], ["ACE-2", "GENE_OR_GENE_PRODUCT", 566, 571], ["Fig. 4a", "GENE_OR_GENE_PRODUCT", 573, 580], ["RPTCs", "CELL", 605, 610], ["RPTCs", "CELL", 614, 619], ["pcDNA 3.1", "ORGANISM", 644, 653], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 691, 697], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 702, 711], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 774, 780], ["RPTCs", "CELL", 811, 816], ["collagen IV", "PROTEIN", 79, 90], ["Fig. 3e", "PROTEIN", 92, 99], ["fibronectin 1", "PROTEIN", 103, 116], ["Fig. 3f", "PROTEIN", 118, 125], ["collagen I", "PROTEIN", 131, 141], ["MethodsHnRNP F", "PROTEIN", 235, 249], ["Ace", "PROTEIN", 274, 277], ["Agt", "PROTEIN", 295, 298], ["\u03b2rII", "DNA", 315, 319], ["rat RPTCs", "CELL_TYPE", 358, 367], ["pcDNA 3.1", "DNA", 407, 416], ["Hnrnpf", "PROTEIN", 417, 423], ["RPTC", "PROTEIN", 425, 429], ["pcDNA 3.1", "PROTEIN", 430, 439], ["Hnrnpf", "PROTEIN", 440, 446], ["hnRNP F", "PROTEIN", 488, 495], ["Fig. 4a,b)", "PROTEIN", 497, 507], ["AGT", "PROTEIN", 527, 530], ["ACE", "PROTEIN", 566, 569], ["non-transfected RPTCs", "CELL_LINE", 589, 610], ["RPTCs", "CELL_LINE", 614, 619], ["pcDNA 3.1", "DNA", 644, 653], ["RPTC", "PROTEIN", 655, 659], ["TGF-\u03b21", "PROTEIN", 691, 697], ["Hnrnpf", "PROTEIN", 774, 780], ["rat", "SPECIES", 358, 361], ["rat", "SPECIES", 358, 361], ["Masson's trichrome", "TEST", 18, 36], ["collagen IV", "TREATMENT", 79, 90], ["fibronectin", "TEST", 103, 114], ["RT", "TEST", 158, 160], ["mRNA levels", "TEST", 184, 195], ["Ace", "TEST", 274, 277], ["Agt", "TEST", 295, 298], ["Tgf", "TEST", 300, 303], ["Tgf", "TEST", 311, 314], ["protein levels", "TEST", 340, 354], ["rat RPTCs", "TEST", 358, 367], ["vitro RPTCs", "TEST", 371, 382], ["pcDNA", "TEST", 407, 412], ["Hnrnpf", "TEST", 417, 423], ["RPTC", "TEST", 425, 429], ["pcDNA", "TEST", 430, 435], ["hnRNP F", "TREATMENT", 488, 495], ["AGT (Fig. 4a", "TREATMENT", 527, 539], ["a higher amount of ACE", "TREATMENT", 547, 569], ["non-transfected RPTCs", "TEST", 589, 610], ["RPTCs", "TEST", 614, 619], ["pcDNA", "TEST", 644, 649], ["RPTC", "TEST", 655, 659], ["MethodsIn contrast", "TEST", 671, 689], ["TGF", "TEST", 691, 694], ["TGF", "TEST", 702, 705], ["RII protein levels", "TEST", 708, 726], ["RPTC", "TEST", 759, 763], ["pcDNA", "TEST", 764, 769], ["non-transfected RPTCs", "TEST", 795, 816], ["RPTC", "TEST", 820, 824], ["pcDNA", "TEST", 825, 830], ["Masson", "OBSERVATION", 18, 24], ["decreased", "OBSERVATION_MODIFIER", 746, 755]]], ["TGF-\u03b2 RI protein level was similar in non-transfected RPTCs, RPTC-pcDNA 3.1 or RPTC-pcDNA 3.1/Hnrnpf (Fig. 4h) .MethodsRT-qPCR of Hnrnpf, Agt, Ace-2, Tgf-\u03b21, Tgf-\u03b2rII and Tgf-\u03b2rI mRNA levels confirmed these findings (ESM Fig. 2a-f ).MethodsTGF-\u03b21 signalling and inhibition of Ace-2 gene expression in rat RPTCs TGF-\u03b21 inhibited rat Ace-2 gene promoter activity (Fig. 5a) , rat Ace-2 mRNA expression (Fig. 5b) and rat ACE-2 protein level (Fig. 5c) in a concentration-dependent manner, which was reversed by SB431542 (a TGF-\u03b2 RI inhibitor) (Fig. 5d-f, respectively) .", [["RPTCs", "ANATOMY", 54, 59], ["SB431542", "CHEMICAL", 506, 514], ["SB431542", "CHEMICAL", 506, 514], ["TGF-\u03b2 RI", "GENE_OR_GENE_PRODUCT", 0, 8], ["RPTCs", "CELL", 54, 59], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 130, 136], ["Agt", "GENE_OR_GENE_PRODUCT", 138, 141], ["Ace-2", "GENE_OR_GENE_PRODUCT", 143, 148], ["Tgf-\u03b21", "GENE_OR_GENE_PRODUCT", 150, 156], ["Tgf-\u03b2rII", "GENE_OR_GENE_PRODUCT", 158, 166], ["Tgf-\u03b2rI", "GENE_OR_GENE_PRODUCT", 171, 178], ["MethodsTGF-\u03b21", "GENE_OR_GENE_PRODUCT", 233, 246], ["Ace-2", "GENE_OR_GENE_PRODUCT", 276, 281], ["rat", "ORGANISM", 301, 304], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 311, 317], ["rat", "ORGANISM", 328, 331], ["Ace-2", "GENE_OR_GENE_PRODUCT", 332, 337], ["rat", "ORGANISM", 373, 376], ["Ace-2", "GENE_OR_GENE_PRODUCT", 377, 382], ["rat", "ORGANISM", 413, 416], ["ACE-2", "GENE_OR_GENE_PRODUCT", 417, 422], ["SB431542", "SIMPLE_CHEMICAL", 506, 514], ["TGF-\u03b2 RI", "GENE_OR_GENE_PRODUCT", 518, 526], ["TGF-\u03b2 RI", "PROTEIN", 0, 8], ["RPTC", "PROTEIN", 79, 83], ["Hnrnpf", "PROTEIN", 94, 100], ["Hnrnpf, Agt, Ace-2", "DNA", 130, 148], ["Tgf", "PROTEIN", 150, 153], ["Tgf", "DNA", 158, 161], ["\u03b2rII", "DNA", 162, 166], ["Tgf", "DNA", 171, 174], ["MethodsTGF", "PROTEIN", 233, 243], ["\u03b21", "PROTEIN", 244, 246], ["Ace-2 gene", "DNA", 276, 286], ["rat RPTCs TGF-\u03b21", "PROTEIN", 301, 317], ["rat Ace-2 gene promoter", "DNA", 328, 351], ["rat Ace-2 mRNA", "RNA", 373, 387], ["rat ACE-2 protein", "PROTEIN", 413, 430], ["TGF", "PROTEIN", 518, 521], ["rat", "SPECIES", 301, 304], ["rat", "SPECIES", 328, 331], ["rat", "SPECIES", 373, 376], ["rat", "SPECIES", 413, 416], ["rat", "SPECIES", 301, 304], ["TGF", "TEST", 0, 3], ["RI protein level", "TEST", 6, 22], ["RPTCs", "TEST", 54, 59], ["RPTC", "TEST", 61, 65], ["pcDNA", "TEST", 66, 71], ["RPTC", "TEST", 79, 83], ["pcDNA", "TEST", 84, 89], ["MethodsRT", "TEST", 112, 121], ["Hnrnpf", "TEST", 130, 136], ["Agt", "TEST", 138, 141], ["Ace", "TEST", 143, 146], ["Tgf", "TEST", 150, 153], ["Tgf", "TEST", 158, 161], ["Tgf", "TEST", 171, 174], ["mRNA levels", "TEST", 179, 190], ["these findings", "TEST", 201, 215], ["ESM Fig", "TEST", 217, 224], ["MethodsTGF", "TEST", 233, 243], ["Ace", "TEST", 276, 279], ["rat", "TEST", 301, 304], ["RPTCs", "TEST", 305, 310], ["TGF", "TEST", 311, 314], ["\u03b2", "TEST", 315, 316], ["Ace", "TEST", 332, 335], ["rat Ace", "TEST", 373, 380], ["rat ACE", "TEST", 413, 420], ["protein level", "TEST", 423, 436], ["a TGF", "TEST", 516, 521], ["-\u03b2 RI inhibitor", "TREATMENT", 521, 536]]], ["Furthermore, TGF-\u03b21 stimulated Smad 2/3 phosphorylation in a concentration-and timedependent manner (Fig. 5g) and reversed by SB431542 (Fig. 5h) .", [["SB431542", "CHEMICAL", 126, 134], ["SB431542", "CHEMICAL", 126, 134], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 13, 19], ["Smad 2/3", "GENE_OR_GENE_PRODUCT", 31, 39], ["SB431542", "SIMPLE_CHEMICAL", 126, 134], ["TGF-\u03b21", "PROTEIN", 13, 19], ["Smad 2/3", "PROTEIN", 31, 39], ["Furthermore", "TEST", 0, 11], ["TGF", "TEST", 13, 16], ["a concentration-and timedependent manner", "TREATMENT", 59, 99]]], ["These data demonstrate that TGF-\u03b21 inhibition of Ace-2 gene transcription is mediated, at least in part, via Smad2/3 signalling.MethodsHnRNP F overexpression prevents TGF-\u03b2 signalling, and TGF-\u03b2 inhibition of Ace-2 and induction of fibrotic gene expression in RPTCs TGF-\u03b21 had no detectable effect on hnRNP F protein levels (Fig. 6a,b) .", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 28, 34], ["Ace-2", "GENE_OR_GENE_PRODUCT", 49, 54], ["Smad2", "GENE_OR_GENE_PRODUCT", 109, 114], ["3", "GENE_OR_GENE_PRODUCT", 115, 116], ["MethodsHnRNP F", "GENE_OR_GENE_PRODUCT", 128, 142], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 167, 172], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 189, 194], ["Ace-2", "GENE_OR_GENE_PRODUCT", 209, 214], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 266, 272], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 301, 308], ["TGF-\u03b21", "PROTEIN", 28, 34], ["Ace-2 gene", "DNA", 49, 59], ["Smad2", "PROTEIN", 109, 114], ["TGF-\u03b2", "PROTEIN", 167, 172], ["TGF-\u03b2", "PROTEIN", 189, 194], ["Ace-2", "PROTEIN", 209, 214], ["TGF", "PROTEIN", 266, 269], ["\u03b21", "PROTEIN", 270, 272], ["hnRNP F", "PROTEIN", 301, 308], ["These data", "TEST", 0, 10], ["TGF", "TEST", 28, 31], ["Ace-2 gene transcription", "TREATMENT", 49, 73], ["TGF", "TEST", 167, 170], ["signalling", "TEST", 173, 183], ["TGF", "TEST", 189, 192], ["Ace", "TEST", 209, 212], ["fibrotic gene expression", "TEST", 232, 256], ["RPTCs", "TEST", 260, 265], ["TGF", "TEST", 266, 269], ["detectable effect", "PROBLEM", 280, 297], ["hnRNP F protein levels", "TEST", 301, 323], ["fibrotic", "OBSERVATION", 232, 240]]], ["Intriguingly, hnRNP F overexpression prevented TGF-\u03b21 stimulation of Smad 2/3 phosphorylation (Fig. 6a,c) , TGF-\u03b2 RII expression (Fig. 6a , d) and fibronectin 1 expression (Fig. 6a,e) .", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 14, 21], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 47, 53], ["Smad 2/3", "GENE_OR_GENE_PRODUCT", 69, 77], ["Fig. 6a", "GENE_OR_GENE_PRODUCT", 95, 102], ["c", "GENE_OR_GENE_PRODUCT", 103, 104], ["TGF-\u03b2 RII", "GENE_OR_GENE_PRODUCT", 108, 117], ["fibronectin 1", "GENE_OR_GENE_PRODUCT", 147, 160], ["hnRNP F", "PROTEIN", 14, 21], ["TGF-\u03b21", "PROTEIN", 47, 53], ["Smad 2/3", "PROTEIN", 69, 77], ["TGF-\u03b2 RII", "PROTEIN", 108, 117], ["fibronectin 1", "PROTEIN", 147, 160], ["TGF", "TEST", 47, 50], ["Smad", "TEST", 69, 73], ["phosphorylation", "TEST", 78, 93], ["c", "TEST", 103, 104], ["TGF", "TEST", 108, 111]]], ["HnRNP F overexpression also prevented TGF-\u03b21-induced downregulation of MasR (Fig. 6a ,f) content in RPTCs.", [["RPTCs", "ANATOMY", 100, 105], ["HnRNP F", "GENE_OR_GENE_PRODUCT", 0, 7], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 38, 44], ["MasR", "GENE_OR_GENE_PRODUCT", 71, 75], ["Fig. 6a ,f)", "SIMPLE_CHEMICAL", 77, 88], ["RPTCs", "PATHOLOGICAL_FORMATION", 100, 105], ["HnRNP F", "PROTEIN", 0, 7], ["TGF-\u03b21", "PROTEIN", 38, 44], ["MasR", "PROTEIN", 71, 75], ["RPTCs", "CELL_TYPE", 100, 105], ["TGF", "TEST", 38, 41]]], ["Addition of TGF-\u03b21 did not affect TGF-\u03b2 RI expression in RPTCs (Fig. 6a,g) .MethodsFurthermore, overexpression of hnRNP F prevented the inhibitory effect of TGF-\u03b21 on ACE-2 protein (Fig. 6a,h) and Ace-2 mRNA (Fig. 6i ) expression in RPTC-pcDNA 3.1/ Hnrnpf.MethodsLocalisation of Hnrnpf-and TGF-\u03b21 (or SMAD)-RE in rat Ace-2 gene promoter To localise the putative DNA-RE(s) that mediate(s) the action of hnRNP F or TGF-\u03b21 on Ace-2 gene promoter activity, plasmids containing various lengths of the rat Ace-2 gene promoter were transiently transfected into RPTC-pcDNA 3.1 or RPTC-pcDNA 3.1/ Hnrnpf.", [["RPTCs", "ANATOMY", 57, 62], ["plasmids", "ANATOMY", 453, 461], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 12, 18], ["TGF-\u03b2 RI", "GENE_OR_GENE_PRODUCT", 34, 42], ["RPTCs", "PATHOLOGICAL_FORMATION", 57, 62], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 114, 121], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 157, 163], ["ACE-2", "GENE_OR_GENE_PRODUCT", 167, 172], ["Fig. 6a", "GENE_OR_GENE_PRODUCT", 182, 189], ["Ace-2", "GENE_OR_GENE_PRODUCT", 197, 202], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 249, 255], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 279, 285], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 290, 296], ["SMAD)-RE", "GENE_OR_GENE_PRODUCT", 301, 309], ["rat", "ORGANISM", 313, 316], ["Ace-2", "GENE_OR_GENE_PRODUCT", 317, 322], ["DNA", "CELLULAR_COMPONENT", 362, 365], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 402, 409], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 413, 419], ["Ace-2", "GENE_OR_GENE_PRODUCT", 423, 428], ["rat", "ORGANISM", 496, 499], ["Ace-2", "GENE_OR_GENE_PRODUCT", 500, 505], ["pcDNA", "GENE_OR_GENE_PRODUCT", 559, 564], ["RPTC", "GENE_OR_GENE_PRODUCT", 572, 576], ["pcDNA", "GENE_OR_GENE_PRODUCT", 577, 582], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 588, 594], ["TGF-\u03b21", "PROTEIN", 12, 18], ["TGF-\u03b2 RI", "PROTEIN", 34, 42], ["RPTCs", "CELL_TYPE", 57, 62], ["hnRNP F", "PROTEIN", 114, 121], ["TGF-\u03b21", "PROTEIN", 157, 163], ["ACE-2 protein", "PROTEIN", 167, 180], ["Ace-2 mRNA", "RNA", 197, 207], ["RPTC", "PROTEIN", 233, 237], ["Hnrnpf", "PROTEIN", 249, 255], ["Hnrnpf", "PROTEIN", 279, 285], ["TGF-\u03b21 (or SMAD)-RE", "DNA", 290, 309], ["rat Ace-2 gene promoter", "DNA", 313, 336], ["putative DNA-RE", "DNA", 353, 368], ["hnRNP F", "PROTEIN", 402, 409], ["TGF-\u03b21", "PROTEIN", 413, 419], ["Ace-2 gene promoter", "DNA", 423, 442], ["plasmids", "DNA", 453, 461], ["rat Ace-2 gene promoter", "DNA", 496, 519], ["RPTC", "DNA", 554, 558], ["RPTC", "PROTEIN", 572, 576], ["Hnrnpf", "PROTEIN", 588, 594], ["rat", "SPECIES", 313, 316], ["rat", "SPECIES", 496, 499], ["TGF", "TEST", 12, 15], ["TGF", "TEST", 34, 37], ["RPTCs", "TEST", 57, 62], ["TGF", "TEST", 157, 160], ["ACE", "TEST", 167, 170], ["Ace", "TEST", 197, 200], ["RPTC", "TEST", 233, 237], ["pcDNA", "TREATMENT", 238, 243], ["Hnrnpf", "TREATMENT", 249, 255], ["MethodsLocalisation", "TEST", 256, 275], ["Hnrnpf", "TEST", 279, 285], ["TGF", "TEST", 290, 293], ["rat Ace-2 gene promoter", "TREATMENT", 313, 336], ["hnRNP F", "TREATMENT", 402, 409], ["TGF", "TEST", 413, 416], ["Ace-2 gene promoter activity", "TREATMENT", 423, 451], ["plasmids", "TREATMENT", 453, 461], ["the rat Ace-2 gene promoter", "TREATMENT", 492, 519], ["RPTC", "TEST", 554, 558], ["pcDNA", "TEST", 559, 564], ["RPTC", "TEST", 572, 576], ["pcDNA", "TREATMENT", 577, 582], ["Hnrnpf", "TREATMENT", 588, 594]]], ["The activity of pGL4.20-Ace-2 promoter (N-1,091/+ 83) and pGL 4.20-Ace-2 promoter (N-499/+83) exhibited respective fivefold and 12-fold increase as compared with the control plasmid, pGL 4.20 in RPTC-pcDNA 3.1 (Fig. 7a) .", [["plasmid", "ANATOMY", 174, 181], ["pGL4", "GENE_OR_GENE_PRODUCT", 16, 20], ["Ace-2", "GENE_OR_GENE_PRODUCT", 24, 29], ["pGL 4.20", "GENE_OR_GENE_PRODUCT", 58, 66], ["Ace-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["pGL4", "PROTEIN", 16, 20], ["20-Ace-2 promoter", "DNA", 21, 38], ["N-1,091/+ 83", "DNA", 40, 52], ["pGL 4.20", "DNA", 58, 66], ["Ace-2 promoter", "DNA", 67, 81], ["N-499", "DNA", 83, 88], ["control plasmid", "DNA", 166, 181], ["pGL 4.20", "DNA", 183, 191], ["RPTC", "DNA", 195, 199], ["pGL", "TEST", 58, 61], ["Ace", "TEST", 67, 70], ["the control plasmid", "TREATMENT", 162, 181], ["pGL", "TEST", 183, 186], ["RPTC", "TEST", 195, 199], ["pcDNA", "TEST", 200, 205], ["activity", "OBSERVATION_MODIFIER", 4, 12], ["pGL", "ANATOMY", 58, 61]]], ["Further deletion of nucleotides N-499 to N-241 (pGL 4.20-Ace-2 promoter [N-240/+83]) significantly reduced the rat Ace-2 promoter activity.", [["N-499", "CHEMICAL", 32, 37], ["N-241", "CHEMICAL", 41, 46], ["nucleotides", "CHEMICAL", 20, 31], ["Ace-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["rat", "ORGANISM", 111, 114], ["Ace-2", "GENE_OR_GENE_PRODUCT", 115, 120], ["nucleotides N-499", "DNA", 20, 37], ["N-241", "DNA", 41, 46], ["pGL 4.20-Ace-2 promoter", "DNA", 48, 71], ["rat Ace-2 promoter", "DNA", 111, 129], ["rat", "SPECIES", 111, 114], ["nucleotides N", "TEST", 20, 33], ["pGL", "TEST", 48, 51], ["Ace", "TEST", 57, 60], ["the rat Ace", "TREATMENT", 107, 118]]], ["Moreover, the activity of pGL4.20-Ace-2 promoter (N-1,091/+83) and pGL4.20-Ace-2 promoter (N-499/+83) was further increased by 1.5-2.0-fold, whereas the activity of pGL4.20-Ace-2 promoter (N-240/+83) did not increase in RPTC-pcDNA 3.1/Hnrnpf as compared with RPTC-pcDNA 3.1 (Fig. 7a) .", [["pGL4", "GENE_OR_GENE_PRODUCT", 26, 30], ["Ace-2", "GENE_OR_GENE_PRODUCT", 34, 39], ["+83", "GENE_OR_GENE_PRODUCT", 58, 61], ["pGL4", "GENE_OR_GENE_PRODUCT", 67, 71], ["Ace-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["N-499", "GENE_OR_GENE_PRODUCT", 91, 96], ["+83", "GENE_OR_GENE_PRODUCT", 97, 100], ["pGL4", "GENE_OR_GENE_PRODUCT", 165, 169], ["Ace-2", "GENE_OR_GENE_PRODUCT", 173, 178], ["pcDNA", "GENE_OR_GENE_PRODUCT", 225, 230], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 235, 241], ["pGL4", "PROTEIN", 26, 30], ["20-Ace-2 promoter", "DNA", 31, 48], ["N-1,091/+83", "DNA", 50, 61], ["pGL4", "DNA", 67, 71], ["20-Ace-2 promoter", "DNA", 72, 89], ["N-499", "DNA", 91, 96], ["pGL4", "PROTEIN", 165, 169], ["20-Ace-2 promoter", "DNA", 170, 187], ["N-240", "DNA", 189, 194], ["RPTC", "PROTEIN", 220, 224], ["pcDNA 3.1", "DNA", 225, 234], ["Hnrnpf", "PROTEIN", 235, 241], ["RPTC", "PROTEIN", 259, 263], ["Ace-2 promoter", "TREATMENT", 173, 187], ["RPTC", "TEST", 220, 224], ["pcDNA", "TEST", 225, 230], ["RPTC", "TEST", 259, 263], ["pcDNA", "TEST", 264, 269], ["activity", "OBSERVATION_MODIFIER", 14, 22], ["increased", "OBSERVATION_MODIFIER", 114, 123]]], ["Interestingly, addition of TGF-\u03b21 inhibited the promoter activity of pGL 4.20-Ace-2 promoter (N-1,091/+83) and did not affect the activity of pGL 4.20-Ace-2 promoter (N-499/+83) and pGL 4.20-Ace-2 promoter (N-240/+83) in RPTC-pcDNA 3.1 (Fig. 7b) .", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 27, 33], ["pGL 4.20", "GENE_OR_GENE_PRODUCT", 69, 77], ["Ace-2", "GENE_OR_GENE_PRODUCT", 78, 83], ["Ace-2", "GENE_OR_GENE_PRODUCT", 151, 156], ["N-499/+83", "GENE_OR_GENE_PRODUCT", 167, 176], ["Ace-2", "GENE_OR_GENE_PRODUCT", 191, 196], ["TGF-\u03b21", "PROTEIN", 27, 33], ["pGL 4.20-Ace-2 promoter", "DNA", 69, 92], ["N-1,091/+83", "DNA", 94, 105], ["pGL 4.20-Ace-2 promoter", "DNA", 142, 165], ["N-499/+83", "DNA", 167, 176], ["pGL 4.20", "DNA", 182, 190], ["Ace-2 promoter", "DNA", 191, 205], ["N-240/+83", "DNA", 207, 216], ["RPTC", "DNA", 221, 225], ["pcDNA 3.1", "DNA", 226, 235], ["TGF", "TEST", 27, 30], ["pGL", "TEST", 69, 72], ["Ace", "TEST", 78, 81], ["pGL", "TEST", 142, 145], ["Ace", "TEST", 151, 154], ["pGL", "TEST", 182, 185], ["Ace", "TEST", 191, 194], ["RPTC", "TEST", 221, 225], ["pcDNA", "TEST", 226, 231]]], ["However, TGF-\u03b21 had no inhibitory effect on the promoter activity of these constructs in RPTC-pcDNA 3.1/Hnrnpf (Fig. 7c) .MethodsIn contrast, transfection of Hnrnpf siRNA significantly inhibited the promoter activity of pGL 4.20-Ace-2 promoter (N-1,091/+83) and pGL 4.20-Ace-2 promoter (N-499/+83) without affecting the activity of pGL 4.20-Ace-2 promoter (N-240/+83) in RPTC-pcDNA 3.1 (Fig. 7d) .", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 9, 15], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 158, 164], ["pGL 4.20", "GENE_OR_GENE_PRODUCT", 220, 228], ["Ace-2", "GENE_OR_GENE_PRODUCT", 229, 234], ["pGL 4.20-Ace-2", "GENE_OR_GENE_PRODUCT", 262, 276], ["Ace-2", "GENE_OR_GENE_PRODUCT", 341, 346], ["TGF-\u03b21", "PROTEIN", 9, 15], ["RPTC", "DNA", 89, 93], ["Hnrnpf", "PROTEIN", 104, 110], ["pGL 4.20-Ace-2 promoter", "DNA", 220, 243], ["N-1,091/+83", "DNA", 245, 256], ["pGL 4.20", "DNA", 262, 270], ["Ace-2 promoter", "DNA", 271, 285], ["N-499", "DNA", 287, 292], ["pGL 4.20-Ace-2 promoter", "DNA", 332, 355], ["N-240/+83", "DNA", 357, 366], ["RPTC", "DNA", 371, 375], ["TGF", "TEST", 9, 12], ["inhibitory effect", "PROBLEM", 23, 40], ["RPTC", "TEST", 89, 93], ["pcDNA", "TEST", 94, 99], ["MethodsIn contrast", "TREATMENT", 122, 140], ["Hnrnpf siRNA", "TREATMENT", 158, 170], ["pGL", "TEST", 220, 223], ["Ace", "TEST", 229, 232], ["pGL", "TEST", 262, 265], ["Ace", "TEST", 271, 274], ["pGL", "TEST", 332, 335], ["Ace-2 promoter", "TREATMENT", 341, 355], ["RPTC", "TEST", 371, 375], ["pcDNA", "TEST", 376, 381], ["pGL", "ANATOMY", 262, 265]]], ["Deletion of the nucleotides N-401 to N-393 (5\u2032-ggggagagg-3\u2032) in the Ace-2 gene promoter markedly attenuated the promoter activity of pGL 4.20-Ace-2 promoter (N-1,091/+83) and pGL 4.20-Ace-2 promoter (N-499/+83) in RPTC-pcDNA 3.1/Hnrnpf (Fig. 7e) .", [["N-401", "CHEMICAL", 28, 33], ["N-393", "CHEMICAL", 37, 42], ["nucleotides", "CHEMICAL", 16, 27], ["5\u2032-ggggagagg-3", "GENE_OR_GENE_PRODUCT", 44, 58], ["Ace-2", "GENE_OR_GENE_PRODUCT", 68, 73], ["pGL 4.20-Ace-2", "GENE_OR_GENE_PRODUCT", 133, 147], ["pGL 4.20-Ace-2", "GENE_OR_GENE_PRODUCT", 175, 189], ["nucleotides N-401 to N-393", "DNA", 16, 42], ["5\u2032-ggggagagg-3\u2032", "DNA", 44, 59], ["Ace-2 gene promoter", "DNA", 68, 87], ["pGL 4.20-Ace-2 promoter", "DNA", 133, 156], ["N", "DNA", 158, 159], ["pGL 4.20", "DNA", 175, 183], ["Ace-2 promoter", "DNA", 184, 198], ["N-499/+83", "DNA", 200, 209], ["RPTC", "DNA", 214, 218], ["Hnrnpf", "DNA", 229, 235], ["the nucleotides N", "TEST", 12, 29], ["N", "TEST", 37, 38], ["ggggagagg", "TEST", 47, 56], ["the Ace", "TEST", 64, 71], ["pGL", "TEST", 133, 136], ["Ace", "TEST", 142, 145], ["pGL", "TEST", 175, 178], ["Ace", "TEST", 184, 187], ["RPTC", "TEST", 214, 218], ["pcDNA", "TEST", 219, 224], ["pGL", "ANATOMY", 175, 178]]], ["Interestingly, deletion of the putative proximal SMAD-RE (nucleotides N-511 to N-504 [5\u2032-cagagaca-3\u2032]) or distal putative SMAD-RE2 (nucleotides N-789 to N-784 [5\u2032-gagaca-3\u2032]) in the Ace-2 gene promoter partially attenuated whereas deletion of both REs (nucleotides N-511 to N-504 and nucleotides N-789 to N-784) completely abolished the inhibitory action of TGF-\u03b21 on pGL 4.20-Ace-2 promoter (N-1,091/+83) activity in RPTC-pcDNA 3.1 (Fig. 7f) .", [["N-789", "CHEMICAL", 144, 149], ["N-511 to N-504", "CHEMICAL", 265, 279], ["N-789", "CHEMICAL", 296, 301], ["N-784", "CHEMICAL", 305, 310], ["nucleotides", "CHEMICAL", 58, 69], ["nucleotides", "CHEMICAL", 132, 143], ["N-784", "CHEMICAL", 153, 158], ["nucleotides", "CHEMICAL", 253, 264], ["nucleotides", "CHEMICAL", 284, 295], ["N-784", "CHEMICAL", 305, 310], ["SMAD", "GENE_OR_GENE_PRODUCT", 49, 53], ["5\u2032-cagagaca-3", "GENE_OR_GENE_PRODUCT", 86, 99], ["SMAD-RE2", "GENE_OR_GENE_PRODUCT", 122, 130], ["gagaca-3", "GENE_OR_GENE_PRODUCT", 163, 171], ["Ace-2", "GENE_OR_GENE_PRODUCT", 182, 187], ["REs", "GENE_OR_GENE_PRODUCT", 248, 251], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 358, 364], ["Ace-2", "GENE_OR_GENE_PRODUCT", 377, 382], ["+83", "GENE_OR_GENE_PRODUCT", 401, 404], ["putative proximal SMAD-RE (nucleotides N-511 to N-504 [5\u2032-cagagaca-3\u2032]", "DNA", 31, 101], ["distal putative SMAD-RE2", "DNA", 106, 130], ["nucleotides N-789 to N-784 [5\u2032-gagaca-3\u2032]", "DNA", 132, 173], ["Ace-2 gene promoter", "DNA", 182, 201], ["REs", "DNA", 248, 251], ["nucleotides N-511 to N-504", "DNA", 253, 279], ["nucleotides N-789 to N-784", "DNA", 284, 310], ["TGF-\u03b21", "PROTEIN", 358, 364], ["pGL 4.20-Ace-2 promoter", "DNA", 368, 391], ["nucleotides N", "TEST", 58, 71], ["N", "TEST", 79, 80], ["cagagaca", "TEST", 89, 97], ["distal putative SMAD", "TEST", 106, 126], ["nucleotides N", "TEST", 132, 145], ["gagaca", "TEST", 163, 169], ["the Ace", "TEST", 178, 185], ["nucleotides N", "TEST", 253, 266], ["nucleotides N", "TEST", 284, 297], ["TGF", "TEST", 358, 361], ["pGL", "TEST", 368, 371], ["Ace", "TEST", 377, 380], ["RPTC", "TEST", 418, 422], ["pcDNA", "TEST", 423, 428], ["proximal", "ANATOMY_MODIFIER", 40, 48], ["SMAD", "ANATOMY", 49, 53], ["distal", "ANATOMY_MODIFIER", 106, 112]]], ["Furthermore, EMSA showed that the double strand DNA fragments, nucleotides N-405 to N-387 (putative Hnrnpf-RE), nucleotides N-518 to N-497 (putative proximal SMAD-RE1) and nucleotides N-797 to N-776 (putative distal SMAD-RE2) bind to the nuclear proteins from RPTCs and they could be displaced by the respective WT DNA fragments, but not by mutated DNA fragments (Fig. 7g,h, respectively) .", [["nuclear", "ANATOMY", 238, 245], ["RPTCs", "ANATOMY", 260, 265], ["N-776", "CHEMICAL", 193, 198], ["nucleotides", "CHEMICAL", 63, 74], ["nucleotides", "CHEMICAL", 112, 123], ["nucleotides", "CHEMICAL", 172, 183], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["Hnrnpf-RE", "GENE_OR_GENE_PRODUCT", 100, 109], ["SMAD-RE1", "GENE_OR_GENE_PRODUCT", 158, 166], ["SMAD-RE2", "GENE_OR_GENE_PRODUCT", 216, 224], ["nuclear", "CELLULAR_COMPONENT", 238, 245], ["RPTCs", "GENE_OR_GENE_PRODUCT", 260, 265], ["DNA", "CELLULAR_COMPONENT", 315, 318], ["DNA", "CELLULAR_COMPONENT", 349, 352], ["double strand DNA fragments", "DNA", 34, 61], ["nucleotides N-405 to N-387", "DNA", 63, 89], ["Hnrnpf", "DNA", 100, 106], ["RE", "DNA", 107, 109], ["nucleotides N-518 to N-497", "DNA", 112, 138], ["putative proximal SMAD", "DNA", 140, 162], ["RE1", "DNA", 163, 166], ["nucleotides N", "DNA", 172, 185], ["N-776", "DNA", 193, 198], ["SMAD", "DNA", 216, 220], ["RE2", "DNA", 221, 224], ["nuclear proteins", "PROTEIN", 238, 254], ["RPTCs", "CELL_TYPE", 260, 265], ["WT DNA fragments", "DNA", 312, 328], ["mutated DNA fragments", "DNA", 341, 362], ["EMSA", "TEST", 13, 17], ["the double strand DNA fragments", "PROBLEM", 30, 61], ["nucleotides N", "TEST", 63, 76], ["nucleotides N", "TEST", 112, 125], ["nucleotides N", "TEST", 172, 185], ["the respective WT DNA fragments", "PROBLEM", 297, 328], ["mutated DNA fragments", "PROBLEM", 341, 362], ["DNA fragments", "OBSERVATION", 315, 328]]], ["Importantly, addition of anti-hnRNP F and anti-Smad 2/3 antibody induced a supershift of the respective Hnrnpf-RE and SMAD-REs with the nuclear proteins, respectively (Fig. 7g,h) .DiscussionThe present report identifies a novel mechanism by which hnRNP F prevents hypertension and kidney injury in diabetic Akita mice, i.e. hnRNP F stimulation of renal Ace-2 gene transcription and mitigation of the inhibitory effect of TGF-\u03b21 on Ace-2 gene transcription.DiscussionWe reported previously that overexpression of hnRNP F prevents systemic hypertension, and inhibits renal Agt gene expression and RPTC hypertrophy in diabetic Akita Hnrnpf-Tg mice [29] .", [["nuclear", "ANATOMY", 136, 143], ["kidney", "ANATOMY", 281, 287], ["renal", "ANATOMY", 347, 352], ["renal", "ANATOMY", 565, 570], ["hypertension", "DISEASE", 264, 276], ["kidney injury", "DISEASE", 281, 294], ["diabetic", "DISEASE", 298, 306], ["hypertension", "DISEASE", 538, 550], ["hypertrophy", "DISEASE", 600, 611], ["diabetic", "DISEASE", 615, 623], ["anti-hnRNP F", "GENE_OR_GENE_PRODUCT", 25, 37], ["anti-Smad 2/3 antibody", "GENE_OR_GENE_PRODUCT", 42, 64], ["Hnrnpf-RE", "GENE_OR_GENE_PRODUCT", 104, 113], ["SMAD-REs", "GENE_OR_GENE_PRODUCT", 118, 126], ["nuclear", "CELLULAR_COMPONENT", 136, 143], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 247, 254], ["kidney", "ORGAN", 281, 287], ["Akita mice", "ORGANISM", 307, 317], ["renal", "ORGAN", 347, 352], ["Ace-2", "GENE_OR_GENE_PRODUCT", 353, 358], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 421, 427], ["Ace-2", "GENE_OR_GENE_PRODUCT", 431, 436], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 512, 519], ["renal", "ORGAN", 565, 570], ["Agt", "GENE_OR_GENE_PRODUCT", 571, 574], ["RPTC", "GENE_OR_GENE_PRODUCT", 595, 599], ["Akita", "ORGANISM", 624, 629], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 630, 636], ["anti-hnRNP F", "PROTEIN", 25, 37], ["anti-Smad 2/3 antibody", "PROTEIN", 42, 64], ["Hnrnpf", "PROTEIN", 104, 110], ["RE", "DNA", 111, 113], ["SMAD", "PROTEIN", 118, 122], ["REs", "DNA", 123, 126], ["nuclear proteins", "PROTEIN", 136, 152], ["hnRNP F", "PROTEIN", 247, 254], ["hnRNP", "RNA", 324, 329], ["renal Ace-2 gene", "DNA", 347, 363], ["TGF-\u03b21", "PROTEIN", 421, 427], ["Ace-2 gene", "DNA", 431, 441], ["hnRNP F", "PROTEIN", 512, 519], ["Agt gene", "DNA", 571, 579], ["mice", "SPECIES", 313, 317], ["mice", "SPECIES", 640, 644], ["mice", "SPECIES", 313, 317], ["anti-hnRNP F", "TREATMENT", 25, 37], ["anti-Smad 2/3 antibody", "TREATMENT", 42, 64], ["hypertension", "PROBLEM", 264, 276], ["kidney injury", "PROBLEM", 281, 294], ["renal Ace-2 gene transcription", "TREATMENT", 347, 377], ["TGF", "TEST", 421, 424], ["Ace-2 gene transcription", "TREATMENT", 431, 455], ["systemic hypertension", "PROBLEM", 529, 550], ["renal Agt gene expression", "PROBLEM", 565, 590], ["RPTC hypertrophy", "PROBLEM", 595, 611], ["hypertension", "OBSERVATION", 264, 276], ["kidney", "ANATOMY", 281, 287], ["injury", "OBSERVATION", 288, 294], ["renal", "ANATOMY", 347, 352], ["hypertension", "OBSERVATION", 538, 550], ["renal", "ANATOMY", 565, 570], ["hypertrophy", "OBSERVATION", 600, 611]]], ["The present paper provides new in vivo and in vitro evidence that hnRNP F stimulates Ace-2 gene transcription via binding to the DNA-RE of the Ace-2 gene promoter, which is critical for the formation of renal Ang 1-7 and subsequent expression of its antihypertensive and renoprotective actions in Akita mice [37] .DiscussionHnRNP F, a member of the pre-mRNA-binding protein family [38] regulates gene expression at both the transcriptional and post-transcriptional levels.", [["renal", "ANATOMY", 203, 208], ["Ang", "CHEMICAL", 209, 212], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 66, 73], ["Ace-2", "GENE_OR_GENE_PRODUCT", 85, 90], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["Ace-2", "GENE_OR_GENE_PRODUCT", 143, 148], ["renal Ang 1-7", "GENE_OR_GENE_PRODUCT", 203, 216], ["Akita mice", "ORGANISM", 297, 307], ["DiscussionHnRNP F", "GENE_OR_GENE_PRODUCT", 314, 331], ["pre-mRNA-binding protein family [38]", "GENE_OR_GENE_PRODUCT", 349, 385], ["hnRNP F", "PROTEIN", 66, 73], ["Ace-2 gene", "DNA", 85, 95], ["DNA-RE", "DNA", 129, 135], ["Ace-2 gene promoter", "DNA", 143, 162], ["renal Ang 1-7", "PROTEIN", 203, 216], ["DiscussionHnRNP F", "PROTEIN", 314, 331], ["pre-mRNA-binding protein family", "PROTEIN", 349, 380], ["mice", "SPECIES", 303, 307], ["Ace-2 gene transcription", "TREATMENT", 85, 109], ["the Ace-2 gene promoter", "TREATMENT", 139, 162], ["renal Ang", "TREATMENT", 203, 212], ["its antihypertensive", "TREATMENT", 246, 266], ["renoprotective actions", "TREATMENT", 271, 293], ["renal", "ANATOMY", 203, 208]]], ["Indeed, hnRNP F engages in alternative splicing of various genes [39] [40] [41] and associates with TATA-binding protein, RNA polymerase II, nuclear cap-binding protein complex and various transcriptional factors.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 8, 15], ["TATA-binding protein", "GENE_OR_GENE_PRODUCT", 100, 120], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 122, 139], ["nuclear cap-binding protein complex", "GENE_OR_GENE_PRODUCT", 141, 176], ["hnRNP F", "PROTEIN", 8, 15], ["TATA-binding protein", "PROTEIN", 100, 120], ["RNA polymerase II", "PROTEIN", 122, 139], ["nuclear cap-binding protein complex", "PROTEIN", 141, 176], ["transcriptional factors", "PROTEIN", 189, 212], ["TATA-binding protein", "TEST", 100, 120], ["RNA polymerase II", "TEST", 122, 139], ["nuclear cap", "TEST", 141, 152], ["binding protein complex", "PROBLEM", 153, 176], ["various transcriptional factors", "PROBLEM", 181, 212]]], ["[42, 43] The Akita mouse is an autosomal-dominant model of spontaneous type 1 diabetes in which the Ins2 gene is mutated.", [["type 1 diabetes", "DISEASE", 71, 86], ["Akita", "ORGANISM", 13, 18], ["mouse", "ORGANISM", 19, 24], ["Ins2", "GENE_OR_GENE_PRODUCT", 100, 104], ["Ins2 gene", "DNA", 100, 109], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["spontaneous type 1 diabetes", "PROBLEM", 59, 86], ["autosomal", "OBSERVATION_MODIFIER", 31, 40], ["-dominant", "OBSERVATION_MODIFIER", 40, 49], ["diabetes", "OBSERVATION", 78, 86]]], ["Akita mice develop hyperglycaemia and systemic hypertension, leading to cardiac hypertrophy, left ventricular diastolic dysfunction, glomerulosclerosis and enhanced oxidative stress in RPTs, closely resembling those observed in patients with type 1 diabetes [44, 45] .DiscussionOur study provides evidence for a novel mechanism for hnRNP F lowering of SBP: inhibition of intrarenal Agt gene expression and RAS activation, concomitant with upregulation of the ACE-2/Ang 1-7/MasR axis.", [["cardiac", "ANATOMY", 72, 79], ["left ventricular", "ANATOMY", 93, 109], ["RPTs", "ANATOMY", 185, 189], ["hyperglycaemia", "DISEASE", 19, 33], ["hypertension", "DISEASE", 47, 59], ["cardiac hypertrophy", "DISEASE", 72, 91], ["left ventricular diastolic dysfunction", "DISEASE", 93, 131], ["glomerulosclerosis", "DISEASE", 133, 151], ["type 1 diabetes", "DISEASE", 242, 257], ["Ang", "CHEMICAL", 465, 468], ["Akita mice", "ORGANISM", 0, 10], ["cardiac", "ORGAN", 72, 79], ["ventricular", "MULTI-TISSUE_STRUCTURE", 98, 109], ["RPTs", "PATHOLOGICAL_FORMATION", 185, 189], ["patients", "ORGANISM", 228, 236], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 332, 339], ["SBP", "SIMPLE_CHEMICAL", 352, 355], ["intrarenal", "GENE_OR_GENE_PRODUCT", 371, 381], ["Agt", "GENE_OR_GENE_PRODUCT", 382, 385], ["RAS", "GENE_OR_GENE_PRODUCT", 406, 409], ["ACE-2", "GENE_OR_GENE_PRODUCT", 459, 464], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 465, 472], ["MasR", "GENE_OR_GENE_PRODUCT", 473, 477], ["hnRNP F", "PROTEIN", 332, 339], ["intrarenal Agt gene", "DNA", 371, 390], ["RAS", "PROTEIN", 406, 409], ["ACE", "PROTEIN", 459, 462], ["Ang 1-7", "PROTEIN", 465, 472], ["MasR", "PROTEIN", 473, 477], ["mice", "SPECIES", 6, 10], ["patients", "SPECIES", 228, 236], ["mice", "SPECIES", 6, 10], ["hyperglycaemia", "PROBLEM", 19, 33], ["systemic hypertension", "PROBLEM", 38, 59], ["cardiac hypertrophy", "PROBLEM", 72, 91], ["left ventricular diastolic dysfunction", "PROBLEM", 93, 131], ["glomerulosclerosis", "PROBLEM", 133, 151], ["enhanced oxidative stress in RPTs", "PROBLEM", 156, 189], ["type 1 diabetes", "PROBLEM", 242, 257], ["DiscussionOur study", "TEST", 268, 287], ["SBP", "TEST", 352, 355], ["intrarenal Agt gene expression", "TREATMENT", 371, 401], ["RAS activation", "PROBLEM", 406, 420], ["the ACE", "TEST", 455, 462], ["Ang", "TEST", 465, 468], ["hyperglycaemia", "OBSERVATION", 19, 33], ["systemic", "OBSERVATION_MODIFIER", 38, 46], ["hypertension", "OBSERVATION", 47, 59], ["cardiac", "ANATOMY", 72, 79], ["hypertrophy", "OBSERVATION", 80, 91], ["left ventricular", "ANATOMY", 93, 109], ["diastolic dysfunction", "OBSERVATION", 110, 131], ["glomerulosclerosis", "OBSERVATION", 133, 151], ["enhanced", "OBSERVATION_MODIFIER", 156, 164], ["oxidative stress", "OBSERVATION", 165, 181]]], ["Indeed, our results show that hnRNP F overexpression inhibited renal AGT and Agt mRNA expression (ESM Fig. 1 c-e), lowered urinary AGT and Ang II levels and normalised urinary Ang 1-7 levels.DiscussionWe consistently observed decreased renal ACE-2 expression in Akita mice as previously reported [23, 24] .", [["renal", "ANATOMY", 63, 68], ["urinary", "ANATOMY", 123, 130], ["urinary", "ANATOMY", 168, 175], ["renal", "ANATOMY", 236, 241], ["Ang II", "CHEMICAL", 139, 145], ["Ang", "CHEMICAL", 176, 179], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 30, 37], ["renal", "ORGAN", 63, 68], ["AGT", "GENE_OR_GENE_PRODUCT", 69, 72], ["Agt", "GENE_OR_GENE_PRODUCT", 77, 80], ["urinary", "ORGANISM_SUBSTANCE", 123, 130], ["AGT", "GENE_OR_GENE_PRODUCT", 131, 134], ["Ang II", "GENE_OR_GENE_PRODUCT", 139, 145], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 176, 183], ["renal", "ORGAN", 236, 241], ["ACE-2", "GENE_OR_GENE_PRODUCT", 242, 247], ["Akita mice", "ORGANISM", 262, 272], ["hnRNP F", "PROTEIN", 30, 37], ["renal AGT", "PROTEIN", 63, 72], ["Agt mRNA", "RNA", 77, 85], ["urinary AGT", "PROTEIN", 123, 134], ["Ang II", "PROTEIN", 139, 145], ["ACE", "PROTEIN", 242, 245], ["mice", "SPECIES", 268, 272], ["mice", "SPECIES", 268, 272], ["hnRNP F overexpression", "PROBLEM", 30, 52], ["renal AGT", "PROBLEM", 63, 72], ["Agt mRNA expression", "TEST", 77, 96], ["ESM Fig.", "TEST", 98, 106], ["lowered urinary AGT", "TEST", 115, 134], ["Ang II levels", "TEST", 139, 152], ["normalised urinary Ang", "TEST", 157, 179], ["decreased renal ACE", "PROBLEM", 226, 245], ["renal", "ANATOMY", 63, 68], ["AGT", "OBSERVATION", 69, 72], ["urinary AGT", "ANATOMY", 123, 134], ["urinary", "ANATOMY", 168, 175], ["decreased", "OBSERVATION_MODIFIER", 226, 235], ["renal", "ANATOMY", 236, 241], ["ACE", "OBSERVATION", 242, 245]]], ["Decreased ACE-2 expression also has been reported in male streptozotocin (STZ)-induced diabetic mice [46] , STZinduced diabetic rats [47, 48] and human type 2 diabetic kidneys [49, 50] .DiscussionThe precise mechanism by which hnRNP F overexpression leads to upregulation of renal Ace-2 and MasR gene expression in diabetes remains unclear.", [["kidneys", "ANATOMY", 168, 175], ["renal", "ANATOMY", 275, 280], ["streptozotocin", "CHEMICAL", 58, 72], ["STZ", "CHEMICAL", 74, 77], ["diabetic", "DISEASE", 87, 95], ["diabetic", "DISEASE", 119, 127], ["diabetic", "DISEASE", 159, 167], ["diabetes", "DISEASE", 315, 323], ["streptozotocin", "CHEMICAL", 58, 72], ["STZ", "CHEMICAL", 74, 77], ["ACE-2", "GENE_OR_GENE_PRODUCT", 10, 15], ["streptozotocin", "SIMPLE_CHEMICAL", 58, 72], ["STZ", "SIMPLE_CHEMICAL", 74, 77], ["mice", "ORGANISM", 96, 100], ["STZinduced diabetic rats", "ORGANISM", 108, 132], ["human", "ORGANISM", 146, 151], ["kidneys", "ORGAN", 168, 175], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 227, 234], ["renal Ace-2", "GENE_OR_GENE_PRODUCT", 275, 286], ["MasR", "GENE_OR_GENE_PRODUCT", 291, 295], ["ACE", "PROTEIN", 10, 13], ["hnRNP F", "PROTEIN", 227, 234], ["MasR gene", "DNA", 291, 300], ["mice", "SPECIES", 96, 100], ["rats", "SPECIES", 128, 132], ["human", "SPECIES", 146, 151], ["mice", "SPECIES", 96, 100], ["human", "SPECIES", 146, 151], ["Decreased ACE", "PROBLEM", 0, 13], ["STZinduced diabetic rats", "PROBLEM", 108, 132], ["human type 2 diabetic kidneys", "PROBLEM", 146, 175], ["renal Ace", "TREATMENT", 275, 284], ["MasR gene expression", "PROBLEM", 291, 311], ["diabetes", "PROBLEM", 315, 323], ["kidneys", "ANATOMY", 168, 175], ["renal", "ANATOMY", 275, 280], ["diabetes", "OBSERVATION", 315, 323]]], ["One possibility is that hnRNP F binds to putative Hnrnpf-RE(s) in the Ace-2 and MasR gene promoters, subsequently enhancing Ace-2 and MasR gene transcription.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 24, 31], ["Hnrnpf-RE", "GENE_OR_GENE_PRODUCT", 50, 59], ["Ace-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["MasR", "GENE_OR_GENE_PRODUCT", 80, 84], ["Ace-2", "GENE_OR_GENE_PRODUCT", 124, 129], ["MasR", "GENE_OR_GENE_PRODUCT", 134, 138], ["hnRNP F", "PROTEIN", 24, 31], ["Hnrnpf", "PROTEIN", 50, 56], ["RE", "DNA", 57, 59], ["Ace-2 and MasR gene promoters", "DNA", 70, 99], ["Ace-2 and MasR gene", "DNA", 124, 143], ["the Ace", "TREATMENT", 66, 73], ["MasR gene promoters", "TREATMENT", 80, 99], ["enhancing Ace-2", "TREATMENT", 114, 129], ["MasR gene transcription", "TREATMENT", 134, 157]]], ["This possibility is supported by our findings that hnRNP F considerably augments the activity of an Ace-2 gene promoter and that the Hnrnpf siRNA and deletion of the putative Hnrnpf-RE markedly reduced the rat Ace-2 gene promoter activity in RPTCs.", [["RPTCs", "ANATOMY", 242, 247], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 51, 58], ["Ace-2", "GENE_OR_GENE_PRODUCT", 100, 105], ["Hnrnpf", "GENE_OR_GENE_PRODUCT", 133, 139], ["Hnrnpf-RE", "GENE_OR_GENE_PRODUCT", 175, 184], ["rat", "ORGANISM", 206, 209], ["Ace-2", "GENE_OR_GENE_PRODUCT", 210, 215], ["RPTCs", "PATHOLOGICAL_FORMATION", 242, 247], ["hnRNP F", "PROTEIN", 51, 58], ["Ace-2 gene promoter", "DNA", 100, 119], ["Hnrnpf siRNA", "DNA", 133, 145], ["putative Hnrnpf-RE", "DNA", 166, 184], ["rat Ace-2 gene promoter", "DNA", 206, 229], ["RPTCs", "CELL_TYPE", 242, 247], ["rat", "SPECIES", 206, 209], ["an Ace-2 gene promoter", "TREATMENT", 97, 119], ["the Hnrnpf siRNA", "TREATMENT", 129, 145], ["the putative Hnrnpf", "TREATMENT", 162, 181], ["the rat Ace", "TREATMENT", 202, 213]]], ["Furthermore, the biotinylated-labelled Hnrnpf-RE specifically bound to RPTC nuclear proteins and the addition of anti-hnRNP F antibody yielded a supershift of biotinylated-labelled Hnrnpf-RE binding with nuclear proteins in EMSA.", [["nuclear", "ANATOMY", 76, 83], ["nuclear", "ANATOMY", 204, 211], ["Hnrnpf-RE", "SIMPLE_CHEMICAL", 39, 48], ["RPTC", "GENE_OR_GENE_PRODUCT", 71, 75], ["anti-hnRNP F antibody", "GENE_OR_GENE_PRODUCT", 113, 134], ["Hnrnpf-RE", "SIMPLE_CHEMICAL", 181, 190], ["nuclear", "CELLULAR_COMPONENT", 204, 211], ["Hnrnpf", "PROTEIN", 39, 45], ["RE", "PROTEIN", 46, 48], ["RPTC nuclear proteins", "PROTEIN", 71, 92], ["anti-hnRNP F antibody", "PROTEIN", 113, 134], ["Hnrnpf", "PROTEIN", 181, 187], ["RE", "PROTEIN", 188, 190], ["nuclear proteins", "PROTEIN", 204, 220], ["anti-hnRNP F antibody", "TEST", 113, 134]]], ["These data demonstrate that hnRNP F binds to the putative Hnrnpf-RE and stimulates Ace-2 gene transcription.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 28, 35], ["Hnrnpf-RE", "GENE_OR_GENE_PRODUCT", 58, 67], ["Ace-2", "GENE_OR_GENE_PRODUCT", 83, 88], ["hnRNP F", "PROTEIN", 28, 35], ["Hnrnpf", "PROTEIN", 58, 64], ["RE", "DNA", 65, 67], ["Ace-2 gene", "DNA", 83, 93], ["stimulates Ace-2 gene transcription", "TREATMENT", 72, 107]]], ["Of note, hnRNP F is not specific for ---+ + + + + + + + + + + -BSA + + + + + + + + + Ace-2 gene expression but also affects the expression of Agt [25] and other genes [51, 52] .DiscussionCurrently, little is known about the mechanisms by which TGF-\u03b21 downregulates renal Ace-2 gene expression in diabetes.", [["---+ + + + + + + + + + + -BSA + + + + + + + + +", "ANATOMY", 37, 84], ["renal", "ANATOMY", 265, 270], ["diabetes", "DISEASE", 296, 304], ["---+ + + + + + + + + + + -BSA + + + + + + + +", "CHEMICAL", 37, 82], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 9, 16], ["---+", "GENE_OR_GENE_PRODUCT", 37, 41], ["Ace-2", "GENE_OR_GENE_PRODUCT", 85, 90], ["Agt [25]", "GENE_OR_GENE_PRODUCT", 142, 150], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 244, 250], ["renal", "ORGAN", 265, 270], ["Ace-2", "GENE_OR_GENE_PRODUCT", 271, 276], ["hnRNP F", "PROTEIN", 9, 16], ["Agt", "PROTEIN", 142, 145], ["TGF-\u03b21", "PROTEIN", 244, 250], ["renal Ace-2 gene", "DNA", 265, 281], ["BSA", "TEST", 63, 66], ["Ace", "TEST", 85, 88], ["Agt", "TEST", 142, 145], ["TGF", "TEST", 244, 247], ["renal Ace", "TREATMENT", 265, 274], ["diabetes", "PROBLEM", 296, 304], ["renal", "ANATOMY", 265, 270], ["diabetes", "OBSERVATION", 296, 304]]], ["Chou et al [53] reported that SB431542 inhibited high glucose and TGF-\u03b21 inhibition of Ace-2 mRNA expression in cultured NRK-52 cells.", [["NRK-52 cells", "ANATOMY", 121, 133], ["SB431542", "CHEMICAL", 30, 38], ["glucose", "CHEMICAL", 54, 61], ["SB431542", "CHEMICAL", 30, 38], ["glucose", "CHEMICAL", 54, 61], ["SB431542", "SIMPLE_CHEMICAL", 30, 38], ["glucose", "SIMPLE_CHEMICAL", 54, 61], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 66, 72], ["Ace-2", "GENE_OR_GENE_PRODUCT", 87, 92], ["NRK-52 cells", "CELL", 121, 133], ["cultured NRK-52 cells", "CELL_LINE", 112, 133], ["SB431542", "TEST", 30, 38], ["high glucose", "PROBLEM", 49, 61], ["TGF", "TEST", 66, 69], ["Ace", "TEST", 87, 90], ["mRNA expression", "TEST", 93, 108], ["NRK", "TEST", 121, 124]]], ["Our present studies also demonstrate that TGF-\u03b21 inhibits the activity of pGL 4.20-rat Ace-2 promoter (N-1, 091/+83) and that deletion of putative SMAD-REs in the Ace-2 gene promoter mitigates the inhibitory effect of TGF-\u03b21 on the Ace-2 gene promoter activity.", [["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 42, 48], ["pGL 4.20", "GENE_OR_GENE_PRODUCT", 74, 82], ["rat", "ORGANISM", 83, 86], ["Ace-2", "GENE_OR_GENE_PRODUCT", 87, 92], ["N-1", "GENE_OR_GENE_PRODUCT", 103, 106], ["+83", "GENE_OR_GENE_PRODUCT", 112, 115], ["SMAD-REs", "GENE_OR_GENE_PRODUCT", 147, 155], ["Ace-2", "GENE_OR_GENE_PRODUCT", 163, 168], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 218, 224], ["Ace-2", "GENE_OR_GENE_PRODUCT", 232, 237], ["TGF-\u03b21", "PROTEIN", 42, 48], ["pGL 4.20-rat Ace-2 promoter", "DNA", 74, 101], ["N-1, 091/+83", "DNA", 103, 115], ["SMAD", "PROTEIN", 147, 151], ["REs", "DNA", 152, 155], ["Ace-2 gene promoter", "DNA", 163, 182], ["TGF-\u03b21", "PROTEIN", 218, 224], ["Ace-2 gene promoter", "DNA", 232, 251], ["rat", "SPECIES", 83, 86], ["Our present studies", "TEST", 0, 19], ["TGF", "TEST", 42, 45], ["pGL", "TEST", 74, 77], ["Ace", "TEST", 87, 90], ["putative SMAD", "TEST", 138, 151], ["the Ace-2 gene promoter", "TREATMENT", 159, 182], ["TGF", "TEST", 218, 221], ["the Ace", "TREATMENT", 228, 235]]], ["Furthermore, biotinylated-labelled SMAD-REs bound to RPTC nuclear proteins and the addition of anti-Smad2/3 antibody yielded a supershift of labelled DNA with nuclear proteins.", [["nuclear", "ANATOMY", 58, 65], ["nuclear", "ANATOMY", 159, 166], ["SMAD-REs", "GENE_OR_GENE_PRODUCT", 35, 43], ["RPTC", "GENE_OR_GENE_PRODUCT", 53, 57], ["anti-Smad2/3", "GENE_OR_GENE_PRODUCT", 95, 107], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["nuclear", "CELLULAR_COMPONENT", 159, 166], ["SMAD", "PROTEIN", 35, 39], ["REs", "PROTEIN", 40, 43], ["RPTC nuclear proteins", "PROTEIN", 53, 74], ["anti-Smad2/3 antibody", "PROTEIN", 95, 116], ["nuclear proteins", "PROTEIN", 159, 175], ["nuclear proteins", "TEST", 58, 74], ["anti-Smad2/3 antibody", "TREATMENT", 95, 116], ["a supershift of labelled DNA", "PROBLEM", 125, 153], ["nuclear proteins", "PROBLEM", 159, 175]]], ["These data demonstrate that the inhibitory effect of TGF-\u03b21 on Ace-2 gene transcription is mediated, at least in part, via the SMAD-REs in the Ace-2 gene promoter.DiscussionIntriguingly, hnRNP F overexpression prevented TGF-\u03b21 signalling on Smad2/3 phosphorylation and on TGF-\u03b21 inhibition of Ace-2 gene promoter activity in RPTCs.", [["RPTCs", "ANATOMY", 325, 330], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 53, 59], ["Ace-2", "GENE_OR_GENE_PRODUCT", 63, 68], ["SMAD-REs", "GENE_OR_GENE_PRODUCT", 127, 135], ["Ace-2", "GENE_OR_GENE_PRODUCT", 143, 148], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 187, 194], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 220, 226], ["Smad2/3", "GENE_OR_GENE_PRODUCT", 241, 248], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 272, 278], ["Ace-2", "GENE_OR_GENE_PRODUCT", 293, 298], ["RPTCs", "PATHOLOGICAL_FORMATION", 325, 330], ["TGF-\u03b21", "PROTEIN", 53, 59], ["Ace-2 gene", "DNA", 63, 73], ["SMAD", "PROTEIN", 127, 131], ["REs", "DNA", 132, 135], ["Ace-2 gene promoter", "DNA", 143, 162], ["hnRNP F", "PROTEIN", 187, 194], ["TGF-\u03b21", "PROTEIN", 220, 226], ["Smad2/3", "PROTEIN", 241, 248], ["TGF-\u03b21", "PROTEIN", 272, 278], ["Ace-2 gene promoter", "DNA", 293, 312], ["RPTCs", "CELL_TYPE", 325, 330], ["These data", "TEST", 0, 10], ["TGF", "TEST", 53, 56], ["Ace-2 gene transcription", "TREATMENT", 63, 87], ["the Ace-2 gene promoter", "TREATMENT", 139, 162], ["TGF", "TEST", 220, 223], ["Smad2/3 phosphorylation", "TREATMENT", 241, 264], ["TGF", "TEST", 272, 275], ["Ace-2 gene promoter activity", "TREATMENT", 293, 321]]], ["At present, the underlying molecular mechanism of how hnRNP F prevents TGF-\u03b21 inhibition of Ace-2 gene transcription is not yet defined.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 54, 61], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 71, 77], ["Ace-2", "GENE_OR_GENE_PRODUCT", 92, 97], ["hnRNP F", "PROTEIN", 54, 61], ["TGF-\u03b21", "PROTEIN", 71, 77], ["Ace-2 gene", "DNA", 92, 102], ["TGF", "TEST", 71, 74], ["Ace-2 gene transcription", "TREATMENT", 92, 116]]], ["One possibility might be that hnRNP F directly inhibits Tgf-\u03b21rII gene expression as shown in our studies.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 30, 37], ["Tgf-\u03b21rII", "GENE_OR_GENE_PRODUCT", 56, 65], ["hnRNP F", "PROTEIN", 30, 37], ["Tgf", "PROTEIN", 56, 59], ["\u03b2", "DNA", 60, 61], ["Tgf", "TEST", 56, 59], ["our studies", "TEST", 94, 105], ["possibility might be", "UNCERTAINTY", 4, 24]]], ["The second possibility is that hnRNP F might interfere or prevent the interaction of Smad2/3 with other transcriptional factor(s) to inhibit Ace-2 gene transcription.", [["hnRNP F", "GENE_OR_GENE_PRODUCT", 31, 38], ["Smad2/3", "GENE_OR_GENE_PRODUCT", 85, 92], ["Ace-2", "GENE_OR_GENE_PRODUCT", 141, 146], ["hnRNP F", "PROTEIN", 31, 38], ["Smad2/3", "PROTEIN", 85, 92], ["transcriptional factor", "PROTEIN", 104, 126], ["Ace-2 gene", "DNA", 141, 151], ["Ace-2 gene transcription", "TREATMENT", 141, 165]]], ["Clearly, more studies are needed to define the molecular interaction of hnRNP F with Smad2/3 on Ace-2 gene transcription.DiscussionIn summary, the present study suggests a major role for hnRNP F in attenuating systemic hypertension and renal fibrosis in experimental diabetes and possibly in diabetic human kidneys.", [["renal", "ANATOMY", 236, 241], ["kidneys", "ANATOMY", 307, 314], ["hypertension", "DISEASE", 219, 231], ["fibrosis", "DISEASE", 242, 250], ["diabetes", "DISEASE", 267, 275], ["diabetic", "DISEASE", 292, 300], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 72, 79], ["Smad2/3", "GENE_OR_GENE_PRODUCT", 85, 92], ["Ace-2", "GENE_OR_GENE_PRODUCT", 96, 101], ["hnRNP F", "GENE_OR_GENE_PRODUCT", 187, 194], ["renal", "ORGAN", 236, 241], ["human", "ORGANISM", 301, 306], ["kidneys", "ORGAN", 307, 314], ["hnRNP F", "PROTEIN", 72, 79], ["Smad2/3", "PROTEIN", 85, 92], ["Ace-2 gene", "DNA", 96, 106], ["hnRNP F", "PROTEIN", 187, 194], ["human", "SPECIES", 301, 306], ["human", "SPECIES", 301, 306], ["Ace-2 gene transcription", "TREATMENT", 96, 120], ["the present study", "TEST", 143, 160], ["attenuating systemic hypertension", "PROBLEM", 198, 231], ["renal fibrosis", "PROBLEM", 236, 250], ["experimental diabetes", "PROBLEM", 254, 275], ["diabetic human kidneys", "PROBLEM", 292, 314], ["attenuating", "OBSERVATION_MODIFIER", 198, 209], ["systemic", "OBSERVATION_MODIFIER", 210, 218], ["hypertension", "OBSERVATION", 219, 231], ["renal", "ANATOMY", 236, 241], ["fibrosis", "OBSERVATION", 242, 250], ["experimental diabetes", "OBSERVATION", 254, 275], ["diabetic", "OBSERVATION", 292, 300], ["human", "ANATOMY_MODIFIER", 301, 306], ["kidneys", "ANATOMY", 307, 314]]], ["Our observations raise the possibility that selective targeting of this antihypertensive and anti-fibrotic protein may represent a novel approach for preventing or reversing the pathological manifestations of DN, particularly tubular fibrosis.", [["tubular", "ANATOMY", 226, 233], ["DN", "DISEASE", 209, 211], ["fibrosis", "DISEASE", 234, 242], ["tubular", "TISSUE", 226, 233], ["anti-fibrotic protein", "PROTEIN", 93, 114], ["this antihypertensive", "TREATMENT", 67, 88], ["anti-fibrotic protein", "TREATMENT", 93, 114], ["a novel approach", "TREATMENT", 129, 145], ["DN", "PROBLEM", 209, 211], ["tubular fibrosis", "PROBLEM", 226, 242], ["raise the possibility", "UNCERTAINTY", 17, 38], ["tubular", "ANATOMY_MODIFIER", 226, 233], ["fibrosis", "OBSERVATION", 234, 242]]]], "04617a86a87b436dd59ee5be9f396e48304e5200": [["J o u r n a l P r e -p r o o f Coronavirus (CoV) belonging to the Coronaviridae family has spikes on the outer surface, making it look like a crown, thus deriving its name (Corona in Latin is Crown).", [["outer surface", "ANATOMY", 105, 118], ["f Coronavirus (CoV", "ORGANISM", 29, 47], ["outer surface", "CELLULAR_COMPONENT", 105, 118], ["Coronaviridae family", "PROTEIN", 66, 86], ["Coronavirus", "PROBLEM", 31, 42], ["a crown", "PROBLEM", 140, 147]]]]}